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Thnlnssaemia and sickle cell disease (SCD) are the most widely distributed blood 
genetic disorders that occur at a high frequency in some populations including 
the Mediterranean region, parts of the Middle East, South East Asia and the 
Indian subcontinent. It is estimated that thalassaemia major affects 100,000 new- 
born every year world-wide. The high incidence of these chronic haemolytic 
diseases in developing countries poses a high load on the national economy 
because of the expensive treatment protocols and the considerably high 
morbidity rates of these patients. Repeated blood transfusion to keep 
haemoglobin above an acceptable level requires well-equipped blood banks with 
expensive facilities to screen, store and manipulate blood and blood products. 
Iron chelation therapy is an essential part of treatment to avoid or delay the 
deleterious effects of iron overload on different organs including the liver, heart, 
pancreas and endocrine glands. This inquires injecting deferoxamine 
subcutaneously for 12 hours daily with a special pump. Both deferoxamine and 
pumps are expensive and therefore not accessible for all patients.
In developing countries, the majority of transfusion-dependent patients with 
chronic haemolytic anaemia (thalassaemia and SCD) suffer from the 
consequences of sub-optimal treatment. The mortality rate is still high and 
usually patients die before the age of 30 years. They also suffer from chronic 
multi-organ damage including cardiac failure, liver cirrhosis, insulin-dependent 
diabetes mellitus, growth and pubertal failure and many skeletal abnormalities 
and fractures. In developed countries the introduction of high transfusion 
regimes and efficient chelation therapy improved survival rates and prevented 
cardiac and hepatic damage. However, a majority of thalassaemic patients still 
have significant growth and pubertal abnormalities, bone disease and multiple 
endocrine disorders.
In Egypt the incidence of thalassaemia major ranges between 0.1 - 0.2% which 
gives very high patient load on the medical services. In our University of 
Alexandria Children's Hospital, Alexandria, Egypt. The Haematology clinic has 
an average of 150 thalassaemic children registered. The same problem is 
encountered by me in the Royal Hospital, Muscat, Oman, with high prevalence 
of SCD and thalassaemia and suboptimal treatment. Because of the restricted 
economic resources, both hospitals adopt a low transfusion therapy (to keep 
haemoglobin above 9 g/dl) with IM chelation 3 times per week. With this form of 
sub-optimal treatment we observed that a large number of our thalassaemic 
children have severe growth and pubertal failure/delay, beside other hepatic, 
cardiac and skeletal abnormalities. In fact they constitute 40% of patients 
attending our Endocrinology clinic. This stimulated me to perform an extensive 
study to survey growth and pubertal development in theses patients (study-1) 
and investigate the different factors that might affect their growth and pubertal 
development (studies 4 through 10) a \veU as bone mass density (studies > 1,12). 
The frequent involvement of the liver in these patients led us to study some 
hepatic functions and the prevalence of transfusion-associated hepatitis B surface 
antigenaemia and hepatitis-C virus antibody scropositivity in relation to their
linear growth (studies 2,3). We studied the nutritional intake of these patients, 
their intestinal absorption of D-Xylosc and 48-h stool fat content in relation to 
their body mass index, subcutaneous 'at thickness and mid-arm circumference 
(studies 4,5,9).
Their defective linear growth urged us to investigate their growth hormone (GH) 
secretion (spontaneous nocturnal as well as after provocation) and insulin-like 
growth factor-I (IGF-I) and IGK-binding protein-3 (IGKBl'3) concentrations. 
Our findings demonstrated high prevalence of defective GH secretion in these 
children that necessitated imaging of their hypothalamic pituitary area. Imaging 
studies revealed original data about structural abnormalities in the anterior 
pituitary gland, different degrees of pituitary atrophy and empty sella and 
infiltration the gland as well as the mid-brain by hacniosidrin in thalassaemic 
children, the mechanism of these findings was explained (studies 4-6,10). 
Because of their slow growth, the presence of abnormal GH/IGF-I/BP3 axis, and 
structural abnormalities of the pituitary gland, the next step dealt with the 
response of IGF-I to exogenous GH and the clinical response of their linear 
growth to GH therapy for a year or more (studies 4,9).
Based on the fact that these patients have high prevalence of bone pains and 
osteoporosis during late childhood and have high risk of spontaneous fracture 
thereafter, we measured their bone mass density to investigate the relation 
between the former and the degree of iron load, growth parameters, and 
different anabolic hormone concentrations in these patients (studies 11,12).
The overview contains the details of all the 12 studies, 
summary and recommendations. For tables and 
figures please refer to the original papers (1-12) 
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OVERVIEW OF THE STUDIES
The aim of the studies
Study-1 : GROWTH AND PUBERTAL DEVELOPMENT IN
TRANSFUSION-DEPENDENT CHILDREN AND ADOLESCENTS 
WITH THALASSAEMIA MAJOR AND SICKLE CELL DISEASE 
(SCO): A COMPARATIVE STUDY
Study-2: STUDY OF HEPATIC FUNCTIONS AND PREVALENCE
OF HEPATITIS-B SURFACE ANTIGENAiEMlA IN OMANl CHILDREN 
WITH SICKLE CELL DISEASE.
Study-3: STUDY OF HEPATIC FUNCTION AND PREVALENCE OF
HEPATITIS-C ANTIBODY SEROPOSITIV1TY IN THALASSAEMIC 
CHILDREN AND THREE HIGH RISK GROUPS.
study-4: CIRCULATING GROWTH HORMONE (GH). INSULIN- 
LIKE
GROWTH FACTOR-I (IGF-I) AND FREE THYROXINE, GH 
RESPONSE TO CLONIDINE PROVOCATION AND CT SCANNING 
OF THE HYPOTHALAMIC-PITU1TARY AREA AND RESPONSE TO 
GH THERAPY IN CHILDREN WITH SICKLE CELL 
study-5: GROWTH HORMONE (GH) SECRETION. AND








1GF-B1NDING PROTEIN-3 CONCENTRATIONS IN CHILDREN WITH 
SICKLE CELL DISEASE.
Study-6: EMPTY SELLA IN SHORT CHILDREN WITH AND
WITHOUT HYPOTHALAMIC-PITUITARY ABNORMALITIES, 
INCLUDING CHILDREN WITH SICKLE CELL DISEASE.
Study-7: INSULIN AND GLUCAGON RESPONSES TO
PROVOCATION WITH GLUCOSE AND ARGININE IN 
PREPUBERTAL CHILDREN WITH THALASSAEMIA MAJOR 
BEFORE AND AFTER LONG-TERM BLOOD TRANSFUSION.
Study-8: INTERLEUKIN-I-BETA, TUMOUR NECROSIS FACTOR- 
ALPHA, ISLET CELL ANTIBODY, AND INSULIN SECRETION IN 
CHILDREN WITH THALASSAEMIA MAJOR ON LONG-TERM 
BLOOD TRANSFUSION
Study-9: GROWTH HORMONE (GH) RESPONSE TO
PROVOCATION. CIRCULATING INSULIN-LIKE GROWTH FACTOR- 
I (IGF-I) AND IGF-BIND1NG PROTEIN-3 CONCENTRATIONS, IGF-I 
GENERATION TEST AND CLINICAL RF.S.X >NSE TO GH THERAPY 
IN CHILDREN WITH BETA-THALASSEMI i 
Study-10: SPONTANEOUS AND PROVOKED GROWTH 
HORMONE (GH) SECRETION AND INSULIN-LIKE GROWTH 
FACTOR-I (IGF-I) AND IGF-BINDING PROTEIN-3 (IGFBP3) 
CONCENTRATIONS IN PATIENTS WITH BETA-THALASSAEMIA 
AND DELAYED GROWTH.
Study-11 : BONE MINERAL DENSITY IN PREPUBERTAL
CHILDREN WITH BETA-THALASSEMIA: CORRELATION WITH 
GROWTH AND HORMONAL DATA.
Study-12: DECREASED BONE MINERAL DENSITY IN
PREPUBERTAL CHILDREN WITH SICKLE CELL DISEASE: 
CORRELATION WITH GROWTH PARAMETERS. DEGREE OF 















The thalassaemias and sickling disorders are genetic disorders of haemoglobin synthesis 
that constitute the most widely distributed blood genetic disorders and occur at a high 
frequency in some populations including the Mediterranean region, South-East Asia, 
the Indian subcontinent and parts of the Middle East (1-3).
I) Beta- thalassaemias:
The thalassaemia syndromes are diverse group of genetic disorders of haemoglobin 
(Hb) synthesis. The overall effect is characterised by reduced rate of synthesis of one or 
more globin chains of Hb giving rise to an imbalance in the alpha-globin to non-alpha- 
globin chain ratio (1). The excess chains frequently associate to form unstable tetramer 
of similar chains (for example gamma 4, beta 4) and precipitate in the red cells thereby 
producing red cell haemolysis. Due to the decreased synthesis of Hb, the red cells 
typically appear pale (hypochromic) and are small (microcytic) in size. The degree of 
hypochromic-microcytic anaemia varies and ranges from a mild state to a severe, 
transfusion-dependent syndrome. These disorders constitute one of the most widely 
distributed blood genetic disorders and occur at a high frequency in some populations, 
particularly those with past or present history of malaria endemicity. These include the 
Mediterranean region, South-East Asia, the Indian subcontinent, part of the Middle 
East and in individuals of African origin (2).
The thalassaemias are classified into groups depending on the type of globin chain, 
which is deficient or not synthesised. The major types of thalassaemias a, P, 5, 5p or 
y§P thalassaemias, there is decreased production of a, P, 8, 8+P or y+5+P globin chains, 
respectively. The most frequently encountered thalassaemias are the a- and P- 
thalassaemias. Other occur at low frequency in some populations. Within each type of 
the thalassaemia, further classification is based on: the genotypic abnormality and 
phenotypic abnormality (3).
The p-thalassaemias result from point mutations or deletion of part or whole of the P- 
globin gene cluster. Over one hundred different mutations causing p-thalassaemia have 
now been identified. Unlike the a-thalassaemias, the majority of the p-thalassaemias 
result from point mutations, in which the p-globin gene and its intervening or flanking 
sequences are intact. However, the rate of synthesis of mRNA, its processing or stability
may be reduced, resulting in decreased P-globin synthesis (4,5). The non-deletional P- 
thalassaemias result from over 95 point mutations, affecting different parts of the (3- 
globin gene or its regulatory regions. The resulting pattern may be P+ type i.e. when 
there is some p-globin chain synthesis, or Po-type i.e. where there is no p-globin chain 
synthesis. Every population that has so far been investigated has six to eight common 
mutations more or less specific to that population, while other mutations occur at a very 
low frequency. Deletion of part or whole of the P-globin gene cluster have been 
reported in different populations. Depending on the extent of deletion the thalassaemia 
may be PO, (8p)o, (y5p)o, or (ey§P)o thalassaemia. The (5p)o thalassaemias have a 
functional y globin gene and often result in hereditary persistence of foetal haemoglobin 
(HPFH) (6,7). Prenatal diagnosis is possible , usually by PCR or Southern blotting, 
carried out on foetal DNA obtained by chorio-villous sampling between 11 and 15 
weeks gestation. Later diagnosis is possible via amniocentesis or foetal blood sampling.
Phenotypically the p-thalassaemias present as p-thalassaemia minor, P-thalassaemia 
intermedia and p-thalassaemia major (8,9):
1. The P-thalassaemia minor (or trait): in general the minor type is clinically
asymptomatic and the red cells are microcytic and hypochromic. But erythrocytosis 
and poikilocytosis are observed. The Hb A2 level is generally elevated but may be 
normal. The P-thalassaemia minor occurs in individuals heterozygous to P+ or PO- 
mutations. The former are generally not anaemic, but the latter have a mild degree 
of anaemia.
2. P-thalassaemia intermedia: the condition is associated with splenomegaly and 
haemolytic anaemia of hypochromic and microcytic type and some patients may 
require blood transfusion. There is a decreased production of Hb A and in majority 
of the cases an elevation of Hb F. Some of the clinical abnormalities listed with P- 
thalassaemia major are also encountered in these patients, but the condition is 
generally milder.
3. P-thalassaemia major: this is the most serious consequences of P-thalassaemia
mutations and is associated with complete absence, or very low production, of Hb A. 
Clinically several abnormalities are apparent in these patients. In general, there is 
associated hepatosplenomegaly, and marked bone changes. The patients require 
blood transfusion due to severe chronic haemolytic anaemia. Blood film reveals a- 
chain inclusion bodies in hypochromic and microcytic red cells. The major clinical 
findings of thalassaemia major include: pallor and jaundice, splenomegaly,
hepatomegaly, transfusion-dependence, skeletal and dental changes, growth 
retardation, gallstones, skin pigmentation, cardiac complications, and susceptibility 
to infections.
Homozygous PO thalassaemia usually becomes symptomatic as severe, progressive 
haemolytic anaemia during the 2nd 6 months of life. Regular blood transfusions are 
necessary in these patients to prevent profound weakness and cardiac decompensation 
caused by the anaemia. In untreated cases or in those receiving infrequent transfusions 
at times of severe anaemia, hypertrophy of erythropoeietic tissue occurs in medullary 
and extramedullary locations. The bones become thin and pathologic fractures may 
occur. Massive expansion of the marrow of the face and skull produce characteristic 
facies. Pallor, haemosiderosis and jaundice combine to produce a greenish brown 
complexion. The spleen, liver and lymph nodes are enlarged by extramedullary- 
haematopoiesis and haemosiderosis. In older patients the spleen may become so 
enlarged that it causes mechanical discomfort and secondary hypersplenism . Growth is 
impaired in older children; puberty is delayed or absent because of secondary 
endocrine abnormalities. Diabetes mellitus resulting from pancreatic siderosis may 
occur. Cardiac complications, including intractable arrhythmias and chronic congestive 
failure caused by myocardial siderosis, are common terminal events. With modern 
regimens of comprehensive care including hypertransfusion and supertransfusion 
protocols and proper iron chelation therapy , many of these complications can be 
prevented and others ameliorated and delayed in their onset (9).
The P thalassaemias occur in populations from the Mediterranean , Africa, the Middle 
East, India, Pakistan, and China. The geographic distribution of thalassaemia bears a 
striking similarity to that for malaria (8). In Egypt, the prevalence of p thalassaemia 
minor ranges between 4.2 and 7 per cent (10,11). This value is similar to that reported 
from North and West Africa (7-8 per cent) (12). The prevalence of P thalassaemia 
major in Egypt ranges between 0.1 to 0.2 per cent with a gene frequency between 0.01 
per cent and 0.04 per cent in different regions (10,11,13).
Iron overload:
Generalised iron loading of the organs has been a recognised complication of 
thalassaemia . The excess iron is derived both from transfusion and from intestinal 
absorption; in adequately transfused children the former mechanism predominates. 
The degree of iron overload derived from blood transfusion obviously depends on the
type of transfusion regime. Each 500 ml of blood delivers about 200 mg of iron to the 
tissues that can not be excreted by physiologic means. Myocardial siderosis is a 
significant contributing factor in the early death of these patients. Whereas siderosis of 
the liver, pancreas, renal and endocrine glands markedly contribute to the morbidity of 
these patients (1,3,8,14). Haemosiderosis can be decreased or even prevented with the 
parenteral administration of the iron-chelating drug, deferoxamine. It is administered 
subcutaneously over 12-hr period using a small portable pump (during sleep) 5 or 6 
nights/week to keep serum ferritin levels below 1000 ng/ml, which is well below the 
toxic range. The proper use deferoxamine has been shown to delay the development of 
iron induced damage of cardiac and liver tissue, resulting in improved survival. The 
ability of deferoxamine to prevent endocrine damage is less clear (15, 16).
II) Sickling Disorders:
Include the carrier trait for HbS (AS), the homozygous state or sickle cell disease (SS), 
or the co-inheritance of the sickle cell gene and other haemoglobin variants, for 
example: HbC, giving sickle cell haemoglobin C disease, and sickle cell-(3o or sickle cell- 
P+ thalassaemia. There are marked haematological and clinical differences between 
these genotypes (17,18).
Sickle haemoglobin (HbS) differs from normal adult haemoglobin by a substitution of 
glutamic acid at the 6th position of its P chains by valine. In the oxygenated state Hb S 
functions normally. When this haemoglobin is deoxygenated, an interaction between the 
P6 valine and a complementary region on the P chains of an adjacent molecule results 
in the formation of highly ordered molecular polymers; these elongate to form 
filamentous structures, which aggregate into rigid , crystal-like rods. This process of 
molecular polymerisation is responsible for the spiny, brittle character of sickle 
erythrocytes under conditions of decreased oxygenation (8).
Certain other abnormal haemoglobins, notably Hb C , Hb D Los Angeles, and Hb O 
Arab, participate in the molecular polymerisation of deoxy Hb S. Hb A does so to a 
smaller degree, but foetal haemoglobin (Hb F) does not. Hb S is readily identified, as 
early as the first day of life, by electrophoresis. A confirmatory solubility test excludes 
other abnormal haemoglobins with similar electrophoretic mobility. These disorders 
can also be determined antenatally using amniocyte or chorionic villous DNA by 
methods that identify the specific psS nucleotide substitution (19,20)
Polymerisation of Hb S molecules within the red cell membrane so that Hb S containing 
cells are less able to negotiate capillary beds leading to premature red cell destruction 
(haemolysis) and obstruction of blood flow (vaso-occlusion) attribute to most 
manifestations of the disease. Haemolytic anaemia usually gradually develops over the 
first 2-4 months, paralleling replacement of much of the foetal haemoglobin by Hb S. 
The consequences of chronic haemolysis include anaemia, jaundice, pigmented 
gallstones, increased folic acid requirements with a tendency to folate deficient 
megaloblastic change, the aplastic crisis, and retarded growth and sexual development. 
The consequences of vaso-occlusion are determined by the site affected and include 
stroke, ocular complications, splenic damage with subsequent tendency to acute splenic 
sequestration and pneumococcal septicaemia, acute chest syndrome, leg ulceration, 
priapism, bone and bone marrow necrosis and possibly renal failure. Both 
erythopoietic expansion secondary to haemolysis and vaso-occlusion may contribute to 
the avascular necrosis of bone resulting in dactylitis (hand- foot syndrome), painful 
crisis, avascular necrosis of the femoral head and other bone damage. The painful crisis 
and leg ulceration are major contributors to morbidity but rarely cause death. The 
major causes of death include acute splenic sequestration , pneumococcal septicaemia 
acute chest syndrome and stroke (21-25). Cardiomegaly is invariably present in older 
children, often caused partly by sickle-related cardiomyopathy. Increased iron 
absorption contributes to parenchymal damage of the liver, pancreas and heart. By 
mid-childhood most patients are underweight, and puberty is frequently delayed (8).
The sickle gene is found in high frequency in those living in regions in which 
Plasmodium falciparum malaria has been endemic, reaching its highest incidence in 
equatorial Africa but occurring also in the Mediterranean area, Southern Turkey, the 
Middle East, Saudi Arabia, and much of Central India (8,18). In Egypt the prevalence 
of sickle cell trait differs considerably among the different regions of the country. In 
Alexandria (on the Mediterranean sea), the prevalence is 1%, similar to those found in 
Syria and Lebanon. (10,26) Whereas in certain areas of Egypt, especially Siwa, El- 
Karga and El-Dakhla Oasis, the prevalence ranges between 9% 22.2% . For centuries 
these oasis have been an important cross road for the Caravans linkage of Egypt and 
Sudan (27,28).
Normal growth and pubertal development and their 
endocrine control:
A description of the endocrine control of growth requires a model which embodies the 
different phases of growth which have important biological connotations and significant 
changes that occur at crucial points in a child's development. Important clinical clues to
the aetiology of a growth problem in an individual child can easily be lost from the 
rather static approach suggested by descriptive models.
The human growth curve comprises at least three distinct functions and our 
understanding of the hormonal regulation of growth concurs with this. Analytic 
descriptions of the curve include three components of the model and the hormones most 
likely to be involved in the expression of each component (29):
1. The infancy component: is the rapid, but rapidly decelerating, growth of the first 2-3 
years of life described by an exponential function representing factors important in 
foetal growth. It appears to be largely nutritionally determined. Long-term effects 
on growth are seen following over or under-nutrition at this stage of life. The 
endocrine control of growth in utero is quite different from that after birth. Major 
growth promoting hormones such as growth hormone (GH) thyroxin, and sex 
steroids have almost no influence on foetal growth (30). In contrast, insulin is 
essential for foetal growth by acting as mitogen on embryonic tissues (31), and via 
stimulation of tissue insulin-like growth factor-I (IGF-I) release (32 ). IGF-I controls 
organ growth and functional differentiation during foetal growth (33,34). These facts 
explain macrosomia in infants of diabetic mothers and those with 
nesidioblastosis(35,36). However, after birth dramatic changes occur with the 
appearance of a quite different physiology. Circulating insulin concentration 
declines, and IGF-I secretion gradually becomes GH dependent and less dependent 
on insulin (31,37). These changes might explain in part the deceleration of growth in 
the infancy component of the growth curve.
2. The childhood component: is represented by a second degree polynominal regression, 
the earliest onset of which could be recognised at 6 months of age. Therefore, until the 
age of 3 years, growth is a combination of the infancy and childhood components acting 
additively. Such a statement is supported by the study of children with GH deficiency
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(particularly where there is gene deletion) who show a growth pattern compatible with 
the infancy component. The childhood component is therefore largely determined by 
GH secretion (GH/IGF-I axis). During childhood, stature is determined by the size that 
an infant has reached by the end of the first year of life, which is determined partly by 
the genetic circumstances and influenced greatly by nutrition, and the rate at which the 
child grows thenceforward. The rate is related in an asymptotic fashion to the amount 
of GH secreted. (38) No relationship was found with cessation of breast feeding, season 
of the year, social group or mid-parental height (29).
3. The pubertal component: when growth is described by a logistic function dependent 
endocrinologically on a combination of GH and sex steroids. This is superimposed 
on the decelerating childhood component which explains the fact that the magnitude 
of the adolescent growth spurt is inversely related to the age at peak height velocity. 
The contribution of the pubertal component is independent of time: what constitute 
the difference is the point at which it is superimposed on the decelerating childhood 
component. The puberty component depends on sex steroids which have both a 
direct anabolic action and a modulating effect on GH secretion (29).
It is evident that any endocrine account on linear growth must explain the three phases 
of that process and must view hormone action as an integrative effect rather than the 
contribution of distinct entities.
in
A) The hypothalamic-pituitary-somatotropic 
growth axis during childhood:
The principal hormone influencing mid-childhood growth is GH, the secretion of which 
is regulated by two hypothalamic peptides, growth hormone releasing hormone 
(GHRH) and somatostatin. GHRH controls synthesis of GH while somatostatin 
modulates its pulsatile secretion (29,30,39-43).
The human GH (hGH) gene is present on chromosome 17 at band q2.3, along with the 
two genes for human somatomammotrophin. Both hormones have 191 amino acids and 
there is 85 per cent homology between the amino acid residues. The currently used hGH 
gene nomenclature refers to the hGHl and hGH2. The hGHl gene and its messenger 
RNA transcript have five exons separated by four interons. Transcription of this gene 
leads to the synthesis of 22 kb hGH which accounts for 90 per cent of the hGH 
synthesis. The excision of the second interon of the hGHl gene leads to an alternative 
splicing site resulting in deletion of the message for amino acid residues 32-46 leading to 
a smaller molecule termed the 20 kb hGH variant which forms 10 per cent of the GH 
synthesised (30,39-43).
Growth hormone becomes the predominant modulator of growth velocity towards the 
end of the first year of extrauterine life. GH is secreted in a pulsatile manner from 
pituitary somatotroph cell. The majority of GH is secreted during night. In children 
and young adults, a peak of GH (upto 40 ng/ml) occurs about 1 hour after the onset of 
deep sleep; other and often smaller peaks can be observed later during sleep. During 
the day, GH secretion may be related to exercise, stress, or nutrient intake. Such a 
pulsatile pattern is important for the numerous metabolic actions of GH resulting in 
normal growth. Normal growth is also dependent on sequential crucial activation events 
occurring in somatotrophs during development. Pulsatile GH secretion results from 
interlacing neuroendocrine pathways (39,43-45)
The hypothalamus produces two neuro-hormones that continually influence the overall 
secretory rate of GH. GHRH, produced in the arcuate nucleus of the medio-basal 
hypothalamus, stimulates GH release at least in part through the adenylcyclase system 
as GH release is preceded by an increase in cyclic AMP. In primary culture of cells, 
treatment with GHRH is associated with an increase in cytosolic GH messenger RNA, a
1i
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result similar to that seen after treatment with cyclic adenosine nucleotide cAMP. 
Somatostatin inhibits GH secretion by inhibiting the production of cAMP . Pulses of 
GH secretion occur at times of maximal GHRH and minimal somatostatin secretion. 
Tonic somatostatin secretion is important for maintaining low GH basal levels. 
Receptors for GHRH and somatostatin are present on somatotropic cells of the anterior 
pituitary. It is likely that somatostatin and its withdrawal sets the timing of each GH 
pulse while GHRH determines the magnitude of the subsequent GH peak. 
Superimposed on this is regulation of somatotroph responsivity by IGF-I (39,43-47)
In addition to the two hypothalamic hormones, many neurotransmitters and 
neuropeptides are involved in the neural control of GH secretion with both stimulatory 
and inhibitory effects on GH release. These effects are exerted mainly via GHRH 
and/or somatostatin rather than directly at the pituitary level. Amid these compounds, 
neurotransmitters such as noradrenaline/adrenaline, acetylcholine and neuropeptides 
such as opioid peptides and galanin seem to play an important role. Adrenergic control 
of GH secretion includes: a-adrenergic, which stimulates, and P- adrenergic, which 
decreases the secretion. Secretion of GH is stimulated by a-adrenergic agents such as 
norepinephrine, clonidine and L-dopa, whereas a-adrenergic blockers inhibit the 
secretion. Opiates and morphine increase GH secretion. Pyridostigmine increases basal 
GH levels and potentiates GHRH-induced GH secretion. Sertonin is probably involved 
in the nocturnal secretion of GH (39,45).
GH itself acts on the hypothalamus to affect its own secretion. IGF-I is able to inhibit 
GH secretion at the hypothalamus level (by stimulating somatostatin secretion) and 
directly at the pituitary level. Several metabolic and nutritional factors regulate GH 
secretion. Hypoglycaemia causes GH secretion by still unclear mechanism, probably 
independent on GHRH. Hyperglycaemia can suppress exercise- or arginine-stimulated 
GH secretion. Fasting and chronic malnutrition are associated with elevated GH levels. 
A high-protein diet and some amino acids (arginine) stimulate GH secretion. Increased 
circulating free fatty acids tend to reduce the GH response to a variety of stimuli (39,48- 
53)
Circulating hormones can modify GH synthesis and secretion. Thyroid hormones affect 
the regulation of transcription rate of GH gene. In patients with hypothyroidism, the 
GH responses to stimuli are decreased; treatment with thyroxin normalises GH 
secretion. Oestradiol and testosterone increase both basal GH levels and GH release
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after arginine infusion or insulin-induced hypoglycaemia. In vitro, glucocorticoids have 
potent stimulatory effects on GH release, whereas in vivo long -term glucocorticoid 
administration can suppress GH response to many pharmacological and physiological 
stimuli. However, short -term administration of dexamethasone can result in 
stimulation of GH release (39,54-61). Post-transcription mechanisms have been 
implicated in the positive regulation of human GH by glucocorticoids (62,63).
Specific binding sites for GH have been found in different human tissues; their 
concentration is high in liver membranes (64). The GH receptor molecule is a 
polypeptide chain of 620 amino acids with a single transmembrane domain. The 
extracellular domain of 246 amino acids is heavily glycosylated. The GH receptor gene 
is on chromosome 5 (5pl3.1) and contains nine exons (65). The first demonstrations of 
GH receptor gene defects have been reported in Laron dwarfs (66). Abnormal 
regulation of GH gene has been found in several situations including fasting, renal 
insufficiency and diabetes (39) In the multihormonal control of GH receptors, GH itself 
and also insulin exert a major role, of up-regulation of GH receptors in most cases 
(39,64). The high-affinity growth hormone-binding protein (GHBP) in serum is derived 
from the extracellular domain of the GH receptor and may reflect GH receptor number 
(65,67) GHBP may confine GH to the intravascular compartment to protect it from 
degradation and to prolong its biological half-life (68). GHBP is reported to be low in 
patients with GH deficiency, many patients with idiopathic short stature (69,70) and 
absent in patients with Laron dwarfism (71). GHBP concentrations positively correlate 
with height in growing children (72) and with pooled GH values in growing females (73) 
yet they were found to correlate negatively with 24-hour GH concentrations in boys at 
mid-puberty (72).This suggests that a higher level of GHBP would decrease the 
neuroendocrine secretory tone of GH and vice versa, implying that the interaction of 
GH with GHBP may be more important in modulating the biological effect of GH than 
the absolute levels alone.
GH acts on many tissues, either directly or through insulin-like growth factor I (IGF-I). 
Its effects on protein synthesis, carbohydrate and lipid metabolism, and cell 
differentiation are direct. Alternatively, IGF-I mediates the growth promoting effects. 
GH exerts its anabolic effects through stimulation of metabolism of nucleic acids and 
proteins in the liver, the adipose tissue and muscles. GH affects the synthesis of most 
types of RNA, and it has been shown to increase the transport of a-amino isobutyric 
acid in the rat diaphragm (39).
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Insulin-like growth factors (Somatomedins):
In human serum the IGFs are associated with binding proteins in complexes of 150 and 
40 kd. The majority of IGFs are present in the 150-kd complex. After acidification the 
IGFs are set free and appear as peptides of 7.5 kd. Both for IGF-I and IGF-II the 
structure is very similar to that of proinsulin. Sequence analysis of cDNA clones 
encoding the IGFs have confirmed the structure as determined by protein analysis. In 
addition it was shown that the IGFs are synthesised as preprohormones, which need 
processing to generate mature IGFs (74,75). This takes place mainly within the tissues. 
The IGF-I gene is localised on the long arm of human chromosome 12. It is a large 
chain containing at least 5 exons, four of which contain coding information consisting of 
a signal peptide, the mature IGF-I (70 amino acids) and a carboxyl-terminal tail (the 
precursor domain) (74,76,77).
The liver is the major source of somatomedins appearing in blood. Its low level of 
expression in foetal life switches toward higher expression postnatally. In liver and 
many other tissues the GH-dependence of IGF-I production has been demonstrated. 
Peak levels of IGF-I mRNA in all tissues' studies are reached within 3 to 9 hours after a 
single GH injection, both in GH-deficient and normal animals (78). All tissues respond 
but its magnitude varies as well as the type of messenger RNA produced. GH is the 
major regulator of IGF-I production. A 10-fold elevation above normal is observed in 
patients with acromegaly, whereas low levels are observed in GH-deficient patients (79- 
80). The responsiveness is also dependent on the presence of mature GH receptors (81). 
Until puberty a gradual increase of serum IGF-I occurs (82). At puberty, a rise in 
plasma level occurs (83). Testosterone appears not to have a direct effect on IGF-I 
levels, but it induces an increase in GH secretion, which in turn appears to cause the 
IGF-I peak during puberty (83,84). Oestrogen in high doses reduces IGF-I activity in 
the serum (85,86). In human, IGF-I levels are normal to slightly decreased in 
hypothyroidism and increase with thyroxin therapy (87). It appears that T3 modulates 
the effect of GH on liver production of IGF-I (88). Though it is possible that insulin 
stimulates IGF-I production in the foetus, it is not likely to be of major influence in 
postnatal life. Children with poorly controlled insulin-dependent diabetes have low 
IGF-I concentrations and insulin infusion increased serum levels of IGF-I (89,90). In 
obese children with hyperphagia normal or elevated insulin levels appear to sustain
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IGF-I activity in the presence of low GH secretion (91). However, in hyperinsulinism 
no increase in IGF-I has been observed (92). Glucocorticoids appear to inhibit in vitro 
the expression of IGF-I (93). Nutrition has impressive effect on IGF-I synthesis, marked 
reduction of IGF-I in the circulation is seen in both acute and chronic undernutrition, 
presumably by a postreceptor blockade of GH effect (53,94).
Biological effects of the IGFs:
Insulin-like growth factors have the capacity to stimulate cell division as well as 
formation of matrix in cartilage. IGF-I is a growth stimulator similar to GH in mice, 
rat and humans. Chondrocytes, kidney, spleen and thymus are extremely sensitive to 
the effects of IGF-I but also all other tissues studied, with the exception of subcutaneous 
tissue, are stimulated (81, 95-99). IGF-I has a 3-fold function as a mediator of the 
growth promoting action of GH, as a potent mitogenic factor and as a metabolic 
regulator with insulin-like activity (95-101).
The possibility that in addition to having an indirect effect through IGFs, GH also has a 
direct effect on growth of tissues was investigated by Isaksson (98). He showed that GH, 
when injected in the tibial growth plate of rats, had a local effect. However, locally 
applied antibodies to IGFs prevented the effect of GH (102). It is proposed that GH 
induces the differentiation of precursors of prechondrocytes (clone formation), which 
thereby acquire the capacity to produce IGF-I and respond to it. IGF-I then causes the 
division of these cells (clonal expansion) by autocrine effect (the dual-effector theory) 
(103).
GH directly enhances IGF-I production in other tissues as well, though the magnitude 
of the effect varies. Thus, besides stimulating IGF-I production in liver (which accounts 
for most IGF-I in blood) and thereby regulating overall growth by the endocrine 
pathway, GH exerts local effects on tissues that induce increased production of IGF-I, 
which then will allow paracrine and autocrine growth stimulation ( 81,104).
The current evidence strongly suggests that IGFs may play a significant role in local 
regulation of growth in specific organs depending on local needs. For example, 
mechanical loading at a local site in bone stimulates local bone growth and not 
generalised skeletal growth. Thus, IGFs may function locally in a variety of cell types; 
including brain, muscle, kidney, lung, pancreas, and bone, in an autocrine/paracrine
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manner in addition to their systemic endocrine actions. IGFs only have two forms that 
are produced by many tissues. However, tissue-specific regulation may be accomplished 
partly by the presence of multiple forms of IGF- binding proteins (IGFBPs) and their 
corresponding proteases (74,105).
The insulin-like growth factor binding proteins:
In the circulation an, about 75 per cent of the IGFs are complexed with IGFBP-3 and 
an acid labile subunit in a 150- to 200-kd ternary complex, whereas the remainder of 
the circulating IGFs are bound to lower molecular mass IGFBPs. Six binding proteins 
have been fully characterised in human (105-107). With the recent development and 
validation of RIAs for accurate measurements of various IGFBPs in biological fluids, it 
is now possible to evaluate the relative contributions of all six IGFBPs to the IGF- 
binding capacity of the serum. The total concentration of the small molecular mass 
IGFBPs (IGFBP-1, -2, -4, -5, and -6) add up to about 50% of the IGFBP3 
concentration. Based on the observation that there is a 50 per cent molar excess of 
IGFBPs over IGFs, it is unlikely that there is much free IGFs in normal adult human 
serum (105).
If the majority of the IGFs circulate in serum as IGF-IGFBP complexes, it should be 
possible to modulate the endocrine actions of IGF-I by several mechanisms, including 
those that regulate the levels of IGFBPs. In this regard, there is evidence that the 
relative concentrations of various IGFBPs in the serum can change depending on 
physiological and pathological situations, such as age, nutrition, serum GH levels, 
diabetes, puberty, pregnancy, etc. (108-114). Studies of serum regulation of various 
IGFBPs to date reveal that the candidate IGFBP chosen as a primary regulator of IGF 
bioavailability may vary depending on the metabolic conditions. For example, IGFBP3 
appears to be the primary regulator of IGF bioavailability in response to changes in the 
circulating GH level, whereas IGFBP1 appears to be the primary regulator of IGF 
bioavailability in response to acute changes in the circulating insulin level. In addition, 
serum levels of IGFBPS, but not IGFBP4, showed significant positive correlation with 
IGF-I and IGF-II suggesting that different mechanisms may regulate the amount of 
inhibitory IGFBP4 and stimulatory IGFBPS in human serum (105)
The stimulatory and inhibitory components of this complex system should be regulated 
in a reciprocal manner to produce to changes in physiological or pathological
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conditions. For example, with age IGFs decrease, the concentration of stimulatory 
IGFBP5 decrease, whereas the concentrations of inhibitory IGFBP-1, -2 and -4 
increase. Collectively this leads to a marked decrease in the ratio of stimulatory 
IGFBPs to inhibitory IGFBPs, which would tend to decrease the endocrine actions of 
IGFs (114). Another potential control mechanism for regulation of endocrine IGF 
action is by IGFBP-specific proteases. For example, IGFBP3 protease has been 
proposed to play an important role in modulating the bioavailability of IGFs by 
breaking down the ternary complex ALS-IGFBP3-IGF-I to form the low molecular 
mass IGF-IGFBP complex, which is capable of crossing the vascular endothelial barrier 
(105,115)
IGFBPs as potential modulators of local IGF actions .
In addition to modulating the endocrine actions of IGF as described above, IGFBPs 
may have other roles including:
a) To increase IGF bioavailability in specific tissue. The proposed mechanisms are 
(105):
1. Increase the level of free IGFs.
2. Increase the ratio of IGFs/inhibitory IGFBPs
3. Increase the ratio of stimulatory IGFBPs/inhibitory IGFBPs
4. Increase the rate of proteolysis of inhibitory IGFBPs in the target tissue
5. Decrease the rate of proteolysis of stimulatory IGFBPs in target tissue
6. Increase IGF receptor abundance in the target tissue.
b) To facilitate storage of IGFs in extracelluar matrixes. For example data suggest that 
IGFs are fixed in bone by means of circulating or locally produced IGFBPS, causing 
high abundance of IGFs in bone (116).
c) To exert IGF-independent effects on target cells. For example, IGFBP3 and IGFBPS 
have been shown to mediate their effects on breast cancer cells, and bone cells, 
respectively, by IGF-independent mechanisms, possibly involving IGFBP-specific 
cell surface binding sites (117-119). Over-expression of IGFBP3 in fibroblasts 
derived from IGF-I receptor knockout mouse embryo inhibited cell growth, 
suggesting that the inhibitory effect of IGFBP3 does not involve signal transduction 
via type I IGF receptor (120).
IGF receptors:
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There are two specific IGF receptors. The type 1 IGF receptor has a structure similar 
to that of the insulin receptor. It has high affinity for IGF-I and cross-reacts well with 
IGF-II but weakly with insulin. It possesses tyrosine kinase activity. Type 2 receptor 
has high affinity for IGF-II and low affinity for IGF-I and does not react with insulin. 
Both IGF-I and IGF-II have mitogenic effects through interaction with type 1 receptor. 
The IGF receptors are distributed widely throughout the body (121-123).
B) The hypothalamic-pituitary somatotropic axis 
during puberty:
The pubertal growth spurt represents the contribution of sex steroids and GH. Each 
contributes approximately 50% of the height gain: children with GH insufficiency not 
treated with exogenous GH attain only 50% to 66% of the expected growth spurt 
(124,125).
Several studies using intermittent sampling techniques have demonstrated a clear rise 
in GH secretion during puberty (126,127) as well as with respect to pubertal stage (128- 
130), and this has been supported from studies using the continuous method of 
sampling (130-132). Growth acceleration in girls takes place during stages 2 and 3 of 
puberty whereas in boys the growth spurt takes place later in puberty at testicular 
volume between 10 and 12 ml or genitalia stage 4. Changes in serum GH concentrations 
parallel these anthropometric changes, and several studies have shown that the change 
in GH secretion is brought about by an alteration in GH pulse amplitude with 
detectable GH pulse periodicity remaining unchanged (128-130,133-135). The 
amplitude of growth hormone peaks increases early in puberty, suggesting that the 
increase of GH secretion is an amplitude-modulated phenomenon that may be related 
to either an increase in the responsiveness of the somatotrophs to endogenous GHRH, 
an increase in GHRH, or a decrease in the tone of somatostatin. Pubertal GH profdes 
differ significantly from prepubertal profiles not only because of the increased pulse 
amplitude, but also by the occurrence of that high amplitude GH pulses during the day. 
In addition, pulse analysis of GH secretion revealed also important changes in the 
regulation of trough concentrations. Values of the latter increased slightly during 
puberty but then fell dramatically in early adult life. These findings also suggest that 
alterations in both GHRH and somatostatin tone take place during childhood and 
adolescence (43). The majority of the known age-related increase in serum GHBP levels 
occurs before the period of active pubertal development. These findings strengthen the 
concept that the midpubertal changes in GH secretion serve a primary role in 
generating the growth spurt.
Few studies follow the induction of puberty using short courses of testosterone (6 
weeks). They reported increased GH secretion and increase in GH pulse amplitude 
(57,136). Induction of puberty using the hypothalamic peptide gonadotropin releasing 
hormone (GnRH) was accompanied by changes in GH pulse amplitude but not the
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pulse frequency (137-139). Data from a longitudinal study suggest that serum 
testosterone concentrations need to be elevated toward the normal adult male range for 
a considerable proportion of the 24-hour period before an increase in serum GH 
concentration can be recorded (139). Rat studies provide some evidence that oestrogen 
is a better modulator of GH gene transcription than testosterone, which might require 
amortisation for its full action (140). In children with gonadotropin-dependent 
precocious puberty, GnRH agonists are effective in switching off gonadotropin 
secretion, and thereby sex-steroid concentrations are reduced. With this reduction in 
sex-steroid concentration there is a decrease in GH secretion and serum IGF-I 
concentrations (137,138,141).
Changes in the serum concentration of IGF-I in early puberty generally parallel the 
changes in GH. Early studies demonstrated an increase in IGF-I levels during the 
pubertal period, but no clear relationship with growth velocity emerged (142,143). 
Longitudinal studies, show clearly however, that IGF-I levels increase beyond the 
pubertal growth spurt when height velocity decreases (144). The results do not seem to 
parallel the GH changes. The interpretation of serum levels of IGF-I is complicated 
both by its documented role as a paracrine hormone in modulation of growth as well as 
by the demonstration of multiple IGFBPs modulating its actions (39). A strong negative 
relationship exists between plasma insulin and IGFBP1 throughout childhood, puberty 
and adult life (145). These findings suggest that changes in serum IGF-I concentrations 
during puberty result from the interaction of a number of endocrine axes that evolve at 
different rates during adolescence and that radioimmunoassay measurement of total 
IGF-I may not convey the whole story.
The peak velocity of puberty results from the combined action of sex steroids, GH, IGF- 
I and probably insulin. The final adult height will depend mainly on the age at which 
puberty is initiated more than on the pubertal growth spurt itself. The earlier the onset 
of puberty, the more stunting can be expected. Height gain at puberty will thus result 
from two parameters of growth, namely, height velocity and the duration of growth, 
both of which will influence final height (146).
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Investigating the hypothalamic-pituitary 
somatotropic axis in growth delayed children:
While the absolute clinical criteria for considering a diagnosis of growth hormone 
deficiency (GHD) may be somewhat arbitrary the following guidelines are suggested 
(147,148):
1. severe growth retardation (height > 3 standard deviations (SD) below the mean for 
age in the absence of an alternative explanation;
2. moderate growth retardation (height -2 to -3 SD below the mean for age plus growth 
deceleration (height velocity <25th percentile for age) in the absence of an alternative 
explanation;
3. severe growth deceleration (height velocity <25th percentile for age) in the absence of 
an alternative explanation;
4. pubertal delay: in certain situations it may be difficult to ascertain whether a child 
who is growing slowly with constitutional delay of growth and puberty is going to 
have an adequate pubertal growth spurt. In such a situation, it may be valuable to 
perform a growth hormone provocation test following "priming" with exogenous sex 
steroid before the start of the investigation. The aim of this is to ascertain whether 
there is going to be sufficient GH available during the puberty growth spurt.
5. a predisposing condition (e.g. cranial irradiation) plus growth deceleration;
6. other evidence of pituitary dysfunction (e.g. other pituitary deficiencies, neonatal
hypoglycaemia, microphalus).
The pulsatile nature of GH secretion renders assessment of random serum GH 
concentrations virtually worthless in the diagnosis of GHD. Instead, the convention for 
over 30 years has been to measure serum GH following pharmacological stimulation of 
the pituitary, an assessment, presumably, of primary GH "reserve" or secretory 
capability" (149). While such provocative testing is of value, particularly in 
identification of patients with complete or severe GHD, total reliance on these tests has 
proven to be problematic for a variety of reasons (150).
a) Provocation testing is, by its very nature, non-physiological. Whether such tests 
employ insulin-induced hypoglycaemia, arginine, L-DOPA, clonidine, glucagon, or 
other secretagogues, such tests clearly do not replicate normal secretory dynamics.
b) No satisfactory mechanism has been developed for resolving conflicting data from 
two or more tests.
c) The definition of what constitutes an abnormal response to provocative testing is 
arbitrary. The cut-off point changed from 5-7 ng/ml before the mid-1980s to 10 
ng/ml after the availability of recombinant DNA-derived human GH, on the basis of 
no physiological data.
d) The age-dependency and sex steroid-dependency of GH secretory dynamics have not 
been established adequately. The studies of Martin et al (151), shown that in the 
absence of sex-steroid priming, the lower normal limit for peak GH in prepubertal 
children is as low as 1.9 ng/ml. Sixty one percent of normal-stature prepubertal 
children failed to raise their GH concentrations above 7 ng/ml following provocative 
stimulation and would, thereby, have met the conventional criteria for a diagnosis of 
GHD.
e) The reproducibility of provocative GH testing has never been demonstrated 
convincingly.
f) The impact of adiposity, and psychiatric disturbances (e.g. depression) on 
responsiveness to GH provocative testing has not been addressed adequately.
g) Inter-assay variations in GH radioimmunoassays can be as great as 2- to 3-fold 
among major reference laboratories.
h) Provocative GH testing is associated with significant cost, discomfort to the patient, 
and some element of risk. Death has occurred during both insulin and arginine 
stimulation tests.
i) Demonstration of normal provocation testing does not exclude the possibility of 
various forms of GH insensitivity (GHI) (152).
j) If it is accepted that growth rate is the most important index (standard) against 
which growth hormone measurements should be compared, then all the GH 
provocative tests have different efficiency, sensitivity and specificity. There is little to 
choose between them (147). At a cut point of GH peak = 15 mU/1 (7.5 ng/ml) insulin 
tolerance test has only 67 per cent efficiency, 69 per cent sensitivity and 63 per cent 
specificity for diagnosing GHD. The performance characteristics of different tests of 
GH secretory status compared with the insulin tolerance test using a cut off point 

















h) A raised GH concentration at time 0 during the test leads to difficulty in
interpretation. Tests are designed to evaluate the secretory pathway, particularly the 
readily releasable pool of GH. If there has recently been a pulse of growth hormone 
and the pool is low the subsequent response will be attenuated (153). 
Despite all the constraints of the tests the likelihood that a slowly growing child is GH 
insufficient is increased twofold in the presence of a positive test but only decreased by 
half in the presence of a negative one (147). These serious limitations of the 
conventional methodology for establishing a diagnosis of GHD have led to the proposal 
that more useful diagnostic tests would correct these deficiencies. Unfortunately; these 
deficiencies of the provocative tests have not been corrected by the use of prolonged 
repeated or continuous sampling of serum for GH (154), or by 24-hour urinary GH 
excretion (155), measurement of metabolic responses to short-term administration of 
GH (156), or assessment of the growth responses to GH (157,158). 
A proposal that a more useful diagnostic paradigm would be the diagnosis of IGF-I 
deficiency appeared reasonable (159). The potential advantages of such an approach 
are: 1) it is clear that IGFs are the major hormones responsible for both intrauterine 
and postpartum growth, 2) serum concentrations of the critical GH-dependent peptides 
namely, IGF-I, IGFBP3, and the acid-labile subunit (ALS) have little, if any, diurnal 
variation and can be readily assessed in a single, random blood sample; 3) 
radioimmunoassays for IGFBP3 can be readily performed on unextracted samples and 
are highly reproducible; 4) normal serum concentrations of IGFBP3 are in the (ig/ml 
range, and assay sensitivity is not an issue, and 5) documentation of IGF-I deficiency 
can then lead to a logical differential diagnosis including:
1. GHD due to hypothalamic dysfunction;
2. GHD due to pituitary dysfunction;
3. GH insensitivity (GHI), either primary or secondary;
4. Primary defects of IGF synthesis or
5. Primary defects of IGF transport/clearance (148).
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Measurement of IGF-I and IGFBP3 offers 75 and 96 per cent efficiency and 95 and 97 
per cent sensitivity in the assessment of GH secretory status (113,147). Smith et al (158), 
support the concept that GH secretory capacity in short children covers a continuum. 
In children who are markedly GH deficient, GH, IGF-I and IGFBP3 are consistently 
low, and IGFBP2 is elevated. At the other end of the spectrum are short children who 
have normal GH secretion and normal serum concentrations of IGF-I, IGFBP3 and 
IGFBP2. Between these two groups are short children in whom GH secretion is 
marginal or in whom other problems, such as inadequate nutrition, may lead to 
suboptimal responsiveness. Patients of this type have variable and indeterminate GH 
secretory responses and may exhibit IGF-I, IGFBP3, and IGFBP2 values that are 
difficult to interpret and are discordant from GH and each other. On the other hand, 
when the results of measurements of IGF-I, IGFBP3 and IGFBP2/IGF-I ratio are 
concordant (as they are in a large percentage of short children), they are likely to 
provide further understanding of a possible abnormality of GH secretion or action that 
is not available from measurement of GH alone.
In summary; there is no completely reliable test for diagnosing or excluding GHD in all 
short children. Also, none of the tests, when used alone, is superior in specificity or 
sensitivity for making a diagnosis. The use of IGFBP2 and -3 measurements, however, 
in conjunction with IGF-I can add confidence to the diagnosis when the results are in 
agreement, even when they do not agree with the GH results. Analysis of the results of 
the all four tests , particularly when this is performed in conjunction with clinical 
findings, give the greatest accuracy in diagnosing GHD (158).
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Skeletal development and bone turnover: relation to 
puberty.
Most organ tissues, including skeleton, go through the developmental stages from foetal 
life to young adulthood. The most critical period in skeletal development is during the 
time of the most rapid bone modelling and turnover of the adolescence. The process of 
bone modelling that takes place from birth until the cessation of longitudinal bone 
growth is characterised by changes in the volume and the shape of the bones. 
Thereafter, bone tissue within the existing skeletal structure is continuously being 
formed and resorbed with minimal change in bone size through the remodelling 
process. From infancy through late adolescence the activity of bone formation 
predominates, resulting in a steady accumulation of bone mass. On average, most of the 
skeletal mass is accumulated by the age of 18 (158-161). Thereafter, there is a minimal 
change in bone mass and density with age up to the time of menopause. Some skeletal 
sites begin to lose bone immediately after the age of 18 (proximal femur, trabecular 
bone in the vertebrae), and the other sites show continuous apposition of bone up to the 
time of menopause (forearm, total spine) (160-162).
Since bone mass is one of the main determinants of fracture, high bone mass at skeletal 
maturity (peak bone mass) is considered the best protection against age-related bone 
loss (163). Small differences in bone mass and bone mineral density at maturity of 5-10 
per cent could contribute to substantial differences in the incidence of osteoporotic 
fractures (164).
Bone mass gain during the second decade of life is non-linear and is linked to skeletal 
age and sexual maturation more so than chronological age. When the influence of 
chronological age, skeletal age, pubertal stage, and the basic anthropometry on the bone 
mass and bone mineral density of the total body, forearm, and the second metacarpal 
bone of females in early puberty have been evaluated simultaneously, of all the 
independent variables, weight, height, and skeletal age emerged as the most significant 
predictors for each of the bone mass parameters (160). When relating bone mass to 
pubertal developmental stage, it becomes obvious that most of the bone mass (37 per 
cent) is being accumulated between pubertal stage 2 and 4 (160). This rapid 
accumulation of bone mass correlates with the rate of the longitudinal bone growth and 
periosteal envelope expansion.
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Bone modelling and skeletal consolidation probably result from a complex sequence of 
hormonal changes in interaction with nutritional factors, where the concerted actions of 
GH, IGFs, and sex hormones and their receptors are responsible for timing of the bone 
modelling process and attainment of skeletal consolidation. The increase in circulating 
IGF-I at puberty correlates with sexual development and results from the interaction 
between oestrogen and GH. Specifically, the surge in sex steroids in turn increases the 
secretion of GH, which stimulates the production of IGF-I (165,166). The amount of 
oestrogen required to stimulate longitudinal growth of long bones is very small. Doses 
of approximately lOOng/kg/day produce maximal growth in agonadal individuals. These 
doses seem to be insufficient to cause either the development of secondary sexual 
characteristics or an increase in sex hormone binding globulin (167,168). These low- 
dose effects are consistent with the observation that girls attain peak height velocity 
early in puberty at serum Oestradiol levels of <30 pg/ml, which is one fourth the mean 
level of adult women (169). During this phase of rapid skeletal modelling (peak growth), 
which is probably dependent on IGF-I, bone mass is not yet consolidated, and bone 
mass per bone volume ratio is relatively low. Bone consolidation through endosteal 
apposition proceeds by the cessation of longitudinal bone growth. This coincides with 
the increase in Oestradiol secretion by the beginning of menarche and thereafter. It 
seems, therefore, that oestrogens play an important role in the timing of the growth 
spurt, stabilisation of bone modelling process, and skeletal consolidation (160).
In a preliminary analysis of bone mass change during puberty in 187 young females 
(age 11-13.5 years), there was an average of about 264 g of calcium accumulated, which 
requires a positive calcium balance of about 289 mg/day (164). Abrams et al. (170) 
measured skeletal calcium kinetics parameters by the use of stable calcium isotope in 
young females. They found that maximal bone calcium accretion rate is in the pre- and 
peri-menarcheal period, with the decline thereafter. This should coincide with the peak 
height velocity or a maximal bone modelling rate in young females. This accumulation 
of calcium is approximately 25-38 per cent of adult peak bone mass or the whole body 
calcium for a reference woman, indicating that puberty leads to a dramatic increase in 
bone mass and correspondingly high skeletal calcium retention, thus presenting the 
ideal period for dietary manipulation and primary prevention of osteoporosis (161).
Anabolic hormones in bone:
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Bone turnover, the product of bone resorption and formation, is a tightly coupled 
process, with the net balance between the two determining the bone mass and the serum 
calcium level (171). Regulation of bone turn-over requires the input of a large number 
of hormones, growth factors, and cytokines (171). An anabolic agent is one that can 
shift the net balance in the direction of increased bone mass. Additionally, an 
antiresorptive agent can increase bone mass if it shifts the regulatory balance toward 
net formation by suppressing resorption. It gradually became clear that a large number 
of factors interact at the level of the osteoblast, osteoclast, and other cells to regulate the 
balance between net resorption and formation. Some of these factors include (172):
1. Parathormone (PTH)/PTH-related peptide (PTHrP):
PTH is the most important hormone that regulates calcium levels (171). In addition to 
its resorptive actions, intermittent administration of PTH produces anabolic effects 
(173). PTHrP mediates terminal differentiation and function of bone and other tissues. 
The interplay between physiological levels of PTH/PTHrP and the common receptor, in 
the osteoblasts, in homeostatic control of serum calcium levels and bone mineral density 
is essential to long term maintenance of bone structure and function (172).
2.Vitamin D: (1-25-dihydroxyvitamin D3):
Is the key hormone that regulates intestinal calcium absorption. It is a primary 
resorbing factor in bone through its ability to stimulate the differentiation of 
undifferentiated bone cell precursor (174). It has effects on the osteoblasts, including 
regulation of the expansion of extra-cellular matrix proteins such as osteocalcin (175). 
Vitamin D alone or with calcium supplementation can increase bone mineral density in 
patients with osteoporosis (176).
3. AlldrOgCIlSI During puberty in boys, administration of androgens
accelerates the accumulation of calcium in bone, consistent with enhanced 
mineralisation (177), and in elderly or hypogonadal men, administration of androgen 
has a positive effect on bone mass (178). Human osteoblast-like cells respond to adrenal 
androgens with changes in gene expression consistent with stimulation of bone 
formation (172,179).
4. Oestrogen (E2)/ progesterone: Loss of cycling hormones at the
menopause results in rapid and significant loss of bone mineral. Although E2 appears to 
act on osteoclast-like cells to inhibit bone resorption (176). Major attention has focused 
on the role of E2 in regulating the behaviour of the osteoblast. E2 has an antiresorptive 
effect on osteoclasts and alters the release of cytokines from osteoblasts and/or 
mononuclear cells involved in remodelling. Cytokines, such as interleukin-1 (IL-1) or 
IL-6, which recruit osteoclasts, are suppressed, whereas possible anabolic growth 
factors, such as IGF-I are stimulated by E2 (180). E2 deficiency also interferes with 
fibronectin production from osteoblasts, a key element of the extracellular matrix 
recruitment (181).
5. (j-H/llj-r -ll The production of IGF-I by osteoblasts has led to speculation that
IGF-I has both systemic and autocrine actions in bone (182). The effects of IGF-I on 
bone are anabolic, stimulating longitudinal growth and possibly bone mass (183,184). 
Gene knockout techniques have shown that mice homozygous for a null IGF-I allele 
have a defect of ossification, are small and die at birth (185). IGF-I interacts with other 
bone-active hormones, including PTH and E2, with the former increasing the synthesis 
of IGF-I (183,186), perhaps accounting for some anabolic effects of PTH on bone (183). 
IGF-I administration to patients with GH resistance due to mutation in the GH 
receptor has resulted in increased lean body mass and bone mineral. IGFs affect 
primarily the differentiated function of the osteoblast with modest mitogenic effects. 
The ability of IGFs to regulate bone turnover and cause a net anabolic effect on bone is 
governed by a host of tissue- and cell-specific interactions, including interactions among 
other growth factors, systemic hormones, extracellular matrix, IGFBPs and different 
proteases(183,187).
Growth and pubertal maturation in patients with 
thalassaemia and sickle cell disease.
A) (3 thalassaemia :
Growth retardation occurs almost invariably in homozygous p thalassaemia. 
Significant size retardation is observed in stature, sitting height, weight, biacromial 
(shoulder) and bicristal (iliac crest) breadths. After the age of 4 years the longitudinal 
growth patterns display rates consistently behind those of normal controls. The bone 
age is frequently delayed after the age of 6-7 years. Before the use of chelation therapy, 
the incidence of normal pubertal development was low. Growth retardation becomes 
markedly severe with the failure of the pubertal growth spurt (1,188-192).
With the introduction of high transfusion regimes and efficient iron chelation 
prepubertal linear growth has been improved markedly (192-194). However, abnormal 
growth is still observed in the majority of patients during late childhood and 
adolescence (193-195). Borgna-Pignatti et al (193) evaluated growth and sexual 
development of 250 well- transfused and properly chelated adolescents with P 
thalassaemia major. Thirty seven percent of their patients were 2 SD below the mean 
for normal height; after the age of 14 years the percentage was 62 per cent for males 
and 35 per cent for females. Eighty-three percent of males and 75% of females had 
delayed skeletal maturation. Complete lack of pubescent changes was present in 38 per 
cent of females and 67 per cent of males aged 12 to 18 years. Only 19 per cent of females 
had experienced menarche; secondary amenorrhoea intervened in a third of them. 
Recently a multi-centre study, performed in 25 Italian centres, surveyed 1861 patients 
with thalassaemia major on frequent blood transfusion and iron chelation. The study 
showed that failure of puberty was the major clinical endocrine problem and was 
present in 51 per cent of boys and 47 per cent of girls, all over the age of 15 years. 
Secondary amenorrhoea was recorded in 23 per cent of patients (mean age 18.3 years) . 
Another cross-sectional study in Hong Kong, performed on 35 girls and 33 boys with 
thalassaemia major, revealed that despite regular transfusion and chelation therapy, 75 
per cent of the girls and 62 per cent of the boys over the age of 12 years were below the 
3 rd percentile for height. Hypogonadism was found in a similar percentage of patients 
(196).
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Bronspiegel-Weintrob N et al (197) reported that beginning chelation treatment with 
deferoxamine well before puberty can help children with transfusion-dependent 
thalassaemia major to attain normal sexual maturation. However, the benefits of early, 
intensive therapy with deferoxamine on sexual maturation must be weighed against the 
reports of deferoxamine-induced growth failure and bony changes in patients treated in 
the first 14 months of life (197,198). It is observed that in the past some of the growth 
retardation of thalassaemic children may have been due to the effect of severe anaemia 
and hypersplenism from early life. In adequately transfused patients linear growth 
retardation occurs during late childhood and adolescence, the basis for this distressing 
symptom remains unclear (1).
B) Sickle cell disease:
Growth and maturational delay are striking features of sickle cell disease. 
Abnormalities include early deficit in height and weight and delay in skeletal 
maturation. The majority of patients have low weight-for-height and height-for-age 
parameters (199-203). Studies using cross-sectional data showed that the onset of 
menarche and pubertal development are also delayed (201-206), but puberty appears to 
progress normally (207). A longitudinal controlled study (208) performed on Jamaican 
cohort with sickle cell disease proved that the onset of the adolescent growth spurt was 
delayed in sickle cell disease by 1.4 years with no sex difference. The age at menarche in 
girls (15.4 +/- 1.3 years) was significantly later than those with normal HbA (13.1 +/- 1.3 
years). They had a characteristically reduced spinal (sitting) to subischial length at the 
age of 16 years. The age at peak height velocity was delayed by 1.6 year compared to 
normal controls. However, the adolescent growth of these patients was otherwise 
normal. This study suggested a normal but delayed pattern of adolescent growth in 
most children with sickle cell disease but failed to explain the extreme growth delay 
found in a subgroup of patients with SCD.
In this study we evaluated the auxological data of two cohorts of children with 
thalassaemia and sickle cell disease including age, weight, height (Ht), Ht SDS, body 
mass index (BMI), upper/lower segment ratio and annual growth velocity (cm/year) and 
compared them to those for normal age-matched normal children and a cohort of 
normal children with constitutional short stature. In addition the pubertal stage was 
assessed (breast development in girls and testicular volume in boys) in all the patients
older than 9 years of age. Skeletal maturation was assessed in these children by 
estimation of the bone age of the left hand and wrist plain-x-rays.
AETIOLOGY OF GROWTH RETARDATION AND PUBERTAL 
ABNORMALITIES IN p THALASSAEMIA AND SCO:
The reason for growth retardation and pubertal delay in these two forms of chronic 
haemolytic anaemias has not been clearly determined. Haemosiderosis- induced 
damage of the endocrine glands is implicated to be one of the main causes for their 
growth failure (195-208). However, other factors could considerably contribute in the 
aetiology of this growth delay including 1. the effect of chronic anaemic hypoxia 
secondary to low haemoglobin concentration; 2. toxicity of desferrioxamine treatment;
3. increased energy expenditure due to high erythopoietic turn-over and cardiac work;
4. nutritional deficiencies including calories, folic-acid, zinc, and vitamin A; 5. 
disturbed calcium homeostasis and 6. hepatic and pancreatic dysfunction (209-220).
Hepatic involvement in thalassaemia and sickle cell 
disease:
Serial liver biopsies from thalassaemic children from early in life show evidence of iron 
loading by both light and electron microscopy. It appears that iron loading and tissue 
damage occurs remarkably early in life. Most of the hepatocytes, especially after two 
years of age, contain large number of round or oval structures, single-membrane bound 
lysosomes (variable amount of ferritin and haemosiderin or both), with increased total 
iron content. Ferritin molecules are seen in association with lamellae, either in 
paracrystalline configuration or without specific arrangement. Early in life there is no 
morphological evidence of subcellular damage or change of hepatic architecture. In 
material obtained from older children and adolescents there is advanced cirrhosis with 
many hepatocytes and Kupfur cells appear totally filled with iron-laden lysosomes. 
Later on, there are excessive numbers of collagen fibres. These findings suggest 
progressive liver damage from very early life in children with thalassaemia. 
Additionally, as a result of repeated blood transfusion, these children are at higher risk 
of developing hepatitis. Surveys in the Mediterranean region and Southeast Asia 
showed high prevalence of hepatitis- B antigenaemia in patients with thalassaemia. It is 
possible that in a number of patients progressive damage and fibrosis results from 
effects of viral hepatitis in addition to the iron overload (1,195-197,218,219).
In this study we evaluated the different hepatic functions in 110 patients with sickle cell 
disease, 70 patients with thalassaemia and 100 normal age-matched children, and 
studied the prevalence of persistent hepatitis-B surface antigenaemia and hepatitis-C 
virus (HCV) antibody in these children. We also studied the prevalence of hepatitis-C 
virus (HCV) antibody and different hepatic functions in a randomly selected sample of 
healthy children, a group of thalassaemic children and in three other high risk groups.
The nutritional Status of these patients were evaluated by measuring their 
auxological parameters including BMI, mid-arm circumference, and subcutaneous fat 
thickness at three different sites (biceps, triceps and scapular skin fold thickness). Their 
food intake was evaluated using the recall method for the last three days. Seventy two- 
hour faecal fat content was measured in two randomly selected groups of patients with 
thalassaemia and sickle cell disease and D-xylose test was performed to evaluate their 
exocrine pancreatic function and intestinal absorption respectively.
Endocrine dysfunction in thalassaemia and sickle cell 
disease:
As a part of iron loading of the tissues which occurs in homozygous (3 thalassaemia 
there is widespread haemosiderosis involving most of the endocrine organs. 
Thalassaemic patients suffer from a variety of endocrine deficiencies, particularly as 
they reach the second decade when iron loading becomes marked. Several recent 
studies analysed the different endocrine function in thalassaemic patients. These studies 
confirm that there is widespread endocrine dysfunction by the time heavily transfused 
thalassaemic children reach the second decade (194-197,221).
1. Impaired glucose tolerance and diabetes mellitus in 
thalassaemia:
Probably the commonest endocrine abnormality is glucose intolerance and diabetes 
mellitus. The reported prevalence of diabetes in treated thalassaemic patients is about 
16 per cent, while the incidence of impaired glucose tolerance approximates 60 per cent 
(222-223). It appears that the duration of the disease and the number of transfusions 
are highly correlated with the degree of glucose intolerance (223-227). Possible 
pathogenic conditions are progressive pancreatic cell destruction with subsequent 
insulin deficiency( 224-228), liver derangement with consequent insulin resistance (229-
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231), genetic factors(223,227), and possible immunological disturbance. In addition, 28 
per cent of these patients develop diabetes niellitus shortly after an acute viral hepatitis 
infection, suggesting an important role of hepatitis virus in precipitating a diabetic state 
in these patients (232). Data about the circulating concentrations of insulin in non- 
diabetic children with thalassaemia are controversial. Toccafondi R et al (233) reported 
lower insulin response to oral glucose in their thalassaemic children with normal oral 
glucose tolerance (OGTT) and Lassman et al (224,234) found a delayed insulin response 
to oral glucose loading. In controversy Flynn et al (226) and Merkel (235) and others 
(236,237) described high insulin level in patients with normal OGTT denoting insulin- 
resistance. Two studies suggested that hyperinsulinaemia is mainly due to decreased 
hepatic insulin extraction (236,237). However, in one of these studies, over time 
patients with thalassaemia experienced a reduction in their circulating insulin levels 
(237) .Kuo et al (238) found that in only 50 per cent of older thalassaemic patients did 
the plasma glucose fall to less than half of the fasting levels after intravenous (iv) 
insulin, whereas Toccafondi et al (239) found that plasma glucose fell normally after iv 
insulin in thalassaemic children under 10 years.
Diabetic hyperglycaemia is generally believed to be a bihormonal disorder where 
absolute or relative lack of insulin and excess of glucagon cause decreased peripheral 
glucose uptake and increased hepatic glucose production (240-244). In agreement with 
this notion, increased hepatic glucose production and plasma glucagon concentrations 
have been demonstrated to correlate with the hyperglycaemic level (241-247). 
Lassman et al (224) found diminished glucagon response to intravenous alanine 
infusion in thalassaemic patients without family history of diabetes and suggested that 
this is due to iron loading of the alpha cells. In controversy, Passariello and Nelson et al 
(248,249) demonstrated elevated glucagon level in thalassaemic and haemochromatic 
patients.
In this study we prospectively evaluated insulin and glucagon secretion in response to 
oral glucose load and arginine infusion in young thalassaemic children before and after 
long-term high transfusion and chelation therapy.
2. The hypothalamic-pituitary somatotropic axis in 
thalassaemia and sickle cell disease: 
Thalassaemia major:
GH secretion has been studied by different authors in thalassaemic patients with 
growth delay. Results are still controversial, both normal (250,251) and subnormal GH 
response (252-254) to different provocative stimuli have been reported in these patients. 
Studying the spontaneous pulsatile secretion in thalassaemic patients with normal GH 
response to provocation also showed different results by different authors. Some 
authors reported neurosecretory dysfunction of GH secretion in the majority of their 
patients (252,255), Others reported dysfunction only in very few subjects of their 
studied cohort (256). In controversy, Pasqualetti et al found normal circadian secretory 
pattern of GH in their patients (257).
In contrast to GH results, circulating IGF-I concentrations have been always reduced in 
all the studies (258-259). Alteration of IGF-I regulation may provide an attractive 
explanation for thalassaemia -associated growth impairment. The predominant insulin- 
like growth factor binding proteins IGFBPs in the blood is IGFBP3, which forms a 
large 150-kilodalton ternary complex. The serum level of this complex determines the 
total concentration of circulating IGF-I and regulates its growth promoting potential 
(105-107). Current opinion favours GH as the major regulator of IGF-I and IGFBP3 
levels in humans. In addition, serum IGF-I and IGFBP3 are positively related to 
nutritional status and affected by other hormones like insulin. Estimation of circulating 
concentrations of IGF-I and IGFBP3 markedly improves the interpretation of GH data 
in response to provocation and allows better evaluation of the hypothalamic-pituitary 
growth axis (113,147,158).
Sickle cell disease;
The basal circulating concentrations of different hormones have been studied by 
different authors (260-262), with no consensus defining the endocrine abnormalities of 
their GH/IGF-I growth axis and their possible contribution to growth impairment in 
these children.
This study was conducted to : 1. investigate the GH/IGF-I/IGFBP3 axis in prepubertal 
children with beta thalassaemia major and sickle cell disease. This included studying 
GH response to provocation by clonidine and glucagon, evaluation of spontaneous 
nocturnal GH secretion in thalassaemic patients who had normal GH release after 
provocation, and estimation of circulating levels of IGF-I and IGFBP3 in these patients; 
2. test the hypothesis that these patients might have GH resistance by applying the IGF-
I generation test; and 3. study the effect of GH therapy for one year on their growth 
parameters.
3. The hypothalamic-pituitary gonadal axis in thalassaemia 
and sickle cell disease:
Studies of gonadotropin levels have given inconsistent results. Lassman et al (263) 
found low luteinising hormone (LH) levels in their post-pubertal subjects who also 
showed clinical hypogonadism and a low concentration of oestrogen and testosterone in 
the blood. This is in contrast to the findings of Flynn et al (226) where there was a 
tendency for LH but not follicle stimulating hormone (FSH) to be raised in both boys 
and girls in relation to their stage of puberty. Tato et al and Danes! et al (264,265), 
reported reduced LH and FSH rise in response to gonadotropin releasing hormone 
(GnRH). Chatterjee et al (266) found low-normal GnRH-stimulated gonadotropin levels 
in 15 thalassaemic girls who developed secondary amenorrhoea. Studying the 
spontaneous pulsatile properties of LH and FSH in those thalassaemic girls revealed 
progressive neurosecretory dysfunction of their gonadotrophins (266). However, 
pulsatile GnRH treatment of boys with thalassaemia and failure of puberty resulted 
only in partial correction of the pituitary-gonadal function (267). In females, sequential 
treatment with human menopausal gonadotropin (HMG) followed by human chorionic 
gonadotropin (HCG) induced ovulation and increased Oestradiol secretion in some 
hypogonadal thalassaemic women (265). HCG administration to hypogonadal boys with 
thalassaemia induced and maintained secondary sexual characteristics in some of them 
(268). On the other hand, testicular autopsies revealed varying degrees of testicular 
interstitial fibrosis with small, heavily pig undifferentiated semineferous tubules, 
hyalinised slings and an absence of Leydig cells suggesting end-organ fibrosis secondary 
to iron loading (269).
4. Other endocrinopathies in thalassaemia:
- Adrenal function studies in thalassaemic patients have also given inconsistent 
results. Many studies reported normal 8.00 AM serum cortisol concentration, normal 
urinary hydroxycorticosteroid levels and normal cortisol response to 
adrenocorticotrophic (ACTH) in thalassaemic patients (225,238,269,270). Basal 
concentrations of other adrenal cortical hormones e.g. andrestenidione and 
dehydroepiandrosterone, were found to be normal in one study (270). However, other
investigators found low basal 17-ketosteroid levels and poor response to metyrapone 
(238), reduced cortisol response to tetracosactrin , and elevated early morning plasma 
ACTH suggesting end-organ unresponsiveness (225).
Mild abnormalities of thyroid function have been found in some patients with (3 
thalassaemia with variable, though low, incidence of thyroid failure (226,234,270,271).
Parathyroid function may be diminished in early childhood and clinical 
hypoparathyroidism has been documented in a few cases (226,271,272) 
In this study we measured 8:00 A.M. serum cortisol, thyroxin (T4) and thyrotropin 
(TSH) concentrations and performed low-dose and high-dose ACTH tests to investigate 
cortisol reserve in a large cohort of thalassaemic children to investigate their adrenal 
and thyroid functions. Serum calcium, phosphate, and alkaline phosphatase 
concentrations were measured to investigate calcium homeostasis in these patients
Skeletal changes in thalassaemia and sickle cell 
disease:
Beta-thalassaemia major is associated with significant bone disease. (272) These 
changes include bone marrow expansion of the medullary cavity, cortical thinning, 
trabecular coarsening with various striations or the appearance of cystic spaces and 
coarsening of the bone pattern with drop out of all but the mechanically most necessary 
trabeculae.(273)
With advances in transfusion management beginning in the 1996s, there has been 
marked improvement in skeletal development and normal cosmetic facial and long 
bone appearance.(274) However, even the well transfused patients remain 
radiographically osteopenic . Prior to hypertransfusion regimens fractures have 
occurred in long bones and were associated with trauma. (275) After high transfusion, 
the pattern changed with less long bone involvement and more vertebral compression 
fractures especially in older patients (276).
Although the aetiology of the bone disease is still debatable, many factors can adversely 
affect bone accretion in thalassaemic children. These include: 1. Chronic hypoxaemia 
and medullary expansion, 2. Defective growth, affecting both height and weight, 3. 
Abnormal calcium-phosphate homeostasis, 4. Delayed or lack of pubertal development 
and decreased sex-steroid secretion, 5. Compromised nutritional status and increased 
energy expenditure, 6. abnormal (GH)/1 (IGF-I)/ (IGFBP3) axis and/or 7. The 
development of diabetes mellitus (194,215,219,221-223,225,226,233-238)
Sickle Cell disease is associated with many risk factors that can adversely affect 
bone acceleration. These factors include:!, avascular necrosis during sickling episodes, 
2. delayed growth and pubertal development, 3. deficiency of important growth factors 
(IGF-I), 4. nutritional deficiencies; 5. disturbed calcium metabolism (199-214). 
Many radiological changes are described in these patients which become marked with 
age. These changes combine two features , namely expansion of the medulla of the long 
bones and the diploic spaces of the cranial vault and the effect of bone infarction and 
infection. The cortex and trabeculae may be thinned and the intertrabecular spaces are 
widened throughout the skeleton. In the small bones of the hands and feet deposition of
periosteal new bone along the shaft is combined with irregular areas of translucency 
within the substance of the bone. The whole bone may be involved. Interference with 
bone growth can be generalised or localised to the metaphysis of the long bones and 
vertebral bodies (273).
Because of the above mentioned risk factors and the significant radiological bone 
changes in patients with thalassaemia and sickle cell disease, we measured bone mineral 
density and investigated some factors affecting bone mineral metabolism in relation to 
linear growth and secretion of growth factors (GH), (IGF-I), and IGFBP3) in 30 
children with thalassaemia, 28 prepupertal children with SCD and a group of age- 
matched normal children.
In SII 111 1113 ry , patients with thalassaemia and sickle cell disease have high
incidence of growth and pubertal delay and secondary dysfunction of their endocrine 
glands, despite improvements in the care of haematological problems. The aetiology of 
this delay has not been clearly determined but likely to be multifactorial. Studying the 
different factors that might adversely affect growth, with early prevention and/or 







THE AIM OF THE STUDIES
These studies were conducted to investigate the different factors that might contribute 
to growth retardation in children with thalassaemia and sickle cell disease and to 
specifically answer the following questions:
1. Do children with thalassaemia and sickle cell disease have significant growth 
retardation and/or pubertal delay?
2. Are these patient undernourished? Do they eat qualitatively and quantitatively 
adequate food?
3. Do children with thalassaemia and sickle cell disease have significant impairment of 
hepatic functions? Is it related to the degree of iron overload and/or transfusion- 
associated hepatitis?
4. Do children with thalassaemia and SCO have abnormalities of GH/IGF-I/IGFBP3 
axis?
5. Does GH therapy increase linear growth in these patients? Do they have resistance 
toGH?
6. Do thalassaemic children on long-term blood transfusion develop progressive 
impairment of insulin secretion?
7. Do children with thalassaemia and sickle cell disease have abnormalities of the 
pituitary-thyroid and/ or the pituitary adrenal axis?
8. Do children with thalassaemia and sickle cell disease have decreased bone mineral
density (osteoporosis)?
To answer the previous question we performed the following studies ( papers 1 through 
12):
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Study -1: GROWTH AND PUBERTAL DEVELOPMENT IN 
TRANSFUSION-DEPENDENT CHILDREN AND ADOLESCENTS WITH 
THALASSAEMIA MAJOR AND SICKLE CELL DISEASE (SCO): A 
COMPARATIVE STUDY
(Journal of Tropical Paediatrics, Accepted for publication, November 1997) 
(Presented in the XXII International Congress of Paediatrics, Amsterdam, 9- 14 
August, 1998) 
THE AIM OF THE WORK:
1. to perform a systematic survey of growth and pubertal development in a large
cohort of patients with thalassaemia major and sickle cell disease (SCD), all received 
the same treatment during the last 10 years to investigate the effect of the current 
regimen on growth and pubertal maturation of these patients.
2. to assess the nutritional status of these children by evaluating their diet and 
measuring their body mass index (BMI), mid-arm circumference (MAC) and 
subcutaneous fat thickness.
PATIENTS AND METHODS:
Patients with transfusion-dependent thalassaemia major and SCD were randomly 
selected from the Haematology Clinics of the Royal Hospital and Alexandria University 
Children's Hospital, Alexandria, Egypt. The participating hospitals were chosen with 
consideration of homogeneity of treatment protocol. Mean pre-transfusion 
haemoglobin (Hb) concentration has been kept at 9 g/dl in the last 7 years in most 
patients; individual variability was not such as to permit comparisons between patients. 
They received desferrioxamine (50 mg/kg/dose) by intramuscular and/or subcutaneous 
injection 3 times weekly. All were on folk -acid supplements and all had been 
vaccinated against pneumococci. Two hundred age and sex matched normal randomly 
selected children , 30 children with constitutional delay of growth (CSS) (height = or > 2 
standard deviations (SD) below the mean for age and sex, with delayed bone age and 
normal growth hormone (GH) response to provocation), and 25 children with isolated 
GH deficiency (GHD), served as controls. None of the children had history of 
intrauterine growth retardation, any other systemic or endocrine disease, dysmorphic
trait, or central nervous system irradiation. Informed consent for the testing 
procedures was obtained from the parents of all children and when appropriate from 
the children. All children were examined with special emphasis on nutritional data. A 
special form was prepared for this study. The anthropometric measurements included 
weight, height, MAC and triceps and sub-scapular skin fold thickness during a hospital 
visit at the time of the study. Harpenden's callipers and anthropometric measurements 
were used. The height SDS (HtSDS) was calculated according to the formula HtSDS = 
(XI - X2) / SD, where X2 and SD are age matched population mean height and SD, 
respectively, and XI is the subject height. The height growth velocity (GV) cm/year was 
calculated for a complete year, following the first measurement. Normal population 
data were according to Tanner et al (277). The BMI was calculated according to the 
formula = weight (Kg) / height (m)2. The bone age and stages of sexual maturation were 
evaluated according to Greulich and Pyle (278) and Tanner et al (277) respectively. In 
girls, the age of menarche and early breast development were recorded. In boys, 
testicular volume was measured and recorded.
Dietary intake, both qualitative and quantitative, was assessed by the dietician for all 
patients and 50 normal age-matched children using the recall method. A standard oral 
glucose tolerance test (OGTT) was performed (1.75 g glucose / kg body weight). Three 
patients with impaired glucose tolerance were excluded from the study.
In a randomly selected sample from short children (height = or > 2 standard deviations 
(SD) below the mean for age and sex) from each group {thalassaemia (n=15), SCD 
(n=21) and CSS ( n=10) a fasting venous blood sample was obtained and kept frozen at - 
20 degree C until analysed for thyroxin (FT4), thyrotropin (TSH), and IGF-I 
concentrations by radio-immunoassay. All samples from all the children were assayed 
simultaneously.
RESULTS: ( see appendix for tables and figures)
The HtSDS , GV and GVSDS of patients with thalassaemia and SCD were significantly 
decreased compared to normal children (p<0.01) (table 1). The HtSDS of thalassaemic 
children was significantly lower than that for children with SCD. Both groups had 
HtSDS higher than those with GHD. The GV and GVSDS of patients with thalassaemia 
were lower than those for SCD, however the difference did not attain statistical 
significance for the GVSDS (p=0.09). Children with thalassaemia and SCD had GV and 
GVSDS significantly higher than those with GHD but not different than those with
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CSS. The bone age delay (yr) did not differ among the three study groups with 
thalassaemia, SCD and CSS. The BMI of thalassaemic patients was significantly higher 
compared with the other groups. The mid-arm circumferences were significantly 
decreased in children with thalassaemia and SCD compared to normal children (table 
2). The triceps skin-fold thickness of children with SCD was significantly decreased 
compared to that for normal children. Assessment of the food intake, using the recall 
method for the last 3 days, failed to detect any qualitative or quantitative deficiency of 
food consumption by children with thalassaemia or SCD. The upper segment / lower 
segment ratio (U/L) in children with thalassaemia (0.85 +/-0.07) and SCD ( 0.89 +/- 0.09) 
was significantly lower than age-matched controls (1.09 +/- 0.06).
Figures A (1-3) and B (1-3) and table 3, show the HtSDS, GVSDS, and BMI data of 
children with thalassaemia and SCD. Linear growth was significantly impaired in both 
groups of children with thalassaemia and SCD. Forty nine per cent of thalassaemic 
children and 27 per cent of those with SCD had HtSDS below -2. Eighty three per cent 
of thalassaemic children and 67per cent of children with SCD had HtSDS below -1. A 
considerably large percentage of thalassaemic and sickler children had slow growth 
velocity; 56 per cent of thalassaemic children and 51 per cent of children with SCD had 
GVSDS below -1 during a full year of linear growth. Figure C (1,2) shows scatter-grams 
of chronological age versus HtSDS and GVSDS in patients with thalassaemia and SCD 
respectively. The age was correlated negatively with HtSDS (r = - 0.405, P <0.01) 
suggesting progressive growth retardation with age in these patients. Serum ferritin 
concentration was correlated negatively with GV (r= -0.45, P <0.001) (figure C).
Pubertal development (table 4): If testicular volume = or > 3ml and breast development 
> Bl are taken as evidence of beginning of pubertal development, a considerable 
number of patients had not experienced sexual maturation, even at ages when this is the 
rule in normal subjects. The data of twenty two thalassaemic boys, between the age of 
14 and 21 years (16.9 +/- 3.8 years), showed that only 6 (27 per cent) of them had 
testicular enlargement (volume > 3ml). Their mean testicular volume = 6.8 +/- 2.5 ml. 
Out of the 19 thalassaemic girls between the age of 13 and 22 years (17.2 +/- 3.2 years) 
only 5 (26 per cent) had spontaneous menarche at a mean age of 17.5 +/- 1.2 years. 
Breast development was delayed in 11 ( B2 at mean age of 15.7 +/- 1.5 years) and absent 
in 8 of them. Three out of the five patients who had spontaneous menarche had 
irregular menstrual cycles and two of the three had secondary amenorrhoea.
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In girls with SCD above the age of 13 years ( 16.5 +/- 3.2) (n=16) , 14 girls had delayed 
breast development (B2) after the age of 13 years (mean age of 13.5 +/- 0.4 years) and 
only 2 had breast development before the age of 13 years (B2 at mean age of 12.5 +/- 0.4 
years). Seven girls, out of the 14, had spontaneous menarche at an age of 15.6 +/- 0.7 
years. Out of the 18 boys with SCD, above the age of 14 years (17.1 +/-2.S years), 14 
had testicular volume above 3 ml (Tanner 2 or more) and four (25 per cent) had 
testicular volume < 3 ml at the age of 14,14.5,15.5 and 16 years respectively. Their 
mean testicular volume = 8.5 +/- 3.1. In thirty normal males (age 16.9 +/- 2.6 years) and 
thirty normal females (age 16.2 +/- 2.3 years) ; between the age of 13 and 21, the mean 
age for starting breast development (B2) ranged between 9.5 and 13.1 years with a 
mean = 10.7 +/- 0.8 years. The mean age of menarche was 13.4 +/- 1.2 years. All the 
normal adolescent boys (n=30, age 16.9 +/- 2.6 years) had testicular volume above 4 ml. 
Their mean testicular volume = 12.4 +/- 3.4 ml.
Serum ferritin , and alanine- transferase concentrations were significantly higher in 
thalassaemic children versus the other two groups (table 5). Insulin-like growth factor-I 
concentration was significantly lower in children with thalassaemia and SCD versus 
children with CSS. Circulating IGF-I concentrations were significantly lower in 
children with thalassaemia compared to those with SCD. FT4 and TSH concentrations 
did not differ among the three study groups.
DISCUSSION:
Subjects from the cohort study were diagnosed either at birth or during infancy; are a 
representative sample of children with thalassaemia and SCD. Analysis of cross- 
sectional and longitudinally collected auxological data and comparison with normal 
children as well as with 2 groups of children with CSS and isolated GHD allowed better 
evaluation of growth in these patients. The present data prove the high prevalence of 
short stature in children with thalassaemia and SCD during childhood and adolescence. 
This was more marked in thalassaemia (about half of the thalassaemic children had 
HtSDS below -2). In addition the linear GV of more than half of the children with 
thalassaemia and SCD was slow (GVSDS below -1). Again this slow GV was more 
marked in thalassaemic children than in SCD. The HtSDS and GVSDS of children with 
thalassaemia and SCD were comparable to those for children with CSS and 
significantly higher compared to children with GHD. The skeletal age, as well, was
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more delayed in children with GHD versus those with thalassaemia and SCD. 
Collectively these data, in accord with the results of other investigators, (188-196) 
confirmed delay in linear growth in children with thalassaemia and SCD. The 
significant (negative) correlation between the chronological age on the one hand and the 
HtSDS and GVSDS on the other hand pointed out to the fact that linear growth delay 
progressively increases with age in these patients.
Patients with thalassaemia and SCD had significantly decreased mid-arm muscle 
circumference, and those with SCD had decreased subcutaneous fat thickness. In these 
patients undernutrition; might be due to decreased food intake , a hypermetabolic state 
( 209) due to increased bone marrow activity, and/or deficiency of the anabolic 
hormones e.g. IGF-I. The higher BMI in patients with thalassaemia does not accurately 
reflect the nutritional status because all of them had significant hepatomegaly with or 
without splenomegaly disturbing the weight to height ratio. Dietary intake of these 
patients appeared to be qualitatively and quantitatively adequate suggesting that 
probably other factors, such as hypermetabolism (209) and/or defective intestinal 
absorption of nutrients (217), might be working.
Delayed onset of puberty was a frequent finding in both boys and girls with 
thalassaemia and SCD. The delay/failure of puberty was more pronounced in patients 
with thalassaemia ; with more than 70 per cent of girls were suffering from primary or 
secondary amenorrhoea and more than 70 per cent of boys older than 14 years had 
delayed testicular development. In these patients the significantly low U/L segment 
ratio reflected their hypogonadal status but can be also due to vertebral changes 
secondary to hyperactivity of the bone marrow.
The aetiology of retarded growth in children with thalassaemia and SCD is probably 
multi-factorial with contributions from abnormal endocrine function,(194-197,221-249) 
suboptimal nutrition (210,215,217), an increase in metabolism due to hyperactivity of 
the bone marrow (209,217) and hypogonadism (193,195,196). In this study serum IGF-I 
concentrations were significantly depressed in short children with thalassaemia and 
SCD compared to short normal children, denoting defective IGF-I synthesis in these 
patients. This might be due to defective GH secretion (251-255,258,259) and/ or 
resistance to GH due to liver siderosis (218, -220, 258). The significant (negative) 
correlation between GV (cm/yr.) and serum ferritin concentrations supports the view of 
decelerated growth with increasing iron load. Under-nutrition, as shown in our patients 
by reduced mid-arm circumference and subcutaneous fat thickness, might contribute to
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growth delay in these children through decreased IGF-I synthesis. Some investigators 
report improvement of growth after increasing the caloric intake of these patients 
(215). Moreover, in many hypermetabolic states there is some degree of GH resistance, 
which might be a contributing factor in decreased synthesis of IGF-I and consequently 
delayed growth (280). Delayed and/or failure of puberty occurred in a considerably 
large numbers of males and females with thalassaemia and SCD. The lack of the 
synergistic action of sex steroids on pubertal growth spurt appears to be a major factor 
contributing to impaired growth in these patients. In this study HtSDS and GVSDS 
were correlated negatively with the chronological age supporting the view that as 
patients with thalassaemia grow older, without achieving pubertal development, their 
linear growth becomes more delayed
In summary, marked delay or failure of growth and puberty in children with 
thalassaemia major and SCD still occur in a large number of patients. This denotes that 
treatment with the current transfusion and chelation protocol is sub-optimal and 
necessitates the application of more aggressive program for hyper-transfusion and iron- 
chelation to improve growth in these patients. Improvement of the nutritional status, by 
increasing the caloric intake, should be an essential part of any recent protocol for 
treatment of these patients. Early detection of delayed / failed puberty and proper 
management by physiological replacement of sex-steroids and/or gonadotrophins 
should improve their pubertal growth.
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Study-2: STUDY OF HEPATIC FUNCTIONS AND PREVALENCE OF 
HEPATITIS-B SURFACE ANTIGENAEMIA IN OMANI CHILDREN WITH 
SICKLE CELL DISEASE.
(Journal of Tropical Pediatrics 1995; 41:174-76)
THE AIM OF THE WORK:
To study the hepatic functions and prevalence of persistent hepatitis-B surface 
antigenaemia and hepatitis-C antibody seropositivity in children with sickle cell disease 
and study the relation, if any, between the liver function and linear growth in these 
patients.
PATIENTS AND METHODS:
One-hundred-and-twenty-five children between the ages of 3 and 12 years with SCD 
were the subject of this study. They represented the sickle cell children in Muscat area 
attending the Paediatric Haematology Clinic of the Royal Hospital, Muscat, Oman. 
One-hundred normal age-matched children served as controls. All the study children 
were subjected to thorough history taking, with special emphasis on previous episodes 
of jaundice, injections, and blood transfusions. Full clinical examination was 
performed, and the size of the liver and spleen recorded. The height and weight were 
measured accurately using Harpenden's measuring instruments and the HtSDS 
calculated and recorded. Blood samples were collected for estimation of serum alanine 
transferase (ALT), alkaline phosphatase (ALP), albumin, and bilirubin concentrations. 
All serum samples of the study children were tested for the presence of hepatitis B 
surface antigen (HBSAg) using the latex quick test (281), and IgG antibody to hepatitis 
C virus (HCV) by indirect ELISA test (Behring).
Statistical analyses were done using the t-test for comparison between the different 
study groups when the data were normally distributed and Wilcoxon test when they 
were not. Data are presented as mean +/- SD.
RESULTS: ( see appendix for tables)
Table 1 shows the hepatic functions of children with SCD and controls. Four out of the 
125 children with SCD were HBSAg carriers (3 per cent) and 10 had circulating HCV 
antibodies ( 8 per cent), while 11 out of the 100 normal children were HBSAg carriers, 
and 7 were HCV-antibody positive. Serum bilirubin and ALT concentrations were 
higher in the sickle group compared to controls. Serum ALT and bilirubin levels were
significantly higher in HBSAg negative sicklers (n=121) than those for HBSAg negative 
controls (n=89) (table 2). Table 3 compares the liver functions of HBSAg positive 
sicklers and controls. Serum bilirubin and ALT concentrations were significantly 
higher and serum albumin levels were markedly lower in sicklers' group. Table 4 
presents a comparison between two groups of sickle cell children with and without 
HBS-antigenaemia. Sicklers with HBS antigenaemia had significantly higher ALT and 
lower albumin concentrations compared to those without HBS antigenaemia. 
Out of six children with SCD who presented with HBSAg positive acute hepatitis, two 
patients did not clear the antigen from their serum after one year, with elevated serum 
bilirubin (59 and 85 umol/L) and ALT (87 and 110 IU/L) concentrations. None of the 
normal children with acute HBSAg positive hepatitis were still carrying the antigen 
after 3 months of the attack.
The concentrations of ALT were correlated significantly with the height SDS in patients 
with SCD (r = -0.21, p = 0.026).
DISCUSSION
This study shows that children with SCD do not have a high prevalence of HBS 
antigenaemia. Our results confirm the findings from Nigeria that the incidence of 
hepatitis in sickle cell children is no higher than the incidence in the general population 
(282).
Significant elevation of serum ALT and bilirubin concentrations in children with SCD 
compared to control children denotes the presence of mild chronic hepatocellular 
dysfunction which might be due to liver siderosis, repeated vascular-hypoxic insults 
and/or chronic viral inflammation. However, this is not related to hepatitis-B virus 
because it is present also in sickle cell patients without HBS antigenaemia. 
Previously normal persons usually clear the HSAg from the serum within 4-6 weeks 
from the onset of acute symptoms. Chronic hepatitis is associated with persistent 
antigenaemia (283). In this study, 33 percent of sicklers with acute hepatitis-B infection 
did not clear the antigen for 1 year whereas, all the normal children cleared the antigen 
from the serum after 3 months. In addition, the comparison in table 4 proves that in 
children with sickle cell disease chronic carrying of HSAg is accompanied with more 
deterioration of hepatic functions (high ALT, and bilirubin concentrations). These 
findings point to the high risk of chronicity and continual parenchymal damage in 
sicklers after acute hepatitis-B infections. This can drastically influence the prognosis of
4Q
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hepatic involvement in this disease. It appears that vaccination against hepatitis-B 
should be a useful tool to eliminate this risk.
The significant correlation between serum ALT concentrations and height standard 
deviation score (HtSDS) (r= -0.21 , p = 0.026) in patients with SCD suggests that 
impairment of hepatic function might adversely affect linear growth in these children.
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Study-3: STUDY OF HEPATIC FUNCTION AND PREVALENCE OF 
HEPATITIS-C ANTIBODY SEROPOSITIVITY IN THALASSAEMIC 
CHILDREN AND THREE HIGH RISK GROUPS.
(Journal of Tropical Pediatrics 1995;41:341-344)
AIM OF THE STUDY:
To evaluate the hepatic function and estimate the prevalence of hepatitis-C virus 
antibody in a sample of healthy Egyptian children (n=110) as well as in four high risk 
groups of children with thalassaemia, insulin-dependent diabetes mellitus (IDDM), 
schistosomal hepatic fibrosis and chronic rheumatic heart disease.
PATIENTS AND METHODS:
186 children between the age of 1-16 years were the subject of this study. Group(l) 
included 18 children with thalassaemia major on regular blood transfusion and iron 
chelation therapy, group (2) included 17 children with insulin-dependent diabetes 
mellitus(IDDM), group (3) included 21 children with schistosomal hepatic fibrosis 
(SHF) and group (4) included 20 children with chronic rheumatic heart disease (RHD). 
All were randomly selected from the Hepatology, Diabetology, Haematology and 
Cardiology outpatient clinics of Alexandria University Children's Hospital, Alexandria, 
Egypt. 110 healthy age matched children served as a control group. All the study 
children were subjected to thorough history taking, with special emphasis on previous 
episodes of jaundice, injections and blood transfusions. Informed consent for the blood 
testing was obtained from the parents of all children before including in the study. Full 
clinical examination was performed and the span of the liver recorded. Blood samples 
were collected for estimation of serum alanine transferase concentrations. All serum 
samples of the study children were tested for the presence of hepatitis B surface antigen 
(HBSAg) using the latex quick test (281) and IgG antibody to HCV by indirect ELISA 
test (Behring).
Analysis of variance( ANOVA) was used to test the differences between mean values in 
the study groups. Significance was accepted at p<0.05. Data are presented as mean +/- 
SD.
RESULTS: ( see appendix for tables)
Table (1) presents the prevalence of HCV antibody, liver size and ALT concentrations 
in the five study groups. Children with SHF were significantly older than children in 
the other groups. The prevalence of HCV seropositivity was significantly higher in 
three of the high risk groups (thalassaemia, IDDM, and SHF) compared to the control 
group. In the RHD group the prevalence of HCV antibody was 0%. BBS antigenaemia 
was found in 7 of the normal children (6.4 per cent), 4 of the thalassaemic children (23.5 
per cent), 2 of the diabetic children (11.8 per cent); 4 of the patients with SHF (19 per 
cent) and one patient with RHD (5 per cent). Liver span was significantly larger in the 
thalassaemic and SHF groups compared to the other groups. ALT concentrations were 
significantly higher in the thalassaemic and SHF groups versus the control group. In a 
large group of thalassaemic patients (r=72) ALT concentration was correlated 
significantly (negatively) with the HtSDS of all the study children (r= -0.42, p< 0.001) 
(figure 1).
Figure 1: Relation between ALT concentrations and HtSDS in 74 thalassaemic children 
(r= -0.42, p< 0.001).
ALTU/ml
Table (2) compares ALT concentrations and liver span among the HCV antibody 
seropositive and seronegative children. In all the 5 study groups ALT concentrations 
were significantly higher in HCV seropositive compared to seronegative children. Liver 
span was significantly larger in HCV seropositive control children as well as those with 
thalassaemia and SHF Vs children who were seronegative in each group respectively.
DISCUSSION
Hepatitis-C virus can be detected in blood within 7-14 days of exposure and persists 
throughout the course of infection. However, the presence of circulating HCV
antibody can not be confirmed until 9-20 weeks after exposure. This creates a window 
period of seronegativity and potential infectivity (284,285). Acute infection carries a 
high risk of developing chronic hepatitis and liver cirrhosis. The HCV antibody test is 
used to detect acute and chronic HCV infections. It is positive in approximately 50 per 
cent of patients with acute HCV infection and 80-90 per cent with chronic NANB 
hepatitis (285,286,287).
In this study the prevalence of HCV antibody in normal (n=110) Egyptian children is 
11.8 per cent. This is a markedly higher prevalence rate compared to those reported 
from different African and Asian countries (288-291). It appears that the risk and 
magnitude of HCV infection are relatively high in Egypt.
The major factors in community-acquired HCV infection include blood transfusions, 
intravenous drug abuse, and inapparent percutaneous exposure (286). One study has 
suggested that household and sexual transmission of HCV is most inefficient (292). In 
3 of the high risk groups of children we studied , namely those with thalassaemia 
major, IDDM and SHF, the prevalence of HCV antibody positivity has been 
significantly high (44.4 , 29.3 and 38.1 per cent respectively). This confirms that 
parental transmission, either through intravenous or subcutaneous route, is a major 
factor in community-acquired infections. In addition, this high prevalence of HCV 
seropositivity and HBS antigenaemia in these groups of children poses a considerable 
danger for development of chronic liver disease. The presence of significantly larger 
liver span in HCV seropositive normal children as well as HCV seropositive children 
with thalassaemia and SHF and the significant elevation of their serum ALT 
concentrations compared to HCV seronegative children in each group respectively 
strongly support this view. Moreover, Masera and colleagues has reported high rate of 
occurrence of chronic liver disease following acute NANB-hepatitis in thalassaemic 
patients (218,219). The significant correlation between ALT concentrations and the 
HtSDS in children with thalassaemia (n = 72) (r= -0.42 , p<0.001) suggested that 
impaired hepatic function might adversely affect linear growth in these children.
In conclusion, the prevalence of HCV antibody and HBSAg seropositivity is relatively 
high (11.8 and 6.4 per cent respectively) in a random sample (n=110) of healthy 
Egyptian children and significantly high in children with thalassaemia major (44.4 and 
23.5 per cent respectively), and SHF (38.1 and 19 per cent respectively). These data 
denoted high prevalence of chronic hepatitis in these patients. Hepatic dysfunction
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might contribute to the impaired linear growth in these children.
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Study 4: CIRCULATING GROWTH HORMONE (GH), INSULIN-LIKE 
GROWTH FACTOR-I (IGF-I) AND FREE THYROXINE, GH RESPONSE TO 
CLONIDINE PROVOCATION AND CT SCANNING OF THE 
HYPOTHALAMIC-PITUITARY AREA AND RESPONSE TO GH THERAPY 
IN CHILDREN WITH SICKLE CELL 
(Journal of Tropical Pediatrics 1995;41: 285-289),
Presented at the Hlrd European Congress of Endocrinology, Amsterdam, The 
Netherland July 1994. (Abstracted in the European J Endocrinology, 1994,130, 
Suppl2; 195.
AIM OF THE WORK:
1. to estimate the circulating levels of IGF-I, FT4, TSH and the responses of GH and 
cortisol to provocation by clonidine and adrenocorticotrophic hormone (ACTH) 
respectively in children with SCD with short stature (Ht below 5th percentile) for age 
and gender and analyse these hormonal data in relation to the anthropometric, clinical 
and biochemical data of the patients.
2. to study the anatomy of the hypothalamic-pituitary area , using CT-scanning, of 
short children with SCD who have abnormal GH/IGF-I axis.
3. to study the effect of GH therapy on linear growth in short children with SCD with 
defective GH/IGF-I axis.
PATIENTS AND METHODS:
Fifteen prepubertal children with SCD and short stature, HtSDS below -2, attending 
the Paediatric Haematology/Endocrinology Clinic of the Royal Hospital, Muscat, 
Oman, were the subjects of this study. All children were on regular blood transfusion 
to keep their Hb concentrations above 9g/dl. All were on folic-acid supplements and all 
had been vaccinated against pneumococci. Fifteen age-matched children with normal 
variant short stature (NVSS) served as controls. None of the children had history of 
intrauterine growth retardation, any other systemic or endocrine disease, dysmorphic 
trait or central nervous system irradiation. Informed consent for the testing procedure 
was obtained from the parents of all children. All the children were examined 
thoroughly with special emphasis on nutritional data. The anthropometric 
measurements included weight, Ht, BMI and MAC. The HtSDS and GV cm/yr for the
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last year were calculated. Normal population data were according to the Tanner et al 
(277).The bone age was determined according to Greulich and Pyle atlas (278). 
On the day of admission, venous blood samples were obtained for determination of 
complete blood count (CBC) and serum albumin, bilirubin, alanine transferase (ALT), 
alkaline phosphatase (ALP),calcium, phosphorus and bicarbonate concentrations. 
Following an overnight fast (8-h) venous blood samples were withdrawn through a 
polyethylene catheter inserted in a forearm vein between 8 and 9 a.m. The serum was 
separated from the formed elements by centrifugation and kept frozen at -20 c until 
analysed for GH, FT4, TSH and IGF-I. After obtaining the basal samples, an oral dose 
of clonidine was given (0.15mg/m2). Blood samples were obtained every 30 min for 2 
hours for measurement of serum GH concentrations. On the next morning and after 
an 8-h overnight fast O.Smg of ACTH (synacthen) was injected iv and blood samples 
obtained before and 60 min after the injection for estimation of cortisol concentrations. 
Human GH was measured by radioimmunometric assay.
CT examination of the hypothalamic pituitary area have been performed in all sicklers 
who did not mount an appropriate GH response to clonidine provocation (n=8). One of 
the children with SCD had a second CT performed after intrathecal injection of the 
contrast material.
Two short children with SCD, defective GH release , low IGF-I and empty sellae were 
treated for three years with human GH (15 units/m2/week, divided on daily 
subcutaneous doses given each night). Their linear growth was recorded for the three 
years.
Statistical analyses were done using the unpaired t-test to compare mean analyte 
concentrations among the 2 study groups when the data were normally distributed and 
Wilcoxon test when they were not. Statistical significance was accepted at p<0.05.
RESULTS
The chronological age, HtSDS, BMI and bone age did not differ significantly between 
the 2 groups (table 1). Creatinine clearance and serum concentrations of creatinine, 
bicarbonate, albumin and ALP were not different among the 2 groups (table 2). Hb 
concentrations and haematocrit values were lower in children with sickle cell disease
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and their serum ALT and bilirubin concentrations were higher compared to the control 
children.
The circulating IGF-I concentrations and the peak GH levels in response to clonidine 
provocation were significantly lower in the sickle cell group (table 3). Eight out of the 
15 children with sickle cell disease did not mount a proper GH peak >10ug/L after 
clonidine intake, whereas all children with NVSS mounted normal GH response 
>10ug/L. Basal and ACTH-stimulated cortisol levels as well as FT4 and TSH 
concentrations did not differ significantly between the 2 groups. CT scanning of the 
hypothalamic-pituitary area revealed a picture of complete (n=5) or partial (n=3) empty 
sella in all the 8 children with SCD who had defective GH response to clonidine. In 
those patients with complete empty sella the contents of the sella had densities around 
cerebrospinal fluid (CSF) values figure (1), whereas in those with partial empty sella 
the contents of the pituitary fossa were between -45 and -27 which was suggestive of 
some fatty degenerative changes figure (2). In the patient who had CT done after 
intrathecal injection of contrast medium figure (3) a significant herniation of the 
suprasellar cistern into the pituitary fossa was noted. Plain skull x-rays for the 
pituitary fossae were normal in all children with NVSS and SCD.
Human GH therapy (15units/m2/week, on daily divided subcutaneous doses) was 
started in two prepubertal children with SCD and ESS who had annual growth velocity 
(GV) of 3.2 and 3.5 cm/yr. respectively. Their GV increased to 9.7 and 8.1 cm/yr. on the 
first year of therapy and declined markedly to 5 and 4.1 cm/yr. and 3.6 and 3.9 cm/yr. 
on the second and third years of GH therapy respectively (figure 4).
Figure 4.
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The hormonal profile of children with sickle cell disease revealed defective GH response 
to clonidine provocation as well as lower circulating concentrations of IGF-I compared 
to the control group. Malnutrition can be excluded as a cause of these changes because 
the BMI and serum albumin concentrations were not different among the 2 study 
groups. In addition, in malnutrition the basal GH concentrations are usually high 
unlike the case in our children with sickle cell disease (53,94). The normal creatinine 
clearance, and normal concentrations of serum bicarbonate, calcium, phosphorus and 
alkaline phosphatase exclude any contribution of renal dysfunction and/or disturbed 
calcium homeostasis in the aetiology of growth impairment or hormonal abnormalities 
in these children.
Although serum ALT and total bilirubin concentrations were higher in the group with 
sickle cell disease compared to the control group, those ALT levels of sicklers were still 
in the normal range of population (10-60 IU/L) and the unconjugated bilirubin 
constituted the main part of the elevated bilirubin. This in addition to normal 
concentrations of serum albumin and ALP and normal albumin/globulin ratio makes it 
unlikely that hepatocellular dysfunction is a cause for low IGF-I production in these
patients.
In summary, it appears that in short children with sickle cell disease low GH secretion 
leads to decreased synthesis of IGF-I and consequently to slow growth velocity and 
short stature. In support of this view CT scanning of the pituitary region revealed an 
empty or partially empty sella in all the eight children with SCD who did not mount an 
appropriate GH response to clonidine stimulation. Defective GH release and empty 
sellae might be due to hypoxic injury or infarction to the pituitary gland during one or
more of the sickling episodes. In our child with severe SCD, and empty sella with 
cisternal herniation figure (3), there was marked reduction in his GH response to high 
dose clonidine (7ug/L) and to insulin-induced hypoglycaemia (6.5ug/L). This finding 
supports our hypothesis of hypoxic pituitary insults in these children. As far as we 
could ascertain, this observation has not been made before. Treatment of 2 children 
with SCD and GHD with human GH accelerated their linear growth during the first 
year of treatment with rapid deceleration during the next two years, suggesting only 
partial response to GH therapy in children with SCD. Further studies are required to 
clarify more the abnormality/abnormalities of the GH/IGF-I axis in these patients.
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Study 5: GROWTH HORMONE (GH) SECRETION, AND CIRCULATING 
INSULIN-LIKE GROWTH FACTOR-I (IGF-I) AND IGF-BINDING 
PROTEIN-3 CONCENTRATIONS IN CHILDREN WITH SICKLE CELL 
DISEASE. (Metabolism 1997,46:1241-1245)
(Presented at the Second Meeting of the European Haematology Association (May 29-
June 1, 1996) Paris, France.
(Abstracted in the British JHaematology, 1996, 93, supplement 2, 34, Abst No 132.
AIM OF THE WORK:
To further test the hypotheses that:
1. SCD is associated with abnormalities of the GH/IGF-I/IGFBP axis; and
2. SCD is associated with GH resistance.
The first issue was addressed by measuring GH response to clonidine and glucagon, and 
the circulating concentration of IGF-I and IGFBP-3 in 21 children with SCD, and the 
second issue was tested by means of IGF-I generation tests. These results were 
compared with those for children with idiopathic short stature (ISS) (n=10) and 
isolated growth hormone deficiency (GHD) (n=ll).
PATIENTS AND METHODS:
Twenty-one prepubertal children with SCD were the subjects of this study. They were 
randomly selected , using random tables, from 58 children with SCD and short stature 
( height 10th percentile for age and sex). The 58 children were all the patients with 
SCD and stature <10th percentile selected from a cohort of 156 children with SCD 
regularly attending the Haematology outpatient clinic of the Royal Hospital, Muscat, 
Oman. According to their peak GH responses to 2 provocation tests (with clonidine and 
glucagon) they were divided into two subgroups. 9 children (group 1) had low peak GH 
response in two or more provocative tests (< 7ug/L) and the other 12 children (group 2) 
had normal GH response to stimulation (>7ug/L). All have been on folic acid 
supplement and vaccinated against pneumococci. None of them had history of 
intrauterine growth retardation, any other systemic or endocrine disease, dysmorphic 
trait or central nervous system irradiation. Ten age-matched children with idiopathic 
short stature (ISS) (HtSDS below -2, and normal GH response to provocation) and 11 
children with isolated GHD (GH peak response < 5ug/L in two or more provocation
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tests) served as controls. Informed consents were obtained from all the parents and 
when appropriate from children before including in the study.
All the children were examined thoroughly with special emphasis on the nutritional 
data . The auxological measurements included weight, height, head circumference, 
MAC, BMI and scapular, triceps and abdominal skin fold thickness. Normal population 
data were according to the Tanner et al (277). The bone age was determined according 
to Greulich and Pyle atlas (278).
Children were admitted to the Royal hospital, Muscat, Oman for the period of their 
investigation. Initial nutritional evaluation , both qualitative and quantitative, was 
performed by the dietician using the recall method and the patient received a high 
protein (2gm/kg/day) diet for 7 days before hormonal evaluation. After an overnight 
fast (8h) venous blood samples were obtained between 8 and 9 am for determination of 
complete blood count (CBC), serum albumin, bilirubin, alanine amino- transferase 
(ALT), bone-specific- alkaline phosphatase (ALP), calcium, phosphorus and 
bicarbonate concentrations. The serum was separated from the formed elements by 
centrifugation and kept frozen at -20 c until analysed for IGF-I, IGFBP3, cortisol, free 
thyroxin (fT4), and TSH by radioimmunoassay. The subjects received a single injection 
of 0.1 mg/kg recombinant human GH subcutaneously. Serum IGF-I and IGFBP-3 levels 
were remeasured 24 hours after the injection (293). Human GH and IGF-I were 
measured by radioimmunometric assays. IGFBP3 was measured by radioimmunoassay 
in Serono (SCL) Bioscience Services employing reagents supplied by Mediagnost.
Results are expressed as the mean +/- SD and analysed by ANOVA test to compare 
analyte concentrations among groups. Paired student-t test was used to compare data in 
the same group before and after GH injections. Correlation between variables of 
interest are examined by linear regression analysis and, when appropriate multiple 
regression analysis.
RESULTS: (see appendix for tables and figures)
Children with SCD and ISS had normal circulating concentrations of albumin, calcium, 
phosphate, ALP, ALT , bicarbonate. Serum levels of FT4, TSH and 8-A.M. cortisol did 
not differ among the two groups. Bilirubin (unconjugated) concentrations were higher
and haemoglobin (Hb) concentrations and haeniatocrit values were lower in the SCD 
group versus the ISS group. The peak D-xylose concentration after ingestion of 5 g D- 
xylose did not differ between the two groups .
Table I shows auxological and hormonal data of children with SCD, GHD and ISS. The 
HtSDS was significantly lower in children with ISS and GHD versus children with 
SCD. Linear growth velocity (GV) , GVSDS and BMI did not differ significantly among 
the two groups with ISS and SCD. However GV and GVSDS were significantly 
decreased in children with GHD. The peak GH response to provocation was 
significantly lower in children with SCD Vs ISS (p<0.001). Basal circulating IGF-I 
concentrations were higher in children with ISS Vs the other two groups. Basal 
circulating IGFBP3 concentrations were significantly lower in the SCD group (p<0.05) 
Vs those for ISS group. The IGF-I response to GH administration (IGF-D; equal to the 
24 h IGF-I value minus the basal value) was significantly lower in children with SCD 
(27.6 +/- 15.6 ng/mL) compared with those for children with ISS (53.5 +/- 17.6 ng/mL). 
The concentrations of IGF-I increased significantly after human GH injection in the 
three study groups. However, the IGF-I response (IGF-I-D) was significantly higher in 
children with GHD and those with ISS Vs those with SCD.
Table II presents a comparison between two groups of children with SCD : Group-1 
with defective GH secretion (n=9) (peak GH response to provocation = 4.2 +/- 2.3 ug/L) 
and group-2 (n=12) with normal peak GH response to provocation = 9.9 +/- 2.4 ug/L. 
The age and BMI did not differ among the two groups. The HtSDS and GVSDS were 
significantly lower in group-1. The basal circulating concentrations of IGF-I and 
IGFBP3 were significantly lower in group I (SCD with defective GH secretion). The 
IGF-I and IGFBP3 responses to GH administration did not differ significantly among 
the two groups and were significantly lower compared to those for children with 
isolated GHD.
Correlations between auxological and hormonal data in the 21 children with SCD are 
presented in Table III. The basal and GH-stimulated concentrations of IGF-I and 
IGFBP3 were correlated significantly with height GV and GVSDS (p<0.01) on the one 
hand and GH peak values on the other hand. The dependence of serum IGFBP3 on GH 
was evident from a significant correlation with peak GH secretion (n=21, r= 0.665, 
p<0.01) and the significant increase of IGFBP3 concentrations after one injection of 
GH. IGFBP3 concentrations correlated significantly with IGF-I levels before and after
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GH administration (r= 0.600, p< 0.01). Serum ferritin concentration was inversely 
correlated with GV, GVSDS, and IGF-I ( r= -0.35, -0.46, and -0.25 respectively, P<0.05)
DISCUSSION
There is no completely reliable test for diagnosing or excluding GH deficiency in all 
short children. When used alone, none of the tests has superior diagnostic specificity or 
sensitivity. Measurement of GH-responsive peptides, such as IGF-I and IGFBP-3, can 
add insights even when results do not agree with GH responses to provocative stimuli. 
Interpretation of the tests together improves the reliability of diagnostic assessment 
(158).
Nine out of the 21 (43%) randomly selected children with SCD had defective GH 
secretion in response to provocation with both clonidine and glucagon. In these children 
the IGF-I concentrations were comparable to those for children with isolated GHD, but 
significantly lower than those for children with ISS and normal GH release. Their 
circulating IGFBP3 concentrations, which reflect the integrated GH secretion over days 
(158,294,295), were significantly lower versus the group with normal GH secretion, but 
not different from those reported by Smith et al. (158) for children with GHD. The 
linear growth of patients with SCD with defective GH secretion was significantly slower 
than those with normal GH secretion. This defective GH secretion might be secondary 
to a hypoxic-vascular insult to the hypothalamic pituitary area during one or more of 
the sickling episodes and/or pituitary atrophy as a result of iron overload. In support 
of this view CT scanning of the pituitary region revealed an empty sella (partial, or 
complete) in all the 9 children with SCD and GHD. Moreover, the SCD severity score , 
as described by ElHazmi et al (260) was significantly higher in the SCD group with 
defective GH secretion versus those with normal GH secretion . Collectively these 
findings suggest that acquired GH deficiency may be a major factor in the aetiology of 
retarded growth in some patients with SCD especially those with severe sickling 
attacks.
It is unclear which of the alterations of GH/IGF-I/IGFBP axis that are found in 
children with SCD are of more clinical significance. Although the influence of SCD on 
adult height is controversial, most data indicate a negative effect of SCD on linear 
growth (1-4,6). In our study, mean HtSDS for all the studied patients with SCD (n=21)
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(-1.34 +/- 0.6) was in the lower range of normal. Those SCD patients with defective GH 
secretion had significantly lower HtSDS and GV compared to those with normal GH 
release. Moreover, we found a good correlation between GVSDS and IGF-I (before and 
after GH injection) on the one hand and a strong correlation between peak GH 
response to provocation and IGF-I and IGFBP3 on the other hand. These findings 
suggest that circulating IGF-I and IGFBP3, as in normal children, are the major 
determinant of linear growth in children with SCD, both are regulated by the GH 
status of the child. On the other hand the degree of GH resistance , as measured by the 
change of IGF-I concentration after GH injection (IGF-I-D) was not correlated with 
linear growth parameters (HtSDS, GV, GVSDS) (r= -0.26, -0.002 and 0.083 
respectively) in these children. This might denote that GH deficiency plays a more 
significant role than GH resistance in the aetiology of impaired linear growth in these 
children.
In children with SCD, growth impairment includes both height and weight (199-203). 
Treatment with human GH has been shown to improve nitrogen balance and linear 
growth in a variety of growth disorders (296). The detection of defective GH secretion 
in about 40 per cent of slowly growing children with SCD suggests a beneficial growth 
promoting effect of GH therapy in these patients. The IGF-I generation test has been 
used to assess IGF-I responsiveness to GH in children with short stature(36). In this 
study, a single, subcutaneous injection of GH has been used to investigate the 
physiological changes of IGF-I/IGFBP3 in children with SCD to test the hypothesis that 
SCD is associated with GH resistance. Subjects with SCD , with or without defective 
GH secretion, had significantly lower IGF-I responses to a single injection of GH 
compared to children with ISS and those with isolated GH deficiency, suggesting partial 
GH resistance. This might attenuate the anabolic effects of GH therapy in these 
children (297). The IGF-I response (IGF-I-D) correlated negatively with BMI (r= -0.31, 
P<0.01) suggesting that in children with SCD increasing wasting may be associated 
with progressive GH resistance. The significant negative correlation between IGF-I 
response to GH injection and peak GH response to provocation (r= -0.505, P<0.01) 
suggests that IGF-I production is better in those children with defective GH secretion. 
However, the IGF-I response of children with SCD and GHD was insignificantly higher 
versus those with normal GH secretion.
Malnutrition can be excluded as an important cause of abnormalities of the GH/IGF-I 
axis in children with SCD because of the following: 1. the BMI, subcutaneous fat 
thickness and mid-arm circumferences and serum albumin concentrations were not
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different among the study groups (SCD, SCD +GHD, and ISS); 2. analysis of their 
nutritional history proved adequate , qualitative and quantitative, intake of nutrients 
compared with normal 20-age matched children; 3. D-Xylose test was normal in all the 
children with SCD and those with ISS; 4. in malnutrition the basal GH concentrations 
are usually high unlike the case in our children with SCD (mean +/- SD= 1.8 +/- 0.25 
ug/L, range : 0.5-3.5 ug/L) (43).
The normal serum creatinine , bicarbonate, calcium, phosphorus, and ALP exclude any 
significant contribution of renal dysfunction, and/or disturbed calcium homeostasis in 
the aetiology of growth impairment or endocrine abnormalities in these children. 
Normal serum concentrations of albumin, ALP, and alanine amino-transferase (ALT) 
concentrations with normal albumin/globulin ratio and prothrombin time in children 
with SCD makes it unlikely that impaired hepatocellular synthetic function is a cause 
for low IGF-I production in these patients.
Serum ferritin concentration, as an indicator of body iron stores, was negatively 
correlated with height GV (r= -0.35, PO.01), GVSDS (r=-0.464, P<0.01), and 
circulating concentrations of IGF-I (r=-0.255, P<0.05). This suggests that 
hepatic/parenchymal iron overload may impair IGF-I synthesis and subsequently slow 
linear growth in children with SCD.
In summary, children with SCD have significantly lower IGF-I production in response 
to GH injection compared to those with ISS and GHD suggesting partial GH resistance. 
Some children with SCD and delayed growth may have GH deficiency. Parenchymal 
iron overload, a potentially treatable factor, may contribute in the aetiology of 
impaired hepatic IGF-I synthesis and/or defective GH secretion by the pituitary gland. 
Because of the presence of partial GH resistance treatment with recombinant IGF-I 
might be more successful than treatment with GH.
fiS
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Study 6: EMPTY SELL A IN SHORT CHILDREN WITH AND WITHOUT 
HYPOTHALAMIC-PITUITARY ABNORMALITIES, INCLUDING 
CHILDREN WITH SICKLE CELL DISEASE.
(Indian Journal of Pediatrics 1995;62:75-81),
(Abstracted in The European Journal of Endocrinology 1994; 130; Suppl 2,144) 
(Presented at The XXI International Congress of Pediatrics, Cairo, Egypt, 
September,1995).
AIM OF THE WORK:
The finding of high incidence of empty sellae in short children with sickle cell disease 
has stimulated us to conduct this comparative study to investigate the growth 
parameters, static and dynamic pituitary function testing and CT imaging of the 
hypothalamic-pituitary area in short children with SCD and compare these data with 
those for two other groups of short children with and without hypothalamic-pituitary 
abnormality. These two control groups included children with GH deficiency and those 
with normal variant short stature (NVSS) respectively .
PATIENTS AND METHODS
Ninety prepubertal ( Tanner stage 1) children with age range between 4 and 10 years 
were the subjects of this study. They included: A) 15 children with SCD and GH 
deficiency, they were diagnosed out of 34 children with SCD and growth retardation 
presented to the same clinic during the same period, B) 25 children with GH deficiency , 
5 with multiple pituitary deficiency including GH,TSH and ACTH , and 20 with 
isolated GH deficiency, they were all the diagnosed cases in the Endocrine clinic of the 
Royal Hospital, Muscat, Oman between April 1991 and August 1993, C) 30 children 
with NVSS ( Height = 2SD or more below the mean for age and gender) who were 
randomly selected from all the children with NVSS who attended the Endocrinology 
clinic and investigated between January 1992 and January 1993 ( 30 out of 95), and D) 
20 age matched children with normal stature (HtSDS between -1 and +1), they were 
selected from the radiology department while taking CT scans for other reasons ( 15 
with head trauma to role out intracranial lesions and 5 to role out intraocular 
pathology). All of them had no pathology in their CT. All the children with SCD were
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on regular blood transfusion to keep their haemoglobin (Hb) concentrations above 9g/dl 
and folic acid supplements. None of the children in this study had history of 
intrauterine growth retardation, malnutrition, any other systemic disease, dysmorphic 
trait, encephalitis ,intracranial lesions or central nervous system irradiation. Informed 
consent for the testing procedure and CT scanning was obtained from the parents of all 
children. CT scans of the brain with 1mm cuts in the hypothalamic pituitary area were 
evaluated by our Neuroradiologist (AD). Empty sella was defined as sella that, 
regardless of its size, is completely or partly filled with CSF (5,6). The anthropometric 
measurements including weight (Wt) and height (Ht) were recorded using the 
Harpenden's anthropometric measuring instruments . The data recorded were the 
average of three sequential measurements determined by the same observer (AST). The 
HtSDS, height GV cm/yr. and GVSDS were calculated. Normal population data were 
according to Tanner et al. (277) The body mass indices (BMI) were calculated 
according to the formula BMI= Wt (kg)/Ht (m)2. The bone age was determined 
according to Greulich and Pyle atlas (278).
On the day of admission, venous blood samples were obtained for determination of 
complete blood count (CBC) and serum albumin, bilirubin, alanine transferase (ALT), 
alkaline phosphatase (ALP), calcium, phosphorus and bicarbonate concentrations. 
Following an overnight fast (8-h) venous blood samples were withdrawn through a 
polyethylene catheter inserted in a forearm vein between 8 and 9 a.m. The serum was 
kept frozen at -20 c until analysed for GH, free T4 (FT4), TSH, and IGF-I. After 
obtaining the basal samples, an oral dose of clonidine (0.15mg/m2) was given and 
venous blood collected every 30 minutes for 2 hours for measurement of serum GH 
concentrations. On the next morning and after an 8-h overnight fast 0.1 mg of glucagon 
(Maximum of Img) was injected i.m. and blood samples obtained before and every 30 
min after the injection for 180 min for estimation of GH and cortisol concentrations (9). 
The first urine sample passed in the morning was analysed including specific gravity 
and osmolality. On the third day and after an overnight fast oral glucose 1.75gm/kg 
(20% solution) was given to the child and blood collected before and 120 minutes after 
the oral glucose load for determination of plasma glucose concentration by glucose 
oxidase method. Human GH and IGF-I, FT4, TSH and cortisol concentrations were 
measured by radioimmunometric assays.
RESULTS: (see appendix for tables)
GV was significantly slower and GVSDS was lower in children with GH deficiency Vs 
those with SCD+GH deficiency(table 1). The bone age was significantly delayed in the 3 
groups of children with short stature compared to the controls, however the degree of 
delay did not differ among the 3 groups.
The biochemical and haematological data of the 4 study groups are presented in table 
(2). Creatinine clearance , and serum concentrations of albumin, ALT, ALP, 
bicarbonate, calcium, phosphate and albumin did not differ among the 4 study groups. 
None of the patients had urine specific gravity below 1015 or osmolality below 465 
mmol/kg ruling out diabetes insipidus.
Table (3) shows the hormonal profile and glucose data of the 4 study groups. Out of 
the 25 children with GH deficiency, 20 (80 per cent) had isolated GH deficiency, and 5 
(20 per cent) had multiple pituitary deficiency (GH , TSH and/or ACTH ). All the 
growth retarded children in the sickle cell group, who had defective GH response to 
stimulation (GH peak<10 ug/L), had empty sella (100 per cent), and their FT4,TSH , 
SAM cortisol concentrations and cortisol response to glucagon were normal. The IGF-I 
concentrations were significantly lower in the 2 groups of children with GH deficiency 
compared to those with NVSS and normal children. Empty sella was noted in 9 out of 
the 20 children with isolated GH deficiency (45 per cent), 4 out the 5 children (80 per 
cent) with multiple hypothalamic-pituitary hormonal deficiencies (none with diabetes 
insipidus), all the children with SCD associated with GH deficiency, 3 out of 30 
children with NVSS (10 per cent) and in none of the normal children. Children with 
isolated GH deficiency and ESS had normal BMI for age and gender (15.4 +/- 1.7), 
whereas children with SCD and ESS had BMI (11.1+/-0.7) below the 5th percentile for 
corresponding age and gender. None of the children had glucose intolerance or high 
blood pressure.
DISCUSSION.
In this study the incidence of empty sella was 45 per cent in children with isolated GH 
deficiency , 80 per cent in those with multiple pituitary deficiency, 100 per cent in 
children with SCD and GH deficiency and 10 per cent in the short children with normal 
hypothalamic-pituitary function. None of the children with normal stature had empty 
sella. These findings suggest that empty sella has a considerably high incidence in
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children with growth and hypothalamic pituitary disorders, particularly those with 
multiple pituitary hormone deficiency . This implicates the importance of CT scanning 
of the hypothalamic-pituitary area, in children with severe short stature, as an 
important tool in the identification of children with pituitary hormonal deficiency. Our 
findings are in agreement with the study of Surtees et al (298) who reported empty sella 
in 90% of patients with multiple pituitary deficiency and in 37 per cent of patients with 
isolated GH deficiency. However, Marwaha et al (299) reported empty sella in 16 out of 
22 children affected by isolated GH deficiency born by normal delivery (72.7 per cent), 
such difference may be partly due to their use of MRI which is more sensitive in the 
diagnosis of empty sella . In addition, some of their patients (23 per cent) had brain 
anomalies in the scan, a characteristic which was not found in our patients.
The association of empty sella and diabetes insipidus has been reported previously in 
CT scans (300,301), however none of our patients with primary empty sella nor those 
with empty sella and SCD had diabetes insipidus. This finding is in agreement with 
those of Cacciaricet et al (301) who reported absence of diabetes insipidus in their 
patients with primary empty sella without other anatomical abnormalities (n=23). It 
seems that the presence of intrasellar CSF does not have an adverse effect on posterior 
lobe function.
The presence of empty sella in all the sickle cell children who did not mount normal GH 
response to pharmacological stimuli suggests that ischaemic injury to the pituitary 
during the sickling episodes might be the cause of both GH deficiency and empty sella 
in these children.
None of the children with empty sella had symptoms or signs of increased intracranial 
pressure, obesity or glucose intolerance reported in adults with empty sella (302). In 
this study the significantly low BMI in children with SCD + empty sella and normal 
BMI in children with isolated GH deficiency and empty sella exclude an important 
effect, if any, of empty sella on the control of body weight in children.
In summary, empty sella is frequently seen in children with GH deficiency secondary to 
SCD and those with idiopathic GH deficiency but it is not rare in very short 
prepubertal children with normal hypothalamic-pituitary function. In short patients 
with SCD; the finding of empty sella was associated with isolated GH deficiency, with
fSQ
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normal thyroid, adrenal, and posterior pituitary functions. Empty sella is not associated 
with impaired glucose tolerance or obesity in these children.
71
Study 7: INSULIN AND GLUCAGON RESPONSES TO PROVOCATION 
WITH GLUCOSE AND ARGININE IN PREPUBERTAL CHILDREN WITH 
THALASSAEMIA MAJOR BEFORE AND AFTER LONG-TERM BLOOD 
TRANSFUSION.
(Journal of Tropical Pediatrics 1996;42:291-296.)
Presented atXIHth meeting of The International Society of Haematology, Istanbul,
Turkey, September 3-8 1995
(Abstracted in Pediatrics 1995; 95:4, supplement 2: 9-10)
AIM OF THE WORK:
1. To evaluate prospectively insulin and glucagon secretion, in response to oral glucose 
and arginine infusion, in young thalassaemic children before and after long term 
high-transfusion and iron chelation; and
2. to evaluate GH and cortisol responses to insulin-induced hypoglycaemia and serum 
concentrations of IGF-I, free thyroxin (FT4) and TSH in thalassaemic children after 
long-term high-transfusion.
SUBJECTS AND METHODS.
Twenty young children with thalassaemia major , diagnosed between January 1988 and 
January 1990, were selected from the Haematology clinic of Alexandria University 
Children's Hospital for the study. Their age ranged between 1.75 and 3.5 years ( mean 
=2.8 +/- 0.6 years). None had family history of diabetes mellitus, intrauterine growth 
retardation or any other systemic or endocrine disease. Informed consent was obtained 
from all the parents of the children before including in the study and the Ethical 
Committee of Alexandria University approved the study protocol. Before receiving the 
first blood transfusion children were admitted and offered high carbohydrate diet for 3 
days. On the 4th day and after an 8-h overnight fast a standard oral glucose tolerance 
test was performed and serum collected at 0, 60 and 120 minutes after oral glucose load 
(1.75g/kg) for estimation of glucose concentration by glucose oxidase method and 
glucagon and insulin concentrations by radioimmunoassay using kits purchased from 
Amersham. On the 5th day and after an overnight fast an i.v. infusion of 10% arginine 
HC1 infusion (0.5g/kg) was started and continued for 30 minutes and serum samples
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obtained before and at 30 and 60 minutes after the start of the infusion for estimation of 
glucose, insulin and glucagon concentrations.
Children were started on frequent transfusion therapy (15ml of packed erythrocytes/kg 
of body weight given every 4 weeks to maintain the haemoglobin level at 9-10g/dl), and 
deferoxamine (50mg/kg/dose for up to six days per week) given by i.m. injection. During 
each clinic visit the children were examined thoroughly with emphasis on nutritional 
and growth data and their anthropometric measurements including weight and height 
recorded. Harpenden's callipers and anthropometric measurements were used. The 
HtSDS, GV (cm/yr) were calculated for each year and recorded. Normal population 
data were according to Tanner et al (277). Lab investigations included complete blood 
count and estimation of serum concentration of albumin, bilirubin, alanine transferase, 
urea and creatinine at 6 month intervals.
After a period of 2.5 to 4 years (mean = 3.1 +/-0.6 years) of high-transfusion and 
chelation 15 out of the 20 patients were admitted and the previous hormonal 
investigations redone. Three children were excluded from the study because of poor 
compliance and the other two because parents refused to give consent for re-testing. In 
addition, after an overnight fast a basal serum sample was collected for measurement of 
GH, cortisol, IGF-I, FT4, and TSH concentrations. GH response to oral clonidine (0.15 
mg/m2) was evaluated in all the thalassaemic children and serum collected at 0,60 and 
90 minutes after clonidine intake for estimation of GH . 15 normal age-matched 
children served as controls for the hormonal and biochemical studies after taking 
parents' consents. Human GH, IGF-I FT4, TSH and cortisol were measured by 
radioimmunometric assay. Skeletal age was determined according to the Atlas of 
Greulich and Pyle (278).
Statistical analyses were done using the ANOVA test to compare analyte concentrations 
before versus after long-term blood transfusion when the data were normally 
distributed and Wilcoxon test when they were not. Statistical significance was accepted 
at p<0.05.
RESULTS: (see appendix for tables)
Glucose, glucagon and insulin data are presented in tables 1 and 2. During fasting, 
serum insulin and glucose concentrations did not differ among the study groups. Serum
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glucagon was significantly higher in thalassaemic children after Vs before frequent 
blood transfusion. After oral glucose load insulin secretion was significantly reduced 
in thalassaemic children after Vs before long-term high-transfusion. Their serum 
insulin/glucose (I/G) ratios were significantly lower {(0.27+/-0.12) at 1-h and (0.28+/- 
0.13) at 2-h} Vs before therapy {(0.62+/-0.26) at 1-h and (0.55+/-22) at 2-h }. In 
thalassaemic children on long-term blood transfusion serum glucagon was not 
suppressed after an oral glucose load. Serum glucagon levels were significantly higher 
at 60 and 120 minutes after the oral glucose load compared to values before therapy 
and to those for the control children. None of the thalassaemic children had impaired 
glucose tolerance after this period of frequent blood transfusion and chelation, however 
their serum glucose levels were significantly higher, at 60 and 120 min after the oral 
glucose load, compared to those for the control group. Thirty minutes after starting 
arginine infusion serum insulin concentration was significantly lower in thalassaemic 
children after long-term high-transfusion Vs before therapy. Basal and arginine- 
stimulated glucagon concentrations were significantly higher in thalassaemic children 
on frequent blood transfusion Vs before therapy. Consequently, serum insulin/glucagon 
ratios at 0, 30 and 60 min after starting arginine infusion were significantly decreased 
in thalassaemic children after (0.10+/-0.06, 0.08+/-0.05 and 0.11+/-0.07) versus before 
therapy (0.15+/-0.07, 0.17+/-0.08, and 0.15+/-0.07).
Table (3) presents growth parameters and hormonal data of thalassaemic children after 
a mean transfusion period of 3.1+/-0.6 years. The HtSDS of thalassaemic children 
decreased significantly from -0.75+/-0.3 before starting blood transfusion to -1.65 +/- 0.5 
at the time of re-testing. HtSDS, GV and BMI were significantly lower in thalassaemic 
children compared to controls. Serum ferritin, bilirubin and ALT concentrations were 
significantly higher in thalassaemics Vs controls. Two out of the thalassaemic children 
were hepatitis-B surface antigen positive but none of the controls was positive. In all 
the thalassaemic children serum glucose concentration dropped significantly to <50% 
of the fasting level after injecting insulin (0.1 U/kg) intravenously. Thalassaemic 
children had significantly reduced peak GH response to both arginine and clonidine, 
with significantly lower serum concentration of IGF-I. Basal (8-h) cortisol, FT4 and 
TSH concentrations did not differ among the two groups. Serum ferritin 
concentrations were correlated significantly (negatively) with peak insulin and glucagon 
responses to arginine (r= -0.48 and r=- 0.42 respectively, p<0.01) and with IGF-I 
concentrations (r= -0.51, P<0.01) in all the study children.
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DISCUSSION
Although the basal serum insulin concentration was normal in thalassaemic children 
after long-term blood transfusion, there was a significant decrease in the maximal 
insulin secretory capability in response to arginine infusion and oral glucose load 
indicating a reduced insulin reserve. This gradual and early decrease of insulin 
secretion in thalassaemic children, before the occurrence of impaired glucose tolerance, 
proves that decreased B-cell mass plays a major role in the later development of glucose 
intolerance.
In patients with chronic pancreatitis and pancreatic fibrosis the fasting plasma glucose 
concentration remains normal as long as 20-40 per cent of the B-cell mass is retained. 
Nonetheless, loss of 20-40 per cent of B-cell mass is associated with a marked 
impairment in glucose-mediated insulin release, whereas a normal response to arginine 
is still retained. A further reduction (by 40-60 per cent) in B-cell mass leads to an 
altered response to arginine. Finally, when the B-cell mass is reduced by more than 80- 
90 per cell, fasting hyperglycaemia and inability to secrete insulin in response to all 
secretagogues is present (303, 304). It appears that in thalassaemic children on frequent 
and prolonged blood transfusion early iron deposition and gradual fibrosis of the 
pancreas (222) leads to gradual loss of B-cell mass and impaired response to 
secretagogues, similar to that of chronic pancreatitis. In addition, impaired insulin 
secretion in response to both oral glucose and arginine denotes a significant loss of B- 
cell mass (40-60 per cent) after a mean of 3.1 years of frequent blood transfusion in 
these patients. Our results support the findings of Dmochowski et al (236) indicating a 
trend towards progressive reduction in circulating insulin levels in thalassaemic 
patients
Although the presence of insulin resistance in patients with thalassaemia has been 
suggested by numerous studies (229, 230,235), the finding is not universal. Brianda et al 
(305) performed euglycaemic insulin clamps in thalassaemic patients and found 
increased insulin sensitivity. Our data showed that Despite hyperglucagonaemia serum 
glucose concentrations decreased properly (< 50 per cent of the fasting glucose level) 
after an intravenous insulin (0.1 U/kg) injection in all the thalassaemic children ruling 
out the presence of a significant insulin insensitivity at this age. However, prolonged 
hyperglucagonaemia and progressive hepatic dysfunction might add an element of 
insulin resistance at an older age.
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In thalassaemic children on long-term transfusion the elevated basal serum glucagon 
concentrations, the significantly higher levels of glucagon and lower insulin/glucagon 
ratios after provocation with arginine in comparison with controls, and the non 
suppression of circulating glucagon levels after oral glucose load indicate a state of 
hyperglucagonaemia in these children. In other diseases with progressive fibrosis of the 
pancreas, inflammation and destruction of the parenchyma is associated with collapse 
between islets leading to formation of clusters of pancreatic islets. Within the 
remaining islets, a rearrangement of the endocrine cell population occurs with a 
proportionally greater loss of B-cells compared with A-cells, leading to a reversal of the 
normal 2:1 ratio (306). This quantitative change of the islet cells might explain in part 
the finding of hyperglucagonaemia in our children with thalassaemia. In addition, the 
A-cells are believed to be an insulin-dependent tissue, since inhibition of glucagon 
secretion by glucose normally occurs in the presence of insulin (307). In our 
thalassaemic patients impaired insulin secretion in response to glucose load might have 
contributed to the non-suppression of hyperglucagonaemia . The subnormal GH and 
cortisol peak responses to provocation exclude any contribution of these anti-insulin 
hormones in the production of insulin-resistance .
The progressive growth impairment in our thalassaemic children might be attributed to 
their low GH secretion and consequently low generation of IGF-I. These data support 
the theory that functional damage in hypothalamic structures for GH control is an 
important factor contributing to growth delay in these children (34-36). Although 
hepatic GH receptor and/or postreceptor defect might explain the low IGF-I generation 
in thalassaemic children with normal GH secretion (255), Postel et al (307), did not find 
evidence for a defect in GH binding to liver membranes in thalassaemic patients and 
there was no correlation between the level of GH binding to liver membranes and the 
degree of hepatic siderosis and fibrosis . Moreover, insulin plays an important role in 
determining the bioavailability of IGF-I through its action on insulin-like growth factor 
binding protein-1 (IGFBP-1) (89,90). Therefore, defective insulin secretion in 
thalassaemic children on long-term blood transfusion might increase hepatic 
production of IGFBP-1 leading to decreased bioavailability of IGF-I.
In summary, thalassaemic children on long-term high-transfusion and iron chelation 
develop progressive and early loss of B-cell mass manifested by decreased insulin 
release in response to secretagogues before impairment of their glucose tolerance.
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However, hyperglucagonaemia and progressive hepatic dysfunction might add an 
element of insulin resistance later in life. The low BMI and slow linear growth in 
thalassaemic children might be explained in part by the defective secretion of the 2 
major anabolic hormones, namely insulin and IGF-I. However, further studies are 
required to investigate the different factors affecting IGF-I secretion/action in these 
patients for better understanding of the aetiology of their impaired growth.
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Study-8: INTERLEUKIN-1-BETA, TUMOUR NECROSIS FACTOR-ALPHA, 
ISLET CELL ANTIBODY, AND INSULIN SECRETION IN CHILDREN 
WITH THALASSAEMIA MAJOR ON LONG-TERM BLOOD 
TRANSFUSION. (Journal of Tropical Pediatrics 1996;42: 362-364.)
AIM OF THE WORK:
Recent studies reported increased production of different cytokines in multitransfused 
thalassaemic patients (308,309). These cytokines might have a role in the pathogenesis 
of diabetes in thalassaemic patients through their cytotoxic effect on islet cells and/or 
inhibition of insulin release (310-212).
To clarify this issue we measured the circulating levels of IL-l-B, TNF-A and islet cell 
antibody (ICA) in 20 children with IDDM, 20 of their non-diabetic siblings , 20 children 
with B-thalassaemia major and 10 normal age-matched children. In addition, we 
investigated the first phase insulin release and oral glucose tolerance (OGT) in the non- 
diabetic and thalassaemic children.
PATIENTS AND METHODS.
Twenty children with IDDM, 20 non diabetic children randomly selected from their 
siblings, and 20 children with B-thalassaemia major were the subjects of this study. 10 
healthy children (mean age 7.8 +/- 1.6 years) with no family history of diabetes served 
as controls. Informed consents were obtained from the parents of all children and 
when appropriate from the children and The Ethical Committee of the University of 
Alexandria approved the study. Children were admitted to Alexandria University 
Children's Hospital for the study. All the children were prepubertal, clinically free 
from infection and had no other systemic diseases. None of them had history of recent 
viral infection. All the control children had normal hepatic and renal functions and 
haemogram. Thalassaemic children were on frequent transfusion therapy (15ml of 
packed erythrocytes / kg of body weight given every four weeks) to keep their 
haemoglobin at or above 10 g/dl and iron chelation therapy using i.m. deferoxamine. All 
had normal thyroid function and none of them had family history of diabetes. None of 




A venous blood sample was obtained from all the children for measuring islet cell 
antibody (ICA), by the indirect immunofluorescent method (INOVA Diagnostics), and 
IL-l-B and TNF-A using ELISA technique. After 3 days on full carbohydrate diet an 
oral glucose tolerance test was performed (1.75 g glucose/kg of body wt) and serum 
glucose measured by glucose oxidase method before and 1 and 2 hours after the oral 
glucose load for all the non-diabetic children. On the second morning and after an 
overnight fast a glucose load ( 0.3 g/kg, 30 per cent solution) was injected iv. over 2 
minutes and blood collected before and 5 minutes after the injection for measuring 
insulin concentration by radioimmunoassay.
Statistical analyses were done using the ANOVA test to compare mean analyte 
concentrations among the study groups when the data were normally distributed and 
Wilcoxon test when they were not. Statistical significance was accepted at p< 0.05.
RESULTS: (see appendix for tables)
IL-l-B and TNF-A concentrations were significantly higher in the IDDM-siblings group 
Vs those for the other groups (table 1). IL-l-B and TNF-A concentrations did not differ 
significantly among the thalassaemic group, diabetic group and healthy controls. Five 
of the thalassaemic children had impaired glucose tolerance after oral glucose load (25 
per cent). All the IDDM-siblings had normal oral glucose tolerance. The early phase of 
insulin release was significantly lower in thalassaemic children compared to normal 
children and IDDM-siblings. ICA were detected in 30 per cent of the diabetic 
children(group II) Vs 60 per cent of their siblings. None of the thalassaemic children 
had detectable circulating ICA.
DISCUSSION.
Cytokines, through modulation of T-cell responses, can induce round cell infiltration 
(insulinitis) (313) and inhibit insulin release by the B-cells (311,312). In the IDDM- 
siblings the significantly high serum levels of IL-l-B and TNF-A, in conjunction with 
high prevalence of ICA suggested that these cytokines play important role in the 
autoimmune aggression against the islet B-cells. Despite their normal OGTT, the per 
cent increment of their insulin levels after iv. glucose was significantly lower than the 
control group. Campbell IL et al (313) suggested that B-cell destruction, in genetically 
susceptible subject, progresses through stages. Stage II; commences with infiltration of 
islets by immunoinflammatory cells (insulinitis), and production of cytokines from 
infiltrating cells. This induces "phenotypic switching" of islet cells. Stage III;
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encompasses autoimmune-mediated destruction of B-cells by the targeted delivery of 
cytotoxic cytokines and other mediators. The normal serum levels of cytokines in 
children with IDDM can be explained by the fact that cytokine production is suppressed 
after extensive destruction of the target cells (B-cells).
In thalassaemic children on frequent blood transfusion, the initiation of immune 
reaction against the B-cells, by the excessive iron deposition and/or by the foreign 
cellular elements in the transfused blood , constitutes a possible pathogenic factor. 
However, the normal serum concentrations of IL-l-B and TNF-A and the absence of 
circulating ICA in thalassaemic children despite their high prevalence of impaired 
glucose tolerance and decreased insulin response to iv. glucose, exclude an important 
role, if any, played by the immune system in the aetiology of diabetes in these children.
In summary, it appears that over time children with thalassaemia experience a 
reduction in their circulating insulin levels which leads to glucose intolerance and 
diabetes mellitus. This B-cell destruction is mediated neither by ICA nor by cytokine 
production.
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Study-9: GROWTH HORMONE (GH) RESPONSE TO PROVOCATION, 
CIRCULATING INSULIN-LIKE GROWTH FACTOR-I (IGF-I) AND IGF-BINDING 
PROTEIN-3 CONCENTRATIONS, IGF-I GENERATION TEST AND CLINICAL 
RESPONSE TO GH THERAPY IN CHILDREN WITH BETA-THALASSEMIA
European J Endocrinology 1998; 138; 394-400.
Presented at the 79"' Annual Meeting of The Endocrine Society, Minneapolis, June 11-14,
1997, USA.
AIM OF THE WORK:
1. To investigate the GH/IGF-I/IGFBP3 axis in prepubertal children with beta 
thalassaemia major,
2. to test the hypothesis that these patients might have GH resistance and;
3. to study the effect of GH therapy for one year on their growth parameters.
PATIENTS AND METHODS
Fifteen prepubertal children, between the age of 7.5 -14 years, with B-thalassaemia 
major were randomly recruited for the study from the thalassaemia clinic of the 
Alexandria University Children's Hospital, Alexandria Egypt for the study. All have 
been treated with a chronic low transfusion regimen (to keep their haemoglobin above 
8g/dl) , with IM chelation treatment ( 3 times/ week) (suboptimal chelation due to 
economic reasons) and were taking 5 mg of folk acid per day. Fifteen prepubertal age- 
matched children with constitutional short stature (CSS), age range 7- 13 years, ( with 
height standard deviation scores at or below -2 and normal GH response to provocation 
) and 11 children with isolated GH deficiency (GHD), age range 6.5 - 10.5 years, (GH 
peak response <5 ug/L in two or more provocative tests) served as controls. Informed 
consent was obtained from the parents of all the patients and when appropriate from 
the children before including in the study. The ethical Committee of Alexandria 
University has approved the protocol of the study. None of the children had 
intrauterine growth retardation, severe malnutrition, diabetes, dysmorphic trait, 
exposure to irradiation, or any other systemic illness. AH patients were prepubertal, 
with pubarche Tanner 2 or less, gonadarche stage in the boys of 1 and thelarche stage 
in the girls of 1 and all were euthyroid
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Anthropometric measurements included weight, height, MAC, and triceps-skinfold 
thickness. Growth velocity cm/yr. was measured over a whole year for all the patients 
before starting any GH therapy. HtSDS and BMI were calculated. Normal population 
data were according to Tanner et al. (277) Nutritional assessment included evaluation 
of dietary intake using the recall method for the previous 3 days . These data were 
recorded every clinic visit for the whole year (minimum of 3 visits/year).
After an overnight fast a venous sample was withdrawn for measurement of free 
thyroxin (FT4) , thyrotropin (TSH), insulin-like growth factor-I, IGFBP3 , and 8 A.M. 
cortisol concentrations. Serum ferritin, albumin, globulin, bilirubin, alanine transferase 
(ALT), creatinine, calcium, phosphate and alkaline phosphatase (ALP) concentrations 
were measured. Cortisol concentration was measured 1-hour after injection of ACTH 
(0.5 mg synacthen ,IV). Two GH provocative testing with Clonidine (0.15 mg/m2 orally) 
and glucagon (0.1 mg/kg IM) were performed on two occasions. After 3 days of 
adequate carbohydrate intake a standard oral glucose tolerance test (1.75 g/kg of 
glucose ) was done in thalassaemic children. IGF-I generation test (293) was performed 
in all the patients. The test entails measurement of morning basal circulating IGF-I 
concentration, followed by injection of human growth hormone (0.1 mg/kg/dose, S.C.) 
and re-measuring IGF-I concentration next morning.
Six patients with beta thalassaemia major with growth retardation (HtSDS and 
GVSDS) at or below -2 for their chronological age and for their respective bone age, 
determined by the method of Greulich and Pyle, and defective GH release in two 
provocative tests were treated with human growth hormone (18 units/m2/week divided 
on daily S.C. doses) for one year. Their growth parameters were followed-up every 
three months for the whole year and IGF-I concentrations re-measured at the end of 
the year. Children with GHD (n=ll) and those with CSS (n = 8) were treated with GH 
(18 units/m2/week divided on daily doses) for the same period used as controls. Oral 
glucose tolerance test was performed every 6 months in the GH treatment groups.
Human GH and IGF-I were measured by radioimmunometric assay. 
Data are presented as mean +/- SD. Statistical analyses were performed using the 
ANOVA test to compare analyte concentrations among groups. The paired t test was 
used to compare data before versus after therapy in the same group. Wilcoxon test was
used when the data were not normally distributed. Correlations between variables of 
interest are examined by linear regression analysis and, when appropriate multiple 
regression analysis.
RESULTS: (see appendix for tables and figures)
Table 1 summarises the auxologic data of prepubertal children with thalassaemia , 
GHD and CSS. The HtSDS was significantly lower in children with GHD Vs children 
with CSS and thalassaemia. Linear GV and BMI did not differ significantly among the 
three studied groups. The bone age was significantly delayed in the GHD group. The 
upper/lower segment ratio was significantly lower in thalassaemic children than in the 
other two groups denoting relatively slower growth of the spine compared to the limbs 
in this group of patients.
The biochemical and hormonal data (table 2) showed that thalassaemic children had 
significantly higher concentrations of serum ferritin, ALT and bilirubin, and lower 
haemoglobin and haematocrit values. All the children had normal serum creatinine 
and albumin concentrations. Two children with thalassaemia had impaired tolerance to 
oral glucose (1.75 g/kg) and were excluded from the GH treatment group. Serum 
calcium, phosphorus and alkaline phosphatase concentrations were comparable to 
those for controls ruling out the diagnosis of hypoparathyroidism in any of the patients. 
After ACTH stimulation, circulating cortisol concentrations were significantly lower in 
thalassaemic children versus controls. In three thalassaemic children cortisol 
concentrations did not rise to 400 nmol/L. However none of them had symptoms or 
signs of cortisol deficiency. Thyroid function was normal in 14 out of 15 children with 
thalassaemia. One patient had mild hypothyroidism . His FT4= 9 pmol/ml (normal, 10- 
25 pmol/L) and elevated TSH of 8 uU/ml (normal 0.5- 5 uU/rnl). Growth hormone 
testing was done after thyroxin replacement for 1 month in this boy. Fasting serum 
insulin concentrations did not differ between thalassaemic (12+/- 7.8 ug/L) and control 
group( 14.5 +/- 5.8 ug/L.
Growth hormone/IGF-I/IGFBP3 data are presented in table 3. Thalassaemic children 
had significantly lower peak growth hormone response to provocation by clonidine and 
glucagon. Their circulating IGF-I and IGFBP3 concentrations were significantly lower
than those for the controls. The IGF-I and IGFBP3 responses to GH injection were 
significantly lower in thalassaemic patients versus controls, suggesting partial 
resistance to GH in these children. Their serum IGF-I concentrations after stimulation 
with GH were still lower than the basal circulating levels for the controls. The peak
GH response to provocation and circulating IGF-I concentrations were significantly 
lower in thalassaemic children compared to those with CSS (p< 0.005). The IGF-I 
response to GH administration (IGF-D); (equal to the 24-h IGF-I value minus the basal 
value) was significantly lower in children with thalassaemia compared to the groups 
with CSS and GHD (p<0.01).
Table 4 compares growth and IGF-I data of 6 thalassaemic children with those for 8 
children with CSS and 11 children with GHD. After one year of GH therapy (18 
units/m2/week divided on daily S.C. doses) the GV of patients with thalassaemia (7.2 +/- 
0.8 cm/yr.) was slower than that for children with CSS (9.9 +/- 1.2 cm/yr.). The
increments of GV/yr. of thalassaemic patients was significantly lower compared to the 
other two groups. Despite slower growth in thalassaemic children, their GV was 
doubled (from 3.8  , 1 -/+ cm/yr. to 7.2 +/- 0.8 cm/yr.). After GH therapy for one year
the circulating IGF-I concentration were significantly lower in thalassaemic patients 
versus those for the control groups. None of the children developed impaired glucose 
tolerance or hypertension during treatment.
Correlation between circulating hormonal and ferritin concentrations for all the study 
children are presented in table 5. Serum ferritin concentration was correlated 
significantly (negatively) with GH peak response, IGF-I, IGFBP3 and insulin 
concentrations. Peak GH response was correlated significantly with IGF-I and IGFBP3 
supporting the view that GH is the major regulator of both IGF-I and IGFBP3 
synthesis.
DISCUSSION
The growth promoting activity of IGF-I is determined not only by the concentration of 
IGF-I but also by the amounts of various IGF binding proteins (IGFBPs).(lOS, 109) 
Among these IGFBP3 is the major binding protein. (314) IGFBP3 has been observed to
potentiate the effects of IGF-I in bone. (183-187,315,316) In addition, recent data 
clearly indicate that IGFBP3 prolongs the half life of circulating IGF-I levels and 
changes the clearance pattern of plasma IGF-I.(317) Current opinion favours GH as 
the major regulator of IGF-I and IGFBP3 in humans. In this study, the GH responses 
to provocation with clonidine and glucagon was impaired in short prepubertal children 
with beta thalassaemia major compared to those for short normal children. Ten out of 
the 15 children with thalassaemia did not mount an appropriate GH response ( > 10 
ug/L) in both provocative tests. These findings support previous reports indicating 
impairment of function along the hypothalamic-pituitary growth axis. (251-255) In 
malnourished children with decreased IGF-I synthesis the basal and stimulated GH 
levels are significantly high (53) indicating stimulation of their hypothalamic-pituitary 
axis by the low circulating concentrations of IGF-I. In thalassaemic children, the 
presence of normal basal GH levels despite low circulating IGF-I levels suggest 
defective hypothalamic-pituitary feedback mechanism. This might be secondary to 
defective GH secretion. Histopathological changes with significant siderosis of the 
pituitary gland and secondary atrophy of the somatotrophs can explain the dysfunction 
of this axis,(318) and the increased incidence of defective GH secretion in our children , 
with defective chelation therapy, compared to other studies with properly chelated 
patients. Impaired GH secretion can explain in part the significantly lower IGF-I and 
IGFBP3 synthesis with subsequent growth impairment in children with thalassaemia 
major. However, haemosiderosis of the liver in these patients with disturbed hepatic 
function might also decrease IGF-I synthesis. In our study Serum ferritin 
concentration was significantly correlated with IGF-I concentration (r = - 0.45, P< 
0.05), IGFBP3 (r=-0.42, p< 0.05) and peak GH response to provocation (r=-0.34, p< 
0.05) which support the view that iron overload might affect adversely the GH/IGF- 
I/IGFBP3 secretion. The deficiency of IGFBP3 in thalassaemic patients might 
contribute to their growth impairment by decreasing the growth promoting effects of 
IGF-I. We (319) and others (236) reported progressive impairment of insulin secretion 
in children with thalassaemia due to haemosiderosis of the pancreas. Other 
investigators stressed as well the importance of insulin resistance in these patients. 
(236,237) The progressive loss of the anabolic functions of insulin might contribute to 
the delayed growth of these children either directly and/or through inhibition of IGF-I 
synthesis and function.(89,90). In our study basal (fasting) serum concentration of 
insulin was correlated significantly with concentrations of IGF-I (r=0.541, P< 0.01) and 
IGFBP3 ( r= 0.42, p<0.05). Delayed or arrest of puberty is common in patients with 
thalassaemia (195,196) probably due to disturbed gonadotropin-releasing hormone
(GnRH) secretion (320) with consequent deficiency of sex-steroids. Sex steroids can 
influence growth through the modulation of IGF-I-induced cellular response. 
(172,176,177,179,180) and their deficiency add significantly to the growth delay and 
osteoporosis of thalassaemic children.(181) This might explain the relatively short 
upper segment, in addition to the mild vertebral changes observed in our thalassaemic 
group.
Malnutrition, primarily caused by inadequate nutrient intake, as indicated by the 
capacity to gain weight appropriately when provided with nutrition support, (215) is 
another correctable cause of growth delay in thalassaemic children. Malnutrition can 
inhibit growth through inhibition of IGF-I (53,93), IGFBP3 (321) synthesis and insulin 
release (322). However, our group of patients had normal BMI, mid-arm circumference 
and skin fold thickness, and normal serum albumin and basal GH concentrations. 
Analysis of their dietary intake, by using the recall method, showed normal quantitative 
and qualitative dietary intake. These factors collectively exclude any major role played 
by malnutrition in this group of children with thalassaemia.
Impaired linear growth in thalassaemic children, despite regular transfusion and 
desferrioxamine therapy , who have normal GH secretion suggests the possibility of 
GH resistance. In this study IGF-I generation test showed that these patients do not 
secrete adequate IGF-I after GH stimulation when compared to normal short children 
or those with GHD. After one year of GH therapy, despite giving the same dose/m2 to 
all the children, their circulating IGF-I concentrations were significantly lower than 
those for the short normal control group and those with GHD. These data are in 
concert with those of Werther GA et al (258) who reported lack of response of non- 
suppressible insulin-like activity to short-term administration of human growth 
hormone in their thalassaemic patients. In our 6 thalassaemic children treated with GH 
the growth velocity increased significantly from 3.8 +/- 0.6 cm/yr. to 7.2 +/- 0.8 cm/yr. 
(doubling). However, the increment of the rate of growth was significantly slower 
compared to the control groups. Collectively these findings might suggest the presence 
of significant GH resistance in these patients which could attenuate the growth 
promoting effects of GH therapy. Low LC et al (323) have shown that with higher 
(supraphysiological) (30units/m2/week divided on daily S.C. doses) doses of exogenous
GH there has been a progressive increase of IGF-I production in their thalassaemic
patients. It is known that higher GH doses during treatment possibly elicit a higher 
IGF-I and GV response, however this high dose might be necessary in thalassaemic 
children to overcome the possible GH resistance. However, supraphysiological doses of 
GH might increase the risk of inducing diabetes and hypertension (324) in these high 
risk patients. Human IGF-I therapy , alone or in combination with GH and/ or 
IGFBP3 , appears to be an attractive alternative to overcome the GH resistance and 
avoid the high risk of developing diabetes in them. In human (325,326) and animal 
(316,317) experiments this combination of growth factors appear to be useful.
In summary; children with beta-thalassaemia and short stature have defective 
GH/IGF-I/IGFBP3 axis that might be secondary to haemosiderosis of their pituitary 
gland, liver and pancreas. Beside regular blood transfusion and proper chelation 
therapy these patients needs early management of their endocrinopathy. Treatment of 
their hypothyroidism, hypogonadothypogonadism , diabetes mellitus and defective 
GH/IGF-I/IGFBP3 axis can markedly improve their growth. In addition, these patients 
might have partial GH resistance that requires supraphysiological doses of growth 
hormone and/or human IGF-I therapy.
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Study 10: SPONTANEOUS AND PROVOKED GROWTH HORMONE (GH) 
SECRETION AND INSULIN-LIKE GROWTH FACTOR-I (IGF-I) AND IGF- 
BINDING PROTEIN-3 (IGFBP3) CONCENTRATIONS IN PATIENTS WITH BETA- 
THALASSAEMIA AND DELAYED GROWTH.
(The Journal of Tropical Pediatrics, Accepted for publication on December 1997) 
(Presented at the XXII International Congress of Paediatrics, Amsterdam, The 
Netherland, 9-14 August, 1998)
AIM OF THE WORK:
1. To investigate the pulsatile properties of spontaneous GH secretion;
2. to measure the circulating levels of IGF-I/IGFBP3 axis in short prepubertal children 
with beta thalassaeniia major and;
3. to measure the pituitary size by MRI in these children.
PATIENTS AND METHODS
Seventeen children with ( thalassaeniia major and delayed puberty were recruited for 
the study from the thalassaeniia clinic of the Alexandria University Children's Hospital, 
Alexandria Egypt for the study. All have been treated with a chronic low transfusion 
regimen (to keep their haemoglobin above 9g/dl), with IM chelation treatment ( 3-5 
times/ week) (suboptimal chelation due to economic reasons) and were taking 5 mg of 
folic acid per day. Fifteen age-matched children with constitutional short stature (CSS) 
(with height standard deviation score at or below -2 and normal GH response to 
provocation ) and matched for the pubertal stage served as controls. Criteria for entry 
into the study were as follows: 1. Age > 15 and < 25 years; 2. height less than the fifth 
percentile; 3. Delayed puberty , defined as pubarche Tanner 2 or less, gonadarche stage 
in the boys of 1 and thelarche stage in the girls of 1, at the age above 14 year and 13 
year respectively. None of the children had intrauterine growth retardation, severe 
malnutrition, diabetes, dysmorphic trait, exposure to irradiation, or any other systemic 
illness. Preliminary investigations included measurement of electrolytes, serum 
calcium, phosphate, alkaline phosphatase, ferritin, urea, and creatinine concentrations, 
urinalysis and complete blood cell count. Skeletal maturation was determined by the 
method of Greulich and Pyle (278). Informed consent was obtained from the patients 
and their parents before including in the study. The ethic Committee of Alexandria 
University has approved the protocol of the study.
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Anthropometric measurements included weight (obtained to the nearest 100 g using a 
digital scale (Seca model 770), height ( using the Harpenden scale), mid-arm 
circumference ( using a metal tape), and triceps-skinfold thickness (using the Holtain 
Calliper). Growth velocity cm/yr was measured over a whole year for all the patients. 
Height standard deviation score (HtSDS) and body mass index (BMI) were calculated. 
Normal population data were according to Tanner et al (277).
After an overnight fast a venous sample was withdrawn for measurement of free 
thyroxin (FT4) , thyrotropin (TSH), insulin-like growth factor-I, IGFBP3 , and 7:00 - 
8:00 A.M. cortisol, testosterone (T), Oestradiol (E2), LH and FSH concentrations. Two 
GH provocative testings with Clonidine (0.15 mg/m2 orally) and glucagon (0.1 mg/kg 
I.M.) were performed on two occasions after priming with ethinyl Oestradiol in females 
and testosterone in males, thalassaemic children with normal GH response to 
provocation (peak GH = or > 10 ug/L) (n = 10 ) underwent a 12-hour study of 
spontaneous GH secretion starting at 8 p.m. An indwelling catheter was inserted in a 
forearm vein, and a continuous blood sample was obtained in 20-min fractions through 
a peristaltic pump (Cormed, Medina, NY). GH peak analysis was performed visually by 
examining a plot of serum GH against time. For each GH profile the integrated 
concentration, the mean pulse amplitude, the maximum nocturnal peak, and the 
number of peaks above 5 ng/ml were analysed. Five randomly selected children with 
CSS matched for the pubertal stage and bone age, underwent similar 12-hour profiles 
ofGH.
LH, FSH, E2 and T concentrations were measured by RIA methods, employing 
reagents purchased from Radium, Pomezia, Italy). The immunoradiometric assay 
(IRMA) on solid phase (coated tube), based on monoclonal double antibody technique, 
was used for LH and FSH detection. Intraassay and interassay coefficients of 
variations were respectively: LH 5.6 and 7.8 per cent, FSH 6.7 and 8.2 per cent, E2 5.8 
and 8.7 per cent and T 6.1 and 9percent. Data are presented as mean +/- SD. Normal 
data for the different hormonal levels were according to published data. 
Human GH and IGF-I were measured by radioimmunometric assay, employing 
reagents purchased from Nichols Institute (San Juan Capistrano, CA). IGFBP3 was 
measured by radioimmunoassay in Serono Bioscientific Laboratories and Bioscience 
Services employing reagents supplied by Mediagnost.
MRI study of the hypothalamic-pituitary area was performed in 10 patients with 
thalassaemia ( five with GH deficiency, two with abnormal spontaneous nocturnal GH
release and 3 with normal GH secretion), using a gyroscan Philips 1.5.T (Tesla) 
machine performing the following sequences : -1. Sagittal Tl,wl, 2. Coronal Tl,wl for 
the sella tursica , 3. Axial Tl wl for the whole brain, 4. Axial T2 wl over the pituitary 
and hypothalamic regions 5. Sagittal T2 wl for the brain. The field of view ranged 
between 180 mm for the pituitary region to 220 mm for the whole brain. Slice thickness 
was 3 and 6 mm and interslice gap = 0.3 and 0.6 mm for the pituitary and the whole 
brain respectively. Data are presented as mean +/- SD. A control group consisted of 10 
aged between 14 and 23 years with HtSDS = 0.5+/- 0.3 were used as controls for the 
evaluation of pituitary size (5 males and 5 females). None of them had received cranial 
radiation therapy and they had all been referred for MRI for various neurological 
reasons.
Statistical analyses were performed using the unpaired t test to compare analyte 
concentrations among groups. Wilcoxon test was used when the data were not normally 
distributed. Correlation between variables of interest are examined by linear regression 
analysis.
RESULTS: (see appendix for tables and figures)
Table (1) summarises the auxologic data of thalassaemic patients and controls. The 
HtSDS, BMI, and GV did not differ significantly among the two groups.
The biochemical and hormonal data (Tables 2,3) showed that thalassaemic children had 
significantly higher concentrations of serum ferritin, ALT and bilirubin and lower 
haemoglobin values versus the control group. Children of both groups had normal 
serum T4, TSH , 8:00 A.M. cortisol, creatinine, albumin, calcium, phosphate and ALP 
concentrations. The circulating concentrations of IGF-I and IGFBP3 were significantly 
decreased in thalassaemic patients versus controls (table 3). The peak GH response to 
provocation by clonidine and glucagon was significantly low in thalassaemic patients. 
Seven , out of the 17, patients with thalassaemia had classic GH deficiency (peak GH < 
7 ug/L after provocation by clonidine and glucagon, with low IGF-I, and IGFBP3 
concentrations).
These 10 patients underwent 12-h study of nocturnal GH release (figure 1). Analysis of 
the pulsatile properties revealed that the integrated and mean GH concentrations over
12h were markedly lower in thalassaemic patients versus controls . Five out of the ten 
studied patients had maximum nocturnal GH peak below 10 ug/L and four of them had 
mean nocturnal GH concentration below 2 ug/L. Two had severe neurosecretory 
dysfunction of GH secretion (patient 6,10). Their circulating IGF-I and IGFBP3 
concentrations were markedly reduced compared to those for controls.
Correlation between circulating hormonal and ferritin concentrations for all the study 
children are presented in table 5. Serum ferritin concentration was correlated 
significantly (negatively) with mean nocturnal GH , IGF-I, IGFBP3 and insulin 
concentrations. Mean nocturnal GH concentration and the peak nocturnal GH level 
were correlated significantly with IGF-I and IGFBP3 supporting the view that GH is 
the major regulator of both IGF-I and IGFBP3 synthesis.
MRI studies revealed marked reduction of the pituitary volume in thalassaemic 
children ( 305 +/- 125 mm3) versus age-matched normal controls (618 +/- 87 mm3) 
(p<001). Those patients with GH deficiency had variable abnormalities including: 
complete empty sella (n= 2) , marked diminution of the pituitary size (n=4) , abnormal 
signal pattern of the gland (n=4) and thinning of the pituitary stalk (n=3) with its 
posterior displacement (n=2) (figure 2). None of the control children had abnormalities 
of the pituitary gland or its stalk.
DISCUSSION
The growth promoting activity of IGF-I is determined not only by the concentration of 
IGF-I but also by the amounts of various IGF binding proteins (IGFBPs).(327,328) 
Among these IGFBP3 is the major binding protein. (329) IGFBP3 has been observed to 
potentate the effects of IGF-I in bone. (315,316,330) In addition, recent data clearly 
indicate that IGFBP3 prolongs the half life of circulating IGF-I levels and changes the 
clearance pattern of plasma IGF-I.(317) Current opinion favours GH as the major 
regulator of IGF-I and IGFBP3 in humans. In this study, the GH responses to 
provocation with clonidine and glucagon was impaired in short prepubertal children 
with beta thalassaemia major compared to those for short normal children. Seven out 
of the 17 children with thalassaemia did not secrete GH after provocation (peak GH <7 
ug/L) in both provocative tests. Five of the children had normal GH response to 
provocation , but abnormal nocturnal spontaneous GH secretion. MRI studies of the
QO
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hypothalamic-pituitary area of 12 patients with thalassaemia ( 7 with GH deficiency, 2 
with abnormal spontaneous nocturnal GH release and 3 with normal GH secretion) 
revealed complete empty sella (n= 2), marked diminution of the pituitary size (n=4), 
abnormal signal pattern of the gland (n=4) and thinning of the pituitary stalk (n=3) 
with its posterior displacement (n=2) in those patients with defective GH secretion (Fig 
2) with relatively normal hypothalamic area, proving a good correlation between the 
structural alterations of the pituitary gland and dysfunction/deficiency of GH secretion 
in these patients. In support to our data previously published autopsy studies showed 
marked histopathological changes with significant siderosis of the pituitary gland and 
secondary atrophy of the somatotrophs (318). The increased incidence of defective GH 
secretion in our thalassaemic children, compared to other studies (252-255), could be 
explained on the basis of incomplete iron chelation in our patients with more siderosis 
of the pituitary gland.
All our patients with thalassaemia had significantly lower concentrations of circulating 
IGF-I and IGFBP3. Impaired GH secretion can explain in part the significantly lower 
IGF-I and IGFBP3 synthesis with subsequent growth impairment in children with 
thalassaemia major. However, haemosiderosis of the liver in these patients with 
disturbed hepatic function might also decrease synthesis of IGF-I and IGFBP3. In our 
study serum ferritin concentration was significantly correlated with IGF-I 
concentration (r = - 0.47, P< 0.01), and IGFBP3 (r=-0.43, p< 0.01). This supports the 
view that siderosis of the liver can adversely affect the IGF-I/IGFBP3 synthesis. 
Deficiency of IGFBP3 in thalassaemic patients might contribute to their growth 
impairment by decreasing the growth promoting effects of IGF-I.
We (319) and others (236) reported progressive impairment of insulin secretion in 
children with thalassaemia due to haemosiderosis of the pancreas. Other investigators 
stressed as well the importance of insulin resistance in these patients. (326,237). Insulin 
deficiency and/or resistance might be a contributing factor compromising the growth 
potential of these children through inhibition of IGF-I synthesis and/or secondary to 
increased production of inhibitory IGF-binding proteins. In this study, although the 
fasting serum insulin concentrations were within the normal range, they were 
correlated significantly with circulating IGF-I and IGFBP3 levels.
Delayed or arrest of puberty is common in patients with thalassaemia (195,196) due to 
disturbed gonadotrophins secretion (320) with consequent deficiency of sex-steroids.
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Sex steroids levels were low in all our patients compared to normal data at the same 
pubertal stage. This can influence growth through the modulation of GH secretion and 
IGF-I-induced cellular response (172,176,177,179,180) and consequently impairs linear 
growth and attenuates the pubertal growth spurt in thalassaemic children (181).
The finding of impaired linear growth in thalassaemic children, despite regular 
transfusion and desferrioxamine therapy, who have normal GH secretion suggests the 
possibility of GH resistance. In a previous report our group studied IGF-I generation 
in a group of thalassaemic patients (n=15) and found that they do not secrete adequate 
IGF-I after GH stimulation when compared to normal short children or those with 
growth hormone deficiency (GHD). After one year of GH therapy, despite giving the 
same dose/m2 to all the children, thalassaemic children had significantly lower IGF-I 
concentrations versus those for the short normal control group and those with 
GHD.(331) These data are in concert with those of Werther GA et al (258) who 
reported lack of response of non-suppressible insulin-like activity to short-term 
administration of human growth hormone in their thalassaemic patients. We treated 6 
thalassaemic children with GH for a year. Their growth velocity increased significantly 
from 3.8 +/- 0.6 cm/yr. to 7.2 +/- 0.8 cm/yr. (doubling). However, the increment of the 
rate of growth was significantly slower compared to a control group with CSS. 
Collectively these findings suggest the presence of significant GH resistance in these 
patients, which could attenuate the growth promoting effects of GH therapy. In concert 
with our view, Low LC et al (323) have shown that with higher (supraphysiological) 
(30units/m2/week divided on daily S.C. doses) doses of exogenous GH there has been a 
progressive increase of IGF-I production in their thalassaemic patients. Although it is 
known that higher GH doses during treatment possibly elicit a higher IGF-I and GV 
response, however this high dose might be necessary in thalassaemic children to 
overcome the possible GH resistance. However, supraphysiological doses of GH might 
increase the risk of inducing diabetes and hypertension (324) in these high-risk patients. 
Human IGF-I therapy, alone or in combination with GH and/ or IGFBP3 , appears to 
be an attractive alternative to overcome the GH resistance and avoid the high risk of 
developing diabetes in them. In human (325,326) and animal (316,317) experiments this 
combination of growth factors appear to be useful.
In summary; children with beta-thalassaemia and short stature have high incidence of 
abnormalities involving the GH/IGF-I/IGFBP3 axis with low circulating IGF-I and 
IGFBP3 concentrations. Decreased GH response to provocation (7/15) and abnormal
properties of spontaneous nocturnal GH secretion (5/15) have been detected in this 
study and appear to be important etiologic factors. In these patients defective GH 
secretion is associated with abnormal structure of the pituitary gland and its stalk. 
These changes might be secondary to haemosiderosis of the pituitary gland. However, 
children with thalassaemia who have normal GH response to provocation and normal 
spontaneous (mean and integrated) GH secretion still have low circulating IGF-I 
concentrations suggesting partial resistance to GH. Early treatment of defective 
GH/IGF-I/IGFBP3 axis in these children might markedly improve their linear growth, 
however, these patients usually require supraphysiological doses of growth hormone.
Study-11: BONE MINERAL DENSITY IN PREPUBERTAL CHILDREN 
WITH BETA-THALASSEMIA: CORRELATION WITH GROWTH AND 
HORMONAL DATA.
Metabolism 1998; 47 (5): 541-548.
AIM OF THE WORK:
1. To measure the bone mineral density and;
2. to investigate some factors affecting bone mineral metabolism in 30 children with 
beta thalassaemia major and attempt to find a relationship, if any, between the 
degree of siderosis, calcium-phosphate balance, GH/IGF-I/IGFBP3 axis, 
parathormone(PTH) secretion and auxologic data on the one hand and BMD on the 
other hand.
PATIENTS AND METHODS
Thirty-three prepubertal patients with b thalassaemia major randomly selected from 
those attending the outpatient Paediatric Haematology Clinic of Alexandria University 
Children's Hospital, Alexandria, Egypt, were the subjects of this study. All children 
were on regular blood transfusion to keep their haemoglobin (Hb) concentration above
lOg/dl. All were on folic acid supplements and iron chelation with daily IM 
desferioxamine. Fifteen age-matched normal short children (CSS) 
(height SDS at or below -2, annual growth velocity at or below 5cm/yr., with normal 
GH response to provocation and delayed bone age) served as controls. None of the 
children had history of intrauterine growth retardation, any other systemic or 
endocrine disease, dysmorphic trait or CNS irradiation. All had normal tolerance to 
oral glucose load (1.75 g/kg of dextrose). Three patients who had abnormal glucose 
tolerance were excluded from the study. Informed consent for the testing procedures 
was obtained from the parents and when appropriate from the children before entering 
into the study. The protocol of the study was approved by the ethics committee of 
Alexandria University. All children were examined with special emphasis on 
nutritional data. The auxologic data included weight, height and mid-arm 
circumference. Harpenden's callipers and anthropometric measurements were used. 
The data recorded were the average of 3 sequential measurements determined by the 
same observer (ATS). The height standard deviation score (HtSDS) and body mass 
index (MBI) were calculated and recorded. The linear growth velocity (GV) cm/yr. was 
calculated for the last year. Normal population data were according to Tanner et al. 
(277) The bone age was determined according to Greulich and Pyle atlas.(278) On the 
day of admission, venous blood samples were obtained for determination of complete 
blood count (CBC), and serum concentrations of albumin, bilirubin, and alanine 
transferase (ALT) concentrations. Following an overnight fast (8-h) venous blood 
samples were withdrawn through a polyethylene catheter inserted in a forearm vein 
between 8 and 9 AM. The serum was separated from the formed elements by 
centrifugation and kept frozen at -20 c until analysed for GH, IGF-I, IGFBP3, free 
thyroxin (FT4), thyrotropin (TSH), cortisol, PTH (intact molecule), calcium (Ca), 
phosphorus (PO4), alkaline phosphatase (ALP), ferritin, interleukin-1-B (IL-l-B) and 
Tumour-necrosis factor-alpha (TNT-A) concentrations. After obtaining the basal 
samples, an oral dose of clonidine (0.15 mg/m2) and iv. dose of ACTH (SYNACTHEN) 
Iug/m2 were given and blood samples collected every 30 min for 2 hours for 
measurement of GH and after 60 min for cortisol. On the next morning a standard 
glucagon test for GH release was performed.
Human GH and IGF-I concentrations were measured by radioimmunometric assay. 
IGFBP3 was measured by radioimmunoassay in Serono Biochemical laboratories 
(SCL) & Bioscience Services employing reagents supplied by Mediagnost. Intact PTH 
was measured in the serum using an immunochemiluminonietric method. IL-l-B and
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TNF-A were measured using ELISA technique (BIOKINE, T-Cell Diagnostics, 
Cambridge, MA.
The bone mineral density (BMD) of the lumbar spine (2nd,3rd and 4th lumbar 
vertebrae) were measured by dual photon absorptiometry (DPA) using a Norland 2600 
bone densitometer. All children were scanned in the supine position. BMD data were 
expressed in g/cm2 and were compared with BMD of normal children of the same age.
(327)
Statistical analyses were done using the unpaired t-test to compare mean analyte 
concentrations among the two study groups when the data were normally distributed 
and Wilcoxon test when they were not. Statistical significance was accepted at p < 0.05. 
Multiple regression analysis was performed using BMD as the dependent variable and 
all the other auxologic and biochemical data as the independent variables. Data are 
presented as mean +/- SEM.
RESULTS: ( see appendix for tables and figures)
The anthropometric and bone age data are presented in "table 1". The chronological 
age, HtSDS, GV, BMI and bone age did not differ significantly between the two study 
groups. The biochemical, hormonal and BMD data are shown in "tables 2,3". The 
circulating concentrations of albumin, creatinine, ALP, and PO4 did not differ 
significantly among the 2 groups. Hypocalcaemia {Ca = or < 1.4 nmol/L (5.7 mg/dl)} 
was detected in 5 patients. Three of them (aged 11, 12.5 and 14 years) had other 
biochemical evidence of hypoparathyroidism (high PO4, normal ALP, and low PTH 
concentrations). The other two patients (aged 9 and 11 years) had biochemical evidence 
of rickets (low PO4, high ALP and PTH and low 25-hydroxy vitamin D3 
concentrations). The circulating concentrations of IGF-I and IGFBP3 were 
significantly lower in thalassaemic children compared with controls. Their peak GH 
responses to provocation with clonidine and glucagon were significantly below those for 
controls. Twelve out of the 30 children with b thalassaemia did not mount GH response 
to provocation above 7 ug/L. Although basal levels of cortisol did not differ between the 
two groups, cortisol response to low dose ACTH test was significantly lower in 
thalassaemic children versus controls. Two children had mild chemical hypothyroidism
(FT4 = 9.5 and 8.7 pmol/L and TSH = 8.6 and 10.3 ulU/ml). Both were treated with L- 
thyroxin for a month before testing their GH response to provocation.
Dual photon absorptiometry revealed that children with b thalassaemia had significant 
reduction of their BMD (30% less) compared to average BMD for age and sex matched 
normal children, corresponding to BMD = -1.5 to -2 SD. Thalassaemic children had 
significantly lower BMD versus age-matched children with CSS. Correlations between 
BMD and different parameters are shown in "Table 4" and "Figurel". BMD was 
correlated significantly (p<0.01) with age, height, weight and BMI as well as with the 
circulating concentrations of IGF-I and IGFBP3. No significant correlations was found 
between BMD on the one hand and PTH, PO4, Ca, or ALP concentrations on the other 
hand. IL-l-B and TNF-A concentrations did not differ significantly between the 
thalassaemic group (25.9 +/- 11.4 pg/ml and 399 +/- 113 pg/ml respectively) and controls 
(21.1 +/- 6.4 pg/ml and 383 +/- 122 pg/ml).
DISCUSSION
From infancy through late adolescence the activity of bone forming exceeds bone 
resorption, resulting in a steady accumulation of bone mass. On average, most of the 
skeletal mass is accumulated by the age of 18 years.(158,161) Since the bone mass is one 
of the main determinants of fractures, high bone mass at skeletal maturity (peak bone 
mass) is considered the best protection against age-related bone loss.(163) Small 
differences in bone mass at skeletal maturity of 5-10% could contribute to substantial 
differences in the incidence of osteoporotic fractures.(164)
Bone modelling and skeletal consolidation result from a complex sequence of hormonal 
changes in interaction with nutritional factors, where the concerted actions of GH, IGF- 
I and sex hormones and their receptors, besides other factors, are responsible for 
timing and attainment of skeletal consolidation. At puberty, circulating IGF-I 
concentrations correlate with sexual development. Specifically, the surge in sex steroids 
in turn increases the secretion of growth hormone, which stimulates the production of 
IGF-I (166,328) and increases bone mass (172). In addition, a large number of other 
factors interact at the level of osteoblast, osteoclast and other cells to regulate the 
balance between net resorption and formation. These include parathormone (PTH), 
vitamin-D, and cytokines.(172)
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The GH/IGF-I/IGFBP3 axis and factors affecting it:
In this study the hormonal profile of children with b thalassaemia showed significant 
deficiency of their circulating IGF-I and IGFBP3 (both are GH dependent peptides). 
The significant correlation between IGF-I levels and HtSDS and BMD supports a major 
role played by IGF-I in stimulating linear growth and bone mineralisation.
Forty percent of our prepubertal thalassaemic children had defective GH secretion 
after provocation by clonidine and glucagon. In concert with our findings Danes! et al 
(329), Saglamer et al (330) and Pintor et al (253) reported low GH response to 
provocation by insulin hypoglycaemia, arginine, L-dopa, and GH-releasing hormone in 
many of their patients denoting impairment of somatotroph function. This can explain 
low IGF-I synthesis in some patients. However, our thalassaemic children with normal 
GH secretion had low circulating IGF-I concentrations (50 +/- 19 ng/ml) comparable to 
those with defective GH release (46 +/- 24 ng/ml) suggesting that other factors 
contribute to low IGF-I synthesis in these children. Leger et al (331) found that 
decreased IGF-I secretion occurs before alteration in GH secretion in response to GH- 
releasing hormone, arginine or insulin. Other investigators reported neurosecretory 
dysfunction of GH secretion to be responsible for decreased IGF-I synthesis in some of 
those patients with normal GH response to provocation (255,256). Some investigators 
indicated that decreased GH secretion may be due to an age-related deterioration of the 
hypothalamic-pituitary function secondary to progressive siderosis. (331,252) In 
support, Perignon et al (332) reported that their patients with b thalassaemia had low 
IGF-I concentration which did not increase at puberty. Although the idea of a defect at 
the hepatic GH receptor or postreceptor level was suggested to explain low IGF-I 
production (26), Postel-Vinay et al (307) found no evidence for a defect in GH binding 
to liver membranes in thalassaemic patients.
It is well recognised that nutritional status has an important influence on the GH/IGF- 
I/IGFBP3 axis. (333) Fasting results in increased GH secretion and decreased IGF-I 
levels (334) and proper nutrition increases IGF-I levels in malnourished children.(53). 
Our children with thalassaemia had BMI and MAC at or below 10th centile for age and 
sex suggesting a mild degree of undernutrition. Decreased food intake(215), pancreatic 
exocrine dysfunction, hepatic cirrhosis (14,217) and /or hypermetabolism secondary to 
bone marrow hyperactivity and increased cardiac work might compromise nutrition 
and growth in these children. In this study circulating IGF-I concentrations were
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correlated significantly with alanine transferase levels (r= -0.465, p <0.01), and 50% of 
our children were hepatitis-B surface antigen carriers and had significantly elevated 
ALT concentrations. Clinically, 25 out of the 30 patients had cirrhotic livers. In one 
study (215) nutrition intervention resulted in improvement of weight for height and 
increased IGF-I concentration. In malnutrition (53) and hypercatabolic states (280) the 
low IGF-I production is associated with high basal and stimulated GH levels denoting 
normal sensitivity of the hypothalamic pituitary axis to the low IGF-I level (normal 
feed-back). In thalassaemia the low-normal GH levels despite the low circulating levels 
of IGF-I proves defective feedback effect of decreased IGF-I on the pituitary (either 
due to lack of sensitivity or defective somatotroph function). We and others reported 
partial resistance to GH in thalassaemic children evidenced by low IGF-I generation in 
response to exogenous administration of GH and slow linear growth on GH therapy 
(323,335-336)
During normal pubertal growth spurt sex steroids increase GH secretion with 
subsequent increase of IGF-I levels. Sex steroids and GH each contribute 
approximately 50 per cent of the height gain. Children with GH insufficiency not 
treated with exogenous GH attain only 50 to 66 per cent of the expected growth spurt 
(43,124,125,136). Reduction of sex-steroid concentration during gonadotrophic- 
releasing hormone therapy decreases GH secretion and serum IGF-I concentration 
(48,137,337). Patients with b thalassaemia have a high incidence of failure of puberty 
(51 per cent of boys and 47 per cent of girls) and secondary amenorrhoea (23 per 
cent).(195) Defective gonadotropin secretion with subsequent sex-steroid deficiency 
have been detected in these patients with low IGF-I levels.(193,197,338) Even those who 
enter puberty do not have the enhanced GH secretion and increased IGF-I synthesis 
pattern accompanying normal puberty (252,332) denoting a major effect of sex-steroid 
deficiency on the GH/IGF-I axis in peripubertal and pubertal children with b 
thalassaemia. Unlike children with constitutional delay of puberty who secrete normal 
GH in response to provocation after priming with sex steroid (43), in our prepubertal 
thalassaemic patients above the age of 12 years (n=8) the peak GH response to 
provocation did not improve after (7.5 +/- 2.1 ug/L) versus before priming with 
oestrogen (6.5 +/- 1.5 ug/L).
The reported prevalence of diabetes mellitus in treated b thalassaemia is about 16 per 
cent, while the incidence of impaired glucose tolerance approximates 60 per cent. Islet 
cell destruction secondary to iron overload and/or exhaustion of B-cells due to long-
term insulin resistance and Liver derangement are possible pathogenic factors. 
(224,235,232,307) Defective insulin secretion and insulin-resistance state can impair 
hepatic IGF-I production (339,93). Moreover, insulin plays an important part in 
determining the bioavailability of IGF-I through its action on IGFBP1. Therefore, 
defective insulin secretion or insulin resistance in thalassaemic children can increase 
hepatic production of IGFBP1 leading to decreased bioavailability of IGF-I (90,340). 
However, this factor can be excluded in our patients with normal glucose tolerance.
In summary, the markedly decreased hepatic production of IGF-I in our thalassaemic 
prepubertal patients with normal glucose homeostasis can be attributed to defective GH 
secretion , hepatic cirrhosis (secondary to siderosis and/or chronic viral hepatitis), 
and/or GH resistance. The delayed or lack of pubertal development and the occurrence 
of IDDM with advancing age, might further impair the secretion and/or the 
bioavailability of IGF-I.
IGF-I is a potent stimulator of linear growth and major determinant of bone 
mineralisation. Exogenous administration of IGF-I has been shown to increase growth 
and bone formation in human and animals This effect is potentiated when IGF-I is 
combined with IGFBP3 (316,317,325,326). In our children with beta thalassaemia the 
decreased production of IGF-I and IGFBP3 and the significant correlation between 
these growth factors and BMD and linear growth (weight, height and HtSDS) 
parameters suggested a major role played by them in the pathogenesis of osteoporosis. 
GH or IGF-I therapy may improve linear growth and bone mineralisation in these 
children as seen in patients with GH deficiency/resistance and other diseases with 
osteopenia.(341-343) This hypothesis needs to be tested by double-blind therapeutic 
trial of GH or IGF-I in these patients.
Calcium-phosphate balance and PTH:
In this study hypocalcaemia occurred in 5 out of 30 children with b thalassaemia. All 
the 5 children had markedly decreased BMD. Analyses of the other biochemical 
parameters differentiated 2 possible disease entities. Two out of the 5 patients had 
evidence of hypoparathyroidism (low Ca, high PO4, normal ALP, and low PTH). This 
can be explained by siderosis of the parathyroid gland (263-344-346) In support to this 
view, Gertner et al (347) found low PTH reserve to induced hypocalcaemia in their 
thalassaemic patients. The other 3 patients had biochemical evidence of rickets (low 
PO4, low Ca, high ALP, high PTH, and low 25-hydroxy vitamin D3). In concert with
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this finding, De Vernejoul et al (348) reported osteomalacia in their thalassaemic 
patients. The cause of rickets/osteomalacia in these patient is defective 25- 
hydroxylation due to hepatic impairment and/or decreased vitamin-D absorption in 
these children. Impaired osteoblast function with diminished bone formation and low 
serum concentration of 25-hydroxy vitamin D3 with high PTH levels have been 
reported in patients with hemochromatosis and liver cirrhosis and in pigs overloaded 
with parenteral iron. (348-352)
The normocalcaemic (25/30) patients with b thalassaemia had slightly higher PTH 
concentration and significantly lower BMD versus normal children. In agreement with 
this finding Pawlotsky Y et al (353) reported elevated PTH concentration, normal 
serum calcium level and increased bone resorption in their haemochromatic patients. It 
appears that both vitamin-D deficiency and hypoparathyroidism might affect bone 
mineralisation in thalassaemic children.
Cytokines:
Cytokines represent a group of factors influencing the balance between bone formation 
and resorption. Increased bone resorption induced by an overproduction of critical 
cytokines, such as IL-1, TNF and GM-CSF by the hyperactive marrow cells and 
monocyte/macrophage lineage, is an attractive theory to explain the pathogenesis of 
osteoporosis seen in patients with b thalassaemia, as with other diseases. IL-1 and TNF 
are among the most powerful stimulators of bone resorption known and are well 
recognised inhibitors of bone formation.(353-355) However, we found normal serum 
levels of IL-1 and TNF in our thalassaemic patients comparable to those for control 
children which might rule out a significant role played by these cytokines in the 
production of osteoporosis in these children.
Cortisol secretion:
In this study children with beta thalassaemia had significantly lower cortisol response 
to provocation with low-dose ACTH. Other studies reported both low (225,356) and 
normal cortisol concentrations and response to high-dose ACTH. (238, 269, 270, 357, 
358) Slate grey pigmentation which becomes progressively intense with time, poor 
weight gain, weakness and absent adrenarche were significant signs in our thalassaemic 
patients. However, the contribution of different factors including adrenal insufficiency 
, siderosis and anaemia in the production of these manifestation is difficult to assess. 
Macintosh et al (225) reported high circulating ACTH in beta thalassaemia and
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suggested that it is the cause of the pigmentation. In concert with these findings, the 
graded dose adrenal cortical stimulation showed significant suppression of cortisol 
secretion. Although iron deposition in the adrenals might be the cause of adrenal 
insufficiency, recently it has been shown that IGF-I enhances the steroidogenesis and 
ACTH responsiveness of human adrenocortical cells in culture.(359-361) Deficiency of 
IGF-I synthesis in beta thalassaemia might contribute to the defective cortisol 
production and possibly other adrenal androgens which might explain the lack or 
delayed adrenarche in thalassaemic patients. These data suggest that replacement with 
physiological doses of hydrocortisone might improve some of the manifestations of the 
disease. In addition, increasing IGF-I level might also improve the secretion of adrenal 
androgens necessary for adrenarche.
The question is what possible therapeutic or preventive options are available that might 
influence bone mineralisation and growth in thalassaemic children? The data from this 
study supports the development of a controlled clinical trial to evaluate several possible 
therapeutic interventions. In addition to proper and aggressive nutritional intervention 
, which should be an integral part of any treatment strategy, possible new therapeutic 
interventions would include: 1. GH and/or IGF-I replacement therapy, especially for 
those with GH and/or IGF-I insufficiency. These measures might increase the 
circulating IGF-I level and consequently increase bone formation and prevent 
osteopenia. Adding IGFBP3 to IGF-I and/or GH therapy might potentiate their effect 
on bone growth and mineralisation.(341 342,343) 2. Treatment with vitamin D or 
vitamin D analogues in the modest doses (800-1500 Ill/day of vitamin-D3) may offer a 
safe and substantial contribution to the prevention of osteoporosis in these children. 
Positive correlation of vitamin-D levels with BMD of the vertebrae and proximal femur 
have been found in young and old women with poor vitamin-D status.(361-363) Those 
patients with osteoporosis and biochemical evidence of rickets need higher doses of 
vitamin-D3 or its analogues for treatment. 3. Calcium supplementation which has been 
shown to increase bone density in the normal prepubertal children is another good 
potential option.(364) 4. The initiation of puberty at an appropriate age through the 
use of progressively increased doses of androgens or oestrogen . These agents would 
prevent osteoporosis and increase their BMD,(172,365-367) putting in consideration the 
risk of advancing the bone age faster than the height age.
In summary, prepubertal children with beta thalassaemia and normal glucose tolerance 
have decreased BMD, delayed growth and a defective GH/IGF-I axis. Biochemical
mi
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evidence of hypoparathyroidism or rickets may be detected in thalassaemic patients 
with hypocalcaemia. It is logical to propose that treatment of these patients with GH 
and/or IGF-I with aggressive nutritional support and supplementation with vitamin-D 
and/or calcium might improve their bone density and prevent the development of 
osteoporosis and subsequently fractures.
irp
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Study 12: DECREASED BONE MINERAL DENSITY IN PREPUBERTAL 
CHILDREN WITH SICKLE CELL DISEASE: CORRELATION WITH GROWTH 
PARAMETERS, DEGREE OF SIDEROSIS AND SECRETION OF GROWTH 
FACTORS.
(Accepted for publication in the Journal of Tropical Pediatrics, in press)
AIM OF THE WORK:
Patients with sickle cell disease appear to be at higher risk for developing skeletal 
abnormalities with significant radiological bone changes (273).
We measured bone mineral density in relation to linear growth and secretion of growth 
factors (growth hormone (GH), insulin-like growth factor-I,(IGF-I), and IGF-binding 
protein-3 (IGFBP3) ) in 28 prepupertal children with SCO.
PATIENTS AND METHODS
Twenty eight prepupertal children with SCD were the subject of this study. They were 
randomly selected from the 162 children with SCD attending the Haematology out- 
patient clinic of the Royal Hospital ,Muscat, Oman. All have been on folic acid 
supplement and vaccinated against pneumococci. None of them had history of 
intrauterine growth retardation, any other systemic or endocrine disease, dysmorphic 
trait or central nervous system irradiation. Informed consents were obtained from all 
the parents and when appropriate from the patients before including in the study. 
Twenty five age matched children with ISS served as controls. The protocol of the study 
was approved by the ethical committee of SQU. All the children were examined with 
special emphasis on the nutritional data. The auxological measurements included 
weight, mid-arm circumference and scapular, triceps and abdominal skin fold 
thickness. Harpenden's callipers were used. Height standard deviation scores were 
calculated according to the formula HtSDS =(X1-X2)/ SD where X2 and SD are 
matched population mean height and ySD respectively and XI is the subject height. The 
body mass indices (BMI) were calculated according to the formula BMI= weight(kg)/Ht 
(m)2. The bone age was determined according to the Greulich and Pyle atlas (278).
After an overnight fast (8 h) venous blood samples were obtained between 8 and 9 a.m. 
for determination of complete blood picture , serum albumin, calcium, phophates and 
alkaline phosphate concentrations. The serum was separated from the formed elements 
by centrifugation and kept frozen at -20 c until analysed for GH, IGF-I and IGFBP3
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radioimmunoassay. GH provocation test was performed using oral clonidine (0.15 
mg/m2), and for those who did not respond (peak GH below lOug/L) GH stimulation 
with glucagon 0. > mg/kg IM was performed . Human GH and IGF-I were measured by
radioimmunometric assay, employing reagents purchased from Nichols Institute (San 
Juan Capistrano, CA).
Lumber spine ( L-2,L-3,L-4) bone mineral density was measured in all patients by dual 
photon absorptiometry (DPA) using a Norlad 2600 bone densitometer. All patients were 
scanned in the supine position . BMD data were expressed in g/cm2 and were compared 
with the BMD of controls and normal children of the same age(20).The densitometer 
was calibrated daily using a phantom standard, the examination was performed with 
the child supine, knee flexed and calves resting on a cushion. These manoeuvres 
separated he spinous processes and prevented overlap of bony structures. All clothing 
that could produce artefacts was removed. No sedation or restraints were used. The 
scan was approximately 15 minutes. All scans were analysed with the assistance of an 
edge detection program in the scanner software. To minimise variability, only one 
experienced observer (H.B) performed all scan analyses . The coefficient of variation on 
repeated scan analyses was 0.7%. The L-2:L-4 spinal BMD was expressed in grams per 
square centimetre.
Data are presented as mean +SD. Correlation coefficients were calculated for each 
variable against BMD using single and multiple regression analyses were performed 
using BMD as the dependent variable.
RESULTS
The table presents the data of the patients and controls. According to the peak GH 
response to provocation , the SCD of the patients were divided into (group I) with 
defective GH release (GHD) and (group II) with normal GH release after provocation. 
The chronological and bone age did not differ significantly among the 3 study groups. 
SCD children had significantly lower IGF-I and IGFBP3 concentration versus controls. 
Those with defective GH secretion had lower IGF-I &IGFBP3 concentration 
compared to those with normal GH peak after provocation. The per cent BMD 
(measured as % of the normal values for age and sex matched children)(20) was 
significantly lower in children with SCD versus controls. The loss of more than 20% of
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the BMD corresponds to loss of more than 1 SD of bone density. The BMD of children 
with SCD+ GHD was significantly lower than those with normal GH secretion. BMD 
was correlated significantly with the weight ( r=0.547),height (r=0.52) HtSDS 
(r=0.369),BMI (r=0.409) and circulating IGF-I (r=0.469) and IGFBP3 (r=0.36). No 
significant correlation was found between BMD and serum concentration of Ca 
(r=0.077), PO4 (r=0.027) ALP (r=0.023), or ferritin (r=0.25,p=0.08).
DISCUSSION
This study demonstrates that children with SCD have significant reduction of BMD. 
The reduction of BMD of this extent (1 SD below the mean ) probably represents a 50 to 
100 per cent increase in the incidence of fractures (368). We attempted to study some 
factors that might affect BMD in those patients with SCD including, auxologic data, the 
degree of siderosis, calcium-phosphate balance and GH/IGF-I/ IGFBP3 axis.
In this study children with SCD had low BMI (20 out of 28 had BMI below 10th centile 
for age and sex) and HtSDS (18 out of the 28 had HtSDS below -2). The significant 
correlation between BMD on the one hand and weight, height and BMI on the other 
hand suggests that slow growth is an important factor in the production of low BMD in 
these children. Delayed sexual maturation, a known feature of SCD, can significantly 
add to the problem by decreasing the peak bone mass(369,370)
Twelve out of the 28 children with SCD had defective GH secretion after provocation, 
and as a group (n=28), sicklers had significantly lower circulating concentration of 
IGF-I and IGFBP3 versus control group. Children and adults with GHD have reduced 
BMD and bone formation (371,372).In those patients, GH replacement increases bone 
turnover and increases BMD within 6-12 months (373).Children with SCD and GHD 
had significantly lower IGF-I and IGFBP3 concentrations and BMD compared with 
those with normal GH secretion .IGF-I, is a GH-dependent polypeptide, that circulates
in the plasma preferentially bound to the high molecular weight IGFBP3 complex 
which acts as a reservoir prolonging the 1/2 life of IGF-I and targeting the IGFs to the 
relevant target organ. The bioactivity of the circulating IGF-I is therefor very much 
dependent on the presence of IGFBP3 in the circulation (314,374,375). IGF-I is a potent 
stimulator of bone formation and exogenous administration of IGF-I has been shown to 
increase bone formation in human and animals (376,377). This effect is potentiated 
when IGF-I is combined with IGFBP3 (317,378). Current opinion favours GH as the 
major regulator of IGF-I and IGFBP3 levels in humans (295,341). In addition , serum
ins
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levels of IGF-I and IGFBP3 are positively related to nutritional status (326,379). GH 
therapy increases both IGF-I and IGFBP3 (341). Therefore GH replacement and/or 
IGF-I therapy might improve growth and BMD in children with SCD (379).
In this study, the normal Ca , PO4 and ALP concentrations excludes an important role, 
if any, of disturbed Ca/PO4 balance in the production of low BMD. The degree of 
siderosis, evidenced by circulating ferritin concentration., was not correlated 
significantly with BMD. However the excess iron might inhibit Ca deposition in the 
bone either directly and/or through decreased hepatic synthesis of IGF-I.
The question is what possible therapeutic or preventive options are available that may 
influence bone mineralisation in SCD. Obviously proper and aggressive nutritional 
intervention is necessary to improve growth. Calcium supplements that have been 
shown to increase bone density in the normal prepupertal children is a potential option 
(379). Growth hormone and/or IGF-I therapy, especially for those with GHD and/or 
low IGF-I concentration , is a reasonable replacement (341,380).The initiation of 
puberty at an appropriate age, using oestrogen or androgens, is another option, putting 
in consideration the risk of advancing the bone age faster than the height age.
In summary, prepupertal children with SCD have decreased BMD, delayed growth and 
defective GH/IGF-I/IGFBP3 axis. It is logical to propose that treatment of these 





This study evaluated growth and pubertal development in a large cohort of patients 
with (3 thalassaemia (n =72) and SCD (n=110), and investigated the different factors 
affecting them in these patients. Linear growth was significantly impaired in children 
with thalassaemia and SCD. Forty nine percent of thalassaemic children and twenty 
seven percent of the sicklers had HtSDS below -2. Eighty three per cent of the 
thalassaemic children and sixty seven per cent of children with SCD had GVSDS below 
-1. Pubertal development showed marked retardation in both group of patients. Only 
27% of thalassaemic boys above the age of 14 years had testicular volume of 3 ml or 
more. Spontaneous menarche and breast development (B2 or more) occurred only in 26 
and 42per cent of thalassaemic girls above the age of 13 years respectively. Secondary 
amenorrhoea occurred in two thirds of those who had spontaneous menarche. Only 50 
per cent of girls with SCD above the age of 13 years had spontaneous menarche. Boys 
with SCD, aged 14 years or more, had significantly small testicular volume and 22.3 per 
cent did not show testicular enlargement ( volume > 3 ml). 
Retardation of growth and puberty was more marked in thalassaemic children 
compared with those with SCD. Thalassaemic children had significantly higher 
circulating ferritin concentrations and lower IGF-I levels compared to children with 
SCD. Linear growth velocity (cm/yr.) was correlated negatively with serum ferritin 
concentration in all the study children. These data denoted that excessive iron overload 
has a major role in the aetiology of delayed growth and impaired pubertal development 
in these patients. Moreover, the delayed and/or failure of puberty in thalassaemic and 
sickler children increases growth impairment through the lack of the synergistic effect 
of sex steroids on pubertal growth spurt. The negative correlation between HtSDS and 
age of these patients as well as the disturbed upper/lower segment ratios supported this 
view.
The hepatic functions and prevalence of HBS antigenaemia and HCV antibody in 
children with P thalassaemia and SCD were studied. Children with thalassaemia had 
significantly high prevalence of HBS antigenaemia and HCV antibody positivity (44.4 
and 23.5 per cent) compared to normal age matched children. They had markedly 
elevated serum ALT concentrations and increased liver span. ALT concentrations were 
correlated significantly with HtSDS ( r= -0.42, p < 0.001). These data suggested that 
impaired liver functions, secondary to chronic viral hepatitis and/or siderosis, might 
contribute to linear growth impairment. Children with cirrhosis and chronic hepatitis 
are known to have a degree of GH resistance with low production of IGF-I (381,382).
Children with SCD did not have high prevalence of HBS antigenaemia or HCV 
antibody positivity. However, they had mild elevation of circulating ALT and bilirubin 
concentrations, which might be secondary to siderosis or hypoxic-ischaemic injury to 
the liver. ALT concentrations were correlated significantly with HtSDS in these 
children ( r=-0.21, p= 0.026). SCD children with HBS antigenaemia had significantly 
elevated bilirubin and ALT concentration compared to those without antigenaemia. 
Two third of children with SCD who had acute hepatitis B infection could not clear the 
antigenaemia for one year after the attack . These data denoted that children with SCD 
are at high risk of developing chronic hepatitis following acute hepatitis B infection. 
Impaired hepatic function, which is more marked in those with HBS antigenaemia, 
might be a factor contributing to their linear growth delay.
This study demonstrated that impaired growth is associated with functional 
abnormalities of the growth hormone (GH)/ insulin-like growth factor -I (IGF-I)/ IGF- 
binding protein-3 (IGFBP3) axis as well as anatomical abnormalities of the pituitary
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gland and its stalk in 21 short children with SCD. Nine out of the 21 children with SCD 
had defective GH response to both clonidine and glucagon provocation ( peak <10 
ug/L). These children differed from the other 12 in having slower linear growth velocity 
(GV and GVSDS), lower circulating concentrations of IGF-I and IGFBP3, and having 
either partial or complete empty sella. It appears that defective GH release and 
consequently low IGF-I production and slow growth velocity in children with SCD 
might be secondary to hypoxic-vascular insults to their hypothalamic-pituitary axis 
during one or more of the sickling episodes. In this group of patients with SCD 
defective GH secretion and consequently low IGF-I production are major etiologic 
factors causing their slow growth. The two groups with SCD, with and without GHD, 
did not differ significantly in their dietary intake, BMI, mid-arm circumference, skin- 
fold thickness, serum albumin concentration or intestinal absorption of D-xylose. These 
findings excluded a significant role played by malnutrition in the production of delayed 
growth in these patients.
A single injection of GH produced a smaller increase in circulating IGF-I in children 
with SCD with or without defective GH secretion compared to that in 10 age-matched 
children with idiopathic short stature (ISS) and 11 children with isolated GH deficiency 
(GHD). Moreover, human GH therapy (15units/m2/week, on daily divided 
subcutaneous doses) was started in two prepubertal children with SCD and empty 
sellae who had annual growth velocity (GV) of 3.2 and 3.5 cm/yr. respectively. Their 
GV increased to 9.7 and 8.1 cm/yr. on the first year of therapy and declined markedly 
to 5 and 4.1 cm/yr. and 3.6 and 3.9 cm/yr. on the second and third years of GH therapy 
respectively. Collectively; these findings denote a degree of resistance to GH in these 
patients. The presence of defective GH secretion, decreased IGF-I synthesis and partial 
resistance to GH in short children with SCD suggest that treatment with IGF-I may be 
superior to GH therapy for improving growth.
The presence of high incidence of empty sellae in short children with SCD stimulated us 
to compare their growth, biochemical, hormonal and radiological data with 3 other 
groups of non-sickler children with short stature. The incidence of empty sella was 
45% in children with isolated GH deficiency, 80% in those with multiple pituitary 
deficiency, 100% in children with SCD and GH deficiency and 10% in the short 
children with normal hypothalamic-pituitary function. None of the children with 
normal stature had empty sella. These findings suggest that empty sella has a 
considerably high incidence in children with growth and hypothalamic pituitary 
disorders, particularly those with multiple pituitary hormone deficiency . This 
implicates the importance of CT scanning of the hypothalamic-pituitary area, in 
children with severe short stature including those with SCD, as an important tool in the 
identification of children with pituitary hormonal deficiency .
None of our patients with primary empty sella nor those with SCD and empty sella had 
diabetes insipidus. It seems that the presence of intrasellar CSF does not have an 
adverse effect on posterior lobe function. None of the children with empty sella had 
symptoms or signs of increased intracranial pressure, obesity or glucose intolerance 
reported in adults with empty sella (302).
Despite defective GH/IGF-LTGFBB3 axis in children with SCD, their circulating 8. 
A.M. cortisol, free thyroxin (FT4), thyroid stimulating hormone (TSH) concentrations 
were normal. Cortisol response to ACTH stimulation was adequate in all of them. Their 
hormonal profile, apart from GH/IGF-LTGFBP3 abnormalities, was not different 
compared to normal short children with constitutional growth delay (CSS) (n= 15). 
None of the children had impaired glucose tolerance.
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Hypertransfusion therapy has dramatically increased the duration and quality of life in 
patients with thalassaemia major, however it leads to chronic iron overload, and is 
frequently complicated by the development of diabetes mellitus or impaired glucose 
tolerance and growth impairment. To determine the early effect of iron overload on 
the endocrine pancreatic function, we studied glucose, insulin and glucagon responses 
to oral load of glucose and to arginine provocation in 15 children with B-thalassaemia 
major, before and after (3.1+/-0.6 years) high-transfusion and iron chelation and 
compared them with 15 age matched normal controls. In addition we evaluated growth 
hormone (GH) responses to oral clonidine and measured the circulating insulin-like 
growth factor-I concentration in thalassaemic children on long-term transfusion and 
controls. After long-term high-transfusion, thalassaemic children had significantly 
decreased serum insulin concentrations and low insulin/glucose ratios at 60 and 120 
minutes after an oral glucose load (1.75g/kg) in comparison with values before therapy 
and those for controls. None of the thalassaemic children had glucose intolerance after 
this period of frequent blood transfusion, however their serum glucose levels at 60 and 
120 minutes after the oral glucose load were significantly higher compared to control 
children. Thirty minutes after starting arginine infusion, serum insulin concentration 
was significantly lower in thalassaemic children after versus before therapy. Basal and 
arginine-stimulated glucagon secretions were significantly elevated in thalassaemic 
children on long-term blood transfusion with significantly low serum insulin/glucagon 
ratios. In addition, the high basal serum glucagon concentrations were not suppressed 
after the oral glucose load. Despite hyperglucagonaemia in all thalassaemic children, 
their blood glucose dropped appropriately below 50% of the fasting glucose level after 
an intravenous insulin dose (O.lU/kg) ruling out significant insulin-resistance. GH 
responses to clonidine provocation were subnormal in thalassaemic children after long 
term blood transfusion compared to controls. In summary, thalassaemic children on 
long-term blood transfusion and iron chelation have progressive and early loss of B-cell 
mass, manifested by decreased insulin release in response to secretagogues, before the 
development of significant insulin resistance or impairment of glucose tolerance.
In vitro, cytokines like interleukin-1-beta (IL-l-B) and tumour necrosis factor-alpha 
(TNF-A) inhibit insulin release and can destroy islet B-cells. We measured blood levels 
of IL-l-B, TNF-A and islet cell antibody (ICA) in 20 children with EODM, 20 of their 
non-diabetic siblings, 20 children with thalassaemia major on long-term 
hypertransfusion therapy and iron chelation, and 10 normal age-matched children. In 
the non-diabetic and thalassaemic children we investigated the early phase of insulin 
release after iv. glucose (0.5 g/kg, 30% solution) and evaluated tolerance to oral glucose 
(1.75 g/kg). Circulating IL-l-B and TNF-A concentrations were significantly higher in 
IDDM-siblings (33.7 +/- 12.7 pg/ml and 655 +/- 165 pg/ml respectively) versus normal 
children (21.1 +/- 6.4 pg/ml and 383 +/- 122 pg/ml respectively). Thalassaemic children 
had no detectable circulating ICA. The prevalence of ICA was 30 per cent in children 
with IDDM, and 60 per cent of their siblings. Impaired oral glucose tolerance was 
detected in 5 children with thalassaemia (25 per cent), but in none of the IDDM- 
siblings. The early phase of insulin release was significantly depressed in thalassaemic 
children (peak insulin = 29.2 +/- 5.1 mill/ml) versus normal children (52.3 +/- 9.5 
mlU/mi) and IDDM-siblings (45.3 +/- 12.4 mill/ml). These data confirm the 
significantly decreased insulin secretion and impaired glucose tolerance in children 
with thalassaemia however, the mechanism of B-cell dysfunction is not mediated by 
neither ICA nor by cytokines.
The growth retardation of children with thalassaemia major is multifactorial. We 
studied the growth hormone (GH) response to provocation by clonidine and glucagon, 
measured the circulating concentrations of insulin, insulin-like growth factor-I (IGF-I),
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IGF-binding protein-3 (IGFBP3), and ferritin, and evaluated the IGF-I generation after 
a single dose of GH (0.1 mg/kg/dose) in 15 prepubertal patients with thalassaemia and 
15 age-matched children with constitutional short stature (CSS) ( height SDS below -2, 
with normal GH response to provocation). Children with thalassaemia had significantly 
lower peak GH response to provocation by clonidine and glucagon (6.9 +/- 2.9 ug/L and 
7.4 +/- 2.2 ug/L respectively) versus controls (18.6 +/- 2.7 ug/L and 16.7 +/- 3.7 ug/L 
respectively). They had significantly decreased circulating concentrations of IGF-I and 
IGFBP3 (49.6 +/- 21 ng/ml and 1.2 +/- 0.25 mg/L respectively) compared to controls ( 
153 +/- 42 ng/ml and 2.06 +/- 0.37 mg/L respectively). These data document defective 
GH/IGF-I/IGFBP3 axis in thalassaemic children. Serum ferritin concentration was
correlated significantly with GH peak response to provocation ( r=-0.34, PO.05), and 
circulating IGF-I (r = -0.45, P <0.01), and IGFBP3 (r = - 0.42, p< 0.01) concentrations. 
IGF-I generation test showed that after GH injection thalassaemic children have 
significantly lower IGF-I and IGFBP3 levels (90.8 +/- 10.8 ng/ml and 2 +/- 0.46 mg/L 
respectively) compared to controls (226 +/- 45.4 ng/ml, and 2.8 +/- 0.43 respectively). 
Six short (height SDS < -2) thalassaemic children who had defective GH response to 
provocation (< 10 ug/L) and 8 short normal children (CSS) were treated for one year 
with human GH (18 units/m2/week divided on daily S.C. doses). After one year of GH 
therapy there was a marked acceleration of growth velocity of both thalassaemic 
children (from 3.8 +/- 0.6 cm/yr. to 7.2 +/- 0.8 cm/yr.) and controls (9.9 +/- 1.2 cm/yr.). 
However, the linear growth velocity on GH therapy was significantly slower in 
thalassaemic children ( 3.3 +/- 0.3 cm increment) vs controls (5.3 +/- 0.4 cm increment) 
(p <0.05). After one year of GH therapy their circulating IGF-I concentrations (105 +/- 
36 ng/ml) were significantly lower compared to controls (246 +/- 58 ng/ml). These data 
show that some children with thalassaemia major have defective GH/IGF-I/IGFBP3 
axis and suggest the presence of partial resistance to GH.
We evaluated the spontaneous nocturnal (12-h) GH secretion and GH response to 
provocation in another group of prepubertal patients with thalassaemia and age- 
matched children with constitutional short stature (CSS) ( height SDS < -2, with normal 
GH response to provocation). The anatomy of the hypothalamic pituitary area was 
studied in patients with abnormal GH secretion using MRI scanning. This piece of 
study confirmed that children with thalassaemia had significantly lower peak GH 
response to provocation by clonidine and glucagon (8.8 +/- 2.3 m/L and 8.2 +/- 3.1 mg/L 
respectively) versus controls (17.6 +/- 2.7 ug/L and 15.7 +/- 3.7 ug/L respectively). They 
had significantly decreased circulating concentrations of IGF-I and IGFBP3 (68.5 +/- 19 
ng/ml and 1.22 +/- 0.27 mg/L respectively) compared to controls ( 153 +/- 42 ng/ml and 
2.16 +/- 0.37 mg/L respectively). Seven of the thalassaemic children had GH peak 
response < 7mg/L after provocation. Thalassaemic patients with normal GH response 
after provocation, also had significantly lower IGF-I and IGFBP3 concentrations 
compared to controls. Serum ferritin concentration was correlated significantly with 
the circulating IGF-I (r = -0.47, P <0.01), and IGFBP3 (r = - 0.43, p< 0.01) 
concentrations.
Analysis of their GH pulse properties revealed lower mean nocturnal GH (2.9 +/- 
1.77mg/L) and integrated nocturnal GH ( 2.53 +/- 1.6 mg/L) concentrations versus 
controls ( 4.9 +/- 0.29 mg/L and 5.6 +/- 0.52 mg/L respectively). They also had lower 
mean pulse amplitude (9.2 +/- 2.2 jag/L) versus controls (17.2 +/- 2 ^ig/L). Five of them 
had mean nocturnal GH concentration < 2mg/L and four had maximum nocturnal peak 




MRI studies revealed complete empty sella (n= 2) , marked diminution of the pituitary 
size (n=4) , abnormal signal pattern of the gland (n=4) and thinning of the pituitary 
stalk (n=3) with its posterior displacement (n=2) in those patients with defective GH 
secretion (n= 9). Collectively, these data confirm the presence of high incidence of 
functional and structural abnormalities of the GH/IGF-I/IGFBP3 axis in short children 
with thalassaemia major as manifested by either defective GH response to provocation 
and/or neurosecretory dysfunction of GH secretion.
Patients with beta-thalassaemia major frequently have bone disorders of multifactorial 
aetiology. We attempted to analyse the relationship between bone mineral density 
(BMD) (measured by dual photon absorptiometry) on the one hand and auxologic 
parameters, degree of siderosis, function of the growth hormone (GH)/insuIin-like 
growth factor-I (IGF-I)/ IGF-binding protein-3 (IGFBP3) axis, calcium-phosphate 
balance, parathormone (PTH), and cytokines {interleukin-1-beta (IL-l-B) and tumour- 
necrosis factor-alpha (TNF-A)} in 30 prepubertal children with thalassaemia major and 
15 age-matched children with constitutional short stature (CSS), who have normal 
glucose tolerance and thyroid function. Children with thalassaemia had significantly 
decreased BMD and BMD% of average for age and sex ( 0.75 +/- 0.24 g/cm2 and 71 +/- 
10% respectively) versus children with CSS (1.06 +/- 0.3 g/cm2 and 92 +/- 7% 
respectively). Thalassaemic patients had significantly lower circulating concentrations 
of IGF-I and IGFBP3 ( 49 +/- 21 ng/ml and 1.2 +/- 0.25 mg/L respectively) compared to 
control children (153 +/- 42 ng/ml and 2.1 +/- 0.37 mg/L respectively). GH response to 
provocation by clonidine and glucagon was defective (peak GH < 7 ug/L) in 12 out of 
the 30 thalassaemic children. Serum concentration of IL-l-B and TNF-A did not differ 
among the two study groups, hypocalcaemia was detected in 5 out of the 30 
thalassaemic patients. Hypoparathyroidism was diagnosed in two of the 5 and rickets 
(osteomalacia) in the other 3 patients. The BMD was highly correlated with the 
circulating concentrations of IGF-I, IGFBP3 as well as with the auxologic parameters 
(age, weight, height, height standard deviation score and body mass index). It is 
suggested that increasing the circulating IGF-I concentration through aggressive 
nutritional therapy and/or via GH/IGF-I therapy with supplementation with vitamin-D 
and/or calcium might improve bone growth and mineralisation and prevent the 
development of osteoporosis and consequently fractures in these patients. Such therapy 
requires blinded controlled trials.
Patients with SCD also frequently have bone disorders of multifactorial aetiology. This 
study analysed the relationships between BMD on the one hand and auxologic 
parameters, degree of siderosis, function of GH/IGF-LTGFBP3 axis, and calcium- 
phosphate balance in 28 prepubertal children with SCD and 15 age-matched children 
with constitutional delay of growth (CSS). Children with SCD had significantly 
decreased BMD (77.9 +/- 11.9 per cent of normal BMD for age and sex) and circulating 
concentrations of IGF-I (91 +/- 31 ng/ml) and IGFBP3 (1.7 +/- 0.44 mg/ml) versus the 
control group (BMD = 93.5 +/- 8.2 per cent of normal BMD for age and sex, IGF-I = 221 
+/- 48 ng/ml, and IGFBP3 = 2.3 +/- 0.34 mg/ml). GH response to provocation was 
defective (peak below 10 ug/L) in 40 per cent of children with SCD. Siclders with 
defective GH secretion had significantly lower circulating IGF-I concentration and 
BMD compared to those with normal GH secretion. Serum calcium, phosphate and 
alkaline phosphatase concentrations were normal in all children with SCD. The BMD 
was correlated significantly with height, weight, and body mass index as well as with 
the circulating concentrations of IGF-I and IGFBP3. It is suggested that increasing the 
circulating IGF-I concentration either through improving nutrition and increasing 
caloric intake and/or via GH/IGF-I therapy can improve growth and bone 
mineralisation in these patients.
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In conclusion, children with thalassaemia major and SCD have significantly high 
incidence of delayed growth and sexual maturation which appear to be multifactorial. 
Assessment of the auxological, biochemical, hormonal and radiological data of these 
children has revealed many original facts and clarified others. 1. Many short 
thalassaemic and sickler children have defective GH secretion in response to 
provocation. 2. Some children with thalassaemia have neurosecretory dysfunction of 
GH secretion. 3. Both thalassaemic and sickler children have significantly decreased 
circulating IGF-I and IGFBP3 concentrations as well as defective IGF-I synthesis in 
response to exogenous GH injection suggesting a state of partial GH resistance 
(insensitivity). 4. Thalassaemic children on high-transfusion and iron chelation develop 
progressive insulin deficiency and hyperglucagonaemia before developing significant 
insulin-resistance or impaired glucose tolerance. Deficiencies of these growth factors 
(GH, IGF-I, IGFBP3, and insulin) appear to play a major role in the production of 
delayed growth in these patients. 5. Hepatic dysfunction, either due to siderosis and/or 
chronic viral hepatitis, might cause state of GH and insulin-resistance in thalassaemic 
patients.. 7. These functional abnormalities of the GH/IGF-I/IGFBP3 axis is 
accompanied by structural abnormalities of the pituitary gland and its stalk in patients 
with thalassaemia and SCD. 8. Thalassaemic children, but not those with SCD, might 
have other endocrinopathies including hypothyroidism, hypoparathyroidism and 
defective cortisol secretion in response to ACTH. 9. GH therapy produced increased 
growth rate in children with thalassaemia however, the increments of GV were 
significantly lower than for those with CSS or GHD denoting that these patients need 
supraphysiologic doses of GH to overcome their partial GH resistance. 10. Delayed 
and/or failure of puberty in patients with thalassaemia and SCD contributes to the 
aetiology of defective linear growth due to the failure or the attenuated pubertal (sex- 
steroid- dependent) growth spurt. 11. Children with thalassaemia and SCD have low 





 Forty nine percent of children with beta thalassaemia on frequent blood 
transfusion and iron chelation are short ( HtSDS below -2) and eighty three 
percent of them had slow linear growth velocity (GVSDS below -1).
  Seventy three percent of thalassaemic males above the age of 14 years do not 
have testicular development. Spontaneous menarche and breast development 
occur only in 26 and 42 percent of thalassaemic females above the age of 13 
years.
  Children with thalassaemia have high prevalence of HBS antigenaemia and 
HCV antibody seropositivity ( 44.4 and 23.5 percent) compared to normal age 
matched children. Serum ALT concentrations are significantly correlated 
with HtSDS. These findings suggest that impaired hepatic function secondary 
to siderosis or chronic hepatitis might contribute to linear growth impairment.
 Thalassaemic children have progressive and early dysfunction of pancreatic 
B-cells manifested by decreased insulin release in response to oral and i.v. 
glucose and arginine infusion, before the development of significant insulin 
resistance or impairment of glucose tolerance. They have significant 
hyperglucagonaemia not suppressible with oral glucose. The mechanism of B- 
cell dysfunction is not mediated neither by ICA nor by cytokines.
 Thalassaemic children have high prevalence of defective GH/IGF-I/BP3 axis 
as shown in this thesis by: 1. Defective GH response to provocation by 
clonidine and glucagon, 2. Defective spontaneous nocturnal secretion of GH 
(neurosecretory dysfunction of GH ) in many children who have normal GH 
response to provocation, 3. Decreased circulating concentrations of IGF-I and 
IGFBP3, 4. Impaired IGF-I generation after exogenous injection of GH, 5. 
Slower linear growth velocity on GH therapy compared to children with CSS 
and those with GHD. The latter two findings suggest the presence of partial 
GH resistance in these patients.
 MRI scanning of their hypothalamic-pituitary area showed many structural 
abnormalities including different degrees of pituitary atrophy and 
haemosiderin infiltration of the pituitary gland and midbrain. These 
structural alterations are correlated with defective spontaneous GH secretion 
in these patients.
 Thalassaemic children had significantly reduced bone mineral density 
(BMD) which significantly increase the risk for fractures. Their BMD is 
correlated significantly with HtSDS and circulating concentrations of IGF-I 
and IGFBP3 and negatively with serum ferritin concentration. Hypocalcaemia 




 Twenty seven percent of children with are short ( HtSDS below -2) and sixty 
seven percent of them had slow linear growth velocity (GVSDS below -1).
 Twenty two percent of males with SCD above the age of 14 years do not 
have testicular development. Spontaneous menarche occurs only in 50 
percent of females with SCD above the age of 13 years.
 Children with SCD do not have high prevalence of HBS antigenaemia and 
HCV antibody seropositivity compared to normal age matched children. 
Sicklers with HBS antigenaemia have higher serum ALT concentration versus 
those without the antigenaemia. Serum ALT concentrations are significantly 
correlated with HtSDS. These findings suggest that impaired hepatic function 
secondary to siderosis or chronic hepatitis might contribute to linear growth 
impairment.
 Children with SCD have high prevalence of defective GH/IGF-I/BP3 axis as 
shown in this thesis by: 1. Defective GH response to provocation by clonidine 
and glucagon, 2. Decreased circulating concentrations of IGF-I and IGFBP3, 
3. Impaired IGF-I generation after exogenous injection of GH, 4. Rapid 
deceleration of linear growth after the first year of GH therapy.
 CT scanning of the hypothalamic-pituitary area of sicklers with defective 
GH secretion reveals empty sella in 100 percent of these patients suggesting 
anoxic injury of the pituitary gland during one or more of the sickling 
episodes with secondary degeneration and atrophy.
 Children with SCD had significantly reduced bone mineral density (BMD) 
which significantly increase the risk for fractures. Their BMD is correlated 
significantly with height, weight, and BMI as well as with the circulating 






1. High- and or super- transfusion and iron chelation programmes should be optimised 
to offer adequate haemoglobin level without the deleterious effects of iron overload 
on all tissues including the liver, pancreas, and pituitary gland in patients with 
transfusion -dependent thalassaemia and SCD.
2. Aggressive nutritional support to improve the quality and quantity of food intake in 
these patients should be an integral part of their treatment protocol.
3. Vaccination against hepatitis B and meticulous screening of blood before transfusion 
should help reduce the high prevalence of chronic hepatitis and deterioration of 
hepatic function in these patients.
4. Linear growth should be monitored closely in these patients and short children 
(HtSDS below -2) or those with slow GV should be investigated for GH/IGF-I 
deficiency. In addition, thyroid function and glucose tolerance of short and/or slowly 
growing children with thalassaemia should be investigated.
5. Adolescents with delayed and/or failure of puberty should be investigated early for 
gonadotropin release and sex-steroid secretion. Those with hypogonadism should be 
treated early and adequately with either gonadotrophins (human chorionic 
gonadotropin) and or sex-steroids to improve their pubertal growth spurt, bone 
accretion and sexual development and function.
6. Studying the anatomy of the pituitary gland by MRI imaging is a helpful tool to 
prove the structural abnormality and support the finding of defective GH secretion 
in these children.
7. Children with thalassaemia and SCD who have defective GH secretion and low 
circulating IGF-I should receive either GH and/or IGF-I replacement therapy to 
improve linear growth and increase bone mass. However, patients with 
thalassaemia might need supraphysiologic doses of GH to overcome their partial GH 
resistance.
8. A large double-blind controlled study is required to investigate the long-term effect 
of GH/IGF-I replacement, vitamin-D and calcium supplementation, and 
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Thalassaemia and sickle cell disease (SCD) are the most widely distributed blood 
genetic disorders that occur at a high frequency in some populations including 
the Mediterranean region, parts of the Middle East, South East Asia and the 
Indian subcontinent. It is estimated that thalassaemia major affects 100,000 new- 
born every year world-wide. The high incidence of these chronic haemolytic 
diseases in developing countries poses a high load on the national economy 
because of the expensive treatment protocols and the considerably high 
morbidity rates of these patients. Repeated blood transfusion to keep 
haemoglobin above an acceptable level requires well-equipped blood banks with 
expensive facilities to screen, store and manipulate blood and blood products. 
Iron chelation therapy is an essential part of treatment to avoid or delay the 
deleterious effects of iron overload on different organs including the liver, heart, 
pancreas and endocrine glands. This requires injecting deferoxamine 
subcutaneously for 12 hours daily with a special pump. Both deferoxamine and 
pumps are expensive and therefore not accessible for all patients.
In developing countries, the majority of transfusion-dependent patients with 
chronic haemolytic anaemia (thalassaemia and SCD) suffer from the 
consequences of sub-optimal treatment. The mortality rate is still high and 
usually patients die before the age of 30 years. They also suffer from chronic 
multi-organ damage including cardiac failure, liver cirrhosis, insulin-dependent 
diabetes mellitus, growth and pubertal failure and many skeletal abnormalities 
and fractures. In developed countries the introduction of high transfusion 
regimes and efficient chelation therapy improved survival rates and prevented 
cardiac and hepatic damage. However, a majority of thalassaemic patients still 
have significant growth and pubertal abnormalities, bone disease and multiple 
endocrine disorders.
In Egypt the incidence of thalassaemia major ranges between 0.1 - 0.2% which 
gives very high patient load on the medical services. In our University of 
Alexandria Children's Hospital, Alexandria, Egypt. The Haematology clinic has 
an average of 150 thalassaemic children registered. The same problem is 
encountered by me in the Royal Hospital, Muscat, Oman, with high prevalence 
of SCD and thalassaemia and suboptimal treatment. Because of the restricted 
economic resources, both hospitals adopt a low transfusion therapy (to keep 
haemoglobin above 9 g/dl) with IM chelation 3 times per week. With this form of 
sub-optimal treatment we observed that a large number of our thalassaemic 
children have severe growth and pubertal failure/delay, beside other hepatic, 
cardiac and skeletal abnormalities. In fact they constitute 40% of patients 
attending our Endocrinology clinic. This stimulated me to perform an extensive 
study to survey growth and pubertal development in theses patients (study-1) 
and investigate the different factors that might affect their growth and pubertal 
development (studies 4 through 10) as well as bone mass density (studies 11,12). 
The frequent involvement of the liver in these patients led us to study some 
hepatic functions and the prevalence of transfusion-associated hepatitis B 
surface antigenaemia and hepatitis-C virus antibody seropositivity in relation to
their linear growth (studies 2,3). We studied the nutritional intake of these 
patients, their intestinal absorption of D-Xylose and 48-h stool fat content in 
relation to their body mass index, subcutaneous fat thickness and mid-arm 
circumference (studies 4,5,9).
Their defective linear growth urged us to investigate their growth hormone (GH) 
secretion (spontaneous nocturnal as well as after provocation) and insulin-like 
growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP3) concentrations. 
Our findings demonstrated high prevalence of defective GH secretion in these 
children that necessitated imaging of their hypothalamic pituitary area. Imaging 
studies revealed original data about structural abnormalities in the anterior 
pituitary gland, different degrees of pituitary atrophy and empty sella and 
infiltration the gland as well as the mid-brain by haemosidrin in thalassaemic 
children, the mechanism of these findings was explained (studies 4-6,10). 
Because of their slow growth, the presence of abnormal GH/IGF-I/BP3 axis, and 
structural abnormalities of the pituitary gland, the next step dealt with the 
response of IGF-I to exogenous GH and the clinical response of their linear 
growth to GH therapy for a year or more (studies 4,9).
Based on the fact that these patients have high prevalence of bone pains and 
osteoporosis during late childhood and have high risk of spontaneous fracture 
thereafter, we measured their bone mass density to investigate the relation 
between the former and the degree of iron load, growth parameters, and 
different anabolic hormone concentrations in these patients (studies 11,12).
The overview contains the details of all the 12 studies, 
summary and recommendations. For tables and 
figures please refer to the original papers (1-12) 
included in the APPENDIX.
Growth and Pubertal Development in 
Transfusion-Dependent Children and Adolescents with 
Thalassaemia Major and Sickle Cell Disease (SCD): 
A Comparative Study
by Ashraf T. Soliman MD,* Mahmoud ElZalabany MD,* Maysa Amer MD, and B. M. Ansari FRCP**
* Department of Paediatrics, University of Alexandria Children's Hospital, Alexandria, Egypt
** Department of Paediatrics, East Glamorgan General Hospital, Church Village, and School of Applied Sciences, 
University of Glamorgan, Pontypridd, Wales, UK
Summary
Despite regular blood transfusion and desferrioxamine treatment, growth impairment and pubertal 
delay are commonly seen in children and adolescents with transfusion-dependent thalassaemia and 
sickle cell disease (SCD). We evaluated growth parameters and sexual maturation in a large cohort of 
children and adolescents with SCD (n = 110) and thalassaemia (n = 72) receiving nearly the same 
protocol of transfusion and chelation, and compared them with those for 200 normal age-matched 
children, 30 children with constitutional delay of growth (CSS), and 25 children with growth 
hormone deficiency (GHD). Before transfusion, haemoglobin concentration had not been less than 
9g/dl in the past 7 years; desferrioxamine was administered for 7-10 years, including by the 
intramuscular and subcutaneous routes, three times or more per week. The height standard deviation 
score (HtSDS), growth velocity (GV) (cm/yr), and growth velocity standard deviation score (GVDSD) 
of children and adolescents with thalassaemia and SCD were significantly decreased compared to 
normal children (p < 0.01). Forty nine per cent of thalassaemic patients and 27 per cent of patients 
with SCD had HtSDS less than -2, and 83 per cent of thalassaemic patients and 67 per cent of SCD 
patients had HtSDS less than  1. Fifty six per cent of thalassaemic children and 51 per cent of 
children with SCD had GVSDS less than -1. The GV of thalassaemic children was significantly 
slower than that for children with SCD. Children with thalassaemia and SCD had HtSDS and 
GVSDS comparable to those for children with CSS but higher than those for patients with GHD. 
Serum ferritin concentration was correlated significantly with the linear GV in all patients (r = 0.45, 
p < 0.001). The bone age delay did not differ among the three groups with thalassaemia, SCD and 
CSS, but the delay was significant in the group with GHD. The mid-arm circumference was 
significantly smaller in children with thalassaemia and SCD than in normal children. The triceps 
skin-fold thickness of patients with SCD was significantly decreased compared to thalassaemic and 
normal children. The upper/lower segment ratio was significantly lower in thalassaemic and SCD 
patients than in normal children. In thalassaemic patients between the ages of 13 and 21 years a 
complete lack of pubescent changes was present in 73 per cent of boys and 42 per cent of girls. Seventy 
four per cent of the thalassaemic girls had primary amenorrhoea. Girls with SCD aged between 13 
and 21 years had markedly delayed breast development and menarche. Twenty five per cent of boys 
with SCD above the age of 14 years had absence of testicular development Males with thalassaemia and 
SCD who had spontaneous testicular development had significantly smaller testicular volume than did 
normal controls. Short children with thalassaemia and SCD had significantly decreased serum insulin- 
like growth factor 1 (IGF-1) concentrations compared to children with CSS. Collectively, these data 
confirm the high prevalence of impaired growth and pubertal delay/failure In children and adolescents 
with thalassaemia and SCD. The aetiology of impaired growth Includes the contributions of lack of 
pubertal growth spurt due to delayed/absent puberty, decreased synthesis of IGF-1 which might be 
secondary to a disturbed GH-IGF-1 axis and/or under nutrition, probably due to the hypermetabolic 
status of these children. It is suggested that newer protocols of treatment, in addition to optimization of 
transfusion and chelation requirements, should increase the caloric intake of these patients and 
properly manage their pubertal delay-failure in order to improve their adult height
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Introduction
The prognosis for transfusion-dependent chronic haemc- 
lytic anaemias has greatly improved. 1 " 2 With more 
intensive transfusion regimens and administration of 
adequate chelation therapy, life expectancy has 
increased. Growth and pubertal delay and/or failure 
represent major obstacles to the fulfilment of successful 
therapy of these diseases. 8 '9 Controversy still exists 
about the effect of different regimens of blood transfu- 
sion and chelation on linear growth and pubertal 
development in these patients. Some investigators 
claim normalization of growth and pubertal develop- 
ment 101 " whereas others report only suboptimal 
improvement of linear growth.6"9 We performed a 
systematic survey of growth and pubertal development 
in a large cohort of patients with thalassaemia major and 
sickle cell disease (SCO), all of whom had received the 
same treatment during the past 10 years, to investigate 
the effect of this regimen on growth and pubertal 
maturation of these patients.
Patients and Methods
All patients with transfusion-dependent thalassaemia 
major and SCD were randomly selected from the 
Haematology Clinics of the Royal Hospital and Alex- 
andria University Children's Hospital, Alexandria, 
Egypt. The participating hospitals were chosen with 
consideration of homogeneity of the treatment protocol. 
Mean pre-transfusion haemoglobin (Hb) concentration 
was 9 g/dl in the past 7 years in most patients; individual 
variability was not such as to permit comparisons 
between patients. They received desferrioxamine 
(50 mg/kg/dose) by intramuscular or subcutaneous 
injection three times weekly. AH were on folic acid 
supplements and all had been vaccinated against 
pneumococci. Two hundred age- and sex-matched 
normal, randomly selected children, 30 children with 
constitutional delay of growth (CSS) (HtSDS =£ - 2, 
with delayed bone age and normal growth hormone (GH) 
response to provocation), and 25 children with isolated 
GH deficiency (GHD) served as controls. None of the 
children had a history of intrauterine growth retardation, 
any other systemic or endocrine disease, dysmorphic 
trait, or central nervous system irradiation. Informed 
consent for the testing procedures was obtained from the 
parents of all children. All children were examined with 
special emphasis on nutritional data. A special form was 
prepared for this study. The anthropometric measure- 
ments included weight to the nearest lOOg, height to the 
nearest mm, mid-arm circumference (MAC), and triceps 
and subscapular skin-fold thickness during a hospital 
visit at the'time of the study, Harpenden's callipers and 
anthropometric measurements were used. The data 
recorded were the average of three sequential measure- 
ments determined by the same observer (A.S.T.). The 
height standard deviation score (HtSDS) was calculated 
according to the formula HtSDS = (X, - X2)/SD, where
X2 and SD are the age-matched population mean height 
and SD, respectively, and X\ is the subject's height. The 
height growth velocity (GV), in cm/year, was calculated 
for a complete year, following the first measurement. 
Normal population data were according to Tanner et 
a/.23 The body mass index (BMI) was calculated 
according to the formula weight (kg)/[height (m)]2 . 
The bone age and stages of sexual maturation were 
evaluated according to Greulich and Pyle2" and Tanner 
et a/. 23 respectively, and the age of menarche and early 
breast development were recorded.
In a randomly selected sample of short children 
(height less than fifth centile for age and sex) from each 
group [thalassaemia (n = 15), SCD (n = 21), and CSS 
(n = 10)] a fasting venous blood sample was obtained 
and kept frozen at  20°C until analysed for thyroxine 
(free T4 , FT4), thyrotrophin (thyroid-stimulating hor- 
mone, TSH), and insulin-like growth factor 1 (IGF-1) 
concentrations by radioimmunoassay. All samples from 
all children were assayed simultaneously. IGF-1 con- 
centrations were measured by radioimmunoassay, 
employing reagents purchased from the Nichols Institute 
(San Juan Capistrano, CA, USA). The intra-assay 
coefficient of variation averaged 8.2 per cent in the 
range of IGF-1 concentrations measured. Free T4 and 
TSH were measured using Amerlex-RIA kits (Kodak 
Clinical Diagnostics). Statistical analyses were per- 
formed using the ANOVA test to compare mean analyte 
concentrations among the different groups. Statistical 
significance was accepted at p < 0.05. The linear 
regression equation was used to test the relation between 
variables.
Results
The anthropometric and bone age data of the four study 
groups are presented in Table 1. The HtSDS, GV, and 
GVSDS of patients with thalassaemia and SCD were 
significantly decreased compared to normal children 
(p<0.01). The HtSDS of thalassaemic children was 
significantly lower than that for children with SGD. Both 
groups had HtSDS higher than those with GHD. The GV 
and HVSDS of patients with thalassaemia were lower 
than that for SCD, but the difference did not attain 
statistical significance for the GVSDS (p = 0.09). 
Children with thalassaemia and SCD had GV and 
GVSDS significantly higher that those with GHD but 
not different from those with CSS. The bone age delay 
(years) did not differ among the three study groups with 
thalassaemia, SCD, and CSS. The BMI of thalassaemic 
patients was significantly higher than that for the other 
groups. The means of the mid-arm circumference and 
triceps skin-fold thickness were significantly decreased 
in children with SCD compared to normal children 
(Table 2). In thalassaemic children, the mid-arm 
circumference was significantly smaller than that for 
normal controls. Their triceps skin-fold thickness was 
comparable to that for normal children. Assessment of 
the food intake, using the recall method for the past three
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TABLE 1 
Anthropometric and bone age data (mean ± SD)
Thalassaemia (n = 70)
SCD(n = 110)
CSS (n = 30)
GHD (n = 25)
Normal





































































* p < 0.05, groups with disease vs. normal children. 
V < 0.05, thalassaemia vs. SCO.
days, failed to detect any qualitative or quantitative 
deficiency in food consumption by children with 
thalassaemia and SCO. The upper segment/lower seg- 
ment (U/L) ratio in children with thalassaemia 
(0.85 ± 0.07) and SCO (0.89 ± 0.09) was significantly 
lower than for age-matched controls (1.09 ± 0.6).
Figures 1 and 2 and Table 3 show the HtSDS, GVSDS, 
and BMI data of children with thalassaemia and SCO. 
Linear growth was significantly impaired in both groups 
of children with thalassaemia and SCD. Forty nine per 
cent of the thalassaemic children and 27 per cent of those 
with SCD had HtSDS < -2. Eighty three per cent of 
thalassaemic children and 67 per cent of children with 
SCD had HtSDS below -1. A considerably large 
percentage of thalassaemic and sickle-cell children had 
slow growth velocity; 56 per cent of thalassaemic 
children and 51 per cent of children with SCD had 
GVSDS below -1 during a full year of linear growth. 
Figure 3 shows scattergrams of chronological age versus 
HtSDS and GVSDS in patients with thalassaemia and 
SCD. The age was correlated negatively with HtSDS 
(r = 0.405, P < 0.01) and GVSDS (r = 0.2, p = 0.04) 
(Fig. 3) suggesting progressive growth retardation with
TABLE 2
Mid-arm circumference (MAC) and triceps skin- 
fold thickness (Tri-SFT)
Thalaxsaemia (n = 72)
SCD (n = 10)

















*p < 0.05, groups with disease vs. controls. 
'p < 0.05, thalassaemia vs. SCD.











Fio. 1. Growth data for patients with thalassaemia major, 
(a) HtSDS vs. age; (b) GVSDS vs. age; and (c) BMI vs. 
age.
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Fio. 2. Growth data for patients with SCD. (a) HtSDS vs. 
age; (b) GVSDS vs. age; (c) BMI vs. age.
age in these patients. Serum ferritin concentration was 
correlated negatively with GV (r = 0.45, p< 0.001) 
(Fig. 4).
Pubertal development data are shown in Table 4. If 
testicular volume &3 ml and breast development >B 1 are 
taken as evidence of the beginning of pubertal develop- 
ment, a considerable number of patients had not 
experienced sexual maturation, even at ages when this 
is the rule in normal subjects. The data from 22 
thalassaemic boys between the ages of 14 and 21 years 
(16.9 ± 3.8 years) showed that only six (27 per cent) of 
them had testicular enlargement (volume >3 ml). Their 
mean testicular volume was 6.8 ± 2.5 ml. Out of the 19 
thalassaemic girls between the ages of 13 and 22 years 
(17.2 ± 3.2 years) only five (26 per cent) had sponta- 
neous menarche at a mean age of 17.5 ± 1.2 years. 
Breast development was delayed in 11 (B2 at mean age 
of 15.7 ± 1.5 years) and absent in eight of them. Three 
out of the five patients who had spontaneous menarche 
had irregular menstrual cycles and two of the three had 
secondary amenorrhoea.
20
-6 -4 -3-2-1012 
GVSDS
Fig. 3. Relationship between age and (a) HtSDS 
(r = -0.405, p < 0.001) and (b) GVSDS (r = -0.02, 
p = 0.04).
In girls with SCD above the age of 13 years 
(16.5 ± 3.2) (n = 16), 14 girls had delayed breast 
development (B2) after the age of 13 years (mean age 
of 13.5 ± 0.4 years) and only two had breast develop- 
ment before the age of 13 years (B2 at mean age of 
12.5 ±0.4 years). Seven girls out of the 14 had 
spontaneous menarche at an age of 15.6 ± 0.7 years. 
Out of the 18 boys with SCD above the age of 14 years 
(17.1 ± 2.8 years) had testicular volume above 3ml 
(Tanner score of 2 or more) and four (25 per cent) had 
testicular volume <3 ml at the age of 14, 14.5, 15.5, and 
16 years respectively. Their mean testicular volume was 
8.5 ± 3.1 ml. The pubertal status of 30 normal males 












Relationship between serum ferritin level and 
velocity (r = -0.45, p < 0.001).
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TABLE 3 

























































*p < 0.05 between groups.
TABLE 4 
Pubenal development in patients and normal controls








































Menarche: age at first menstrual period; B2: age at 'tanner stage 2' of breast development. 
* p < 0.05, groups vs. controls.
16.2 ± 2.3 years) between the ages of 13 and 21 served 
as controls. The mean age for starting breast develop- 
ment (B2) ranged between 9.5 and 13.1 years with a 
mean of 10.7 ± 0.8 years. The mean age of menarche 
was 13.4 ± 1.2 years. All the normal adolescent boys 
(n = 30, age 16.9 ± 2.6 years) had testicular volume 
above 4 ml. Their mean testicular volume was 
12.4 ±3.4 ml.
The auxological, biochemical, and hormonal data of 
the short children (height less than fifth percentile) with 
thalassaemia, SCD, and CSS are presented in Table 5. 
Serum ferritin and alanine-transferase concentrations 
were significantly higher in thalassaemic children versus 
the other two groups. Insulin-like growth factor 1 
concentration was significantly lower in children with 
thalassaemia and SCD than in children with CSS. 
Circulating IGF-1 concentrations were significantly 
lower in children with thalassaemia than in those with 
SCD. FT4 and TSH concentrations did not differ among 
the three study groups.
Discussion
Subjects from the study cohort were diagnosed either at 
birth or during infancy and constitute a representative 
sample of children with thalassaemia and SCD. Analysis
Journal of Tropical Pediatrics Vol.00 Month 1998
of cross-sectional and longitudinally collected auxolo- 
gical data and comparison with normal children as well 
as with two groups of children with CSS and isolated 
GHD allowed better evaluation of growth in these 
patients. The present data show the high prevalence of 
short stature in children with thalassaemia and SCD 
during childhood and adolescence. This was more 
marked in thalassaemia; about half of the thalassaemic 
children had HtSDS <  2, denoting marked linear 
growth retardation. In addition the linear growth velocity 
of more than half of the children with thalassaemia and 
SCD was slow (GVSDS < -1). Again this slow GV was 
more marked in thalassaemic children than in children 
with SCD. The HtSDS and GVSDS of children with 
thalassaemia and SCD were comparable to those for 
children with CSS and significantly higher than for 
children with GHD. The skeletal age, as well, was more 
delayed in children with GHD versus those with 
thalassaemia and SCD. Collectively these data, in 
accord with the results of other investigators, 1 "9 confirm 
a delay in linear growth in children with thalassaemia 
and SCD. The significant (negative) correlation between 
the chronological age on the one hand and the HtSDS 
and GVSDS on the other hand point to the fact that linear 
growth delay increases progressively with age in these 
patients.
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TABLE 5 
Auxological parameters and biochemical data
M/F
Age (years)









































































*/> < 0.05, groups vs. CSS.
The mean MAC of patients with thalassaemia and 
SCD was significantly smaller than that for the age- 
matched controls. In addition, children with SCD had 
significantly smaller skin-fold thickness and lower BMI 
than normal controls. These findings indirectly denoted 
decreased mis-arm muscle mass in patients with 
thalassaemia and SCD and decreased subcutaneous fat 
deposition in patients with SCD. Undemutrition, either 
due to decreased food intake and/or secondary to a 
hypermetabolic state23 '26 due to increased bone marrow 
activity, and/or deficiency of the anabolic hormones (e.g. 
IGF-1) could be aetiologic factors. The higher BMI in 
patients with thalassaemia does not accurately reflect the 
nutritional status because of the frequent finding of 
considerable hepatomegaly and/or splenomegaly in 
thalassaemic patients, disturbing the ratio of weight 
and height. Assessment of dietary intake of these patients 
did not detect any qualitative or quantitative abnorm- 
ality, denoting that probably other factors such as 
hypermetabolism and/or defective intestinal absorption 
of nutrients27 might be the case.
Delayed onset of puberty was a frequent finding in 
both boys (testicular enlargement) and girls (breast 
develoment and menarche) with thalassaemia and SCD. 
The delay/failure of puberty was more pronounced in 
patinets with thalassaemia, with more than 70 per cent of 
girls having primary or secondary amenorrhea and more 
than 70 per cent of boys older than 14 years having 
delayed testicular development. In these patients the 
significantly low U/L segment ratio might reflect the 
hypogonadal status of these children, but it might also be 
due to vertebral changes secondary to hyperactivity of 
the bone marrow.
The aetiology of retarded growth in children with 
thalassaemia and SCD is probably multifactorial, 
with contributions from abnormal endocrine function,8" 
11,20,22.28-34 suboptjmai nutrition,34'35 an increase in 
metabolism due to hyperactivity of the bone
marrow, ' and hypogonadism. In this study, serum 
IGF-1 concentrations were significantly depressed in 
short children with thalassaemia and SCD compared to 
short normal children, denoting defective IGF-1 synth- 
esis in these patients. This might be due to defective GH 
secretion36 and/or resistance to GH due to liver 
siderosis.41 The significant (negative) correlation 
between GV (cm/year) and serum ferritin concentrations 
supports the view that decelerated growth occurs with 
increasing iron load. Undemutrition, shown in our 
patients by reduced mid-arm circumference and sub- 
cutaneous fat thickness, might contribute to growth delay 
in these children through decreased IGF-1 synthesis. 
Although analysis of qualitative and quantitative food 
intake, using the recall method, failed to detect any 
abnormality, Undemutrition might nevertheless be 
caused by the hypermetabolic state of these children 
presumably due to hyperactivity of their erythropoiesis. 
Some investigators report improvement of growth after 
increasing the caloric intake of these patients.42 More- 
over, in many hypermetabolic states there is some degree 
of GH resistance, which might be a contributing factor in 
decreased synthesis of IGF-1 and consequently delayed 
growth.43 Although other endocrinopathies, like 
hypothyroidism and diabetes mellitus, could adversely 
affect growth in these patients, none of the patients 
included in this study had abnormal thyroid function or 
impaired glucose tolerance.
Delayed and/or failure of puberty occurred in 
considerably large numbers of males and females with 
thalassaemia and SCD. The lack of the synergistic action 
of sex steroids on the pubertal growth spurt appears to be 
a major factor contributing to growth delay in these 
patients. In this study, HtSDS and GVSDS were 
correlated negatively with chronological age, denoting 
that as patients with thalassaemia grow older without 
achieving pubertal development, their linear growth 
becomes more delayed. The low U/L segment ratio in
Journal of Tropical Pediatrics Vol.00 Month 1998
Journal of Tropical Pediatrics 648 JTP JT0195 AP 15/9/98 15:31
A. T. SOUMAN ET AL.
patients, similar to those with hypogonadism, supports 
the concept that lack of sex steroid affects linear growth 
in these patients.
Collectively, the marked delay or failure of growth 
and puberty in children with thalassaemia major and 
SCO denotes that treatment with the current transfu- 
sion and chelation protocol is suboptimal and necessi- 
tates the application of a more aggressive programme 
of hypertransfusion and iron chelation to improve 
growth in these patients. Improvement of nutritional 
status, by increasing caloric intake, should be an 
essential part of any new protocol of treatment for 
these patients. Early detection of delayed/failed pub- 
erty and management by proper physiological replace- 
ment of sex steroids and/or gonadotrophins should 
improve their pubertal growth.
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lepatitis-B Surface Antigenaemia in Omani Children 
rith Sickle Cell Disease
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Summary
The prevalence of persistent hepatitis-B surface (HBS) antigenaemia and hepatic functions have been 
determined in 125 children with sickle cell disease (SCO) as well as in 100 age-matched healthy children. 
Hepatic functions and the presence of HBS antigenaemia have been followed for 1 year in six children with 
SCO and 10 normal children following acute hepatitis-B infection. The prevalence of chronic HBS 
antigenaemia (3 per cent) in children with SCO is not higher than in normal children (11 per cent). The 
significant elevation of serum alanine transferase (ALT) and bilirubin concentrations in sickle cell children 
denotes a process of mild bepatocellular dysfunction which is unrelated to hepatitis-B viral antigenaemia. 
The high incidence of chronic HBS antigenaemia accompanied by elevated serum ALT and bilirubin 
concentrations in sickle cell children following acute hepatitis-B infection, in addition to the significant 
impairment of hepatic functions in sicklers with chronic HBS antigenaemia compared to those without the 
antigenaemia, point out to the high risk of continual parenchyma! hepatic damage in these children 
following acute hepatitis-B infection. Vaccination against hepatitis-B virus should eliminate this risk.
Introduction
Jaundice can occur in any haemolytic anaemia, owing 
loan increase in the level of unconjugated bilirubin. 
Patients with chronic haemolytic anaemias, undergo- 
ing repeated blood transfusions, have an increased risk 
of developing hepatitis. 1 In sickle cell disease the liver 
is often enlarged and tender during acute crisis, with 
some abnormalities of hepatic functions. 2 Histology 
reveals clumps of erythrocytes, platelets, and fibrin in 
the sinusoids with area of focal necrosis. 2^1 Occasion- 
ally, the hepatic manifestations may dominate the 
clinical picture with conjugated hyperbilirubinaemia 
and bilirubinuria. These attacks closely mimic viral 
hepatitis. Although the clinical findings in patients 
with sickle hepatic crisis, who have hepatitis-B anti- 
genaemia, are similar to the findings in other patients, 
the histological changes differ, with aggressive cellular 
infiltration of the portal tracts and disruption of the 
limiting plates. 5 One report raises the possibility that 
viral hepatitis might be more severe in these patients. 6 
In a large series of adults with sickle cell anaemia 
hepatic histology showed cirrhosis in 10 per cent of 
them, with unexplained hepatic necrosis, portal fibro- 
sis, and regenerative nodules. 7 In addition, Masera 
and colleagues reported high rate of occurrence of 
chronic hepatitis following acute hepatitis B and non- 
A non-B attacks in thalassemic patients. 8 ' 9
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This led us to study the prevalence of persistent 
hepatitis-B surface antigenaemia in children suffering 
from sickle cell disease and their significance in 
relation to hepatic functions.
Materials and Methods
One-hundred-and-twenty-five children between the 
ages of 3 and 12 years with sickle cell disease were the 
subject of this study. They represented the sickle cell 
children in Muscat area attending the Pediatric 
Hematology Clinic of the Royal Hospital, Muscat, 
Oman. One-hundred normal age-matched children 
served as controls. All the study children were 
subjected to thorough history taking, with special 
emphasis on previous episodes of jaundice, injections, 
and blood transfusions. Full clinical examination was 
performed, and the size of the liver and spleen 
recorded. Blood samples were collected for estimation 
of serum alanine transferase (ALT), alkaline phospha- 
tase (ALP), albumin, and bilirubin concentrations. All 
serum samples of the study children were tested for the 
presence of hepatitis B surface antigen (HBSAg) using 
the latex quick test. 10
Hepatic function tests and hepatitis-B surface anti- 
genaemia have been followed every 3 months, for 1 
year, in six sicklers and 10 normal children with acute 
hepatitis B infection.
Statistical analyses were done using the r-test for 
comparison between the different study groups when
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the data were normally distributed and Wilcoxon test' 
when they were not. Data are presented as mean ± SD.
Results
Table 1 shows the hepatic functions of children with 
SCD and controls. Four out of the 125 children with 
SCD were HBSAg carriers (3 per cent), while 11 out of 
the 100 normal children were carriers. Serum bilirubin 
and ALT concentrations were higher in the sickle
group compared to the controls. Scrum ALT and 
bilirubin levels were significantly higher in HBSAg 
negative sicklers (n = 121) than those for HBSAg 
negative controls (n = 89) (Table 2). Table 3 compares 
the liver functions of HBSAg positive sicklers and 
controls. Serum bilirubin and ALT concentrations 
were significantly higher and serum albumin levels 
were markedly lower in the sicklers' group. Table 4 
presents a comparison between two groups of sickle 
cell children with and without HBS antigenaemia.
TABLE 1 



















108 + 4.4 38.6 + 3.8* 41.2 + 6.3* 
90.0 + 5.2 17.1 + 2.8 21.9±1.9
141+7.1 38.7 + 3.0 8.3 + 0.3* 3.2% (4) 
161+9.2 37.4+1.1 12.5 + 0.8 11% (11)
•/><0.05. Bili = bilirubin.
TABLE 2 
Hepatic functions and HBS antigenaemia in children with sickle cell disease and controls
Age Bili ALT ALP 
(months) C"mol/l) (IU/1) (IU/1)
Children with SCD (n= 121) 108.6 + 4.5 38.9±3.9* 40.4 + 6.3* 141 ±7.3
Normal children (n- 89) 97.2±5.1 17.9 + 3.2 20.4 ±1.7 164+10.0
Albumin Hb 
(g/1) (g/dl)
38.9 ±3.1 8.0 + 0.2*
37.5+1.3 12.5+0.5
•?<0.05. Bili = bilirubin.
TABLE 3 
Hepatic functions in HBSAg positive children with sickle cell disease and controls (mean±SD)
Children with sickle 
cell disease
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live children. In all the five study groups ALT 
concentrations were significantly higher in HCV 
seropositive compared to seronegative children. Liver 
size was significantly larger in HCV seropositive 
control children, as well as those with thalassemia, and 
SHF «. children who were seronegative in each group, 
respectively.
Discussion
Hepatitis-C virus can be detected in blood within 7-14 
days of exposure and persists throughout the course of 
infection. However, the presence of circulating HCV 
antibody cannot be confirmed until 9-20 weeks after 
exposure. This creates a window of seronegativity and 
potential infectivity. 2 Acute infection carries a high 
risk of developing chronic hepatitis and liver cirrhosis. 
The HCV antibody test is used to detect acute and 
chronic HCV infections. It is positive in approximately 
50 per cent of patients with acute HCV infection and 
80-90 per cent with chronic NANB hepatitis. 2 ' 1V1 *
In this study the prevalence of HCV antibody in 
normal (n — 110) Egyptian children is 12 per cent. This 
is a markedly higher prevalence rate compared to 
those reported from different African and Asian 
countries."~ 14 It appears that the risk and magnitude 
of HCV infection are relatively high in Egypt.
The major factors in community-acquired HCV 
infection include blood transfusions, intravenous drug 
abuse, and inapparent percutaneous exposure. 15 One 
study has suggested that household and sexual 
transmission of HCV is most inefficient. 17 In three of 
the high risk groups of children we studied, namely 
those with thalassemia major, IDDM, and SHF, the 
prevalence of HCV antibody positivity has been 
significantly high (44, 29, and 38 per cent, respect­ 
ively). This confirms that parental transmission, either 
through intravenous or subcutaneous route, is a major 
factor in community-acquired infections. In addition, 
this high prevalence of HCV seropositivity in these 
groups of children poses a considerable danger for 
development of chronic liver disease. The presence of 
significantly larger liver size in HCV seropositive 
normal children as well as HCV seropositive children 
with thalassemia and SHF, and the significant eleva­ 
tion of their serum ALT concentrations compared to 
HCV seronegative children in each group, respec­ 
tively, strongly support this view. Moreover, Masera 
and colleagues has reported high rate of occurrence of 
chronic liver disease following acute NANB-hepatitis 
in thalassemic patients. 18 ' 19
In conclusion, the prevalence of HCV antibody 
seropositivity is relatively high (12 per cent) in a 
random sample (n= 110) of healthy Egyptian children 
and significantly high in children with thalassemia 
major (44 per cent), SHF (38 per cent), and IDDM (29 
per cent).
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Sicklers with HBS antigenaemia had significantly 
higher ALT and lower albumin concentrations com­ 
pared to those without HBS antigenaemia.
Out of six children with sickle cell disease who 
presented with HBSAg positive acute hepatitis, two 
patients did not clear the antigen from their serum 
after one year, with elevated serum bilirubin (59 and 85 
umol/1) and ALT (87 and 110 IU/1) concentrations. 
None of the normal children with acute HBSAg 
positive hepatitis were still carrying the antigen after 3 
months of the attack.
Discussion
This study shows that children with sickle cell disease 
do not have a high prevalence of HBS antigenemia. 
Our results confirm the findings from Nigeria that the 
incidence of hepatitis in sickle cell children is no higher 
than the incidence in the general population."
Significant elevation of serum ALT and bilirubin 
concentrations in children with sickle cell disease 
compared to control children denotes the presence of 
mild chronic hepatocellular dysfunction which might 
be due to repeated vascular-hypoxic insults and/or 
chronic viral inflammation. However, this is not 
related to hepatitis-B virus because it is present also in 
sickle cell patients without HBS antigenaemia.
Previously normal persons usually clear the antigen 
from the serum within 4-6 weeks from the onset of 
acute symptoms. Chronic hepatitis is associated with 
persistent antigenemia. 12 In our study, 33 per cent of 
sicklers with acute hepatitis-B infection did not clear 
the antigenaemia for 1 year whereas, all the normal 
children cleared the antigen from the serum after 3 
months. In addition, the comparison in Table 4 proves 
that in children with sickle cell disease chronic carrying 
of HSAg is accompanied with more deterioration of 
hepatic functions (high ALT and bilirubin concentra­ 
tions). These findings point to the high risk of 
chronicity and continual parenchyma! damage in
sicklers after acute hepatitis-B infections. This can 
drastically influence the prognosis of hepatic involve­ 
ment in this disease. It appears that vaccination 
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Summary
We studied the prevalence of HCV antibody seropositivity and serum alanine concentrations in a random 
sample of healthy Egyptian children (n = 110) as well as in four high risk groups of children. Group 1 
included 18 children with thalassemia major, group 2 included 17 children with insulin-dependent diabetes 
mellitus (IDDM), group 3 included 21 children with schistosomal hepatic fibrosis (SHF), and group 4 
included 20 children with chronic rheumatic heart disease (RHD).
The prevalence rate of HCV seropositivity was 12 per cent in normal children, 44 per cent in thalassemic 
children, 29 per cent in children with IDDM, 38 per cent in children with SHF and 0 per cent in patients 
with RHD. The liver size was significantly larger in HCV seropositive normal children as well as in HCV 
seropositive children with thalassemia and SHF compared to the seronegative children in each group 
respectively (P < 0.05). In all groups serum alanine transferase concentrations were significantly higher in 
HCV seropositive »>. seronegative children. This pointed out to the high risk of continuous parenchymal 
hepatic damage in these children following acute HCV infection.
In summary, our data revealed a relatively high prevalence of HCV antibody seropositivity in healthy 
Egyptian children compared to reports from other countries, and a significantly high prevalence of HCV 
seropositivity in children with thalassemia, IDDM, and SHF which carries a considerably high risk for 
development of chronic liver disease in these patients.
Introduction
Hepatitis-C virus (HCV) has a global distribution and 
causes parentally acquired and sporadic non-A-non-B 
(NANB) hepatitis. It is responsible for the majority of 
post-transfusion NANB hepatitis. 1 "3 The non-paren­ 
tal modes of spread are poorly defined. Intrafamilial 
transmission suggests a horizontal rather than a 
vertical mode of spread.*"7 In addition, HCV has been 
incriminated in the aetiology of chronic liver disease 
and hepatic malignancy. 8" 10
The prevalence of HCV antibody varies among 
different populations. It ranges between 0.3 and 1.5 per 
cent in some Western countries and Taiwan 2 ' 8 - 1 1 to 6 
per cent in Zaire. 12 In a population based survey in 
Saudi Arabia significant variations in the prevalence of 
HCV antibody are reported from different regions 
with a range from 0 to 6 per cent. 13 - 14
The aim of this study was to estimate the prevalence 
of HCV antibody in a sample of healthy Egyptian 
children (n = 110) as well as in four high risk groups of 
children with schistosomal hepatic fibrosis, thalasse­ 
mia, insulin-dependent diabetes mellitus (IDDM), and 
chronic rheumatic heart disease (RHD).
Materials and Methods
One-hundred children between the age of 1 and 16 
years were the subject of this study. Group 1 included 
18 children with thalassemia major on regular blood 
transfusion and iron chelation therapy, group 2 
included 17 children with insulin-dependent diabetes 
mellitus (IDDM), group 3 included 21 children with 
schistosomal hepatic fibrosis (SHF) and group 4 
included 20 children with chronic rheumatic heart 
disease (RHD). All were randomly selected from the 
Hepatology, Diabetology, Hematology and Cardio­ 
logy out-patient clinics of Alexandria University 
Children's Hospital, Alexandria, Egypt. One- 
hundred-and-ten healthy age-matched children served 
as a control group. All the study children were 
subjected to thorough history taking, with special 
emphasis on previous episodes of jaundice, injections, 
and blood transfusions. Informed consent for the 
blood testing was obtained from the parents of all 
children before including in the study. Full clinical 
examination was performed and the size of the liver 
recorded. Blood samples were collected for estimation 
of serum alanine transferase (ALT) concentrations. All
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scrum samples of the study children were tested for the 
presence of IgG antibody to HCV by indirect ELISA 
test (Behring).
Analysis of variance (ANOVA) was used to test the 
differences between mean values in the study groups. 
Significance was accepted at /><0.05. Data are 
presented as mean±SD.
Results
Table 1 presents the prevalence of HCV antibody, liver 
size and ALT concentrations in the five study groups.
Children with SHF were significantly older than 
children in the other groups. The prevalence of HCV 
seropositivity was significantly higher in three of the 
high risk groups (thalassemia, IDDM, and SHF) 
compared to the control group. In the RHD group the 
prevalence of HCV antibody was 0 per cent. Liver size 
was significantly increased on palpation in the thalas- 
semic and SHF groups compared to the other groups. 
ALT concentrations were significantly higher in the 
thalassemic and SHF groups v. the control group.
Table 2 compares ALT concentrations and liver size 
among the HCV antibody seropositive and seronega-
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live children. In all the five study groups ALT 
concentrations were significantly higher in HCV 
seropositive compared to seronegative children Liver 
size was significantly larger in HCV seropositive 
control children, as well as those with thalassemia, and 
SHF v. children who were seronegative in each group, 
respectively.
Discussion
Hepatitis-C virus can be detected in blood within 7-14 
days of exposure and persists throughout the course of 
infection. However, the presence of circulating HCV 
antibody cannot be confirmed until 9-20 weeks after 
exposure. This creates a window of seronegativity and 
potential infectivity. 2 Acute infection carries a high 
risk of developing chronic hepatitis and liver cirrhosis. 
The HCV antibody test is used to detect acute and 
chronic HCV infections. It is positive in approximately 
50 per cent of patients with acute HCV infection and 
80-90 per cent with chronic NANB hepatitis. 2 - 1 5 - 16
In this study the prevalence of HCV antibody in 
normal (n = 110) Egyptian children is 12 per cent. This 
is a markedly higher prevalence rate compared to 
those reported from different African and Asian 
countries. u~'* It appears that the risk and magnitude 
of HCV infection are relatively high in Egypt.
The major factors in community-acquired HCV 
infection include blood transfusions, intravenous drug 
abuse, and inapparent percutaneous exposure. 15 One 
study has suggested that household and sexual 
transmission of HCV is most inefficient. 17 In three of 
the high risk groups of children we studied, namely 
those with thalassemia major, IDDM, and SHF, the 
prevalence of HCV antibody positivity has been 
significantly high (44, 29, and 38 per cent, respect­ 
ively). This confirms that parental transmission, either 
through intravenous or subcutaneous route, is a major 
factor in community-acquired infections. In addition, 
this high prevalence of HCV seropositivity in these 
groups of children poses a considerable danger for 
development of chronic liver disease. The presence of 
significantly larger liver size in HCV seropositive 
normal children as well as HCV seropositive children 
with thalassemia and SHF, and the significant eleva­ 
tion of their serum ALT concentrations compared to 
HCV seronegative children in each group, respec­ 
tively, strongly support this view. Moreover, Masera 
and colleagues has reported high rate of occurrence of 
chronic liver disease following acute NANB-hepatitis 
in thalassemic patients. 18 - 19
In conclusion, the prevalence of HCV antibody 
seropositivity is relatively high (12 per cent) in a 
random sample (n = 110) of healthy Egyptian children 
and significantly high in children with thalassemia 
major (44 per cent), SHF (38 per cent), and IDDM (29 
per cent).
References
1. Alter HJ. Descartes before the horse: I clone, therefore I 
am: the hepatitis-C virus in current perspective. Ann 
Intern Med 1991; 115: 644-9.
2. Alter HJ, Purcell RH, Shin JW. Detection of antibody to 
hepatitis C virus in prospectively followed transfusion 
recipients with acute and chronic non-A, non-B hepatitis. 
N Engl J Med 1989; 321: 1494-7.
3. Gibas AL, Dienstang JL. Viral hepatitis. In: Copra S, 
May RM, (eds) Pathophysiology of Gastrointestinal 
Diseases. Little Brown Company, Boston, USA, 1989. 
pp. 235-83.
4. Takahashi M, Yamada G, Tsuji T. Intrafamilial 
transmission of hepatitis C. Gastroenterol Jpn 1991; 26: 
483-8.
5. Balayan MS, Andzhaparidze AG, Savinskaya SS. Evi­ 
dence for a virus in non-A/non-B hepatitis transmitted 
via the fecal oral route. Intervirology 1983; 20: 23-26.
6. Ramalingaswami V, Purcell RH. Waterbourne non-A, 
non-B hepatitis. Lancet 1988; i: 571-4.
7. Reinus JF, Leikin EL, Alter HJ. Failure to detect vertical 
transmission of hepatitis-C virus. Ann Intern Med 1992; 
117: 881-4.
8. Liaw YF, Chien RN, Sheen IS, Lin DY. Hepatitis C virus 
infections in patients with chronic liver diseases in an 
endemic area for hepatitis B virus infection. Gastroen­ 
terol Jpn 1991; 26: 167-9.
9. Seeff LB, Buskell-Bales Z, Wright EC. Long-term 
mortality after transfusion-associated non-A, non-B 
hepatitis. N Engl J Med 1992; 327: 1906-9.
10. Tzomio A, Trichopoulos D, Koklamani E. Epidemiolo- 
gic assessment of interactions of hepatitis C virus with 
seromarkers of hepatitis B and D viruses, cirrhosis and 
tobacco smoking in hepatocellular carcinoma. Int J 
Cancer 1991; 49: 377-80.
11. Koksal I, Biberoglu K, Biberoglu S. Hepatitis C virus 
antibodies among risk groups in Turkey. Infection 1991; 
19: 228-9.
12. Tibbs CJ, Palmer SJ, Coker R. Prevalence of hepatitis C 
in tropical communities: the importance of confirmatory 
assays. J Med Virol 1991; 34: 143-7.
13. Al-Faleh FZ, Ayoola EA, Al Jeffry M. Prevalence of 
antibody to hepatitis C virus among Saudi Arabian 
children: a community-based study. Hepatology 1991; 
14: 215-8.
14. Bahakim H, Bakir TM, Arif M. Hepatitis C virus 
antibodies in high risk Saudi groups. Vox Sang 1991; 60: 
162-4.
15. Chopra S. Viral hepatitis. In: Lea S, Febiger M (eds). 
Disorders of the Liver. W.B. Saunders, Philadelphia 
1988; 215-48.
16. Esteban JL, Lopes T, Talavera JC, Giostra J. High rate of 
infectivity and liver disease in blood donors with 
antibodies to hepatitis C virus. Ann Intern Med 1991; 
115:443-7.
17. Everhart JE, DiBisceglie AM, Murray LM. Risk for non- 
A, non-B (type-C) hepatitis through sexual or household 
contact with chronic carriers. Ann Intern Med 1990; 112: 
554-6.
18. Masera G, Jean G, Gassda G. Role of chronic hepatitis in 
development of thalassemic liver disease. Arch Dis 
Childh 1976; 51: 680-6.
19. Masera G, Jean G, Center V. Sequential study of liver 
biopsy in thalassemia. Arch Dis Childh 1980; 55: 800-2.
Journal of Tropical Pediatrics Vol. 41 December 1995 343

A.T. SOLIMANETAL.
Circulating Growth Hormone (GH), Insulin-like 
Growth Factor-I (IGF-I) and Free Thyroxine, GH 
Response to Clonidine Provocation and CT Scanning 
of the Hypothalamic-pituitary Area in Children with 
Sickle Cell Disease
by Ashraf T. Soliman,* MD, Assim Darwish,** MD, Said H Mohammed,** MD, Mohammed R Bassiony,*** 
MD, Nagwa El Banna,* MD, and Maurice Asfour.t MD
Departments of * Pediatrics, f Endocrinology and ** Radiology, The Royal Hospital and Qaboos University, 
***College of Medicine, Sultanate of Oman
Summary
Serum growth hormone (GH), cortisol, free thyroxine (FT4), thyroid-stimulating hormone (TSH), and 
insulin like growth factor I (IGF-I) concentrations were measured in 15 children with sickle cell disease 
(SCO) together with their heights <5th percentile for age and gender, and in 15 healthy age-matched 
children who had normal variant short stature (NVSS). GH response to an oral dose of clonidine 
(0.15 mg/m:) and cortisol response to ACTH stimulation were determined in the two groups.
Children with SCD had significantly lower serum concentrations of IGF-I and decreased GH response 
to stimulation. Eight out of the 15 children with SCD did not mount an appropriate GH response to 
clonidine provocation (> 10 ug/1). CT scanning of the hypothalamic-pituitary area in those eight children 
with SCD revealed a partial or complete empty sella in all of them. It appears that defective GH release, 
and consequently low IGF-I production and slow growth velocity in children with SCD might be secondary 
to hypoxic-vascular insults to their hypothalamic-pituitary axis during one or more of the sickling 
episodes.
Introduction
Growth and maturational delay are striking features of 
sickle cell disease (SCD). 1 After 6 months of life, 
affected children have impaired growth involving both 
the height and weight. 2"4
Many factors have been implicated in the aetiology 
of growth impairment in children with SCD. These 
include chronic anaemic hypoxia, increased energy 
expenditure due to high erythropoietic turn-over and 
cardiac work, 5 nutritional deficiencies including zinc, 
foiic acid and vitamin-A,6~8 disturbed calcium 
metabolism, 9 repeated infections due to defective 
immune functions, 10 and dysfunction of the endocrine 
glands. 12
The basal circulating concentrations of different 
hormones have been studied by various authors, 12 ~ 14 
with no consensus in defining the endocrine status and 
response of different glands to provocation in children 
with SCD, and their possible contribution to growth 
impaiwnent in these children.
Correspondence: Dr Ashraf T. Soliman, Pediatric Endo­ 
crinology, Royal Hospital, PO Box 1331 Seeb, Muscat, 
Sultanate of Oman.
Our aim was to estimate the circulating levels of 
IGF-I, free thyroxine (FT4), thyroid-stimulating hor­ 
mone (TSH), and the responses of GH and cortisol to 
provocation by clonidine and adrenocorticotrophic 
hormone (ACTH), respectively, in children with SCD 
who had short stature [height (Ht) <5th percentile] 
for age and gender. These hormonal data were 
analysed in relation to the anthropometnc, clinical, 
and biochemical data of the patients.
Patients and Methods
Fifteen prepubertal children with SCD and short 
stature, height standard deviation score (HtSDS) 
<—2, attending the Pediatric Hematology/Endo- 
crinology Clinic of the Royal Hospital, Muscat, 
Oman, were the subjects of this study. All children 
were on regular blood transfusion to keep their 
haemoglobin (Hb) concentrations above 9 g/dl. All 
were on folic-acid supplements and all had been 
vaccinated against pneumococci. Fifteen age-matched 
children with normal variant short stature (NVSS) 
served as controls. None of the children had history of 
intra-uterine growth retardation, any other systemic 
or endocrine disease, dysmorphic trait, or central
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nervous system irradiation. Informed consent for the 
testing procedure was obtained from the parents of all 
children. All the children were examined with special 
emphasis on nutritional data. The anthropometric 
measurements included weight, height, and mid-arm 
circumference. Harpenden's calipers and anthropo­ 
metric measurements were used. The data recorded 
were the average of three sequential measurements 
determined by the same observer (AST). The HtSDS 
was calculated according to the formula HtSDS = 
(XI-X2)/SD, where X2 and SD are age matched 
population mean height and SD, respectively, and XI 
is the subject height. The height growth velocity (GV) 
cm/year was calculated for the last year. Normal 
population data were according to the Tanner et al. li 
The body mass index (BMI) were calculated according 
to the formula = weight (kg)/height (m) 2 . The bone age 
was determined according to Greulich and Pyle atlas. 16
On the day of admission, venous blood samples 
were obtained for determination of complete blood 
count (CBC) and serum albumin, bilirubin, alanine 
transferase (ALT), alkaline phosphatase (ALP), cal­ 
cium, phosphorus, and bicarbonate concentrations. 
Following an overnight fast (8-h) venous blood 
samples were withdrawn through a polyethylene 
catheter inserted in a forearm vein between 8 and 
9 a.m. The serum was separated from the formed 
elements by centrifugation and kept frozen at -20°C 
until analysed for GH, FT4, TSH, and IGF-I. After 
obtaining the basal samples, an oral dose of clonidine 
was given (0.15 mg/m 2 ). Blood samples were obtained 
every 30 min for 2 h for measurement of serum GH 
concentrations. On the next morning and after an 8-h 
overnight fast 0.5 mg of ACTH (synacthen) was 
injected i.v. and blood samples obtained before and 60 
min after the injection for estimation of cortisol 
concentrations. Human GH was measured by
TABLE 1
Anthropometric and bone age data of children with sickle cell disease (SCD) and those with normal
variant short stature (NVSS)
SCD(n = lS)
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radioimmunometric assay, employing reagents pur­ 
chased from Nichols Institute (San Juan Capistrano, 
CA). Intra-assay coefficient of variations averaged 6 
percent in the range of GH values detected and 5.8 per 
cent in the range of IGF-I concentrations measured. 
All samples from all the children were assayed 
simultaneously.
CT examination of the hypothalamic pituitary area 
have been performed in all sicklers who did not mount 
an appropriate GH response to clonidine provocation 
(n=8). One of the children with SCD had a second CT 
performed after intrathecal injection of the contrast 
material.
Statistical analyses were done using the unpaired r- 
test to compare mean analyte concentrations among 
the two study groups when the data were normally 
distributed and Wilcoxon test when they were not. 
Statistical significance was accepted at P< 0.05.
Results
The anthropometric and bone age data of the two 
study groups are presented in Table 1 . The chronologi­ 
cal age, HtSDS, body mass index (BMI), and bone age 
did not differ significantly between the two groups
The biochemical data of all the children are 
presented in Table 2. Creatinine clearance and serum 
concentrations of creatinine, bicarbonate, albumin, 
and ALP were not different among the two groups. 
Haemoglobin concentrations and haematocrit values 
were lower in children with sickle cell disease and their 
serum ALT and bilirubin concentrations were higher 
compared to the control children.
The hormonal profiles of all the children are shown
in Table 3. The circulating IGF-I concentrations and 
the peak GH levels in response to clonidine provoca­ 
tion were significantly lower in the sickle cell group. 
Eight out of the 15 children with sickle cell disease did 
not mount a proper GH peak > 10 ^g/1 after clonidine 
intake, whereas all children with NVSS mounted 
normal GH response > 10 /jg/1. Basal and ACTH- 
stimulated cortisol levels as well as FT4 and TSH 
concentrations did not differ significantly between the 
two groups. CT scanning of the hypothalamic- 
pituitary area revealed a picture of complete (n = 5) or 
partial (n = 3) empty sella in all the eight children with
FIG. 1. CT of a 7-year-old boy with SCD and empty 
sella. Average attenuation values of the sella was 6 
Hounsfield Units.
FIG. 2. CT of a 10-year-old girl with SCD: (a) CT 
without i.v. contrast medium; and (b) CT taken after 
i.v. injection of contrast medium. Attenuation values 
of the sella contents were between -35 and 8 
Hounsfield Units; compatible with partial empty sella 
with fatty degenerative changes.
Journal of Tropical Pediatrics Vol. 41 October 1995 287
A. T. SOL1MANETAL.
SCD who had defective GH response to clonidine. In 
those patients with complete empty sella the contents 
of the sella had densities around cerebrospinal fluid 
(CSF) values Fig. 1, whereas in those with partial 
empty sella the contents of the pituitary fossa were 
between —45 and -27 which was suggestive of some 
fatty degenerative changes Fig. 2. In the patient who 
had CT done after intrathecal injection of contrast 
medium Fig. 3 a significant herniation of the suprasel­ 
lar cistern into the pituitary fossa was noted. Plain 
skull X-rays for the pituitary fossae were normal in all 
children with NVSS and SCD.
Discussion
In this study we compared the growth, biochemical, 
and hormonal data of two groups of children with 
sickle cell disease and normal variant short stature 
(NVSS). The hormonal profile of children with sickle 
cell disease revealed defective GH response to cloni­ 
dine provocation as well as low circulating concentra­ 
tions of IGF-I compared to the control group. 
Malnutrition can be excluded as a cause of these 
changes because the BMI and serum albumin concen­ 
trations were not different among the two study 
groups. In addition, in malnutrition the basal GH 
concentrations are usually high unlike the case in our 
children with sickle cell disease. 15 The normal creati- 
nine clearance, and normal concentrations of serum 
creatinine, bicarbonate, calcium, phosphorus, and 
alkaline phosphatase exclude any contribution of 
renal dysfunction, and/or disturbed calcium homeo-
stasis in the aetiology of growth impairment or 
hormonal abnormalities in these children.
Although serum ALT and total bilirubin concentra­ 
tions were higher in the group with sickle cell disease 
compared to the control group, those ALT levels of 
sicklers were still in the normal range of population 
(10-60 IU/1) and the unconjugated bilirubin consti­ 
tuted the main part of the elevated bilirubin. This in 
addition to normal concentrations of serum albumin 
and ALP, and normal albumin/globulin ratio makes it 
unlikely that hepatocellular dysfunction is a cause for 
low IGF-I production in these patients.
It appears that in children with sickle cell disease 
low GH secretion leads to decreased synthesis of IGF- 
I and, consequently, to slow growth velocity and short 
stature. This defective GH release might be secondary 
to a hypoxic-vascular insult to the hypothalamic 
pituitary area and/or an intrinsic abnormality in the 
children associated with the disease. In support of this 
view CT scanning of the pituitary region revealed ?n 
empty or partially empty sella in all the eight children 
with SCD who did not mount an appropriate GH 
response to clonidine stimulation. This might be due 
to hypoxic injury or infarction to the pituitary gland 
during one or more of the sickling episodes. In our 
child with severe SCD, according to severity index of 
SCD, 12 and empty sella with cisternal herniation Fig. 
3, there was marked reduction in his GH response to 
high dose clonidine (7 /jg/1) and to insulin-induced 
hypoglycemia (6.5 ng/l). This finding supports our 
hypothesis of hypoxic pituitary insults in these chil­ 
dren.
FIG. 3. CT after intrathecal contrast examination in a 12-year-old girl with SCD: sagittal reconstruction (left) and 
coronal reconstruction (right). Both show gross herniation of the suprasellar cisterna.
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Growth Hormone Secretion and Circulating Insulin-Like
Growth Factor-I (IGF-I) and IGF Binding Protein-3 Concentrations
in Children With Sickle Cell Disease
Ashraf T. Soliman, Nagwa El Banna, Issa AlSalmi, Vasantha De Silva, Alan Craig, and Maurice Asfour
Impaired growth involving both height and weight accompanying sickle cell disease (SCO) poses diagnostic and therapeutic 
problems. We undertook this study to test the hypothesis that this impaired growth is associated with abnormalities of the 
growth hormone (GH)/insulin-like growth factor-l (IGF-D/IGF binding protein-3 (IGFBP-3)axis in 21 children with SCO and that 
SCO is associated with GH resistance. Mine of 21 children with SCO had a defective GH response to both clonidine and 
glucagon provocation (peak, < 10 M-g/L); these children differed from the 12 others in having slower linear growth velocity 
(GV and GVSDS), lower circulating concentrations of IGF-I and IGFBP-3, and either partial or complete empty sellae in 
computed tomographic scans of the hypothalamic-pituitary area. In this group of patients with SCO, it appears that defective 
GH secretion and consequent low IGF-I production are the major etiological factors causing the slow growth. The two groups 
with SCO did not differ significantly in dietary intake, body mass index (BMI), midarm circumference, skinfold thickness, serum 
albumin concentration, or intestinal absorption of D-xylose. A single injection of GH produced a smaller increase in circulating 
IGF-I in children with SCD with or without defective GH secretion versus 10 age-matched children with idiopathic short stature 
(ISS) and 11 children with isolated GH deficiency (GHD), suggesting partial GH resistance in the SCD group. The presence of 
defective GH secretion, decreased IGF-I synthesis, and partial resistance to GH in short children with SCD suggests that 
treatment with IGF-I may be superior to GH therapy for improving growth. 
Copyright© 1997by W.B. Saunders Company
GROWTH AND MATURATIONAL DELAY are striking features of sickle cell disease (SCD). 1 After 6 months of 
life, affected children have impaired growth involving both 
height and weight. 2 "4 Many factors have been implicated in the 
etiology of growth impairment in children with SCD. These 
include chronic anemic hypoxia, increased energy expenditure 
due to high erythropoietic turnover and cardiac work,5 nutri­ 
tional deficiencies including zinc, folic acid, and vitamin A,6'" 
disturbed calcium metabolism,9 repeated infections due to 
defective immune functions,'°-" and dysfunction of the endo­ 
crine glands. 12
The basal circulating concentrations of different hormones 
have been studied by different groups, 12 ' 14 with no consensus 
for defining the endocrine abnormalities of the growth hormone 
(GH)/insulin-like growth factor-I (IGF-I) axis and their possible 
contribution to growth impairment in these children.
Recently, we have reported a high incidence of defective 
clonidine-induced GH secretion and low circulating IGF-I 
concentrations in children with SCD and short stature. 15 IGF-I 
is a GH-dependent polypeptide that has a threefold function as a 
mediator of the growth-promoting action of GH, as a potent 
mitogenic factor, and as a metabolic regulator with insulin-like 
activity. 16' 18 Alteration of IGF-I regulation may provide an 
attractive explanation for SCO-associated growth impairment.
The predominant IGF binding protein (IGFBP) in the blood 
is IGFBP-3, which forms a large 150-kd ternary complex. The 
serum level of Ihis complex determines the total concentration 
of circulating IGF-I and regulates its growth-promoting poten­ 
tial. 19' 25 Current opinion favors GH as the major regulator of 
IGFBP-3 and IGF-1 levels in humans. 2f> In vivo and in vitro 
experiments indicate relatively poor control of IGFBP-3 concen­ 
trations by IGF-1. 27 " 1" In addition, serum levels of IGF-I and 
IGFBP-3 are positively related to nutritional status. 27 "1 '-" No 
study to dale has examined the different components of the 
GH/IGF-I/IGFBP system in children with SCD.
Treatment of SCD children with marked growth retardation 
using human GH may also be compromised by an associated 
GH resistance due to hepatic iron overload, malnutrition, or
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repeated infections. 14 - 15 The IGF-I generation tcsl provides 
valuable information on IGF-I sensitivity.-16
We undertook the present study to test the hypothesis that (I) 
SCO is associated with abnormalities of the GH/IGF-I/IGFBP 
axis and (2) SCO is associated with GH resistance. The first 
issue was addressed by measuring the GH response to clonidine 
and glucagon and the circulating concentrations of IGF-1 and 
IGFBP-3 in 21 children with SCO, and the second issue was 
tested using IGF-I generation tests. The results were compared 
wilh those for children with iiliopiilhic short siiilure (|ISS| 
n = 10) and isolated GH deficiency (|GHD| n =11).
SUBJECTS AND METHODS
Twenty-one prcpubertal children with SCO were the subjects of this 
study. They were randomly selected, using random tables, from 58 
children with SCO niul shorl Mature (height, IOth perccnlile tor age and 
sex). The 5K children were all (he piilienl.s wilh SCI) and slaliuo less 
than the 10th percentile selected from a cohort of 156 children with 
SCD regularly attending the hematology outpatient clinic of the Royal 
Hospital in Muscat, Oman. According to peak GH responses to two 
provocation tests (with clonidine and glucagon), they were divided into 
two subgroups. Nine of them (group 1) had a low peak GH response on 
at least two provocation tests (<7 ug/L), and the other 12 children 
(group 2) had a normal GH response to stimulation (>7 ug/L). All have 
been on folic acid supplementation and vaccinated against pneumo- 
cocci. None of them had a history of intrauterine growth retardation or 
any other systemic or endocrine disease, dysmorphic trait, or central 
nervous system irradiation. Ten age-matched children with idiopathic 
short stature (ISS) (height standard deviation score [HtSDS] < -2 and 
normal GH response to provocation) and 11 children with isolated GHD 
(GH peak response < 5 ug/L on at least 2 provocation tests) served as 
controls. Informed consent was obtained from all the parents and, when 
appropriate, from the children before inclusion in the study.
All of the children were examined thoroughly, with special emphasis 
on the nutritional data. Auxanological measurements included weight, 
height, head circumference, midarm circumference, and scapular, 
triceps, and abdominal skinfold thickness. Harpenden calipers were 
used. The data recorded were the average of three sequential measure­ 
ments determined by the same observer (A.T.S.). HtSDS was calculated 
according to the formula, HtSDS = (XI - X2)/SD, where X2 and SD 
are the age-matched population mean height and SD, respectively, and 
XI is the subject height.
Height growth velocity (GV) in centimeters per year was calculated 
for the previous 2 years. Normal population data were from Tanner et 
al. 37 Body mass index (BMI) was calculated according to the formula.
BMI = wcighi (kg)/hcighl(m)2 . Bone aye was determined according to 
Ihc Grculich and I'ylc alias.'*
Children were admitted to the Royal Hospital in Muscat, Oman for 
the period of investigation. The initial nutritional evaluation, both 
qualitative and quantitative, was performed by the dietitian using the 
recall method, and the patients received a high-protein (2 g/kg/d) diet 
for 7 days before hormonal evaluation. After an overnight fast (8 hours) 
venous blood samples were obtained between 8 and 9 AM for 
determination of complete blood cell count, serum albumin, bilirubin 
alaninc aininoiransfer.'isc (AIT), hone-specific alkaline phosphatase 
(AI,I'|. ciik'iinn. phosphorus, anil hicaihonatc ciinccnlralions. The 
scrum was separated from the formed elements by centrifugation and 
kept frozen at -20°C until analy/.ed for IGF-I, IGFBP-3, cortisol, free 
thyroxine (IT4 ), and thyrotropin (TSH) by radioimmunoassay. The 
subjects received a single injection of recombinant human GH 0.1 
mg/kg subculaneously. Serum IGF-I and IGFBP-3 levels were remea- 
surcd 24 hours after Ihc injection."1
llnnmn Gil and IGI : -I levels wi-rr measured by radiciimmunomctric 
ussiiy using icagnils purchased liom Nichols Insliiute (San Juan 
Capistrano, CA). Intraassay coefficients of variation (CVs) were 5.6% 
and 6.8%, respectively, and interassay CVs were 7.8% and 8.3%, 
respectively, in the range of GH and IGF-I values detected. IGFBP-3 
concentration was measured by radioimmunoassay at SCL Bioscience 
Services using reagents supplied by Mediagnost. The assay sensitivity 
was 0.06 ug/mL. with intraassay and interassay CVs of 5.2% and 8.6%, 
respectively.
Results are expressed as the mean ± SD and analyzed by ANOVAto 
compare analyte concentrations among groups. A paired Student (test 
was used to compare data in the same group before and after GH 
injection. Correlations between variables of interest were examined by 
linear regression analysis and, when appropriate, multiple regression 
analysis.
RESULTS
Children with SCD and ISS had normal circulating concentra­ 
tions of albumin, calcium, phosphate, ALP, ALT, and bicarbon­ 
ate. Serum levels of fT4 , TSH, and 8 AM cortisol did not differ 
among the two groups. Bilirubin (unconjugated) concentrations 
were higher and hemoglobin and hematocrit values were lower 
in the SCD group versus the ISS group. The peak D-xylose 
concentration after ingestion of 5 g D-xylose did not differ 
between the two groups.
Table 1 shows auxanological and hormonal data for children 
with SCD, GHD. and ISS. The HtSDS was significantly lower 
in children with ISS and GHD versus children with SCD. Linear



































































































NOTE. Plasma IGF-I and IGFBP-3 were measured immediately before (B) and 24 hours after (A) GH administration (0.1 mg/kg). The suffix "-D" 
indicates the change in IGF-I and IGFBP-3 from basal to 24 hours. 
*P<.05, SCD vlSS. 
tP< .05, SCD i/GHD.
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GV, GVSDS, and BMI did not differ significantly among the 
two groups with ISS and SCO. However, GV and GVSDS were 
significantly decreased in children with GHD. The peak GH 
response to provocation was significantly lower in children with 
SCO versus ISS (P < .001). Basal circulating IGF-I concentra­ 
tions were higher in children with ISS versus the other two 
groups. Basal circulating IGFBP-3 concentrations were signifi­ 
cantly lower in the SCO group (/> < .05) versus the ISS group. 
The IGF-I response to GH administration ([IGF-I-D], equal to 
the 24-hour IGF-I value minus the basal value) was signifi­ 
cantly lower in children with SCO (27.6 ± 15.6 ng/mL) com­ 
pared with children with ISS (53.5 ± 17.6 ng/mL). IGF-I 
increased significantly after human GH injection in the three 
study groups. However, the IGF-I response (IGF-I-D) was 
significantly higher in children with GHD and those with ISS 
versus children with SCD.
Table 2 presents a comparison between two groups of 
children with SCD: group 1 with defective GH secretion 
(n = 9; peak GH response to provocation, 4.2 ± 2.3 ug/L) and 
group 2 (n = 12) with a normal peak GH response to provoca­ 
tion (9.9 ± 2.4 ng/L). Age and BMI did not differ among the 
two groups. HtSDS and GVSDS were significantly lower in 
group 1. Basal circulating concentrations of IGF-I and IGFBP-3 
were significantly lower in group 1 (SCD with defective GH 
secretion). IGF-I responses to GH administration did not differ 
significantly among the two groups and were significantly lower 
than those for children with isolated GHD.
Correlations between auxanological and hormonal data in 21 
children with SCD are presented in Table 3. Basal and 
GH-stimulated concentrations of IGF-I and IGFBP-3 were 
correlated significantly with height GV and GVSDS (P < .01) 
and GH peak values. The dependence of serum IGFBP-3 on GH 
was evident from a significant correlation with peak GH 
secretion (n = 21, r = .665, P < .01) and the significant in­ 
crease in IGFBP-3 after one injection of GH. IGFBP-3 concen­ 
trations correlated significantly with IGF-I levels before and 
after GH administration (r = .600, P < .01). Serum ferritin was 
inversely correlated with GV, GVSDS, and IGF-I (r = -.35, 
-.46, and -.25, respectively, P < .05).
DISCUSSION
There is no completely reliable test for diagnosing or 
excluding GHD in all short children. When used alone, none of 
the tests have superior diagnostic specificity or sensitivity. 
Measurement of GH-response peptides such as IGF-I and 
IGFBP-3 can add insights even when the results do not agree 
with GH responses to provocative stimuli. Interpretation of the 
tests together improves the reliability of diagnostic assess­ 
ment.39
Nine of 21 randomly selected children with SCD (43%) had 
defective GH secretion in response to provocation with both 
clonidine and glucagon. In these children, IGF-I concentrations 
were comparable to those in children with isolated GHD, but 
were significantly lower than those in children with ISS and 
normal GH release. Their circulating IGFBP-3 concentrations, 
which reflect the integrated GH secretion over a period of 
days,26-39-41 were significantly lower versus the group with 
normal GH secretion, but were not different from those reported 
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Abbreviations: B, before GH; A, after GH.
*P<.05.
tP<.01.
patients with SCO with defective GH secretion was signifi­ 
cantly slower than (hat of patients with normal GH secretion. 
This defective GH secretion may be secondary to a hypoxic 
vascular insult to the hypothalamic-pituitary area during one or 
more of the sickling episodes and/or to pituitary atrophy as a 
result of iron overload. In support of this view, computed 
tomographic scanning of the pituitary region revealed empty 
sellae (partial or complete) in all nine children with SCD and 
GHD. Moreover, the SCD severity score, as described by El 
Hazmi et al,' 2 was significantly higher in the SCD group with 
defective GH secretion versus those with normal GH secretion. 
Collectively, these findings suggest that acquired GHD may be 
a major factor in the etiology of retarded growth in some 
patients with SCD, especially those with severe sickling attacks.
It is unclear which of the alterations of the GH/IGF-I/IGFBP 
axis found in children with SCD are of greater clinical 
significance. Although the influence of SCD on adult height is 
controversial, most data indicate a negative effect of SCD on 
linear growth. M - 6 In our study, the mean HtSDS for all patients 
with SCD (n = 21, -1.34 ± 0.6) was in the lower range of 
normal. SCD patients with defective GH secretion had a 
significantly lower HtSDS and GV versus those with normal 
GH release. Moreover, we found a good correlation between 
GVSDS and IGF-I (before and after GH injection) and a strong 
correlation between the peak GH response to provocation and 
IGF-I and IGFBP-3. These findings suggest that circulating 
IGF-I and IGFBP-3, as in normal children, are the major 
determinants of linear growth in children with SCD. and both 
are regulated by the GH status of the child. On the other hand, 
the degree of GH resistance as measured by the change in IGF-I 
concentration after GH injection (IGF-I-D) was not correlated 
with linear growth parameters (HtSDS, GV, and GVSDS, 
r = -.26, -.002 and .083, respectively) in these children. This 
may denote that GHD plays a more significant role than GH 
resistance in the etiology of impaired linear growth in these 
children.
In children with SCD, growth impairment includes both 
height and weight. 2 "4 Treatment with human GH has been 
shown to improve nitrogen balance and linear growth in a 
variety of growth disorders. 4: The detection of defective GH 
secretion in about 40% of slowly growing children with SCD 
suggests a beneficial growth-promoting effect of GH therapy in
these palicnis. The IGF-I generation test has been used to assess 
IGF-I rcsponsivcness to GH in children with short stature.36 In 
this study, a single subcutaneous injection of GH has been used 
to invcsligale the physiological changes of IGF-I/IGFBP-3 in 
children with SCD to test the hypothesis that SCD is associated 
with GH resistance. Subjects with SCD with or without 
defective GH secretion had significantly lower IGF-I responses 
to a single injection of GH versus children with ISS and those 
with isolated GHD, suggesting partial GH resistance. This 
might attenuate the anabolic effects of GH therapy in these 
children. 34-15 The IGF-I response (IGF-I-D) correlated nega­ 
tively with the BMI (r = -.31, P < .01), suggesting that in 
children with SCD, increasing wasting may be associated with 
progressive GH resistance. The significant negative correlation 
between the IGF-I response to GH injection and the peak GH 
response to provocation (r = —.505, P < .01) suggests that 
IGF-I production is better in children with defective GH 
secretion. However, the IGF-I response was nonsignificantly 
higher in children with SCD and GHD versus those with normal 
GH secretion.
Malnutrition can be excluded as an important cause of 
abnormalities of the GH/IGF-I axis in children with SCD 
because of the following: (1) BMI, subcutaneous fat thickness, 
midarm circumference, and serum albumin concentration were 
not different among the study groups (SCD, SCD + GHD, and 
ISS); (2) analysis of the nutritional history showed adequate 
qualitative and quantitative intake of nutrients as compared with 
20 normal age-matched children; (3) the D-xylose test was 
normal in all children with SCD and those with ISS; and (4) in 
malnutrition, basal GH concentrations are usually high, unlike 
the case in our children with SCD (mean ± SD, 1.8 ±0.25 
ug/L; range, 0.5 to 3.5 J. 4 -1
The normal serum levels of creatinine, bicarbonate, calcium, 
phosphorus, and ALP exclude any significant contribution of 
renal dysfunction and/or disturbed calcium homeostasis in the 
etiology of growth impairment or endocrine abnormalities in 
these children. Normal serum concentrations of albumin, ALP, 
and ALT with a normal albumin to globulin ratio and prothrom- 
bin time in children with SCD make it unlikely that impaired 
hepatocellular synthetic function is a cause of the low IGF-I 
production in these patients.
The serum ferritin concentration, as an indicator of body iron 
stores, was negatively correlated with the height GV (r = -.35, 
P< .01), GVSDS (;•= -.464,P< .01), and circulating concen­ 
tration of IGF-I (r= -.255, /><.05). This suggests that 
hepatic/parenchymal iron overload may impair IGF-I synthesis 
and subsequently slow linear growth in children with SCD.
In summary, children with SCD have significantly lower 
IGF-I production in response to GH injection versus children 
with ISS and GHD, suggesting partial GH resistance. Some 
children with SCD and delayed growth may have GHD. 
Parenchyma! iron overload, a potentially treatable factor, may 
contribute to the etiology of impaired hepatic IGF-I synthesis 
and/or defective GH secretion by the pituitary gland. Because of 
the presence of partial GH resistance, treatment with recombi- 
nant IGF-I may be more successful than treatment with GH.
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Empty Sella in Short Children With and Without 
Hypothalamic-Pituitary Abnormalities
Ashraf T. Soliman, Assim Darwish* and Maurice G. Asfour**
Department of Pediatrics, Radiology* and Endocrinology** Royal Hospital, Muscat
Sultanate of Oman
Abstract. A sludy was conducted on growth hormone (GH) response to oral clonidine (0.15 mg/ 
m2 ), GH and cortisol responses to i.m. glucagon (0.1 mg/kg), and glucose response to an oral load 
of glucose (1.75 g/kg). Measurements were made on the circulating concentrations of free 
thyroxine (FT4). thyroid stimulating hormone (TSH) and different growth parameters and CT sellar 
images .in 25 GH deficient children (Peak'GH response to clonidine and glucagon < 7 ug/ml), 15 
growth retarded children (Ht < 5th percentile for age.and-gender) with sickle cell disease (SCO) 
and GH deficiency. 30 randomly selected children With normal variant short stature (NVSS) 
(HtSDS 2SD below the mean for age and gender with normal GH response to stimulation (> 10 ug/ 
ml) and 20 age-matched normal children were evaluated. Out of the 25 children with GH 
deficiency, five had multiple pituitary hormonal deficiency (GHj-TSH and/or ACTH. deficiencies), 
and 20 had isolated GH deficiency. Empty sella, either corfipfete or partial, was detected in 9 out 
the 20 children with isolated GH deficiency (45%), 4 out of the 5 children with multiple pituitary 
deficiency (80%), all the children with SCO and GH deficiency (100%), 3 out of the 30 children with 
NVSS (10%) and in none of the normal children. The insulin-like growth factor-l (IGF-I) 
concentrations \veffl significantly lower In the two groups of children with GH deficiency compared 
to those with NVSS. The height standard deviation scores (HTSDS) were significantly lower and 
the annual growth velocity was slower in children with idiopathic GH deficiency and empty sella 
compared to those with NVSS and those v/ith empty sella associated with SCO. The bone age 
delay (yr) did not differ among the 3 groups of children with, short stature. All children with isolated 
GH deficiency associated with empty sella had normal body mass indices (BMI), while all the 
children with SCO and empty sella had BMI below the 5th percentile for the corresponding age and 
gender. None of the children had glucose Intolerance, in conclusion,'children'with growth 
retardation and abnormal hypothalamic pituitary functions have high incidence of empty sella. 
However, empty sella is detected in considerable number (10%) of short children with normal 
hypothalamic pituitary function. (Indian J Pediatr 1995; 62 : 75-1)
Key words :
For sella most frequently radiographic empty sella syndrome (ESS) refers to the
studies are undertaken on children as a herniation of the supraseller subarachnoid
part of the investigation of growth disor- spaces in the sella turcica with various de-
ders and in them as many as one fourth is grees of flattening of the pituitary. Empty
found to have an empty sella. 1 The term sella is classified as primary (idiopathic),
~——————————————" or secondary to pituitary tumprs, surgical
Reprint requests: Dr. Ashraf T. Solimnn Chief, Qr radiation therapy and, probably, to pi-
Pediatric Endocrinology Royal Hospital, Seeb hypoplasia. In adults, empty sella is
Airport 1331, Muscat, Sultanate of Oman. J Jf r > r j
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a relatively common finding and is often sen ted'to the same clinic during the same 
asymptomatic. In contrast, cases reported period, (C) 30 children with NVSS (HtSDS 
in children are more often associated with > 2SD below the mean for age and gender) 
endocrine abnormalities in .25-45% of pa- who were randomly selected from all the 
tients. Endocrine abnormalities reported children with NVSS who attended the en- 
include growth hormone (GH) deficiency, docrinology clinic and investigated be- 
diabetes insipidus, sexual precocity, hy- tween January 1992 and January 1993 (30 
perprolactinemia and panhypopituit- out of 95), and (D) 20 age-matched chil- 
rism. 2 '* In most of the reported series the dren with normal stature (HtSDS = +/-1), 
patients have enlarged sella turcica with who were selected from the radiology de- 
more than 50% of the sella replaced with partment while taking CT scans for other 
CSF. Tine finding of normal srze sella (less reasons (15 wit head trauma to role out in- 
than 50% of the sella being replaced with tracranial lesions and 5 to role out in- 
SCF) has been considered a normal variant traocular pathology). All of them had no 
by many radiologist. However, recently pathology in their CT. All the children 
Michaels et nl* reported significant endo- with SCD were^n regular blood transfu- 
crine abnormalities in patients with normal sion to keep their hemoglobirt (Hb) concen- 
size empty sella. trations above 9g/dl and folic acid supple- 
Here are reported the growth param- ments. None of the children in this study 
eters, static and dynamic pituitary function had history of intrauterine growth retarda- 
testing and result of CT evaluation of the tion, malnutrition, any other systemic dis- 
hypothalamic-pituitary area in 25 children ease, dysmorphic trait, encephalsits, in- 
with GH deficiency/ 15 children with sickle tracranial lesions or central nervous sys- 
cell disease (SCD) and GH deficiency, 30 tern irradiation. Informed consent for the 
age-matched children with normal variant testing procedure and CT Scanning was 
short stature (NVSS) and 20 normal age- obtained from the parents of all children, 
matched normal children. CT scans of the brain with 1 mm cuts in the
	hypothalamic pituitary area were evalu- 
MATERIAL AND METHODS ated by the team Neuroradiologist (AD).
	Empty sella was defined as sella that, re- 
Ninety prepubetral (Tanner stage 1) chil- gardless of its size, is completely or partly 
dren with age range between 4 and 10 filled with CSF,w The anthropometric mea- 
years were the subjects of this study. They surements including .weight (Wt) and 
included : (A) 25 children with GH defi- height (Ht) -were recorded using the 
ciency (5 with multiple pituitary deficinecy Harpenden's anthropometric measuring 
including GH, TSH and ACTH, and 20 instruments. The data recorded were the 
with isolated GH deficiency), they were all average of three sequential measurements 
the diagnosed cases in the endocrine clinic determined by the same observed (AST), 
of the Royal Hospital, Muscat, Oman be- The HtSDS was 'calculated according to the 
tween April 1991 and August 1993, (B) 15 formula HtSDS= (X1-X2)/SD where X2 
children with SCD and GH deficiency, and SD are age-matched population mean 
they were diagnosed out of 34 children , height and SD respectively and XI is the 
with SCD and growth retardation pre- subject height. The height growth velocity
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(GV) cm/yr and GV standard deviation 
scores (GVSDS) were calculated for the last 
year. Normal population data were ac­ 
cording to Tanner et nl. 7 The body mass in­ 
dices (BMI) were calculated according to 
the formula BMI = Wt (kg)/Ht (m)2 . The 
bone age was determined according to 
Greulich and Pyle atlas.8
On the day of admission, venous blood 
samples were obtained for determination 
of complete blood count (CBC) and serum 
albumin, bilirubin, alanine transferase 
(ALT)/ alkaline phosphatase (ALP), cal­ 
cium, phosphorus and bicarbonate concen­ 
trations. Following an overnight fast (S-h) 
venous blood samples were withdrawn 
through a polyethylene catheter inserted in 
a forearm vein between 8 and 9 a.m. The 
serum was separated from the formed ele­ 
ments by centrifugation and kept frozen at 
-20°C until analyzed for GH, free T< (FT,), 
TSH, and 1GF-1. After obtaining the basal 
samples, an oral dose of clonidine (0.15 
mg/m 2) was given and venous blood col­ 
lected every 30 minutes for 2 hours for 
measurement of serum GH concentrations. 
On the next morning and after an 8-h over­ 
night fast 0.1 mg of lucagon (max 1 mg) 
was injected and i.m. and blood samples 
obtained before and every 30 min after the 
injection for 180 min for estimation of GH 
and cortisol concentrations." On the third 
day and after an overnight fast oral glu­ 
cose 1.75 gm/kg (20% solution) was given 
to the child and blood collected before and 
120 minutes after the oral glucose load for 
determination of plasma glucose concen­ 
tration by glucose oxidase method. Human 
GH and IGF-I concentrations were mea­ 
sured by radioimmunometric assay, em­ 
ploying reagents purchased from Nichols 
Institute (San Juan Capistrano, CA). Intra- 
assay coefficient of variations showed on
average of 6% in the range 1 of GH values 
detected and 5,7% in the range of IGE-I 
concentrations measured. All samples 
from the patients were assayed simulta­ 
neously. .FT4, TSH and cortisol concentra­ 
tions were measured using Amerlex-RIA 
kits, Kodak Clinical Diagnqstics, 
Amersham, UK. Statistical analyses were 
done using ANOVA test to compare mean 
analyte concentrations among the study 
groups when the data were normally dis­ 
tributed and Wilcoxone test when they 
were not. Statistical significance was ac­ 
cepted at p < 0.05.
RESULTS
Table 1 presents anthropometeric and bone 
age data of the patients and controls. The 
HtSDS was significantly lower in the 2 
groups of children 'with GH deficiency 
compared to those with NVSS and normal 
children. Growth velocity was significantly 
slower and GVSDS was lower in children 
with GH deficiency vs those with 
SCD+GH deficiency. The bone age was 
significantly delayed in the 3 groups of 
children with short stature compared to 
the controls. However, the degree of delay 
did not differ among the 3 groups.
The biochemical and hemarological data 
of the 4 study groups are presented in 
Table 2. Creatinine clearance, and serum 
concentrations .of albumin, ALT, ALP,,, bi­ 
carbonate, calcium, phosphate and albu­ 
min did not differ among the 4 study 
groups.
Table 3 shows the hormonal profile and 
glucose data of the 4 study groups. Out of 
the 25 children with GH deficiency, 20 
(80%) had isolated GH deficiency, nnd 5 
(20%) had multiple pituitary deficiency 
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retarded children in the sickle cell group, 
who had defective GH response to stimu­ 
lation (GH Peak < 10 ug/L), had empty 
sella (100%), and their FT4, TSH, SAM cor- 
tisol concentrations and cortisol response 
to glucagon were normal. The IGF-I con­ 
centrations were significantly lower in the 
2 groups of children with GH deficiency 
compared to those with NVSS and normal 
children. Empty sella was noted in 9 out of 
the 20 children with isolated Gh deficiency 
(45%), 4 out of the 5 children (80%) with 
multiple hypothalamic-pituitary hormonal 
deficiencies (none with diabetes insipidus), 
all the children with SCD associated with 
GH deficiency,'3 out of 30 children with 
NVSS (10%) and in none of the normal 
children. Children with isolated GH defi­ 
ciency and ESS had normal BMI for age 
and gender (15.4 +/- 1.7), whereas children 
with SCD and ESS had BMI (11.1 +/-0.7) 
below the 5th percentile for corresponding 
age and gender. None of the children had 
glucose intolerance or high blood pressure.
DISCUSSION
In this study the incidence of empty selln 
was 45% in children with isolated GH defi­ 
ciency, 80% in those with multiple pitu­ 
itary deficiency, 100% in children with 
SCD and GH deficiency and 10% in the 
short children with normal hypothalamic- 
pituitary function. None of the children 
with normal stature had empty sella. These 
findings suggest that empty sella has a 
considerably high incidence in children 
with growth and hypothalamic pituitary 
disorders, particularly those with multiple 
pituitary hormone deficiency. This impli­ 
cates the importance of CT scanning of the 
hypothalamic-pituitary area in children 
with severe short stature as an important
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tool in the identification of children with 
pituitary hormonal deficiency . Our find­ 
ings are in agreement with the study of 
surtees ct n/ 10 who reported empty sella in 
90% of patients with multiple pituitary 
deficinecy and in 37% of patients with iso­ 
lated GH deficiency. However, Marwaha 
et al 11 reported empty sella in 16 out of 22 
children affected by isolated GH deficiency 
born by normal delivery (72.7%). Such dif­ 
ference may be partly due to their use of 
MR1 which is more sensitive in the diagno­ 
sis of empty sella. In addition, some of 
their patients (23%) had brain anomalies in 
the scan, a characteristic which was not 
found in the patients of present study.
The association of empty sella and dia­ 
betes insipidus has been reported previ­ 
ously in CT scans. 12'" However, none of 
our patients with primary empty sella nor 
those with empty sella and SCD had diabe­ 
tes insipidus. This finding is in agreement 
with those of Cacciaricet et al 14 who re­ 
ported absence of diabetes insipidus in 
their patients (n = 23) with primary empty 
sella without other anatomical abnormali­ 
ties. It seems that the presence of 
intrasellar CSF does not have an ady.erse 
effect on posterior lobe function.
The presence of empty sella in all the 
sickle cell children who did not mount 
normal GH response to pharmacological 
stimuli suggests that ischemic injury to the 
pituitary during the • sickling episodes 
might be the cause of both GH deficiency 
and empty sella in these children. The hy- 
pothalamic-pituitary adrenal and thyroid 
functions were normal in these children.
None of the children with empty sella 
had symptoms or signs of increased in- 
tracranial pressure, obesity or glucose in­ 
tolerance reported in adults with empty 
sella. ir' In the present study the signifi­
cantly low BM! in children with SCD 
+empty sella and normal BMI in children 
with isolated GH deficiency and empty 
sella exclude an important effect, if any, of 
empty sella on the control of body weight 
in children.
In summary, empty sella is frequently 
seen in children with idiopathic GH 
deficinecy and children with GH -defi­ 
ciency secondary to SCD but it is not rare 
in very short prepubertal children with 
normal hypothalamic-pituitary function.
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Insulin and Glucagon Responses to Provocation with 
Glucose and Arginine in Prepubertal Children with 
Thalassemia Major Before and After Long-term Blood 
Transfusion
by Ashraf T. Soliman,* MD, Nagwa El Banna,** MD, Issa AJSalmi,** MB Ch B, and Maurice Asfour,** MD
*Department of Pediatrics, University of Alexandria, Alexandria, Egypt
**Department of Endocrinology, Royal Hospital, Muscat, Oman
Summary
Hyper-transfusion therapy has dramatically increased the duration and quality of life in patients with B- 
thalassemia major; however, it leads to chronic iron overload, and is frequently complicated by the 
development of diabetes mellitus or impaired glucose tolerance. To determine the early effect of iron 
overload on the endocrine pancreatic function, we studied glucose, insulin, and glucagon responses to 
oral load of glucose and to arginine provocation in 15 children with B-thalassemia major, before and 
after (3.1 ±0.6 years) high-transfusion and iron dictation and compared them with 15 age matched 
normal controls. In addition, we evaluated growth hormone (GET) responses to oral clonidine and 
measured the circulating insulin-like growth factor-I concentration in thalassemic children on long-term 
transfusion and controls. After long-term high-transfusion, thalassemic children had significantly 
decreased serum insulin concentrations and low insulin/glucose ratios at 60 and 120 min after an oral 
glucose load (1.75 g/kg) in comparison with values before therapy and those for controls. None of the 
thalassemic children had glucose intolerance after this period of frequent blood transfusion; however, 
their serum glucose levels at 60 and 120 min after the oral glucose load were significantly higher 
compared to control children. Thirty minutes after starting arginine infusion, serum insulin 
concentration was significantly lower in thalassemic children compared to before therapy. Basal and 
arginine-stimulated glucagon secretions were significantly elevated in thalassemic children on long-term 
blood transfusion with significantly low serum insulin/glucagon ratios. In addition, the high basal serum 
glucagon concentrations were not suppressed after the oral glucose load. Despite hyperglucagonaemia in 
all thalassemic children, their blood glucose dropped appropriately below 50 per cent of the fasting 
glucose level after an intravenous insulin dose (0.1 U/kg) ruling out any significant insulin-resistance. 
GH responses to clonidine provocation were subnormal in thalassemic children after long-term blood 
transfusion compared to controls. In summary, thalassemic children on long-term blood transfusion and 
iron chelation have progressive and early loss of B-cell mass, manifested by decreased insulin release in 
response to secretagogues, before the development of significant insulin resistance or impairment of 
glucose tolerance.
Introduction
In thalassemia major, frequent blood transfusions are 
required and this leads to massive iron overload.' 
The duration of the disease and the number of 
transfusions are highly correlated with the degree of 
glucose intolerance. 2"6 The reported prevalence of 
diabetes in treated thalassemia major is about 16 per 
cent, while the incidence of impaired glucose 
tolerance approximates 60 per cent. 7 Possible patho-
Correspondence: Dr Ashraf T. Soliman, Pediatric Endocri­ 
nology, Royal Hospital, P.O. Box 2331, Seeb, Muscat, Code 
111, Oman.
genie conditions are pancreatic cell destruction with 
subsequent insulin deficiency, 3 '4 ' 15 liver derangement 
with consequent insulin resistance, 8"10 genetic fac­ 
tors,2'6 and possible immunological disturbance." In 
addition, 28 per cent of these patients develop 
diabetes mellitus shortly after an acute viral hepatitis 
infection, suggesting an important role of hepatitis 
virus in precipitating a diabetic state in these 
patients. 12
Data about the circulating concentrations of 
insulin in non-diabetic children with thalasseraia are 
controversial. Toccafondi R et a/. 13 reported lower 
insulin response to oral glucose in their thalassemic 
children with normal oral glucose tolerance (GTT) 
and Lassman et a/. 3 ' 14 found a delayed insulin
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response to oral glucose loading. In controversy, 
Flynn el a/. 5 and Merkel 15 described high insulin 
level in patients with normal GTT and suggested the 
possibility of insulin-resistance. Kuo el a/. 16 found 
that in only 50 per cent of older thalassemic patients 
did the plasma glucose fall to less than half of the 
fasting levels after intravenous (iv) insulin, whereas 
Toccafondi et a/. 17 found that plasma glucose fell 
normally after (iv) insulin in thalassemic children 
under 10 years.
Diabetic hyperglycaemia is generally believed to be 
a bihormonal disorder where absolute or relative lack 
of insulin and excess of glucagon cause decreased 
peripheral glucose uptake and increased hepatic 
glucose production. ^ In agreement with this 
notion, increased hepatic glucose production and 
plasma glucagon concentrations have been demon­ 
strated to correlate with the hyperglycemic level. [9~25
Lassman et al. 3 found diminished glucagon re­ 
sponse to intravenous alanine infusion in thalassemic 
patients without family history of diabetes and 
suggested that this is due to iron loading on the 
alpha cells. In controversy, Passariello26 and Nelson 
et al?-1 demonstrated elevated glucagon level in 
thalassemic and hemochromatic patients.
In our prospective study we have evaluated insulin 
and glucagon secretion in response to oral glucose 
and arginine infusion in young thalassemic children 
before and after long-term (3.1 ±0.6 years) high- 
transfusion and iron chelation. In addition, growth 
hormone (GH) and cortisol responses to insulin- 
induced hypoglycemia were evaluated, and serum 
concentrations of insulin-like growth factor-I (IGF- 
I), free thyroxine (FT4), and TSH measured in 
thalassemic children after long-term high-transfusion 
and results compared to an age-matched normal 
group of children.
Subjects and Methods
Twenty young children with thalassemia major, 
diagnosed between January 1988 and January 1990, 
were selected from the Hematology clinic of Alexan­ 
dria University Children's Hospital for the study. 
Their ages ranged between 1.75 and 3.5 years (mean 
2.8 ±0.6 years). None had family history of diabetes 
mellitus, intra-uterine growth retardation, or any 
other systemic or endocrine disease. Informed con­ 
sent was obtained from all the parents of the children 
before including in the study. The Ethical Committee 
of Alexandria University approved the study proto­ 
col. Before receiving the first blood transfusion, 
children were admitted and offered high carbohy­ 
drate diet for 3 days. On the 4th day and after an 8- 
hour overnight fast a standard oral glucose tolerance 
test was performed and blood collected at 0, 60, and 
120 min after the oral glucose load (1.75 g/kg) for 
estimation of glucose concentration by glucose 
oxidase method, and glucagon and insulin concen­
trations by radio-immunoassay using kits purchased 
from Amersham. On the 5th day and after an 
overnight fast an intravenous (iv) infusion of 10 per 
cent arginine HC1 infusion (0.5 g/kg) was started and 
continued for 30 min and serum samples obtained 
before and at 30 and 60 min after the start of the 
infusion for estimation of glucose, insulin, and 
glucagon concentrations.
Children were started on frequent transfusion 
therapy (15 ml of packed erythrocytes/kg of body 
weight given every 4 weeks to maintain the haemo­ 
globin level at 9-10 g/dl) and deferoxamine (50 mg/ 
kg/dose for up to 6 days per week) given by 
intramuscular injection. During each clinic visit the 
children were examined, and nutritional and growth 
data, as well as their anthropometric measurements 
including weight and height recorded. The Height 
standard deviation score (HtSDS) was calculated 
according to the formula HtSDS = (X1-X2)/SD, 
where X2 and SD are age-matched_populations mean 
height and SD, respectively, and XI is the subject's 
height. The height growth velocity (GV) cm/year and 
body mass index (BMI) were calculated for each year 
and recorded. Normal population data were accord­ 
ing to Tanner el al Laboratory investigations 
included complete blood count (CBC) and estimation 
of serum concentration of albumin, bilirubin, alanine 
transferase, urea, and creatinine at 6-month intervals.
After a period of 2.5-4 years (mean = 3.1 ±0.6 
years) of high-transfusion and chelation 15 out of the 
20 patients were admitted and the previous hormonal 
investigations redone. Three children were excluded 
from the study because of poor compliance and the 
other two because parents refused to give consent for 
retesting. In addition, after an overnight fast, a basal 
serum sample was collected for measurement of GH, 
cortisol, IGF-I, FT4, and TSH concentrations. GH 
response to oral clonidine (0.15 mg/m2) was evalu­ 
ated in all the thalassemic children and serum 
collected at 0, 60, and 90 min after clonidine intake 
for estimation of GH. Fifteen normal age-matched 
children served as controls for the hormonal and 
biochemical studies after taking parents' consents. 
GH and IGF-I were measured by radio-immuno- 
metric assay, employing reagents purchased from 
Nichols Institute (San Juan Capistrano, CA). Intra- 
assay coefficient of variation averaged 6.7 per cent in 
the range of GH values detected and 8.1 per cent in 
the range of IGF-I concentrations measured. FT4, 
TSH, and cortisol were measured using Amerlex- 
RIA kits, Kodak Clinical Diagnostics, Amersham, 
UK. Skeletal age was determined according to the 
Atlas of Greulich and Pyle. 29
Statistical analyses were done using the ANOVA 
test to compare analyte concentrations before versus 
after long-term blood transfusion when the data were 
normally distributed and Wilcoxon test when they 
were not. Statistical significance was accepted at 
/><0.05.
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Results
Glucose, glucagon, and insulin data are presented in 
Tables 1 and 2. During fasting, serum insulin, and 
glucose concentrations did not differ among the 
study groups. Serum glucagon was significantly 
higher in thalassemic children after compared to 
before frequent blood transfusion commenced. After 
oral glucose load insulin secretion was significantly 
reduced in thalassemic children after v. before long- 
term high-transfusion. Their serum insulin/glucose 
(I/G) ratios were significantly lower [(0.27 ± 0.12) at 1 
h and (0.28 ±0.13) at 2 hours] v. before therapy 
[(0.62 ±0.26) at 1 hour and (0.55 ±22) at 2 hours]. In 
thalassemic children on long-term blood transfusion 
serum glucagon was not suppressed after an oral 
glucose load. Serum glucagon levels were signifi­ 
cantly higher at 60 and 120 min after the oral glucose 
load compared to values before therapy and to those 
in the control children. None of the thalassemic 
children had impaired glucose tolerance after this 
period of frequent blood transfusion and chelation; 
however, their serum glucose levels were significantly 
higher at 60 and 120 min after the oral glucose load, 
compared to those for the control group. Thirty 
minutes after starting arginine infusion serum insulin 
concentration was significantly lower in thalassemic 
children after long-term high-transfusion v. before 
therapy. Basal and arginine-stimulated glucagon 
concentrations were significantly higher in thalasse­ 
mic children on frequent blood transfusion v. before 
therapy. Consequently, serum insulin/glucagon ratios 
at 0, 30, and 60 min after starting arginine infusion 
were significantly decreased in thalassemic children 
after (0.10±0.06, 0.08±0.05 and 0.11 ±0.07) v. 
before therapy (0.15 ±0.07, 0.17 ±0.08, and 
0.15±0.07).
Table 3 presents growth parameters and hormonal 
data of thalassemic children after a mean transfusion 
period of 3.1 ±0.6 years. The HtSDS of thalassemic 
children decreased significantly from —0.75 ±0.3 
before starting blood transfusion to —1.65 ±0.5 at 
the time of retesting. HtSDS, GV, and BMI were
significantly lower in thalassemic children compared 
to controls. Serum ferritin, bilirubin and ALT 
concentrations were significantly higher in thalasse- 
mics v. controls. Two of the thalassemic children 
were hepatitis-B surface antigen positive, but none of 
the controls was positive. In all the thalassemic 
children serum glucose concentration dropped sig­ 
nificantly to < 50 per cent of the fasting level after 
injecting insulin (0.1 U/kg) intravenously. Thalasse­ 
mic children had significantly reduced peak GH 
response to both arginine and clonidine, with 
significantly lower serum concentration of IGF-I. 
Basal (8 hour) cortisol, FT4 and TSH concentrations 
did not differ among the two groups. Serum ferritin 
concentrations were correlated significantly with 
peak insulin and glucagon responses to arginine 
(r=-0.48 and r = 0.42 respectively, P<0.01) and 
with IGF-I concentrations (r= -0.51, P<0.01) in all 
the study children.
Discussion
Although the basal serum insulin concentration was 
normal in thalassemic children after long-term blood 
transfusion, there was a significant decrease in the 
maximal insulin secretory capability in response to 
arginine infusion and oral glucose load indicating a 
reduced insulin reserve. This gradual and early 
decrease of insulin secretion in thalassemic children, 
before the occurrence of impaired glucose tolerance, 
proves that decreased B-cell mass plays a major role 
in the development of glucose intolerance later.
In patients with chronic pancreatitis and pancrea­ 
tic fibrosis the fasting plasma glucose concentration 
remains normal as long as 20—40 per cent of the B- 
cell mass is retained. Nonetheless, loss of 20-40 per 
cent of B-cell mass is associated with a marked 
impairment in glucose-mediated insulin release, 
whereas a normal response to arginine is still 
retained. A further reduction (by 40-60 per cent) in 
B-cell mass leads to an altered response to arginine. 
Finally, when the B-cell mass is reduced by more
TABLE 1 
Serum glucose, insulin, and glucagon concentrations before and after arginine infusion
Glucose mg/dl Insulin ulU/ml Glucagon pg/ml





































































* P<0.5 groups v. controls, t .P<0.05 before v. after prolonged blood transfusion. 
Journal of Tropical Pediatrics Vol.42 October 1996 293
A. T. SOLIMAN ET AL.
Table 2 
Serum glucose, insulin, and glucagon concentrations after oral glucose (1.75 gjkg)
Glucose mg/dl Insulin ulU/ml Glucagon pg/ml


























































SD 8.9 11.1 9.8 5.8 10.6 9.8 39.9 44.2 38.1
* P<0.05 groups v. controls; f /*<0.05 before v. after prolonged blood transfusion.
TABLE 3 




















































































































































B-age = bone age, GH-b-basal GH, GH-p = peak GH, GH-p-arg = GH peak after 
arginine, GH-p-Clon=GH peak after clonidine, P<0.05 thalassemics v. controls.
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than 80-90 per cent, fasting hyperglycemia and 
inability to secrete insulin in response to all 
secretagogues is present. 7 - 30 It appears that in 
thalassemic children on frequent and prolonged 
blood transfusion early iron deposition and gradual 
fibrosis of the pancreas 1 leads to gradual loss of B- 
cell mass and impaired response to secretagogues, 
similar to that of chronic pancreatitis. In addition, 
impaired insulin secretion in response to both oral 
glucose and arginine denotes a significant loss of B- 
cell mass (40-60 per cent) after a mean of 3.1 years of 
frequent blood transfusion in these patients. Our 
results support the findings of Dmochowski el a/. 31 
indicating a trend towards progressive reduction in 
circulating insulin levels in thalassemic patients.
Although the presence of insulin resistance in 
patients with thalassemia has been suggested by 
numerous studies, 8 '9 ' 15 the finding is not universal. 
Brianda et a/. 32 performed euglycemic insulin clamps 
in thalassemic patients and found increased insulin 
sensitivity. Our data showed that despite hyperglu- 
cagonaemia serum glucose concentrations decreased 
properly (< 50 per cent of the fasting glucose level) 
after an intravenous insulin (0.1 U/kg) injection in all 
the thalassemic children ruling out the presence of a 
significant insulin insensitivity at this age. However, 
prolonged hyperglucagonaemia and progressive 
hepatic dysfunction might add an element of insulin 
resistance at an older age.
In thalassemic children on long-term transfusion 
the elevated basal serum glucagon concentrations, 
the significantly higher levels of glucagon and lower 
insulin/glucagon ratios after provocation with argi­ 
nine in comparison with controls, and the non- 
suppressions of circulating glucagon levels after oral 
glucose load prove a state of hyperglucagonaemia in 
these children. In other diseases with progressive 
fibrosis of the pancreas, inflammation and destruc­ 
tion of the parenchyma is associated with collapse 
between islets leading to formation of clusters of 
pancreatic islets. Within the remaining islets, a 
rearrangement of the endocrine cell population 
occurs with a proportionally greater loss of B-cells 
compared with A-cells, leading to a reversal of the 
normal 2:1 ratio. 7 This quantitative change of the 
islet cells might explain in part the finding of 
hyperglucagonaemia in our children with thalasse­ 
mia. In addition, the A-cells are believed to be an 
insulin-dependent tissue, since inhibition of glucagon 
secretion by glucose normally occurs in the presence 
of insulin. In our thalassemic patients impaired 
insulin secretion in response to glucose load might 
have contributed to the non-suppression of hyper­ 
glucagonaemia. The subnormal GH and cortisol 
peak responses to provocation exclude any contribu­ 
tion of these anti-insulin hormones in the production 
of insulin-resistance.
The progressive growth impairment in our thalas­ 
semic children might be attributed to their low GH
secretion and, consequently, low generation of IGF- 
I. These data support the view that functional 
damage in hypothalamic structures for GH control 
is an important factor contributing to growth delay 
in these children.34"36 Although hepatic GH receptor 
and/or post-receptor defect might explain the low 
IGF-I generation in thalassemic children with normal 
GH secretion34 , Postel et a/. 37 , did not find evidence 
for a defect in GH binding to liver membranes in 
thalassemic patients, and there was no correlation 
between the level of GH binding to liver membranes 
and the degree of hepatic siderosis and fibrosis. 
Moreover, insulin plays an important role in 
determining the bioavailability of IGF-I through its 
action on insulin-like growth factor binding protein-1 
(IGFBP-1).38 Therefore, defective insulin secretion in 
thalassemic children on long-term blood transfusion 
might increase hepatic production of IGFBP-1 
leading to decreased bioavailability of IGF-I. The 
low BMI in thalassemic children might be explained 
in part by the defective secretion of the two major 
anabolic hormones, namely insulin and IGF-I.
In summary, thalassemic children on long-term 
high-transfusion and iron chelation develop progress­ 
ive and early loss of B-cell mass manifested by 
decreased insulin release in response to secretagogues 
before impairment of their glucose tolerance. How­ 
ever, hyperglucagonaemia and progressive hepatic 
dysfunction might add an element of insulin resis­ 
tance later in life.
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Interleukin-1-beta, Tumour Necrosis Factor-alpha, 
Islet-cell Antibody, and Insulin Secretion in Children 
with Thalassemia Major on Long-term Blood 
Transfusion
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Mohammed N. Massoud, MD, Salah Marzouk,* PhD, and Fathia Ibrahim, MD, and Laila Hclal, MD 
Departments of Pediatrics and * Clinical Pathology, College of Medicine, University of Alexandria, 
Alexandria, Egypt
Summary
In vitro, cytoldnes like interleukin-l-beta (IL-l-B) and tumour necrosis factor-alpha (TNF-A) inhibit 
insulin release and can destroy islet B-cells. We measured blood levels of IL-l-B, TNF-A, and islet cell 
antibody (ICA) in 20 children with ID DM, 20 of their non-diabetic siblings, 20 children with 
thalassemia major on long-term hypertransfusion therapy; and Iron cbeladon, and 10 normal age- 
matched children. In the non-diabetic and thalassemic children we investigated the early phase of insulin 
release after i.v. glucose (0.5 g/kg, 30 per cent solution) and evaluated tolerance to oral glucose (1.75 g/ 
kg). Circulating IL-l-B and TNF-A concentrations were significantly higher in EDDM-siblings 
(33.7 ±12.7 pg/ml and 655 ±165 pg/ml, respectively) v. normal children (21.1 ±6.4 pg/ml and 
383 ± 122 pg/ml, respectively). Thalassemic children had no detectable circulating ICA. The prevalence 
of ICA was 30 per cent in children with U)DM and 60 per cent of their siblings. Impaired oral glucose 
tolerance was detected in five children with thalassemia (25 per cent), but in none of the EDDM-siblings. 
The early phase of insulin release was significantly depressed in thalassemic children (peak 
insulin-29.2 ±5.1 mTU/ml) v. normal children (52.3 ±9.5 mlU/ml) and EDDM-siblings (45.3 ±12.4 
mlU/ml). It appears that thalassemic children had significantly decreased insulin secretion and impaired 
glucose tolerance, however, the mechanism of B-cell dysfunction is not mediated by ICA nor by 
cytoldnes.
Introduction
Despite iron chelation, hypertransfusion regimens 
lead to chronic iron overload which results in hepatic, 
cardiac and endocrine dysfunction. Insulin-depend­ 
ent diabetes (IDDM) and impaired glucose tolerance 
occurs in a large number of thalassemic patients. 1 
Although insulin deficiency secondary to iron deposi­ 
tion has been assumed to be the principle cause of the 
abnormalities of in glucose metabolism observed in 
thalassemia, 1"3 other studies reported hyperinsulin- 
aemia suggesting a role of insulin resistance in 
mediating these metabolic abnormalities.4 ' 3 How­ 
ever, the early age of onset of diabetes in these 
patients suggests that an active process contributes to 
the deterioration of B-cell function.6
Recent studies reported increased production of 
different cytokines in multitransfused thalassemic
Correspondence: Ashraf T. Soliman, MD, Pediatric En­ 
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patients. 7 ' 8 These cytoldnes might have a role in the 
pathogenesis of diabetes in thalassemic patients 
through their cytotoxic effect on islet cells and/or 
inhibition of insulin release.9"''
To clarify this issue we measured'the circulating 
levels of IL-l-B, INF-A, and islet cell antibody 
(ICA) in 20 children with IDDM, 20 of their non- 
diabetic siblings, 20 children with B-thalassemia 
major, and 10 normal age-matched children. In 
addition, we investigated the first phase insulin 
release and oral glucose tolerance (OGT) in the 
non-diabetic and thalassemic children.
Patients and Methods
Twenty children with IDDM, 20 non-diabetic 
children randomly selected from their siblings, 
and 20 children with B-thalassemia major were 
the subjects of this study. Ten healthy children 
(mean age 7.8± 1.6 years) with no family history of 
diabetes served as controls. Informed consent was 
obtained from the parents of all children and, when
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appropriate, from the children, and the Ethical 
Committee of the University of Alexandria ap­ 
proved the study. Children were admitted to 
Alexandria University Children's Hospital for the 
study. All the children were prepubertal, clinically 
free from infection, and had no other systemic 
disease. None of them had history of recent viral 
infection. All the control children had normal 
hepatic and renal functions and haemogram. 
Thalassemic children were on frequent transfusion 
therapy (15 ml of packed erythrocytes/kg of body 
weight given every 4 weeks) to keep their haemo­ 
globin at or above 10 g/dl, and iron chelation 
therapy using i.m. deferoxamine. All had normal 
thyroid function and none of them had family 
history of diabetes. None of the diabetics had 
pancreatic calcification in either plain abdominal 
X-ray films or by sonographic examination.
A venous blood sample was obtained from all 
the children for measuring islet cell antibody (1CA), 
by the indirect immunofluorescent method (INOVA 
Diagnostics), and IL-l-B and TNF-A using ELISA 
technique (Medgenix). After 3 days on full 
carbohydrate diet an oral glucose tolerance test 
was performed (1.75 g glucose/kg of body wt) and 
serum glucose measured by glucose oxidase method 
before and 1 and 2 hours after the oral glucose 
load for all the non-diabetic children. On the 
second morning and after an overnight fast a
glucose load (0.3 g/kg, 30 per cent solution) was 
injected i.v. over 2 min and blood collected before 
and 5 min after the injection for measuring insulin 
concentration by radio-immunoassay (Diagnostic 
Product Corporation).
Statistical analysis was carried out using the 
ANOVA test to compare mean analyte concentra­ 
tions among the study groups when the data were 
normally distributed and Wilcoxon test when they 
were not. Statistical significance was accepted at 
P<O.Q5.
Results
Table 1 presents the anthropometric and laboratory 
data of the study groups. IL-l-B and TNF-A 
concentrations were significantly higher in the 
IDDM-siblings group v. those for the other groups. 
IL-l-B and TNF-A concentrations did not differ 
significantly among the thalassemic group, diabetic 
group, and health controls. Five of the thalassemic 
children had impaired glucose tolerance after oral 
glucose load (25 per cent). All the IDDM-siblings 
had normal oral glucose tolerance. The early phase of 
insulin release was significantly lower in thalassemic 
children compared to normal children and IDDM- 
siblings. ICA was detected in 30 per cent of the 
diabetic children (group II) v. 60 per cent of their
TABLE 1 









































































































































Glu-glucose; (b)-basal; (p)-pealc; ND-not done; * ?<0.05.
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siblings. None of the thalassemic children had 
detectable circulating ICA.
Discussion
Cytokines, through modulation of T-cell responses, 
can induce round cell infiltration (insulinitis) 12 and 
inhibit insulin release by the B-cells. 101 " In the 
IDDM-siblings the significantly high serum levels of 
IL-l-B and TNF-A, in conjunction with high 
prevalence of ICA suggested that these cytokines 
play an important role in the autoimmune'aggression 
against the islet B-cells. Despite their normal OGTT, 
the percentage increment of their insulin levels after 
i.v. glucose was significantly lower than the control 
group. Campbell IL el al. suggested that B-cell 
destruction, in genetically susceptible subject, pro­ 
gresses through stages. Stage 1 is initiated by 
modification of.B-ceU either by viral, chemical, or 
environmental factor. This leads to hyperexpression 
of Class-I major histocompatibih'ty complex (MHQ 
molecules and induction of MHC class II molecules. 
Stage II commences with infiltration of islets by 
immune-inflammatory cells (insulinitis) and produc­ 
tion of cytokines from infiltrating cells. This induces 
"phenotypic switching' of islet cells. Stage in 
encompasses autoimmune-mediated destruction of 
B-cells by the targeted delivery of cytotoxic cytokines 
and other mediators. The normal serum levels of 
cytokines in children with IDDM can be explained by 
the fact that cytokine production is suppressed after 
extensive destruction of the target cells (B-cells).
In thalassemic children on frequent blood transfu­ 
sion, the initiation of immune reaction against the B- 
cells, by the excessive iron deposition and/or by the 
foreign cellular elements in the transfused blood, 
constitutes a possible pathogenic factor. However, 
the normal serum concentrations of IL-l-B and 
TNF-A and the absence of circulating ICA in 
thalassemic children despite their high prevalence of 
impaired glucose tolerance and decreased insulin 
response to i.v. glucose, exclude an important role, if 
any, played by the immune system in the aetiology of 
diabetes in these children.
In summary, it appears that over time children
with thalassemia experience a reduction in their 
circulating insulin levels which leads to glucose 
intolerance and diabetes mcllitus. This B-cell destruc­ 
tion Is mediated neither by ICA nor by cytokine 
production.
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Abstract
The causes of growth retardation of children with thalassaemia major are multifactorial. We studied 
the GH response to provocation by clonidine and glucagon, measured the circulating concentrations of 
insulin, IGF-I. IGF-binding protein-3 (IGFBP-3) and ferritin, and evaluated IGF-I generation after a 
single dose of GH (0.1 mg/kg per dose) in 15 prepubertal patients with thalassaemia, 15 age-matched 
children with constitutional short stature (CSS) (height standard deviation score less than —2, with 
normal GH response to provocation) and 11 children with isolated GH deficiency (GHD). Children with 
thalassaemia had significantly lower peak GH response to provocation by clonidine and glucagon 
(6.2 ± 2.3 and 6.8 ± 2.1/ig/l respectively) than the CSS group (18.6 ± 2.7 and 16.7 ± 3.7/ig/l 
respectively). They had significantly decreased circulating concentrations of IGF-I and IGFBP-3 
(49.7 ± 19ng/ml and 1.2 ±0.27mg/l respectively) compared with those with CSS (153 ± 42 ng/ 
ml and 2.06 ± 0.37mg/l respectively), but the IGF-I and IGFBP-3 concentrations were not different 
from those with GHD (56 ±25 ng/ml and 1.1 ± 0.32 mg/1 respectively). These data demonstrate that 
the GH-IGF-I-IGFBP-3 axis in thalassaemic children is defective. Serum ferritin concentration 
correlated significantly with GH peak response to provocation (r = —0.36, P < 0.05) and circulating 
IGF-I (r = -0.47, P < 0.01) and IGFBP-3 (r = -0.42, P < 0.01) concentrations. In the IGF-I genera­ 
tion test, after GH injection, the thalassaemic children had significantly lower IGF-I and IGFBP-3 levels 
86.7 ± 11.2 ng/ml and 2.07 ± 0.45 mg/1 respectively) than those in the CSS group (226 ±45.4ng/ 
ml and 2.8 ± 0.43 mg/1 respectively). The IGF-I response was significantly higher in children with 
GHD (158 ± 50 ng/ml) than in thalassaemic children. Six short (height standard deviation score less 
than —2) thalassaemic children who had defective GH response to provocation (<10/ig/l), all the 
children with GHD and eight short normal children (CSS) were treated for 1 year with human GH (18 
units/m2 per week divided into daily s.c. doses). After 1 year of GH therapy there was a marked 
acceleration of growth velocity in both thalassaemic children (from 3.8 ± 0.6cm/year to 
7.2 ± 0.8 cm/year) and controls. However, the linear acceleration of growth velocity on GH therapy 
was significantly slower in thalassaemic children (3.3 ± 0.3 cm/year increment) compared with those 
with CSS (5.3 ± 0.4 cm/year increment) and GHD (6.9 ±1.2 cm/year increment) (P < 0.05). Their 
circulating IGF-I concentration (105 ± 36 ng/ml) was significantly lower than those for CSS 
(246 ± 58 ng/ml) and GHD (189 ± 52 ng/ml) after 1 year of GH therapy. These data prove that 
some children with /3-thalassaemia major have a defective GH-IGF-I-IGFBP-3 axis and suggest the 
presence of partial resistance to GH.
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Introduction damage of the endocrine glands is implicated as one of
	the main causes for the growth failure (6).
Growth and maturational delay are striking features of Basal circulating concentrations of various hormones
]3-thalassaemia major. After the age of 4 years, have been studied by different authors with no consensus
significant growth retardation involves stature, sitting defining the different endocrine abnormalities of the
height, weight and skeletal maturation (1-3). Delayed growth hormone (GH)-insulin-like growth factor-I
or complete lack of pubescent changes are common in (IGF-I)-IGF-binding protein-3 (IGFBP-3) axis. Both
both girls and boys (4, 5). Haemosiderosis-induced normal (7, 8) and subnormal GH response (9, 10) to
6 1998 Society of the European Journal of Endocrinology
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provocative stimulation tests have been reported. Some 
of those with normal GH response to provocation have 
neurosecretory dysfunction of GH secretion (9, 11, 12).
IGF-I is a GH-dependent polypeptide that has a 3-fold 
function as a mediator of the growth-promoting action 
of GH, as a potent mitogenic factor, and as a metabolic 
regulator with insulin-like activity (13, 14). Alterations 
in IGF-I regulation may provide an attractive explana­ 
tion for thalassaemia-associated growth impairment. 
The predominant IGFBP in blood is IGFBP-3, which 
forms a large 150 kDa ternary complex. The serum level 
of this complex determines the total concentration of 
circulating IGF-I and regulates its growth-promoting 
potential (15, 16). Current opinion favours GH as the 
major regulator of IGF-I and IGFBP-3 levels in humans. 
In addition, serum IGF-I and IGFBP-3 are positively 
related to nutritional status (17) and affected by other 
hormones such as insulin (18). Estimation of circulat­ 
ing concentrations of IGF-I and IGFBP-3 markedly 
improves the interpretation of GH data in response to 
provocation and allows better evaluation of the 
hypothalamic-pituitary growth axis.
This study was conducted to (1) investigate the GH- 
IGF-I-IGFBP-3 axis in prepubertal children with 0- 
thalassaemia major, (2) test the hypothesis that these 
patients might have GH resistance, and (3) study the 
effect of GH therapy for 1 year on their growth 
parameters.
Patients and methods
Fifteen prepubertal children, between the age of 7.5 and 
14 years, with jS-thalassaemia major were randomly 
recruited for the study from the thalassaemia clinic of 
the Alexandria University Children's Hospital, Alexan­ 
dria, Egypt. All had been treated with a chronic low- 
transfusion regimen (to keep haemoglobin concentration 
above 8 g/dl), with i.m. administered chelation treat­ 
ment (3 times per week; suboptimal chelation for 
economic reasons) and were taking 5 mg folic acid per 
day. Fifteen prepubertal age-matched children with 
constitutional short stature (CSS), age range 7-13 
years (with height standard deviation scores (HtSDS) at 
or below —2 and normal GH response to provocation) 
and 11 children with isolated GH deficiency (GHD), age 
range 6.5-10.5 years (GH peak response <5/^g/l in two 
or more provocative tests) served as controls. Informed 
consent was obtained from the parents of all the 
patients and, when appropriate, from the children 
before including them in the study. The ethical 
committee of Alexandria University approved the 
protocol of the study. None of the children had 
intrauterine growth retardation, severe malnutrition, 
diabetes, dysmorphic traits, exposure to irradiation, or 
any other systemic illness. All were prepubertal, with 
pubarche Tanner 2 or less, gonadarche stage in the boys 
of 1 and larche stage in the girls of 1, and all were 
eu thyroid.
Anthropometric measurements included weight 
(obtained to the nearest lOOg using a digital scale 
(Seca model 770)), height (using the Harpenden scale), 
mid-arm circumference (using a metal tape) and triceps 
skinfold thickness (using the Holtain calliper). Growth 
velocity (cm/year) was measured over a whole year for 
all the patients before the start of any GH therapy. 
HtSDS and body mass index (BMI) were calculated. 
Normal population data were those reported by Tanner 
& Whitehouse (19). Nutritional assessment included 
evaluation of dietary intake using the recall method for 
the preceding 3 days. These data were recorded every 
clinic visit for the whole year (minimum of three visits a 
year).
After an overnight fast, a venous sample was with­ 
drawn for measurement of free thyroxine (FT4), thyrotro- 
phin, IGF-I, IGFBP-3 and 0800 h cortisol concentrations. 
Serum ferritin, albumin, globulin, bilirubin, alanine 
aminotransferase, creatinine, calcium, phosphate and 
alkaline phosphatase were measured. Cortisol concen­ 
tration was measured 1 h after i.v. injection of 
adrenocorticotrophin (ACTH; 0.5 mg Synacthen). Two 
GH provocative testings with clonidine (0.15 mg/m2 
orally) and glucagon (0.1 mg/kg i.m.) were performed 
on two occasions. After 3 days of adequate carbohydrate 
intake, a standard oral glucose tolerance test (1.75 g/kg 
glucose) was carried out in thalassaemic children. The 
IGF-I generation test (20) was performed in all the 
patients. The test entails measurement of morning basal 
circulating IGF-I concentration, followed by injection of 
human GH (0.1 mg/kg per dose, s.c.) and remeasuring 
IGF-I concentration next morning.
Six patients with j3-thalassaemia major with growth 
retardation (HtSDS and growth velocity standard 
deviation score at or below —2 for their chronological 
age and for their respective bone age, determined by the 
method of Greulich and Pyle) and defective GH release 
in two provocative tests were treated with human GH 
(18 units/m2 per week divided into daily s.c. doses) for 
1 year. Growth parameters were followed-up every 
3 months for the whole year, and IGF-I concentrations 
remeasured at the end of the year. Children with GHD 
(n = 11) and those with CSS (n = 8) treated with GH 
(18 units/m2 per week divided into daily doses) for the 
same period were used as controls. The oral glucose 
tolerance test was performed every 6 months in the GH 
treatment groups.
Human GH and IGF-I were measured by radio- 
immunometric assay, employing reagents purchased 
from Nichols Institute (San Juan Capistrano, CA, USA). 
Intra-assay coefficients of variation (CVs) averaged 5.8 
and 6.6% respectively, and interassay CVs averaged 7.6 
and 8.4% respectively in the range of GH and IGF-I 
values detected. IGFBP-3 was measured by RIA by 
SCL Bioscience Services employing reagents supplied 
by Mediagnost. The assay sensitivity was 0.06/ig/ml 
with intra- and inter-assay CVs of 5.2 and 8.6% 
respectively.
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Data are presented as mean±s.d. Statistical analyses 
were performed using the ANOVA test to compare 
analyte concentrations among groups. The paired (-test 
was used to compare data before and after therapy in 
the same group. Wilcoxon test was used when the data 
were not normally distributed. Correlations between 
variables of interest were examined by linear regression 
analysis and, when appropriate, multiple regression 
analysis.
Results
Table 1 summarises the auxologic data of prepubertal 
children with thalassaemia, GHD and CSS. The HtSDS 
was significantly lower in children with GHD vs children 
with CSS and thalassaemia. Linear growth velocity and 
BMI did not differ significantly among the three groups 
studied. The bone age was significantly delayed in the 
GHD group. The upper/lower segment ratio was 
significantly lower in thalassaemic children than in 
the other two groups denoting slower growth of the 
spine compared with the limbs in this group of patients. 
The biochemical and hormonal data (Table 2) show 
that thalassaemic children had significantly higher 
concentrations of serum ferritin and bilirubin and 
alanine aminotransferase activity, and lower haemo­ 
globin and haematocrit values than those with CSS. All 
the children had normal serum creatinine and albumin 
concentrations. Two children with thalassaemia had 
impaired tolerance to oral glucose (1.75 g/kg) and were 
excluded from the GH treatment group. Serum calcium 
and phosphorus concentrations and alkaline phospha- 
tase activity were comparable with those for controls, 
ruling out the diagnosis of hypoparathyroidism in any of 
the patients. After ACTH stimulation, circulating 
cortisol concentrations were significantly lower in 
thalassaemic children than controls. In three thalas­ 
saemic children, cortisol concentrations did not rise to 
400 nmol/1. However, none of them had symptoms or 
signs of cortisol deficiency. Thyroid function was normal 
in 14 of 15 children with thalassaemia. One patient had 
mild hypothyroidism. His FT4 was 9 pmol/ml (normal 
10-25 pmol/1) and elevated TSH of 8/xU/ml (normal 
0.5-5/xU/ml). GH testing was performed after T4 
replacement for 1 month in this boy. Fasting
serum insulin concentrations did not differ between 
thalassaemic children (12 ± 7.8/jg/l) and controls 
(14.5 ± 5.8/ig/l).
GH/IGF-I/IGFBP-3 data are presented in Table 3. 
Thalassaemic children had significantly lower peak GH 
response to provocation by clonidine and glucagon 
than the childre with CSS. Their circulating IGF-I and 
IGFBP-3 concentrations were significantly lower than 
those for the controls with CSS. The IGF-I and IGFBP-3 
responses to GH injection were significantly lower in 
thalassaemic patients than controls, suggesting partial 
resistance to GH in these children. Their serum IGF-I 
concentrations after stimulation with GH were still 
lower than the basal circulating levels for the controls.
Table 3 shows the GH. IGF-I and IGFBP-3 data of all 
the patients. The peak GH response to provocation and 
circulating IGF-I concentrations was significantly lower 
in thalassaemic children than in those with CSS 
(P< 0.005). The IGF-I response to GH administration 
(IGF-I D in Table 3) (equal to the 24 h IGF-I value minus 
the basal value) was significantly lower in children with 
thalassaemia than in those with CSS or GHD (P < 0.01).
Table 4 compares growth and IGF-I data of six 
thalassaemic children with those for eight children with 
CSS and 11 children with GHD. Alter 1 year of GH 
therapy (18 units/m2 per week divided into daily s.c. 
doses) the growth velocity of patients with thalassaemia 
(7.2 ± 0.8 cm/year) was slower than that for children 
with CSS (9.9 ± 1.2 cm/year). The increments of 
growth velocity per year of thalassaemic patients was 
significantly lower than for the other two groups. 
Despite slower growth in thalassaemic children, their 
growth velocity doubled (from 3.8 ± 0.6 cm/year to 
7.2 ± 0.8 cm/year). After GH therapy for 1 year the 
circulating IGF-I concentrations were significantly 
lower in thalassaemic patients than controls. None of 
the children developed impaired glucose tolerance or 
hypertension during treatment.
Correlations between circulating hormonal and 
ferritin concentrations for all the children are presented 
in Table 5. Serum ferritin concentration correlated 
significantly (negatively) with GH peak response, IGF-I, 
IGFBP-3 and insulin concentration. Peak GH response 
correlated significantly with IGF-I and IGFBP-3, sup­ 
porting the view that GH is the major regulator of both 
IGF-I and IGFBP-3 synthesis.
















































HtSDS-1 and -2 means before and after 1 year of GH therapy. 
' P < 0.05 among groups.
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The growth-promoting activity of IGF-I is determined 
not only by the concentration of IGF-I but also by the 
amounts of various IGFBPs (21, 22). Of these, IGFBP-3 
is the major binding protein (23). It has been observed 
to potentiate the effects of IGF-I in bone (24-26). In 
addition, recent data clearly indicate that IGFBP-3 
prolongs the half-life of circulating IGF-I levels and 
changes the clearance pattern of plasma IGF-I (27). 
Current opinion favours GH as the major regulator of 
IGF-I and IGFBP-3 in humans. In this study, the GH 
response to provocation with clonidine and glucagon 
was impaired in short prepubertal children with /3- 
thalassaemia major compared with that in short 
normal children. Ten of the 15 children with thalassae­ 
mia did not mount an appropriate GH response 
(> 10/ig/1) in both provocation tests. These findings 
support previous reports indicating impairment of 
function along the hypothalamic-pituitary growth 
axis (9-12, 28). In malnourished children with 
decreased IGF-I synthesis, the basal and stimulated 
GH levels are significantly higher than normal (29), 
indicating stimulation of their hypothalamic-pituitary 
axis by the low circulating concentrations of IGF-I. In 
thalassaemic children, the presence of normal basal GH 
levels despite low circulating IGF-I levels suggests a 
defective hypothalamic-pituitary feedback mechanism. 
This might be secondary to defective GH secretion. 
Histopathological changes with significant siderosis of 
the pituitary gland and secondary atrophy of the 
somatotrophs can explain the dysfunction of this axis 
(6) and the increased incidence of defective GH secretion 
in our children, with defective chelation therapy, 
compared with other studies with properly chelated 
patients. Impaired GH secretion can explain in part the 
significantly lower IGF-I and IGFBP-3 synthesis with 
subsequent growth impairment in children with tha­ 
lassaemia major. However, haemosiderosis of the liver in 
these patients with disturbed hepatic function may also 
decrease IGF-I synthesis. In our study serum ferritin 
concentration correlated significantly with IGF-I con­ 
centration (r = -0.45. P < 0.05), IGFBP-3 (r = -0.42, 
P<0.05) and peak GH response to provocation 
(r = -0.34, P<0.05), which supports the view that 
iron overload may affect GH/IGF-I/IGFBP-3 secretion 
adversely. The deficiency of IGFBP-3 in thalassaemic 
patients may contribute to their growth impairment by 
. decreasing the growth-promoting effects of IGF-I. We 
(3 0) and others (31) reported progressive impairment of 
insulin secretion in children with thalassaemia because 
of haemosiderosis of the pancreas. Other investigators 
stressed as well the importance of insulin resistance in 
these patients (31, 32). The progressive loss of the 
anabolic functions of insulin may contribute to the 
delayed growth of these children either directly and/or 
through inhibition of IGF-I synthesis and function (18, 
33). In our study basal (fasting) serum concentrations
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Table 3 Responses of IGF-1 and IGFBP-3 to GH. Values are mean ± S.D.
IGF-I (ng/ml) before GH
IGF-I (ng/ml) after GH
IGF-I (ng/ml) D
IGFBP-3 (mg/l) before GH
IGFBP-3 (mg/l) after GH
IGFBP-3 (mg/l) D
Peak GH response to clonidine tg/l)





































D means the response of IGF-I or IGFBP-3 above basal levels after GH injection. ND, not determined. 
* P < 0.05 compared with values for thalassaemic children.
of insulin correlated significantly with concentrations of 
IGF-I (r= 0.541, P<0.01) and IGFBP-3 (r = 0.42, 
P<0.05). Delayed or arrested puberty is common in 
patients with thalassaemia (4, 5) because of disturbed 
gonadotrophin-releasing hormone secretion (5, 34) 
with consequent deficiency of sex steroids. Sex steroids 
can influence growth through the modulation of IGF-I - 
induced cellular response (35-37). and their deficiency 
adds significantly to the growth delay and osteoporosis 
of thalassaemic children (38). This may explain the 
relatively short upper segment, in addition to the mild 
vertebral changes observed in our thalassaemic group.
Malnutrition, primarily caused by inadequate nutrient 
intake, as indicated by the capacity to gain weight 
appropriately when provided with nutritional support 
(39), is another correctable cause of growth delay in 
thalassaemic children. Malnutrition can inhibit growth 
through inhibition of IGF-I (29) and IGFBP-3 (17) 
synthesis and insulin release (29). However, our group 
of patients had normal BMI, mid-arm circumference 
and skinfold thickness, and normal serum albumin and 
basal GH concentrations. Analysis of their dietary 
intake, by using the recall method, showed normal 
quantitative and qualitative dietary intake. These 
factors collectively exclude any major role played by 
malnutrition in our children with thalassaemia.
Impaired linear growth in thalassaemic children, 
despite regular transfusion and desferroxamine therapy, 
who have normal GH secretion suggests the possibility 
of GH resistance. In this study the IGF-I generation test
showed that these patients do not secrete adequate IGF-I 
after GH stimulation when compared with normal short 
children or those with GHD. After 1 year of GH therapy, 
despite the same dose/m2 being given to all the children, 
their circulating IGF-I concentrations were significantly 
lower than those for the short normal control group and 
those with GHD. These data are in concert with those of 
Werther et al. (40), who reported lack of response of 
non-suppressible insulin-like activity to short-term 
administration of human GH in their thalassaemic 
patients. In our six thalassaemic children treated with 
GH, the growth velocity increased significantly from 
3.8 ± 0.6 cm/year to 7.2 ± 0.8 cm/year (doubling). 
However, the increment in the rate of growth was 
significantly smaller than that of the control groups. 
Collectively these findings may suggest the presence of 
significant GH resistance in these patients, which could 
attenuate the growth-promoting effects of GH therapy. 
Low et al. (41) showed that, with higher (supraphysio- 
logical) (30 units/m2 per week divided into daily s.c. 
doses) doses of exogenous GH, there was a progressive 
increase in IGF-I production in their thalassaemic 
patients. It is known that higher GH doses during 
treatment possibly elicit a higher IGF-I and growth 
velocity response; however, this high dose may be 
necessary in thalassaemic children to overcome the 
possible GH resistance. However, supraphysiological 
doses of GH may increase the risk of inducing diabetes 
(30-32) and hypertension (42) in these high-risk 
patients. Human IGF-I therapy, alone or in combination
Table 4 Auxological and IGF-1 data before and after GH therapy. Values are mean + S.D.
Growth velocity (cm/year) HtSDS IGF-I (ng/ml)
Age
(years)
Thalassaemia (n = 6)










































1 and 2, before and after 1 year of GH therapy.
* P < 0.05 vs before GH therapy, t P < 0.05 vs values for thalassaemic children.
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Table 5 Correlation between hormonal and ferritin values (r values)
















with GH and/or IGFBP-3, appears to be an attractive 
alternative to be used to overcome the GH resistance 
and avoid the high risk of developing diabetes. In 
human (43, 44) and animal (26, 27) experiments this 
combination of growth factors appears to be useful.
In summary, children with /3-thalassaemia and short 
stature have a defective GH-IGF-I-IGFBP-3 axis that 
might be secondary to haemosiderosis of the pituitary 
gland, liver and pancreas. In addition to regular blood 
transfusion and proper chelation therapy, these patients 
need early management of their endocrinopathy. Treatment 
of their hypothyroidism, hypogonadotropic hypogonadism, 
diabetes mellitus and defective GH-IGF-I-IGFBP-3 axis can 
markedly improve their growth. In addition, these 
patients may have partial GH resistance which requires 
supraphysiological doses of GH and/or human IGF-I 
therapy.
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ABSTRACT
The growth retardation of children with thalassaemia major is multifactorial. We studied the 
growth hormone (GH) response to provocation by clonidine and glucagon, measured the 
circulating concentrations of insulin, insulin-like growth factor-I (IGF-I), IGF-binding protein-3 
(IGFBP3), and ferritin, and evaluated the spontaneous nocturnal (12-h) GH secretion in 
prepubertal patients with thalassaemia and age-matched children with constitutional short stature 
(CSS) ( height SDS < -2, with normal GH response to provocation). The hypothalamic pituitary 
area was studied in patients with anormal GH secretion using MRI scanning. Children with 
thalassaemia had significantly lower peak GH response to provocation by clonidine and glucagon 
(8.8 +/- 2.3 n/L and 8.2 +/- 3.1 jag/L respectively) vs controls (17.6 +/- 2.7 ug/L and 15.7 +/- 3.7 ug/L 
respectively). They had significantly decreased circulating concentrations of IGF-I and IGFBP3 
(68.5 +/- 19 ng/ml and 1.22 +/- 0.27 mg/L respectively) compared to controls (153 +/- 42 ng/ml and 
2.16 +/- 0.37 mg/L respectively). Seven of the thalassemic children had GH peak response < 7jag/L 
after provocation. Thalassemic patients with normal GH response after provocation, also had 
significantly lower IGF-I and IGFBP3 concentrations compared to controls. Analysis of their GH 
pulse properties revealed lower mean (2.9 +/-1.77|ag/L) and integrated ( 2.53 +/- 1.6 |ig/L) 
concentrations versus controls ( 4.9 +/- 0.29 jag/L and 5.6 +/- 0.52 ^ig/L respectively). They also had 
lower mean pulse amplitude (9.2 +/- 2.2 |ag/L) versus controls (17.2 +/- 2 |J.g/L). Five of them had 
mean nocturnal GH concentration < 2^g/L and four had maximum nocturnal peak below 10 |ig/L. 
These data denoted neurosecretory dysfunction of GH secretion in some of these patients. MRI 
studies revealed complete empty sella (n= 2), marked diminution of the pituitary size (n=4). focal 
hypo/isointense lesions within anterior lobe pituitary gland at Tl and markedly hypointense at T2 
(n=4) with variable sized focal hypo/isointense lesions within the midbrain at Tl and markedly 
hypointense at T2 ( n=6). These findings are Consistent with heamosedrin deposition in the 
anterior pituitary and mid-brain of thalassaemic patients with defective GH secretion. Serum 
ferritin concentration was correlated significantly with the circulating IGF-I (r = -0.47, P <0.01), 
and IGFBP3 (r = - 0.43, p< 0.01) concentrations. These data prove high incidence of functional and 
structural abnormalities of the GH/IGF-I/IGFBP3 axis in short children with thalassemia major 
manifested by either defective GH response to provocation and/or neurosecretory dysfunction of 
GH secretion. However, partial resistance to GH can not be excluded in some of these patients.
1.
INTRODUCTION
Growth and maturational delay are striking features of beta thalassaemia major. After the age o 
years significant growth retardation involves stature, sitting height, weight as well as skeletal 
maturation.(1-3) Delayed or complete lack of pubescent changes are common in both girls and 
boys.(4,5) Haemosiderosis-induced damage of the endocrine glands is implicated to be one of the 
main causes for their growth failure. (6)
The basal circulating concentrations of different hormones have been studied by different author 
with no consensus defining the different abnormalities of their growth hormone (GH) / insulin-lit 
growth factor-I (IGF-I) / IGF-binding protein-3 Axis. Both normal (7,8) and subnormal GH 
response (9,10) to provocative stimulation test have been reported. Some of those with normal Gl 
response to provocation might have neurosecretory dysfunction of GH secretion. (9,11,12)
IGF-I is a GH- dependent polypeptide that has a 3-fold function as a mediator of the growth 
promoting action of GH, as a potent mitogenic factor, and as a metabolic regulator with insulin- 
like activity. (13,14) Alteration of IGF-I regulation may provide an attractive explanation for 
thalassaemia -associated growth impairment. The predominant insulin-like growth factor bindin 
proteins IGFBPs in the blood is IGFBP3, which forms a large 150-kilodalton ternary complex. 
The serum level of this complex determines the total concentration of circulating IGF-I and 
regulates its growth promoting potential. (15,16) Current opinion favours GH as the major 
regulator of IGF-I and IGFBPS levels in humans. In addition, serum IGF-I and IGFBPS are 
positively related to nutritional status (17) and affected by other hormones like insulin (18). 
Estimation of circulating concentrations of IGF-I and IGFBPS markedly improves the 
interpretation of GH data in response to provocation and allows better evaluation of the 
hypothalamic-pituitary growth axis.
This study was conducted to 1. investigate the GH/IGF-I/IGFBP3 axis in short prepubertal 
children with beta thalassaemia major and 2. measure the pituitary size by MRI in these children
2 .
PATIENTS AND METHODS
Seventeen children with P thalassaemia major and delayed puberty were recruited for the study 
from the thalassaemia clinic of the Alexandria University Children's Hospital, Alexandria Egypt 
for the study. All have been treated with a chronic low transfusion regimen (to keep their 
haemoglobin above 9g/dl), with IM chelation treatment ( 3-5 times/ week) (suboptimal chelation 
due to economic reasons) and were taking 5 mg of folic acid per day. Fifteen prepubertal age- 
matched children with constitutional short stature (CSS) ( with height standard deviation scores at 
or below -2 and normal GH response to provocation ) served as controls. Criteria for entry into the 
study were as follows: 1. Age> 13 and < 25 years; 2. height less than the fifth percentile; 3. Delayed 
puberty , defined as pubarche Tanner 2 or less, gonadarche stage in the boys of 1 and thelarche 
stage in the girls of 1, at the age of 14 year and 13 year respectively, or slow progression of the 
puberty was diagnosed in 12 out of the 17 thalassemic patients. None of the children had 
intrauterine growth retardation, severe malnutrition, diabetes, dysmorphic trait, exposure to 
irradiation, or any other systemic illness. Preliminary investigations included measurement of 
electrolytes, serum calcium, phosphate, alkaline phosphatase, ferritin, urea, and creatinine 
concentrations, urinalysis and complete blood cell count. Skeletal maturation was determined by 
the method of Greulich and Pyle.(19) Informed consent was obtained from the patients and their 
parents before including in the study. The ethic Committee of Alexandria University has approved 
the protocol of the study.
Anthropometric measurements included weight (obtained to the nearest 100 g using a digital scale 
(Seca model 770), height ( using the Harpenden scale), mid-arm circumference ( using a metal 
tape), and triceps-skinfold thickness (using the Holtain Calliper). Growth velocity cm/yr was 
measured over a whole year for all the patients. Height standard deviation score (HtSDS) and 
body mass index (BMI) were calculated. Normal population data were according to Tanner et al. 
(20)
After an overnight fast a venous sample was withdrawn for measurement of free thyroxine 
(FT4), thyrotropin (TSH), insulin-like growth factor-I, IGFBP3 , and 8:00 A.M. cortisol 
concentrations. Two GH provocative testings with Clonidine (0.15 mg/m2 orally) and 
glucagon (0.1 mg/kg I.M.) were performed on two occasions. Thalassemic children with 
normal GH response to provocation (peak GH = or > 10 UG/L) (n = 10 ) underwent a 12-hour 
study of spontaneous GH secretion starting at 8 p.m. An indwelling catheter was inserted in a 
forearm vein, and a continuous blood sample was obtained in 20-min fractions through a 
peristaltic pump (Cormed, Medina, NY). GH peak analysis was performed visually by 
examining a plot of serum GH against time. For each GH profile the integrated 
concentration, the mean pulse amplitude, and the number of peaks above 5 ng/ml were 
analysed. Three randomly selected children with CSS, matched for chronological age, 
underwent similar 12-hour profiles of GH.
Human GH and IGF-I were measured by radioimmunometric assay, employing reagents 
purchased from Nichols Institute (San Juan Capistrano, CA). Intra-assay coefficients of variations 
(CVs) averaged 5.8% and 6.6% respectively, and interassay CVs averaged 7.6% and 8.4% 
respectively in the range of GH and IGF-I values detected. IGFBP3 was measured by 
radioimmunoassay in Serono Bioscientific Laboratories and Bioscience Services employing 
reagents supplied by Mediagnost. The assay sensitivity = 0.06 ug/ml with intra and inter CVs of 
5.2% and 8.6% respectively.
3.
MRI study of the hypothalamic-pituitary area was performed in 10 patients with thalassemia (fivi 
with GH deficiency, two with abnormal spontaneous nocturnal GH release and 3 with normal GH 
secretion), using a gyroscan Philips 1.5.T (Tesla) machine performing the following sequences: -1, 
Sagittal Tl,wl, 2. Coronal Tl,wl for the sella tursica , 3. Axial Tl wl for the whole brain, 4. Axial 
T2 wl over the pituitary and hypothalamic regions 5. Sagittal T2 wl for the brain. The field of 
view ranged between 180 mm for the pituitary region to 220 mm for the whole brain. Slice 
thickness was 3 and 6 mm and interstice gap = 0.3 and 0.6 mm for the pituitary and the whole 
brain respectively. Data are presented as mean +/- SD. A control group consisted of 10 aged 
between ] 4 and 23 years with HtSDS = 0.5+/- 0.3 were used as controls for the evaluation of 
pituitary -size (5 males and 5 females). None of them had received cranial radiation therapy and 
they had all been referred for MRI for various neurological reasons.
Statistics 1 analyses were performed using the unpaired t test to compare analyte concentrations 
among groups. Wilcoxon test was used when the data were not normally distributed. Correlations 
between variables of interest are examined by linear regression analysis .
RESULTS
Table (1) summarises the nuxologic data of thalasscmic patients and controls. The HtSDS, BMI, 
and GV did not differ significantly among the two groups.
The biochemical and hormonal data (Tables 2,3) showed that thalassemic children had 
significantly higher concentrations of serum ferritin, ALT and bilirubin and lower hemoglobin 
values versus the control group. Children of both groups had normal serum T4, TSH , 8:00 A.M. 
cortisol, creatinine, albumin, calcium, phosphate and ALP concentrations. The circulating 
concentrations of IGF-I and IGFBP3 were significantly decreased in thalassemic patients versus 
controls (table 3). The peak GH response to provocation by clonidine and glucagon was 
significantly low in thalassemic patients. Seven , out of the 17, patients with thalassemia had 
classic GH deficiency (peak GH < 7 jig/L after provocation by clonidine and glucagon, with low 
IGF-I, and IGFBP3 concentrations).
These 10 patients underwent 12-h study of nocturnal GH release (figure 1). Analysis of the 
pulsatile properties revealed that the integrated and mean GH concentrations over 12h were 
markedly lower in thalassemic patients versus controls . Five out of the ten studied patients had 
maximum nocturnal GH peak below 10(ig/L and four of them had mean nocturnal GH 
concentration below 2)j.g/L. Two had severe neurosecretory dysfunction of GH secretion (patient 6, 
10). Their circulating IGF-I and IGFBP3 concentrations were markedly reduced compared to 
those for controls.
Correlation between circulating hormonal and ferritin concentrations for all the study children 
are presented in table 5. Serum ferritin concentration was correlated significantly (negatively) 
with mean nocturnal GH , IGF-I, IGFBP3 and insulin concentrations. Mean nocturnal GH 
concentration and the peak nocturnal GH level were correlated significantly with IGF-I and 
IGFBP3 supporting the view that GH is the major regulator of both IGF-I and IGFBP3 synthesis.
MRI studies revealed marked reduction of the pituitary volume in thalassemic children ( 305 +/- 
125 mm3) versus age-matched normal controls (618 +/- 87 mm3) (p<001). Those patients with GH 
deficiency had variable abnormalities including: complete empty sella (n= 2), marked diminution 
of the pituitary size (n=4), focal hypo/isointense lesions within anterior lobe pituitary gland at Tl 
and markedly hypointense at T2 (n=4) with variable sized focal hypo/isointense lesions within the 
midbrain at Tl and markedly hypointense at T2 ( n=6) Consistent with heamosedrin deposition. 
None of the control children had abnormalities of the pituitary gland or its stalk.
5.
DISCUSSION
The growth promoting activity of IGF-I is determined not only by the concentration of IGF-I but 
also by the amounts of various IGF binding proteins (IGFBPs).(21,22) Among these IGFBP3 is th< 
major binding protein. (23) IGFBP3 has been observed to potentiate the effects of IGF-I in bone. 
(24-26) In addition, recent data clearly indicate that IGFBP3 prolongs the half life of circulating 
IGF-I levels and changes the clearance pattern of plasma IGF-I.(27) Current opinion favours GH 
as the major regulator of IGF-I and IGFBP3 in humans. In this study, the GH responses to 
provocation with clonidine and glucagon was impaired in short prepuberatal children with beta 
thalassaemia major compared to those for short normal children. Seven out of the 17 children 
with thalassaemia did not secrete GH after provocation (peak GH <7 ug/L) in both provocative 
tests. Five of the children had normal GH response to provocation , but abnormal nocturnal 
spontaneous GH secretion. MRI studies of the hypothalamic-pituitary area of 12 patients with 
thalassemia ( 7 with GH deficiency, 2 with abnormal spontaneous nocturnal GH release and 3 wit 
normal GH secretion) revealed complete empty sella (n= 2), marked diminution of the pituitary 
size (n=4), abnormal signal pattern of the gland (n=4) and thinning of the pituitary stalk (n=3) 
with its posterior displacement (n=2) in those patients with defective GH secretion (Fig 2) with 
relatively normal hypothalamic area, proving a good correlation between the structural alteration 
of the pituitary gland and dysfunction/deficiency of GH secretion in these patients. In support to 
our data previously published autopsy studies showed marked histopathological changes with 
significant siderosis of the pituitary gland and secondary atrophy of the somatotrophs. (6) The 
increased incidence of defective GH secretion in our thalassemic children, compared to other 
studies (9-12,28), could be explained on the basis of incomplete iron chelation in our patients with 
more siderosis of the pituitary gland.
All our patients with thalassemia had significantly lower concentrations of circulating IGF-I and 
IGFBP3. Impaired GH secretion can explain in part the significantly lower IGF-I and IGFBPS 
synthesis with subsequent growth impairment in children with thalassaemia major. However, 
haemosiderosis of the liver in these patients with disturbed hepatic function might also decrease 
synthesis of IGF-I and IGFBP3. In our study serum ferritin concentration was significantly 
correlated with IGF-I concentration (r = - 0.47, P< 0.01), and IGFBP3 (r=-0.43, p< 0.01). This 
supports the view that siderosis of the liver can adversely affect the IGF-I/IGFBP3 synthesis. 
Deficiency of IGFBPS in thalassemic patients might contribute to their growth impairment by 
decreasing the growth promoting effects of IGF-I.
We (29) and others (30) reported progressive impairment of insulin secretion in children with 
thalassaemia due to haemosiderosis of the pancreas. Other investigators stressed as well the 
importance of insulin resistance in these patients. (30,31). Insulin deficiency and/or resistance 
might be a contributing factor compromising the growth potential of these children through 
inhibition of IGF-I synthesis and/or secondary to increased production of inhibitory IGF-binding 
proteins. In this study, although the fasting serum insulin concentrations were within the normal 
range, they were correlated significantly with circulating IGF-I and IGFBP3 levels.
Delayed or arrest of puberty is common in patients with thalassaemia (4,5) due to disturbed 
gonadotrophins secretion (5,34) with consequent deficiency of sex-steroids. Sex steroids can 
influence growth through the modulation of GH secretion and IGF-I-induced cellular response 
(35-37) and consequently their deficiency impairs linear growth and attenuates the pubertal 
growth spurt in thalassaemic children.(38)
6.
The finding of impaired linear growth in thalassaemic children, despite regular transfusion and 
(IcsfciToxiuniiiG therapy, who have normal GH secretion suggests the possibility of Gil resistance. 
In a previous report our group studied IGF-I generation in a group of thalassemic patients (n=15) 
and found that they do not secrete adequate IGF-I after GH stimulation when compared to normal 
short children or those with growth hormone deficiency (GHD). After one year of GH therapy, 
despite giving the same dose/m2 to all the children, thalassemic children had significantly lower 
IGF-I concentrations versus those for the short normal control group and those with GHD.(39) 
These data are in concert with those of Werther GA et al (40) who reported lack of response of 
nonsuppressible insulin-like activity to short-term administration of human growth hormone in 
their thalassaemic patients. We treated 6 thalassaemic children with GH for a year. Their growth 
velocity increased significantly from 3.8 +/- 0.6 cm/yr to 7.2 +/- 0.8 cm/yr (doubling). However, the 
increment of the rate of growth was significantly slower compared to a control group with CSS. 
Collectively these findings suggest the presence of significant GH resistance in these patients 
which could attenuate the growth promoting effects of GH therapy. In concert with our view, Low 
LC et al (38) have shown that with higher (supraphysiological) (30units/m2/week divided on daily 
S.C. doses) doses of exogenous GH there has been a progressive increase of IGF-I production in 
their thalassaemic patients. Although it is known that higher GH doses during treatment possibly 
elicit a higher IGF-I and GV response, however this high dose might be necessary in thalassemic 
children to overcome the possible GH resistance. However, supraphysiological doses of GH might 
increase the risk of inducing diabetes and hypertension (29,30,39) in these high risk patients. 
Human IGF-I therapy , alone or in combination with GH and/ or IGFBP3 , appears to be an 
attractive alternative to overcome the GH resistance and avoid the high risk of developing diabetes 
in them. In human (41,42) and animal (26,27) experiments this combination of growth factors 
appear to be useful.
In summary; children with beta-thalassaemia and short stature have high incidence of 
abnormalities involving the GH/IGF-I/IGFBP3 axis with low circulating IGF-I and IGFBP3 
concentrations. Decreased GH response to provocation (7/15) and abnormal properties of 
spontaneous nocturnal GH secretion (5/15) have been detected in this study and appear to be 
important etiological factors. In these patients defective GH secretion is associated with abnormal 
structure of the pituitary gland and its stalk. These changes are likely to be secondary to 
hemosiderosis of the pituitary gland as evidenced by the presence of iron deposits in the pituitary 
gland (with different degrees of pituitary atrophy), as well as in the mid-brain of these patients. 
However, children with thalassemia who have normal GH response to provocation and normal 
spontaneous (mean and integrated) GH secretion still have low circulating IGF-I concentrations 
suggesting partial resistance to GH. Early treatment of the defective GH/IGF-I/IGFBP3 axis in 
these children might markedly improve their linear growth, however, these patients usually 
require supraphysiological doses of growth hormone.
7.
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B-age= bone age, HtSDS= height standard deviation score, 1 and 2 = before and after 1 year, 
GV= growth velocity , *p <0.05 among groups





















































































*p below 0.05, ferrit= ferritin, alb = albumin, Insu = fasting insulin , Cor= 8:00 A.M. cortisol.
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P-GH to clonidine (ug/L)













• p< 0.05. IGF-D= the response of IGF-I above basal levels after GH injection, P-GH= peak 
GH response



















































































































































































































lnteg-N-GH= ntegrated nocturnal GH, pulse-Ampli= mean pulse amplitude, Max-N-peak= maximum nocturnal pe































*p <0.05, **p <0.01
Figure 1: Nocturnal GH secretion in
thalassaemic patients (left) and
controls (right)
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Nocturnal 12-hour profile of plasma GH (ug/L) in some patients with 
thalasscmia major who had normal Gil response to provocation and 
defective overnight GH secretion compared to controls (1-3) 
Patient 1: Age= 13.5 years, HtSDS= -2.5, peak GH response =8.9 ug/L 
Patient 6: Age = 25 years, HtSDS = -1.9, peak GH response = 8.1 ug/L 
Patient 7: Age= 18 years, HtSDS = -2, peak GH response = 9.4 ug/L 
Patient 8: Age= 14.5 years, HtSDS = -4.1, peak GH response = 7.8 ug/L 
Patient 9: Age= 13 years, HtSDS = -1.9, peak GH response = 9.9 ug/L 
Patient 10: Age= 16 years, HtSDS = -2.75, peak GH response = 9.1 ug/L 
Control 1: Age= 14 years, HtSDS = -1.8, peak GH response = 16.2 ug/L 
Control 2: Age= 15 years, HtSDS= -1.8, peak GH response = 12.7 ug/L 
Control 3: Age= 16 years, HtSDS= -2.2, peak GH response= 14.8 ug/L
Figure 2:
MRI images in thalassaemic patients
SE 600/20 Tl weighted image sagittal scan at the level of the mid-pituitary
gland demonestrating:
2-A: normal volume anterior and posterior pituitary lobes, with ill-defined
iso/hypointense focal lesion identified within the lower part of mid-brain and
partial atrophic changes of the cerebral cortex .
2-B: slightly diminished volume of the anterior pituitary lobe, normal
posterior pituitary, focal hypo/ isointense area identified within the anterior
pituitary substance and the lower part of the mid brain with increased CSF
within the dorsal part of the sella tursica and suprasellar cistern. Partial
atrophic changes of the cerebral cortex.
2-C: markedly diminished volume of the anterior pituitary lobe and normal
posterior pituitary with relatively large focal hypointense area within the
remenant of the anterior pituitary lobe and small hypo/isointense focal area
within the lower part of the mid-brain and increased CSF at the dorsal aspect
20
of the sella turcica and suprasellar cistern (partial empty sella). The 
calvarium is markedly thickened due to increased diploic space. 
2-D: Total loss of the anterior pituitary lobe and mild posterior hooking of 
the lowermost part of the pituitary stalk. Normal volume of the posterior 
pituitary. There is an iso/hypointense focal lesion at the lower part of the 
mid-brain. The anterior part of the sella tursica is filled with CSF ( empty 
sella).
2-E: Total loss of the anterior pituitary lobe with normal posterior pituitary 
with empty sella and focal iso/hypointense area in the lower part of the mid- 
brain. Partial atrophic changes of the cerebral cortex are observed. 
2-F: Sagittal SE 2000/80 T2 weighted image at the level of the mid-pituitary 
demonstrating marked hypointensity of the anterior pituitary, large focal 
area of marked hypointensity identified within the midbrain, partial atrophic 
changes of the cerebral and cerebellar cortices.
Bone Mineral Density in Prepubertal Children With p-Thalassemia: 
Correlation With Growth and Hormonal Data
Ashraf T. Soliman, ISIagwa El Banna, Mohammed Abdel Fattah, Mahmoud M. ElZalabani, and 
B.M. Ansari
Patients with p-thalassemia major ip-thalassemia) frequently have bone disorders of multifactoria
l etiology. We attempted to 
analyze we relationship between the bone mineral density ([BMD] measured by dual-photon abso
rptiometry) and auxanologic 
l^c^i- 9'8.8 °f Slderosis. 'unction of the growth hormone (GH)/insulin-like growth factor-l 
(IGF-l)/IGF-binding protein-3 
IGFBPdl axis calcium-phosphate balance, parathyroid hormone (PTH), and cytokines (interleukin-
lp [IL-1] and tumor necrosis 
factor-alpha ITNF-a] | in 30 prepubertal children with p-thalassemia major and 15 age-matched 
children with constitutional 
short stature (CSS), who have normal glucose tolerance and thyroid function. Chijdren with p-tha
lassemia had a significantly 
decreased BMD and mean BMD% for age and sex (0.75 ± 0.24 g/cm2 and 71% ± 10%, respectivel
y) versus children with CSS 
(1.06 ± 0.3 g/cm and 92% ± 7%, respectively). Thalassemic patients had significantly lower circul
ating concentrations of IGF-I 
and!GFBP3(49 ± 21 ng/mLand 1.2 ± 0.25 mg/L. respectively) compared with control children (15
3 ± 42ng/mLand2.1 ± 0.37 
mg/L, respectively). The GH response to provocation by clonidine and glucagon was defective (pe
ak GH < 7 |xg/L) in 12 of the 
30 thalassemic children. Serum concentrations of IL-1P and TNF-a did not differ among the two s
tudy groups. Hypocalcemia 
was detected in five of the 30 thalassemic patients: hypoparathyroidism was diagnosed in two 
of the five and rickets in the 
other three. BMD was highly correlated with the circulating concentrations of IGF-I and IG
FBP3, as well as with the 
auxanologic parameters (age, weight, height, height standard deviation score [HSDS], and bo
dy mass index [BMW. It is 
suggested that increasing the circulating IGF-I concentration through aggressive nutritional thera
py and/or GH/IGF-I therapy 
with supplementation with vitamin D and/or calcium might improve bone growth and mine
ralization and prevent the 
development of osteoporosis and consequent fractures in these patients. Such therapy requires b
linded controlled trials. 
Copyright© 1998by W.B. Sounders Company
OSTEOPOROSIS is a disease characterized by loss of bone mass and microarchitectural deterioration, resulting in a 
reduced mechanical competence and consequent increased risk 
of fractures.' p-Thalassemia major is associated with significant 
bone disease. 2 These changes include bone marrow expansion 
of the medullary cavity, cortical thinning, trabecular coarsening 
with various striations or the appearance of cystic spaces, and 
coarsening of the bone pattern with a drop out of all but the 
mechanically most necessary trabeculae. 3
With advances in transfusion management beginning in the 
1960s, there has been marked improvement in terms of skeletal 
development and normal cosmetic facial and long bone appear­ 
ance.4 However, even well-transfused patients remain radio- 
graphically osteopenic. Prior to institution of aggressive transfu­ 
sion regimens, fractures occurred primarily in the long bones 
and were associated with trauma.5 After the introduction of 
aggressive transfusion, the pattern changed, with less involve­ 
ment of long bone and an increased in vertebral compression 
fractures, especially in older patients. 6
Although the etiology of the bone disease is still debatable, 
many factors can adversely affect bone accretion in thalassemic 
children. These include (I) chronic hypoxemia and medullary 
expansion, (2) defective growth affecting both height and 
weight, (3) abnormal calcium-phosphate homeostasis, (4) de­ 
layed or lack of pubertal development and decreased sex steroid 
secretion, (5) compromised nutritional status and increased 
energy expenditure, (6) abnormal growth hormone (GH)/insulin- 
like growth factor-I (IGF-I)/IGF-binding protein-3 (IGFBP3) 
axis, and/or (7) development of diabetes mellitus.7 lo
The aim of this study was to investigate some factors 
affecting bone mineral metabolism in 30 children with (3- 
thalassemia and to attempt to find a relationship, if any, between 
the degree of siderosis, calcium-phosphate balance, the GH/IGF- 
I/IGFBP3 axis, parathyroid hormone (PTH) secretion, and 
auxanologic data, on one hand, and bone mineral density 
(BMD) on the other.
SUBJECTS AND METHODS
Thirty-three prepubertal patients with P-thalassemia major randomly 
selected from those attending the outpatient Pediatric Hematology 
Clinic of Alexandria University Children's Hospital, Alexandria. Egypt, 
were the subjects of this study. All children underwent regular blood 
transfusions to keep the hemoglobin (Hb) concentration above 10 g/dL. 
All were taking folic acid supplements and iron chelation with daily 
intramuscular desferoxamine. Fifteen age-matched normal short chil­ 
dren (constitutional short stature |CSS), height standard deviation score 
IHtSDS] •& -2, annual growth velocity |GV] •& 5 cm/yr, normal GH 
response to provocation, and delayed bone age) served as controls. 
None of the children had a history of intrauterine growth retardation, 
other systemic or endocrine disease or dysmnrphic trait, or central 
nervous system irradiation. All had normal tolerance to an oral glucose 
load (1.75 g/kg dextrose). Three patients who had abnormal glucose 
tolerance were excluded from the study.
Informed consent for the testing procedures was obtained from the 
parents and, when appropriate, from the children before entering the 
study. The study protocol was approved by the ethics committee of 
Alexandria University.
All children were examined with a special emphasis on nutritional 
data. The auxanologic data included weight, height, and mklarm 
circumference. Harpenden calipers and anthropometric measurements 
were used. The data recorded were the average of three sequential 
measurements determined by the same observer (A.T.S.). The HtSDS 
and body mass index (BMI) were calculated and recorded. The linear 
GV in centimeters per year was calculated for the past year. Normal
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population data were from Tanner etal." The bone age was determined 
according to the Greulich and Pyle atlas. 12
On the day of admission, venous blood samples were obtained for 
determination of the complete blood cell count, and serum concentra­ 
tions of albumin, hilinibin. and alanine aminotransferase (ALT). 
Following an overnight fast (8 hours) venous blood samples were drawn 
through a polyethylene catheter inserted in a forearm vein between 8 
and 9 AM. The serum was separated from the formed elements by 
centrifugation and kept frozen at -20°C until analyzed for GH, IGF-I, 
IGFBP3, free thyroxine (FT4 ), thyrotropin (TSH), cortisol, PTH (intact 
molecule), calcium (Ca), phosphorus (PO4), alkaline phosphatase 
(ALP), ferritin, interleukin-IB (IL-IB), and tumor necrosis factor-alpha 
(TNF = ot) concentrations. After obtaining the basal samples, an oral 
dose of clonidine 0.15 mg/m2 and intravenous dose of corticolropin 
(ACTH) (Synacthen; Ciba-Geigy, Basel, Switzerland) I ug/m2 were 
given, and blood samples were collected every 30 minutes for 2 hours 
for measurement of GH levels and after fiO minutes for cortisol levels. 
On the next morning, a standard glucagon test for GH release was 
performed.
Human GH and 1GF-] concentrations were measured by radioimmu- 
nometric assay using reagents purchased from Nichols Institute (San 
Juan Capistrano, CA). Mean intraassay coefficients of variation (CVs) 
were 5.8% and 7.6%. respectively, and interassay CVs were 7.8% and 
8.5%, respectively, in the range of GH and IGF-I values detected. The 
IGFBP3 level was measured by radioimmunoassay in Serono Biochemi­ 
cal Laboratories (SCL) & Bioscience Services (London, UK) using 
reagents supplied by Mediagnost (Rome, Italy). The assay sensitivity is 
0.06 ug/mL with intraassay and interassay CVs of 5.2% and 8.6%, 
respectively. The level of intact PTH was measured in the serum using 
an immunochemiluminometric method. Intraassay and inlerassay CVs 
were 3.6% and 6.2%, respectively. IL-lp and TNF-a levels were 
measured using an enzyme-linked iminunosorhcnl assay technique 
(Biokine: T-Cell Diagnostics, Cambridge, MA; intraassay CVs, 8.4% 
and 6%, respectively, interassay CVs, 8.8% and 7%, respectively).
BMD of the lumbar spine (second, third, and fourth lumbar verte­ 
brae) was measured by dual-photon absorpliometry using a Norland 
2600 bone densitometer (Cambridge, UK). All children were scanned in 
the supine position. BMD data were expressed as grams per centimeter 
squared and were compared with BMD values of normal children of the 
same age. 11
Statistical analyses were performed using the unpaired / test to 
compare mean analyte concentrations among the two study groups 
when the data were normally distributed, and the Wilcoxon test when 
they were not. Statistical significance was accepted at P less than .05. 
Multiple regression analysis was performed using BMD as the depen­ 
dent variable and all of the other auxanologic and biochemical data as 
independent variables. Data are presented as the mean ± SEM.
RESULTS
Anthropomelric and bone age data are presented in Table I. 
The chronological age, HtSDS, GV, BMI, and bone age did not 
differ significantly between the two study groups. Biochemical, 
hormonal, and BMD data are shown in Tables 2 and 3. The 
circulating concentrations of albumin, creatinine, ALP, and PO4 
did not differ significantly among the two groups. Hypocalce-









(n - 30) 1.95 <-0.il 4.1 + 0.24 8.8*0.27 13.9 + 0.24 
CSS (n = 15) 2.6 • 0.13 4.6 ± 0.03 8.2 + 0.26 14.9 +• 0.013
"P< .05, (i-thalassemia vCSS.
mia (Ca s ] .4 nmol/L, 5.7 mg/dL) was detected in five patients. 
Three of them (aged II, 12.5, and 14 years) had other 
biochemical evidence of hypoparathyroidism (high PO4, nor­ 
mal ALP, and low PTH concentrations). The other two patients 
(aged 9 and 11 years) had biochemical evidence of rickets (low 
PO4, high ALP and PTH, and low 25-hydroxyvitamin D3 
concentrations). Circulating concentrations of IGF-I and IG- 
FBP3 were significantly lower in thalassemic children com­ 
pared with controls. Their peak GH responses to provocation 
with clonidine and glucagon were significantly less than those 
for the controls. Twelve of the 30 children with B-thalassemia 
did not mount a GH response to provocation above 7 ug/L. 
Although basal levels of cortisol did not differ between the two 
groups, the cortisol response to a low-dose ACTH test was 
significantly lower in thalassemic children versus controls. Two 
children had mild chemical hypothyroidism (FT,,, 9.5 and 8.7 
pmol/L; TSH, 8.6 and 10.3 uIU/mL). Both were treated with 
L-thyroxine for I month before testing their GH response to 
provocation.
Dual-photon absorptiometry showed that children with B- 
thalassemia had a significant reduction of BMD (30% less) 
compared with the mean BMD for age-and sex-matched normal 
children, corresponding to a BMD of - 1.5 to -2 SD. Thalasse­ 
mic children had significantly lower BMD versus age-matched 
children with CSS. Correlations between BMD and different 
parameters are shown in Table 4 and Fig I. BMD was correlated 
significantly (P < .01) with age, height, weight, and BMI, as 
well as with the circulating concentrations of IGF-I and 
IGFBP3. No significant correlations were found between BMD, 
on one hand, and PTH, PO4, Ca, or ALP concentrations on the 
other. IL-l(i and TNF-a concentrations did not differ signifi­ 
cantly between the thalassemic group (25.9 ± 11.4 and 
399 ± 113 pg/mL, respectively) and controls (21.1 ±6.4 and 
383 ± !22pg/mL).
DISCUSSION
From infancy through late adolescence, bone-forming activ­ 
ity exceeds bone resorption, resulting in a steady accumulation 
of bone mass. On average, most of the skeletal mass is 
accumulated by the age of 18 years. 1 "1 - 18 Since the bone mass is 
one of the main determinants of fractures, a high bone mass at 
skeletal maturity (peak bone mass) is considered the best 
protection against age-related bone loss. 19 Small differences in 
bone mass at skeletal maturity of 5% to 10% could contribute to 
substantial differences in the incidence of osteoporotic frac­ 
tures. 20
Bone modeling and skeletal consolidation result from a 
complex sequence of hormonal changes in interaction with 
nutritional factors, where the concerted actions of GH, IGF-I, 
and sex hormones and their receptors, besides other factors, are 
responsible for the liming and attainment of skeletal consolida­ 
tion. At puberty, circulating IGF-I concentrations correlate with 
sexual development. Specifically, the surge in sex steroids, in 
turn, increases the secretion of GH, which stimulates the 
production of IGF-1 21 ' 22 and increases bone mass. 2 ' In addition, 
a large number of other factors interact at the level of the 
ostcoblast, osleoclast, and other cells to regulate the balance 
between net resorption and formation. These include PTH, 
vitamin D, and cytokines. 21
BONE MINERAL DENSITY IN THALASSEMIA 543
Group
































8.2 ± .27" 
12.4 + 0.3
*P< .05, p-thalassemia vCSS.
The GH/1GF-I/IGFBP3 Axis and Factors Affecting It
In this study, the hormonal profile of children with B- 
thalassemia showed a significant deficiency of circulating IGF-I 
and IGFBP3 (both are GH-dependent peptides). The significant 
correlation between the IGF-I levels and HtSDS and BMD 
supports a major role played by IGF-I in stimulating linear 
growth and bone mineralization.
Forty percent of these prepubertal thalassemic children had 
defective GH secretion after provocation by clonidine and 
glucagon. In concert with our findings, Danesi et al, 24 Saglamer 
et al, 25 and Pintor et al 26 reported a low GH response to 
provocation by insulin hypoglycemia, arginine, L-dopa, and 
GH-releasing hormone in many of their patients, denoting 
impairment of somatotroph function. This can explain the low 
IGF-I synthesis in some patients. However, the thalassemic 
children with normal GH secretion had low circulating IGF-I 
concentrations (50 ± 19 ng/mL) comparable to those seen with 
defective GH release (46 ± 24 ng/mL), suggesting that other 
factors contribute to low IGF-I synthesis in these children. 
Leger et al 27 found that decreased IGF-I secretion occurs before 
an alteration in GH secretion in response to GH-releasing 
hormone, arginine, or insulin. Other investigators reported the 
neurosecretory dysfunction of GH secretion to be responsible 
for decreased IGF-I synthesis in some patients with a normal 
GH response to provocation. 28-29 Some investigators indicated 
that decreased GH secretion may be due to an age-related 
deterioration of the hypothalamic-pituitary function secondary 
to progressive siderosis.27-30 In support, Perignon et al 31 re­ 
ported that their patients with p-thalassemia had a low IGF-I 
concentration that did not increase at puberty. Although the idea 
of a defect at the hepatic GH receptor or postreceptor level was 
suggested to explain the low IGF-I production,26 Postel-Vinay







































et al 32 found no evidence for a defect in GH binding to liver 
membranes in thalassemic patients.
It is well recognized that the nutritional status has an 
important influence on the GH/IGF-I/IGFBP3 axis." Fasting 
results in increased GH secretion and decreased 1GF-I levels,34 
and proper nutrition increases IGF-I levels in malnourished 
children." Our children with (i-thalassemia had a BMI and 
MAC at or below the lOth centile for age and sex, suggesting a 
mild degree of undernutrition. Decreased food intake, 16 pancre­ 
atic exocrine dysfunction, hepatic cirrhosis,"-38 and/or hyperme- 
labolism secondary to bone marrow hyperaclivity and increased 
cardiac work might compromise nutrition and growth in these 
children. In this study, circulating IGF-I concentrations were 
correlated significantly with ALT levels (r = -.465, P < .01), 
and 50% of the children were hepatitis B surface antigen 
carriers and had significantly elevated ALT concentrations. 
Clinically, 25 of 30 patients had cirrhotic livers. In one study,36 
nutritional intervention resulted in an improvement of weight 
for height and increased IGF-I concentration. In malnutrition 35 
and hypercatabolic states,39 low IGF-I production is associated 
with high basal and stimulated GH levels, denoting a normal 
sensitivity of the hypothalamic-pituitary axis to the low IGF-I 
level (normal feedback). In p-thalassemia, the low-normal GH 
levels despite low circulating levels of IGF-I prove a defective- 
feedback effect of decreased IGF-I on the pituitary (either due to 
lack of sensitivity or defective somatotroph function). We and 
others reported partial resistance to GH in thalassemic children 
as evidenced by low IGF-I generation in response to exogenous 
administration of GH and slow linear growth on GH therapy. 4(M2
During a normal pubertal growth spurt, sex steroids increase 
GH secretion with a subsequent increase of IGF-I levels. Sex 
steroids and GH each contribute approximately 50% of the 
height gain. Children with GH insufficiency not treated with 
exogenous GH attain only 50% to 66% of the expected growth 
spurt.43 47 Reduction of the sex steroid concentration during 
gonadotropic-releasing hormone therapy decreases GH secre­ 
tion and serum IGF-I concentrations.4MI1 Patients with B- 
thalassemia have a high incidence of failure of puberty (51% of 
boys and 47% of girls) and secondary amenorrhea (23%).'" 
Defective gonadotropin secretion with subsequent sex steroid 
deficiency have been detected in these patients with low IGF-I 
levels." ^ Even those who enter puberty do not have the
Table 4. Correlation Between BMD and Auxanologlc 
and Biochemical Data (r)
Abbreviations: GH-P-Clon, GH peak after clonidine; Glu, glucagon; 
cortisol-b, before ACTH; a, after ACTH.
*P< .05, tP< .01, p-thalassemia vCSS.
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enhanced GH secretion and increased 1GF-I synthesis pattern 
accompanying normal puberty, '"•" denoting a major effect of 
sex steroid deficiency on the GH/1GF-I axis in peripuhertal and 
pubertal children with p-lhalassemia. Unlike children with a 
constitutional delay of puberty, who secrete normal GH in 
response to provocation after priming with sex steroid,43 in our 
prepubertal thahtssemic patients older than 12 years (n = 8), the 
peak GH response to provocation did not improve after 
(7.5 ± 2.1 |Jg/L) versus before priming with estrogen (6.5 ± 1.5
The reported prevalence of diabetes mellitus in treated 
P-thalassemia is about 16%, and the incidence of impaired 
glucose tolerance is approximately 60%. Islet cell destruction
secondary to iron overload and/or exhaustion of B cells due to 
chronic insulin resistance and liver derangement are possible 
pathogenic factors. 5458 Defective insulin secretion and an 
insulin-resistant state can impair hepatic IGF-I production.59'60 
Moreover, insulin plays an important part in determining the 
bioavailability of IGF-I through its action on IGFBPI. There­ 
fore, defective insulin secretion or insulin resistance in thalasse- 
mic children can increase hepatic production of IGFBPI, 
leading to decreased bioavailability of IGF-I.61 -62 However, this 
factor can be excluded in our patients with normal glucose 
tolerance.
In summary, the markedly decreased hepatic production of 
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Fig 1. Correlation between BMD (g/cm2 ) and different variables in 
30 patients with fl-thalassemla. (A) Correlation between BMD (g/ 
cm2) and IGFBP3 (mg/LI (r = .694, P < .0011; (B) correlation between 
BMO (g/cm2 ) and IGF-I (ng/mL) (r = .74. P < .001); (C) correlation 
between BMD (g/cm2 ) and HtSDS (r = .52. P < .001); (D) correlation 
between BMD and serum ferritin level (ng/mL) (r = .27, P = .022); (E) 
correlation between circulating concentrations of IGF-I (ng/mL) and 
IGFBP3 (mg/L) (r = .72, P < .002).
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glucose homeostasis can be attributed to defective GH secre­ 
tion hepatic c.rrhosis (secondary to siderosis and/or chronic 
viral hepatitis), and/or GH resistance. The delay or lack of 
pubertal development and the occurrence of type I diabetes with 
advancing age might further impair the secretion and/or bioavail- 
abilityof IGF-I.
1GF-I is a potent stimulator of linear growth and a major 
determinant of bone mineralization. Exogenous administration 
of IGF-1 has been shown to increase growth and bone formation 
in humans and animals.6166 This effect is potentiated when 
IGF-I is combined with IGFBP3.67-68 In our children with 
B-thalassemia, the decreased production of IGF-I and IGFBP3 
and the significant correlation between these growth factors and 
BMD and linear growth (weight, height, and HtSDS) param­ 
eters suggested a major role for them in the pathogenesis of 
osteoporosis. GH or IGF-I therapy may improve linear growth 
and bone mineralization in these children, as seen in patients 
with GH deficiency/resistance and other diseases with osteope- 
nia.69'71 This hypothesis needs to be tested by a double-blind 
therapeutic trial of GH or IGF-I in these patients.
Calcium-Phosphate Balance and PTH
In this study, hypocalcemia occurred in five of 30 children 
with B-thalassemia. All five children had markedly decreased 
BMD. Analyses of the other biochemical parameters differenti­ 
ated two possible disease entities. Two of the five patients had 
evidence of hypoparathyroidism (low Ca, high PO4, normal 
ALP, and low PTH). This can be explained by siderosis of the 
parathyroid gland. 72'75 In support of this view, Gertner et al 76 
found a low PTH reserve to induced hypocalcemia in thalasse- 
mic patients. The other three patients had biochemical evidence 
of rickets (low PO4, low Ca, high ALP, high PTH, and low 
25-hydroxyvitamin D,). In concert with this finding, De Verne- 
joul et al77 reported osteomalacia in their thalassemic patients. 
The cause of rickets/osteomalacia in these patients is a defective 
25-hydroxylation due to hepatic impairment and/or decreased 
vitamin D absorption in these children. Impaired osteoblast 
function with diminished bone formation and a low serum 
concentration of 25-hydroxyvitamin D, with high PTH levels 
have been reported in patients with hemochromatosis and liver 
cirrhosis and in pigs overloaded with parenteral iron.78 -" 1
The normocalcemic (25 of 30) patients with B-thalassemia 
had a slightly higher PTH concentration and significantly lower 
BMD versus normal children. In agreement with this finding, 
Pawlotsky et al 82 reported an elevated PTH concentration, 
normal serum calcium level, and increased bone resorption in 
their hemochromatic patients. It appears that both vitamin D 
deficiency and hypoparathyroidism might affect bone mineral­ 
ization in thalassemic children.
Cytokinex
Cytokines represent a group of factors influencing the 
balance between bone formation and resorption. Increased bone 
resorption induced by an overproduction of critical cytokines, 
such as IL-I, TNF, and GM-CSF, by the hyperactive marrow 
cells and monocyte/macrophage lineage is an attractive theory 
to explain the pathogenesis of osteoporosis seen in patients with
B-thalassemia, as with other diseases. IL-1 and TNF are among 
the most powerful stimulators of bone resorplion known and are 
well recognized inhibitors of bone formation. 83'87 However, we 
found normal serum levels of IL-1 and TNF in our thalassemic 
patients comparable to those for control children, which might 
rule out a significant role for these cytokines in the development 
of osteoporosis in these children.
Cortisol Secretion
In this study, children with B-thalassemia had a significantly 
lower cortisol response to provocation with low-dose ACTH. 
Other studies reported both low88 ' 8"' and normal'" 1'"" cortisol 
responses to high-dose ACTH. Slate gray pigmentation that 
becomes progressively intense with time, poor weight gain, 
weakness, and absent adrenarche were significant signs in our 
thalassemic patients. However, the contribution of different 
factors including adrenal insufficiency, siderosis, and anemia in 
the production of these manifestations is difficult to assess. 
Mclntosh89 reported high circulating ACTH in B-thalassemia, 
and suggested that it is the cause of the pigmentation. In concert 
with these findings, the graded-dose adrenal cortical stimulation 
showed significant suppression of cortisol secretion. Although 
iron deposition in the adrenals might be the cause of adrenal 
insufficiency, it has been shown recently that IGF-1 enhances 
the steroidogenesis and ACTH responsiveness of human adreno- 
cortical cells in culture.92 "9'1 A deficiency of IGF-I synthesis in 
B-thalassemia might contribute to the defective cortisol produc­ 
tion and possibly other adrenal androgens, which might explain 
the lack of or delay in adrenarche in thalassemic patients. These 
data suggest that replacement with physiological doses of 
hydrocortisone might improve some of the manifestations of the 
disease. In addition, increasing the IGF-I level might also 
improve the secretion of adrenal androgens necessary for 
adrenarche.
The question is, what possible therapeutic or preventive 
options are available that might influence bone mineralization 
and growth in thalassemic children? The data from this study 
support the development of a controlled clinical trial to evaluate 
several possible therapeutic interventions. In addition to proper 
and aggressive nutritional intervention, which should be an 
integral part of any treatment strategy, possible new therapeutic 
interventions would include the following: (I) GH and/or IGF-I 
replacement therapy, especially for those with GH and/or IGF-I 
insufficiency. These measures might increase the circulating 
IGF-I level and consequently increase bone formation and 
prevent osteopenia. Adding IGFBP3 to IGF-I and/or GH 
therapy might potentiate their effect on bone growth and 
mineralization.67 '69- 71 (2) Treatment with vitamin D or vitamin 
D analogs at modest doses (800 to 1,500 lU/d vitamin Di) may 
offer a safe and substantial contribution to the prevention of 
osteoporosis in these children. Positive correlations of vitamin 
D levels with BMD of the vertebrae and proximal femur have 
been found in young and old women with poor vitamin D 
status. 1**- 9 " Patients with osteoporosis and biochemical evidence 
of rickets need higher doses of vitamin D3 or its analogs for 
treatment. (3) Calcium supplementation, which has been shown 
to increase hone density in normal prcpubertal children, is 
another good potential option.99 (4) Initiation of puberty al an
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appropriate age through the use of progressively increased 
doses of androgens or estrogens. These agents would prevent 
osteoporosis and increase the BMD,21-" 10" 1 "2 forcing into consid­ 
eration the risk of advancing the bone age faster than the height 
age.
In summary, prepubertal children with 3-thala.ssemia and 
normal glucose tolerance have decreased BMD, delayed growth,
and a defective GH/IGF-I axis. Biochemical evidence of 
hypoparathyroidism or rickets may be detected in thalassemic 
patients with hypocalcemia. It is logical to propose that 
treatment of these patients with GH and/or IGF-1 with aggres­ 
sive nutritional support and supplementation with vitamin D 
and/or calcium might improve the bone density and prevent the 
development of osteoporosis and subsequent fractures.
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Decreased Bone Mineral Density in Prepubertal Children 
with Sickle Cell Disease: Correlation with Growth 
Parameters, Degree of Siderosis and Secretion of Growth 
Factors
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Summary
Patients with sickle cell disease (SCO) frequently have bone disorders of multifactorial aetiology. We 
attempted to analyse the relationships between bone mineral density (BMD) on the one hand and 
auxologic parameters, degree of siderosis, function of the growth hormone (GH)/insulin-like growth 
factor-I (IGF-I)AGF-binding protein 3 (IGFBP3) axis, and calcium-phosphate balance in 28 
prepubertal children with SCD and 15 age-matched children with constitutional short stature (CSS). 
Children with SCO had significantly decreased BMD (77.9 ± 11.9 per cent of normal BMD for age 
and sex) and circulating concentrations of IGF-I (91 ± 31 ng/ml) and IGFBP3 (1.7 ± 0.44 mg/1) 
compared with the control group (BMD = 93.5 ± 8.2 per cent of normal BMD for age and sex, 
IGF-I = 221 ± 48 ng/ml, and IGFBP3 = 2.3 ± 0.34 mgVml). GH response to provocation was 
defective (peak below 10^g/l) in 40 per cent of children with SCD. Those with SCD with 
defective GH secretion had significantly lower circulating IGF-I concentration and BMD than 
those with normal GH secretion. Serum calcium, phosphate and alkaline phosphatase 
concentrations were normal in all children with SCD. BMD was correlated significantly with 
height, weight, and body mass index as well as with the circulating concentrations of IGF-I and 
IGFBP3. It is suggested that increasing the circulating IGF-I concentration, either through 
increasing the caloric intake of subjects and/or via GH/IGF-I therapy, may improve growth and bone 
mineralization in these patients.
Introduction
Peak bone mass is defined as the highest level of bone 
mass achieved as a result of normal growth. It is one of 
the principal factors determining bone mass late in life. 
Studying the normal process and factors influencing 
bone mass accumulation are essential for understanding 
childhood growth and development as well as for the 
prevention of osteoporosis in later life.
Studies have shown that acquisition of bone mineral is 
gradual in early childhood and accelerates during 
adolescence until sexual maturity is reached. 14 Peak 
bone mass is mainly achieved by late adolescence, and 
pubertal development and sex steroids play a crucial role 
in accumulation of bone mass.*1 " 7 Recent data indicate
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that patients with constitutionally delayed puberty had 
their bone accretion complete by their mid-twenties and 
their bone mass density does not improve with time. 8 '9 
Several studies have demonstrated the presence of 
osteopenia in many chronic childhood conditions. I0~ 12 
Although a variety of factors are of importance, the 
effect of poor nutrition and delayed puberty appear to be 
the strongest determinants. 2
Sickle cell disease (SCD) is associated with many risk 
factors that can adversely affect bone accretion. These 
factors include
(1) avascular necrosis during sickling episodes;
(2) delayed growth and pubertal development; 13
(3) deficiency of important growth factors like IGF-I; 14
(4) nutritional deficiencies; I5 ' IA and/or
(5) disturbed calcium metabolism. 17
Many radiological changes are described in these 
patients, which become marked with age. These changes 
combine two features, namely expansion of the medulla
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of the long hones and the diploic spaces of the cranial 
vault and the effect of bone infarction and infection. The 
cortex and trabcculac may be thinned and the inter- 
irabccular spaces arc widened throughout the skeleton. 
In the small bones of the hands and feet deposition of 
pcriostcal new hone along the shaft is combined with 
irregular areas of transluccncy within the substance of 
the hone. The whole bone may be involved. Inter­ 
ference with bone growth can be generalized or 
locali/.cd to the metaphysis of the long bones and 
vertebral bodies. 18
Because of the risk factors mentioned above and the 
significant radiological bone changes in these children, 
we measured bone mineral density (BMD) in relation to 
linear growth and secretion of growth factors [growth 
hormone (GH), insulin-like growth factor-I (1GF-I), and 
IGF-binding protein-3 (IGFBP3)] in 28 prepubertal 
children with SCO.
Patients and Methods
Twenty-eight prepubertal children with SCO were the 
subject of this study. They were randomly selected from 
the 162 children with SCD attending the Hematology 
outpatient clinic of the Royal Hospital, Muscat, Oman. 
All had been on folic acid supplement and vaccinated 
against pneumococci. None of them had a history of 
intrauterine growth retardation, any other systemic or 
endocrine disease, dysmorphic trait, or central nervous 
system irradiation. Informed consents were obtained 
from all the parents and when appropriate from the 
patients before enrolment in the study. Twenty-five age- 
matched children with CSS served as controls. The 
protocol of the study was approved by the ethical 
committee of the hospital. All the children were 
examined thoroughly with special emphasis on nutri­ 
tional data. The auxological measurements included 
weight, mid-arm circumference, and scapular, triceps, 
and abdominal skin-fold thickness. Harpenden's calipers 
were used. Height standard deviation scores (Ht SDS) 
were calculated according to the formula (x t -jr2 )/SD 
where .r: and SD are the mean height and SD 
respectively, for the matched population, and x\ is the 
subject's height. The body mass indices (BMI) were 
calculated according to the formula weight (kg)/Ht (m*). 
The hone age was determined according to Greulich and 
Pylc's atlas. 19
After an overnight fast (8h) venous blood samples 
were obtained between 8 and 9a.m. for determination of 
the complete blood picture, serum albumin, calcium, 
phosphates, and alkaline phosphate concentrations. The 
scrum was separated from the formed elements by 
centrifugation and kept frozen at -20"C until analysed 
for GH, IGF-I, and IGFBP3 by radioimmunoassay. A 
GH provocation test was performed using oral clonidine 
(0.15 mg/m 2 ), and for those who did not respond (peak 
GH below 10/ig/l), GH stimulation with glucagon 
O.lmg/kg IM was performed. Human GH and IGF-I 
were measured by radioimmunometric assay, using
reagents purchased from Nichols Institute (San Ji 
Capistrano, CA). Intra-assay coefficients of variati 
(CVs) averaged 5.6 and 7.2 per cent respectively, a 
inter-assay CVs averaged 7.8 and 8.5 per a 
respectively in the range of GH and IGF-I vali 
detected. IGFBP3 was measured by radioimmunoass 
by SCL. Bioscience Services (London) using reaget 
supplied by Mcdiagnost (Rome). The assay sensitivi 
was 0.06/ig/ml with intra- and inter-assay CVs of j 
and 8.9 per cent respectively.
Lumbar spine (L-2, L-3, L-4) BMD was measured 
all patients by dual photon absorptiometry (DPA) usii 
a Norlad 2600 bone dcnsitometer. All patients we 
scanned in the supine position. BMD data we 
expressed in g/cm 2 and were compared with the BM 
of control and normal children of the same age. 20 Tl 
densitometer was calibrated daily using a phanto 
standard. The examination was performed with the chi 
supine, knee flexed, and calves resting on a cushio 
This positioning separated the spinous processes ar 
prevented overlap of bony structures. All clothing th 
could produce artefacts was removed. No sedation i 
restraints were used. The scan took approximate: 
15min. All scans were analysed with the assistance < 
an edge detection program in the scanner software. 7 
minimize variability, one experienced observer onl 
(H.B.) performed all scan analyses. The coefficient ( 
variation on repeated scan analyses was 0.7 per cen 
The L-2: L-4 spinal BMD was expressed in g/cm2 .
Data are presented as mean ±SD. Statistical analyse 
were performed using the unpaired Student's /-test fc 
comparison between the groups. The Wilcoxon test w< 
used when the data were not normally distributee 
Correlation coefficients were calculated for each var 
able against BMD using single and multiple regressio 
analyses in which BMD was the dependent variable.
Results
Table 1 presents the data for the patients and control; 
According to the peak GH response to provocation, th 
SCD patients were divided into two groups: group I wit 
defective GH release (GHD), and group II with norma 
GH release after provocation. The chronological am 
bone ages did not differ significantly among the threi 
study groups. Children with SCD had significantly lowe 
IGF-I and IGFBP3 concentrations compared to thi 
controls. Those with defective GH secretion had lowe 
IGF-I and IGFBP3 concentrations compared to thost 
with a normal GH peak after provocation. Thi 
percentage BMD (measured as a percentage of thi 
normal values for age- and sex-matched children)20 wa 
significantly lower in children with SCD compared t< 
controls. The loss of more than 20 per cent of BMI 
corresponds to a loss of more than I SD of bone density 
The BMD of children with SCD and GHD wa 
significantly lower than those who had normal GF 
secretion. BMD was correlated significantly with weigh 
(r = 0.547), height (r = 0.52), HtSDS (r = 0.369)
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BMI (r = 0.409), and circulating 
IGF-I (r = 0.469) and IGFBP3 (r •. 
No significant correlation was found 
serum concentration of calcium (r = 
(r = 0.027), alkaline phosphatase (r 
(r = 0.25, p = 0.08).
concentrations of 
= 0.36) (/?<0.05). 
between BMD and 
= 0.077). phosphate 
= 0.023). or fcrritin
Discussion
This study demonstrates that children with SCD have 
significant reduction of BMD. A reduction in BMD of 
this extent (1 SD below the mean) probably represents u 
50-100 per cent increase in the incidence of fractures. :i 
We attempted to study some factors that might affect 
BMD in those patients with SCD, including auxologic 
data, the degree of siderosis, calcium-phosphate bal­ 
ance, and ihe GH/IGF-I/IGFBP3 axis.
In (his study children with SCD had low BMI (20 out 
of 28 had BMI below the 10th centile for age and sex) 
and Hi SD S (18 out of the 28 had Ht SD S s2). The 
significant correlation between BMD on the one hand 
and weight, height, and BMI on the other suggests that 
slow growth is an important factor in the produciion of 
low BMD in these children. Delayed sexual maturation, 
a known feature of SCD, can significantly add to the 
problem by decreasing the peak bone mass. 8 '9
Twelve out of the 28 children with SCD had defective 
GH secretion after provocation, and as a group (n = 28), 
children with SCD had significantly lower circulating 
concentrations of IGF-I and IGFBP3 compared to the 
control group. Children and adults with GHD have 
reduced BMD and bone formation. 22 23 In those patients, 
GH replacement increases bone turnover and increases 
BMD within 6-12 months. 24 Children with SCD and 
GHD had significantly lower IGF-I and IGFBP3 
concentrations and BMD compared with those with 
normal GH secretion. IGF-I is a GH-dependent poly- 
peptide that circulates in the plasma preferentially bound 
to the high molecular weight IGFBP3 complex which 
acts as a reservoir, prolonging the half-life of IGF-I and 
targeting the IGFs to the relevant target organ. The 
bioactivity of the circulating IGF-I is therefore very 
much dependent on the presence of IGFBP3 in the 
circulation. 2<i " 27 IGF-I is a potent stimulator of bone 
formation and exogenous administration of IGF-I has 
been shown to increase bone formation in humans 
and animals. ~"' 2<> This effect is potentiated when 
IGF-I is combined with IGFBP3.-10"" Current 
opinion favours GH as the major regulator of 
IGF-I and IGFBP3 levels in humans. 32 ' 11 GH therapy 
increases both IGF-I and IGFBP3. 1 ' 14 Therefore, GH 
replacement and/or IGF-I therapy might improve 
growth and BMD in children with SCD, as seen in 
other diseases with osteopema. 10' 11
In addition, serum levels of IGF-I and IGFBP3 are 
positively related to nutritional status. 1516 Despite their 
growth delay, dietary evaluation of our patients with 
SCD revealed thai they have normal qualitative and 
quantitative food intake compared to age-malchcd
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normal children. This can he explained in part hy the 
increased protein turnover and energy expenditure of 
these patients, pulling them in a hypcrmeiabolic stale that 
requires greater dietary energy compared with normal 
children (HhAAi." One study showed an improvement 
in hoih growth parameters and clinical course following 
caloric supplementation." This nutritional supply exerts 
some of its effects through increasing \GF-l and 
therefore might also improve BMD in these 
patients. <VUl Moreover, in many diseases associated 
with hypcrmctabolism there is a stale of acquired GH 
resistance with low IGF-I and IGFBP3 production 
despite normal or high levels of GH. Preliminary data 
in animals and humans suggest that GH/1GF-I adminis­ 
tration can improve nitrogen economy and anabolism in 
these conditions. w
In this study, (he normal scrum calcium, phosphate, 
and alkaline phosphatasc concentrations exclude an 
important role, if any, of disturbed calcium-phosphate 
balance in the production of low BMD. The degree of 
siderosis, evidenced by circulating fenritin concentration, 
was not correlated significantly with BMD. However, the 
excess iron might inhibit calcium deposition in the bone 
either directly and/or through decreased hepatic synth­ 
esis of IGF-I.40
The question is. what possible therapeutic or 
preventive options are available that may influence 
bone mineralization in SCD? Obviously proper and 
aggressive nutritional intervention is necessary to 
improve growth. Calcium supplements, which have 
been shown to increase bone density in normal 
prcpubertal children, is a possible option.41 Growth 
hormone and/or IGF-I therapy, especially for those with 
GHD and/or low IGF-I concentration, would seem to be 
a reasonable option."'' 37 The initiation of puberty at an 
appropriate age, using oestrogens or androgens, is 
another option, taking into consideration the risk of 
advancing the bone age faster than the height age.
In summary, prepubertal children with SCD have 
decreased BMD, delayed growth, and a defective GH/ 
IGF-I/IGFBP3 axis. It is logical to propose that treatment 
of these patients with GH and/or IGF-I may improve 
their linear growth and bone mineralization.
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